

Nippon AMR One Health Report (NAOR) 2025

July 10, 2026

The AMR One Health Surveillance Committee

TABLE OF CONTENTS

1.	Preface.....	5
2.	Abbreviations.....	6
3.	Classes and Abbreviations of Antimicrobials.....	7
4.	Executive Summary.....	10
5.	Outcome Indices for the Action Plan.....	14
6.	Current Status of Antimicrobial-resistant Bacteria in Japan.....	18
(1)	Humans.....	18
	1) Gram-negative bacteria.....	18
	2) Gram-positive bacteria.....	25
	3) Antimicrobial-resistant bacteria infection.....	33
	4) Other antimicrobial-resistant bacteria.....	34
	5) <i>Candida auris</i>	44
	6) <i>Mycobacterium tuberculosis</i>	44
	7) <i>Clostridioides difficile</i> infection.....	45
	8) Antimicrobial resistance surveillance linked to JANIS.....	46
	9) Status of health care associated infection.....	50
	10) Survey of infection treatment and control and the disease burden at hospitals.....	51
	11) Survey of infections and antimicrobial use at facilities for the elderly.....	54
(2)	Animals.....	56
	1) Livestock animals.....	56
	2) Farm-raised aquatic animals.....	72
	3) Companion animals.....	74
	4) Wild animals.....	82
(3)	Food.....	87
(4)	Environment.....	89
(5)	Genome comparison of Antimicrobial-resistant Bacteria: Exploring the relationships between humans, animals, food, and the environment.....	98
7.	Current Volume of Use of Antimicrobials in Japan.....	114
(1)	Antimicrobials for humans.....	114
	1) Usage of antimicrobials in Japan.....	114

2) Usage of parenteral antimicrobials in hospitals	121
(2) Veterinary agents.....	123
1) Livestock animals	125
2) Aquatic animals	126
3) Companion animals	127
(3) Antimicrobial feed additives	129
(4) Agrochemicals.....	130
(5) Current status of antimicrobial use in Japan	131
(6) Research into antimicrobial stewardship.....	136
(7) Research on the prudent use of antimicrobial agents for veterinary use	140
(8) -Environment.....	141
8. Public Awareness regarding Antimicrobial Resistance in Japan	143
(1) Surveys of the general public	143
1) Surveys of attitudes among the public	143
(2) Surveys of healthcare providers	146
1) Awareness survey of clinic physicians	146
2) Research on infectious diseases and antimicrobials in pharmacy education	147
(3) Survey of Stakeholders in the Animal Field	148
(4) Survey of veterinary medicine students	150
9. Way Forward	152
Appendix 154	
(1) Japan Nosocomial Infections Surveillance (JANIS).....	154
1) Overview.....	154
2) Methods for submission.....	154
3) Prospects	154
(2) National Epidemiological Surveillance of Infectious Disease	155
1) Overview.....	155
2) Reporting criteria	155
3) System.....	156
4) Prospects	156
(3) Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE)	157
1) Overview.....	157

2) System.....	157
3) Prospects	157
(4) Trend surveillance of antimicrobial-resistant <i>Mycobacterium tuberculosis</i>	158
1) Overview.....	158
2) Survey methods.....	158
3) System.....	158
4) Prospects	158
(5) Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM)	158
1) Overview.....	158
2) System for the antimicrobial resistance monitoring.....	159
3) Monitoring the sales volumes of veterinary antimicrobials.....	162
4) Future prospects	163
(6) Trend Surveillance of Antimicrobial Agents in Japan (JSAC, J-SIPHE)	164
1) Overview.....	164
2) Monitoring methods.....	164
3) Prospects	164
(7) Monitoring on the antimicrobial-resistant <i>Campylobacter</i> spp. isolated from humans and from food.....	165
1) Overview.....	165
2) Survey methods.....	165
3) Prospects	165
(8) Monitoring on the antimicrobial-resistant non-typhoidal <i>Salmonella</i> spp. isolated from humans and from food	166
1) Overview.....	166
2) Methods	166
3) Prospects	166
(9) Monitoring on the antimicrobial-resistant <i>Neisseria gonorrhoeae</i>	167
1) Overview.....	167
2) Survey methods.....	167
3) Prospects	167
(10) Monitoring on the antimicrobial-resistant <i>Salmonella</i> Typhi, <i>Salmonella</i> Paratyphi A, and <i>Shigella</i> spp.	169
1) Overview.....	169
2) Methods	169
3) Prospects	169
(11) Antimicrobial Resistance (AMR) One Health Platform	170
Overview	170
Websites of Key Trend Surveys.....	171

The Process of Preparation of This Report	173
---	-----

1. Preface

Japan's "National Action Plan on Antimicrobial Resistance (AMR) 2016-2020" was published in April 2016, clearly indicating the implementation of integrated One Health surveillance regarding antimicrobial-resistant bacteria that are isolated from humans, animals, food and the environment. This One Health surveillance is endorsed as an important strategy for correctly identifying the current status and issues related to AMR, which leads to promoting appropriate national AMR policy. In presenting the results of this surveillance, this report aims to identify the current status of and trends in antimicrobial-resistant bacteria and national antimicrobial amount used (or sold) in the areas of human health, animals, food and the environment, with the objective of assessing measures to combat antimicrobial-resistant bacteria and clarify challenges in this area.

Due to the impact of the COVID-19 pandemic, the implementation period of the "National Action Plan on Antimicrobial Resistance (AMR) (2016-2020)" was extended until the end of the fiscal year 2022. In 2023, an updated National Action Plan on Antimicrobial Resistance (AMR) (2023-2027) was developed based on the achievements and experiences of the previous Action Plan. The new plan proposes updated goals and strategies to strengthen and promote AMR control further, reemphasizing the importance of the One Health approach to the AMR challenge and promoting measures that take into account the close relation of human, animal, food and environmental health. Additionally, the data collection and analytical methods regarding trends in antimicrobial resistance (AMR) and antimicrobial drug usage, both domestically and internationally, have been revised. The introduction of genome-based surveillance has enabled a more detailed understanding of the emergence and transmission pathways of drug-resistant bacteria. Furthermore, the importance of deepening international cooperation and collaboration in AMR countermeasures has also been emphasized.

This report has demonstrated Japan's efforts in the One Health approach to AMR both domestically and internationally, and through the results of this survey, the evaluation of AMR countermeasures is conducted, and the challenges are identified, which have been utilized by relevant government ministries, agencies, organisations, and academic societies to promote countermeasures and research on AMR. The content includes more refined analyses that incorporate new insights and data resulting from the introduction of genome analysis.

Future efforts under the new Action Plan are expected to contribute to the further development of Japan's AMR control measures and support effective responses to the AMR challenge in Japan and abroad. We hope that the data and analyses provided by this report will serve as a basis for strengthening AMR measures, promoting new research, and formulating policies by domestic and international stakeholders. Ultimately, we hope that these efforts will result in a more comprehensive and effective approach to the challenge of AMR and contribute to improving people's health and public health of the nation.

This report contains data for up to 10 years. For data from other years, please refer to the Antimicrobial Resistance (AMR) One Health Platform (<https://amr-onehealth-platform.jihs.go.jp/home>).

2. Abbreviations

AMED	Japan Agency for Medical Research and Development
AMU	Antimicrobial Use
AMR	Antimicrobial Resistance
AMRCRC	Antimicrobial Resistance Clinical Reference Center
AUD	Antimicrobial Use Density
BP	Breakpoint
CDI	<i>Clostridioides (Clostridium) difficile</i> Infection
CLSI	Clinical and Laboratory Standards Institute
CRE	Carbapenem-resistant Enterobacterales
DID	Defined Daily Dose per 1,000 Inhabitants per Day
DDD(s)	Defined Daily Dose(s)
DOT	Days of Therapy
DOTID	Days of therapy per 1,000 Inhabitants per Day
ESBL	Extended-spectrum β -lactamase
EUCAST	European Committee on Antimicrobial Susceptibility Testing
FAMIC	Food and Agricultural Materials Inspection Center
FAO	Food and Agricultural Organization of the United Nations
GLASS	Global Antimicrobial Resistance and Use Surveillance System
HAI	Healthcare-associated Infection
ICU	Intensive Care Unit
JANIS	Japan Nosocomial Infections Surveillance
JSAC	Japan Surveillance of Antimicrobial Consumption
J-SIPHE	Japan Surveillance for Infection Prevention and Healthcare Epidemiology
JVARM	Japanese Veterinary Antimicrobial Resistance Monitoring System
MIC	Minimum Inhibitory Concentration
MDRA	Multidrug-resistant <i>Acinetobacter</i> spp.
MDRP	Multidrug-resistant <i>Pseudomonas aeruginosa</i>
MRSA	Methicillin-resistant <i>Staphylococcus aureus</i>
MSSA	Methicillin-susceptible <i>Staphylococcus aureus</i>
NDB	National Database of Health Insurance Claims
PID	Number of patients per 1,000 Inhabitants per Day
PPCPs	Pharmaceuticals and Personal Products
PRSP	Penicillin-resistant <i>Streptococcus pneumoniae</i>
SSI	Surgical Site Infection
WHO	World Health Organization
VRE	Vancomycin-resistant <i>Enterococci</i>
WOAH	World Organisation for Animal Health
VRSA	Vancomycin-resistant <i>Staphylococcus aureus</i>
DALY(s)	Disability-adjusted life year(s)
PPS	Point Prevalence Survey

3. Classes and Abbreviations of Antimicrobials

Class			Nonproprietary name	Abbreviation*				
Beta-lactam antibiotics	Penicillins		benzylpenicillin (penicillin G)	PCG				
			ampicillin	ABPC				
			sulbactam/ampicillin	SBT/ABPC				
			piperacillin	PIPC				
			oxacillin	MPIPC				
			tazobactam/piperacillin	TAZ/PIPC				
			amoxicillin	AMPC				
			clavulanic acid/amoxicillin	CVA/AMPC				
	Cephalosporins		1st generation		cefazolin	CEZ		
					cephalexin	CEX		
			2nd generation		cefotiam	CTM		
					cefaclor	CCL		
					cefmetazole	CMZ		
					cefoxitin	CFX		
					3rd generation		cefotaxime	CTX
			ceftazidime	CAZ				
			ceftriaxone	CTRX				
			sulbactam/cefoperazone	SBT/CPZ				
			cefdinir	CFDN				
			cefcapene pivoxil	CFPN-PI				
			cefditoren pivoxil	CDTR-PI				
			cefixime	CFIX				
			4th generation				cefepime	CFPM
							cefpirome	CPR
					cefozopran	CZOP		
					Cephalosporins combined with beta-lactamase inhibitor	tazobactam/ceftolozane	TAZ/CTLZ	
			Siderophore cephalosporins				cefiderocol	CFDC
	Cephameycins			cefmetazole	CMZ			
				cefoxitin	CFX			
	Oxacephems			flomoxef	FMOX			
				latamoxef	LMOX			
	Monobactams			aztreonam	AZT			
	Carbapenems			meropenem	MEPM			
				doripenem	DRPM			
				biapenem	BIPM			
imipenem/cilastatin				IPM/CS				
imipenem/cilastatin/relebactam				REL/IPM/CS				
panipenem/betamipron				PAPM/BP				
tebipenem pivoxil				TBPM-PI				
Penems			faropenem	FRPM				
ST			sulfamethoxazole-trimethoprim	ST				
			sulfamonomethoxine	SMMX				

Class	Nonproprietary name	Abbreviation*
Macrolides	erythromycin	EM
	clarithromycin	CAM
	azithromycin	AZM
	tylosin	TS
	spiramycin	SPM
Macrolides for the treatment of CDI	fidaxomicin	FDX
Ketolides	telithromycin	TEL
Lincomycins	clindamycin	CLDM
	lincomycin	LCM
Streptogramins	quinupristin/dalfopristin	QPR/DPR
	virginiamycin	VGM
Tetracyclines	minocycline	MINO
	tetracycline	TC
	doxycycline	DOXY
	oxytetracycline	OTC
Aminoglycosides	streptomycin	SM
	tobramycin	TOB
	gentamicin	GM
	amikacin	AMK
	arbekacin	ABK
	kanamycin	KM
	spectinomycin	SPCM
	dihydrostreptomycin	DSM
Quinolones (©fluoroquinolones)	©ciprofloxacin	CPFX
	©levofloxacin	LVFX
	©lascufloxacin	LSFX
	©pazufloxacin	PZFX
	©norfloxacin	NFLX
	©prulifloxacin	PUFX
	©moxifloxacin	MFLX
	©garenoxacin mesylate hydrate	GRNX
	©sitafloracin	STFX
	©ofloxacin	OFLX
	©enrofloxacin	ERFX
	oxolinic acid	OA
	nalidixic acid	NA
Glycopeptides	vancomycin	VCM
	teicoplanin	TEIC
Oxazolidinones	linezolid	LZD
	tedizolid	TZD
Polypeptides	polymyxin B	PL-B
	colistin	CL
	bacitracin	BC
Lipopeptides	daptomycin	DAP
Chloramphenicols	chloramphenicol	CP
	florfenicol	FF

Class	Nonproprietary name	Abbreviation*
Other antibacterial agents	fosfomycin	FOM
	salinomycin	SNM
	bicozamycin	BCM
	trimethoprim	TMP
Antitubercular antibiotics	isoniazid	INH
	ethambutol	EB
	rifampicin (rifampin)	RFP
	pyrazinamide	PZA
	rifabutin	RBT
	bedaquiline	BDQ

* Quoted from the Glossary of Antimicrobial Chemotherapy (Japanese Society of Chemotherapy), the Annual Report of the Japanese Society of Antimicrobials for Animals 36 (2014), and the Guidelines for the Use of Antimicrobial Substances in Cooperative Livestock Insurances (2009, Ministry of Agriculture, Forestry and Fisheries)

[Reference] There are multiple relevant terminologies with different definitions. However, in medical practice, the following four terms are often used interchangeably to refer agents that act against bacteria: “antimicrobial agents,” “antibiotics,” “antibiotic agents,” and “antibacterial agents.” In the areas of agriculture and livestock, the expressions “antibacterial agents” and “antimicrobial agents” are commonly used, because these agents are not only used for therapeutic purposes, but also in antibiotic feed additives.

Antimicrobial agents or antimicrobials: Antimicrobial agents, or antimicrobials, are active against microorganisms, which are generally categorized into bacteria, fungi, viruses and parasites. These are the general term for agents to treat and prevent infectious diseases. They contain antibacterial agents, antifungal agents, antiviral agents and antiparasitic agents.

Antibacterial agents: Antimicrobial agents that are active against bacteria.

Antibiotics: Chemical substances that inhibit or control the cell activities of microorganisms and other cells (referred to as antimicrobial activity) and are, strictly speaking, produced by microorganisms.

Antibiotic agents: Used as a generic term for anti-microbial agents that act against bacteria.

Reference: The Manual of Antimicrobial Stewardship, (4th Edition) — Medical Outpatient Section / Medical Inpatient Section

In terms of active ingredients (veterinary agents), in terms of effective value (antibiotic feed additives), in terms of active ingredients (agrochemicals), antimicrobial consumption in terms of potency by weight (humans): All these terms refer to active ingredient weight. Quantities in terms of the weight of active ingredients in veterinary agents are calculated from sales data collected from marketing authorization holders for the volume of each agent sold. When doing so, the marketing authorization holders also submit estimates of the percentage of sales for each animal species, so the estimated volumes sold are calculated for each species based on those estimated percentages. As with the figures for veterinary agents, quantities of antibiotic feed additives in terms of effective value, quantities of agrochemicals in terms of active ingredients, and human antimicrobial consumption in terms of potency by weight refer to active ingredient weight.

Indicators of antimicrobial use:

- **AUD:** Mainly used to ascertain usage in medical institutions, AUD is calculated by dividing the total titer of antimicrobials used (or presumed to have been used) over a specified period by defined daily dose (DDD) as defined by the World Health Organization (WHO), and correcting the result with the total patient-days. The units used for AUD include DDDs per 100 bed-days and DDDs per 1,000 patient-days. In some countries, AUD is also expressed as DDD.
- **DOT :** DOT is a unit mainly used to grasp the usage in medical institutions. It is calculated by correcting the total days of therapy (DOTs) using antimicrobials in a specified period with the total patient-days. The units used for DOT include DOTs per 100 bed-days and DOTs per 1,000 patient-days.
- **DID (DDD/1,000 inhabitants/day):** DID is a unit of measurement of use, mainly in a region or country; DID is expressed per 1,000 inhabitants as the total titer used (or presumed to have been used) over a specified period divided by DDD, with the denominator corrected for the number of inhabitants per day in the region (‘inhabitants’). The DID is expressed as a value per 1,000 inhabitants, corrected for the number of inhabitants per day.
- **DOTID (DOT/1,000 inhabitants/day):** DOTID is a unit that uses claims information to determine usage in a region or country. It is expressed per 1,000 inhabitants as the total number of days of antimicrobial treatment (DOTs) over a period of time in the numerator, with the denominator corrected for the number of inhabitants per day in the region.
- **PID (number of patients/1,000 inhabitants/day):** PID is a unit that uses insurance claims information to determine usage in a region or country. It is expressed as a value per 1,000 inhabitants with the total number of people using antimicrobials over a period of time as the numerator and the denominator corrected for the number of inhabitants per day in the region.

4. Executive Summary

Background:

Japan's "National Action Plan on AMR (2016-2020)" positioned efforts to ascertain the current status of antimicrobial-resistant bacteria and national antimicrobial use in the areas of human health, animals, food and the environment and trends therein as an important strategy for both evaluating current policy and examining future policy.

Due to the impact of the COVID-19 pandemic, the implementation period of the "National Action Plan on Antimicrobial Resistance (AMR) (2016-2020)" was extended until the end of the fiscal year 2022. In 2023, the Action Plan for AMR Control (2023-2027) was developed, setting updated goals and strategies. The plan reemphasizes the importance of the One Health approach to the AMR challenge, expands the genomic database, and calls for the promotion of measures that take into account the interconnectedness of human, animal, and environmental health. It also emphasizes the importance of international cooperation and joint efforts to combat AMR.

Internationally, Japan submits data to the Global Antimicrobial Resistance and Use Surveillance System (GLASS) established by the World Health Organization (WHO), to the monitoring of Animal Antimicrobial Use (ANIMUSE) conducted by the World Organisation for Animal Health (WOAH), using standardized methodologies, and to the International FAO Antimicrobial Resistance Monitoring System (InFARM) by the Food and Agriculture Organization of the United Nations (FAO).

Accordingly, it is crucial for Japan to update both domestic and overseas stakeholders about the current status and progress of our AMR policy, in order both to reaffirm Japan's position in the global community and to accelerate and advance AMR policy internationally. The data and analyses provided by this report are intended to serve as a basis for strengthening AMR control, promoting new research, and formulating policy by national and international stakeholders.

Method:

The AMR One Health Surveillance Committee, comprised of experts on AMR in the areas of human health, animals, food and the environment, discussed current surveillance/monitoring systems and reviewed published research on AMR and antimicrobial use. Data on the proportion of antimicrobial resistance among major pathogens in the human medical setting were derived from the Japan Nosocomial Infections Surveillance (JANIS) program organized by the Ministry of Health, Labour and Welfare of Japan. Data on the proportion of antimicrobial resistance among animals and related antimicrobial sales were derived from the Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM) implemented by the Ministry of Agriculture, Forestry and Fisheries of Japan (MAFF). We obtained data on sales and consumption of antimicrobials for human use from IQVIA Solutions Japan G.K., the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), and Japan Surveillance for Infection Prevention and Health-care Epidemiology (J-SIPHE). Data on sales of antimicrobials in animals were obtained from the National Veterinary Assay Laboratory, Ministry of Agriculture, Forestry and Fisheries. Data on the distribution of antimicrobial feed additives were provided by the Food and Agricultural Materials Inspection Center (FAMIC) and the Japan Scientific Feeds Associations (JSFA). Data on the volume of domestic shipments of antimicrobials used as agrochemicals was obtained from MAFF, while information on outbreaks of infectious diseases and the implementation of infection control measures was obtained from the National Epidemiological Surveillance of Infectious Diseases, JANIS and J-SIPHE.

The research utilized findings from the Ministry of Health and Labour Sciences Research Groups, among others, regarding factors not addressed in current surveillance nor monitoring systems, but considered pertinent from a public health perspective, which include antimicrobial resistance, antimicrobial resistance and residual antimicrobial agents in the environmental, and public awareness of antimicrobial resistance. In the animal field the results of a survey conducted by the Ministry of Agriculture, Forestry and Fisheries on the awareness levels of producers, clinical veterinarians, and pet owners and a survey of attitudes of veterinary students at 16 universities towards antimicrobial resistance were used.

Results:

In Japan, the carbapenem resistance rate in Enterobacterales, particularly *Escherichia coli* and *Klebsiella pneumoniae* has remained below 1% during the observed period, despite its global increase in human isolates. While the resistance rates of *E. coli* to third-generation cephalosporins and fluoroquinolones had shown an increasing trend in Japan, in 2021, a slight decrease was observed for the first time, followed by stable or reduced levels in 2022. In 2023, there was a slight increase in the resistance rates. On the other hand, the resistance rates of third generation cephalosporins in *Klebsiella pneumoniae* remained on the rise. The resistance rates of carbapenem in *Pseudomonas aeruginosa* are on a decreasing trend. Internationally, the increase in vancomycin resistance among enterococci is a problem. In Japan, although vancomycin (VCM) resistance in *Enterococcus faecium* remains relatively low compared with that observed in other countries, it showed a transient increase to 2.6% in 2021 and 2022. In certain regions, large-scale nosocomial outbreaks involving multiple healthcare facilities caused by vancomycin (VCM)-resistant *Enterococcus faecium* have been documented, underscoring the need for continued

vigilance.

Although the percentage of methicillin-resistant *Staphylococcus aureus* (MRSA) had been in an increasing trend again since 2019, started to decrease in 2021. The trend remained the same in 2022 and 2023, but it is still high compared to other countries. Clear similarities in the pattern of resistance rates to antimicrobials were observed in serotypes of *Salmonella* spp. isolated from food and from humans, strongly suggesting a link between resistant strains derived from food and from humans.

In research based on genomic analysis, human-derived strains of non-typhoidal *Salmonella* spp. isolated from patients with infectious enteritis or food poisoning are generally considered to have likely been transmitted to humans through animals or food. Occasionally, strains harboring resistance genes that suggest transmission from food to humans have been detected. In *Enterococcus* spp., it was found that human-derived VRE strains and food-derived strains were phylogenetically distinct. The Tricycle Project revealed that food-derived (poultry) strains shared fewer sequence types (STs) with human-derived and environmental strains, whereas human-derived and environmental strains shared a higher number of common STs, accounting for 28.2% of the total (27 strains).

Antimicrobial use based on human antimicrobial sales in Japan was 12.96 DID in 2024, a 27.3% increase compared to 2020, and was comparable to that observed in 2019 (12.75), prior to the COVID-19 pandemic. Oral antimicrobial agents accounted for 91.9% of all antimicrobial agents, with a total of 63.1% of oral antimicrobials being comprised of third generation cephalosporins, fluoroquinolones, and macrolides. The three most frequently used antimicrobial classes in 2023 showed, a 2.2% decrease, a 45.8% increase, and a 34.8% increase, respectively, compared with 2020 and a 40.0% decrease, a 4.3% increase, and a 2.9% increase, respectively, compared with 2019. Injectable carbapenems have decreased by 14.3% compared to 2020. The proportion of “Access” in the AwaRe classification, a guidance for appropriate antimicrobial use recommended by WHO has gradually increased since 2015, from 12.49% to 23.22% in 2024, while the proportion of “Watch” has been decreasing from 86.07% to 75.72%.

Surveillance of antimicrobial resistance in animals focuses on livestock animals (cattle, swine, and chickens), aquatic animals (all farmed fish species), and companion animals (dogs and cats). The resistance rate of Enterobacterales to carbapenems, an important antimicrobial class in human medicine, were 0.0% for all animal species and bacterial strains, except for *Klebsiella* spp. derived from dogs, where the resistance rate was 1.1% (with one resistant strain). The resistance rates of *Enterococcus* spp. to vancomycin, a major problem in human nosocomial infections, were 0.0% for all.

Among livestock animals, the resistance rates to tetracyclines in *E. coli* derived from healthy livestock, as an outcome indicator of the Action Plan (2023-2027), were 20.0% in cattle, 56.3% in swine, and 53.5% in chickens. The resistance rates to third-generation cephalosporins were 1.0% in cattle, 0% in swine, and 3.9% in chickens, while the resistance rates to fluoroquinolones were 0.5% in cattle, 0.7% in swine, and 16.1% in chickens. No significant increases or decreases in resistance rates were observed for any of the animal species or antimicrobial agents.

Among aquatic animals, resistance rates to lincosamides were 53.8% in 2020, 66.0% in 2021, 82.3% in 2022, and 82.6% in 2023 in the causative agents of α -hemolytic lactococcosis from diseased fish, showing an increasing trend. Resistance rates to erythromycin (EM) and oxytetracycline (OTC) remained low, at 3.0% and 0.4%, respectively, in 2023.

Among companion animals, while *E. coli* isolated from diseased dogs and cats demonstrated lower resistance rate to tetracyclines and aminoglycosides than among livestock animals, resistance rates to the fluoroquinolones and third generation cephalosporins that are critically important antimicrobials for human medicine tended to be higher. *E. coli* isolated from healthy companion animals (dogs and cats) indicated that they generally remained susceptible to all drugs.

The volume of sales of antimicrobials used for animals (livestock animals, aquatic animals, and companion animals) was calculated in metric tons (t) of the active ingredients, based on sales reports for antibiotics and synthetic antimicrobials mandated by Article 71-2 of the Regulatory Rules for Veterinary Medicinal Products (Ordinance of the Ministry of Agriculture, Forestry and Fisheries No. 107 of 2004). In 2023, as before, tetracyclines represented the largest share of antimicrobial sales, but their sales volume has been declining in recent years, falling below 40% of the total. Third generation cephalosporins and fluoroquinolones accounted for approximately 0.2% and around 1% of the total, respectively. The total volume of veterinary antimicrobial sales remained around 800 t, with 717.5 t in 2023, down approximately 59 t from 776.9 t in 2022. Looking at the figures by class, tetracyclines decreased by approximately 17 t and macrolides by approximately 16 t. Of the reduction in tetracyclines, approximately 7 t were attributable to decreased use in livestock, while approximately 10 t were attributable to decreased use in aquatic animals. The total sales volume of antimicrobial agents in the livestock sector, newly added as a performance indicator, was 559.4 t, representing a 10.8% decrease compared to 2020. The sales volume of second-line drugs decreased from 26.7 t in 2020 to 23.5 t.

The estimated use (or sales) of antimicrobials in 2023, based on sales volumes and other data for each sector, were 601.1 t for humans, 559.4 t for livestock, 150.4 t for aquatic animals, 7.7 t for companion animals, 219.2 t for antimicrobial feed additives, and 132.9 t for agrochemicals, totaling 1670.8 t.

Observations:

In the human sector, antimicrobial use based on sales of oral antimicrobials, including oral third generation cephalosporins, oral macrolides, and oral fluoroquinolones, had shown a continuous decline since 2020 but began to increase in 2023. Although the resistance rates in methicillin-resistant *Staphylococcus aureus* (MRSA) and *E. coli* to fluoroquinolones have decreased slightly, the resistance rate of *E. coli* to third-generation cephalosporins, after a transient and modest decrease around 2021, has exhibited a gradual increase again since 2023, warranting continued vigilance. The resistance rate to third generation cephalosporins in *K. pneumoniae* has been increasing and should continue to be monitored closely. On the other hand, VCM-resistant *E. faecium* has been observed in widespread hospital outbreaks involving multiple facilities, with the number of cases reported in the Infectious Disease Surveillance consistently exceeding the performance indicator since 2020. Continued comprehensive outbreak response in the region is required.

The proportion of antimicrobial-resistant bacteria and the volume of antimicrobial use have increased in many countries in the post-COVID-19 era. Following the trend seen in 2023, antimicrobial use in Japan also increased in 2024. Conversely, the proportion of Access-category antibiotics under the AWaRe classification has increased, possibly reflecting the impact of the antimicrobial stewardship program incentive newly introduced in the 2024 revision of the national medical fee schedule. Given that the impact of the COVID-19 pandemic is also to be considered, it is essential to closely monitor future trends. The data in this report demonstrates that further promotion of measures against AMR will be required.

Unnecessary use of third generation cephalosporins, fluoroquinolones, and macrolides must be continuously reduced, and the Manual of Antimicrobial Stewardship employed to promote the proper use of antimicrobials, primarily in respect of acute respiratory tract infections. In November 2023, the Manual of Antimicrobial Stewardship was updated to include a section on the appropriate use of antimicrobial agents in hospitalized patients. This edition is expected to improve patient outcomes and promote the proper use of antimicrobial agents in hospitals. In promoting the appropriate use of antimicrobials, it is essential that appropriate antimicrobials are available when needed, and it is important to ensure a stable supply of basic antimicrobials.

Strengthening educational and awareness-raising activities and the use of monitoring systems are also important in AMR control. The new Action Plan calls for the formulation of effective countermeasures through detailed analysis of information on antimicrobial resistance and antimicrobial use in each region. Systems such as JANIS, NESID, J-SIPHE, J-SIPHE for clinics or OASCIS (Online monitoring system for antimicrobial stewardship at clinics) and the AMR One Health Platform should be used to promote antimicrobial selection and infection control measures according to local conditions. Furthermore, in promoting the appropriate use of antimicrobials, it is necessary to continue education and awareness-raising activities using various methods for the public and healthcare professionals.

Among animals, the resistance rates of Enterobacterales to carbapenems, an important antimicrobial class for human medicine, were 0.0 % for all animal species and bacterial strains, except for one strain of *Klebsiella* spp. derived from companion animals. The resistance rates of *enterococci* to vancomycin, a major problem in nosocomial infections in humans, were 0.0% for all animal species and bacterial strains. However, in bacteria isolated from diseased companion animals, some strains showed high rates of resistance to third generation cephalosporins and fluoroquinolones. Therefore, in addition to promoting the dissemination of the "Guide for Antimicrobial Use in Companion Animals", it is necessary to continue and strengthen antimicrobial resistance countermeasures in the companion animal sector, including the appropriate selection of antimicrobial agents, the preferential use of veterinary antimicrobials specifically approved for companion animals, and the implementation of infection prevention and control measures.

It was considered that the resistance rates of *E. coli* from healthy livestock animals to third generation cephalosporins and fluoroquinolones, an outcome indicator of the National Action Plan on AMR (2023-2027), have remained at a low level, which have shown little fluctuation. Regarding tetracycline, which is also used as a performance indicator, although the sales volume in swine decreased by approximately 10%, no significant increase or decrease in resistance rates was observed in any animal species. The usage of veterinary antimicrobial agents in the livestock sector and the usage of second-line drugs have been newly established as performance indicators. Moving forward, it is essential to reduce the overall opportunity for antimicrobial use by promoting the development, practical application, and use of vaccines, improving management standards for animal husbandry hygiene, and other measures. Furthermore, efforts must be made to ensure the appropriate and prudent use of antimicrobial agents, while analyzing and evaluating the factors that maintain resistance rates and the trends in resistance rates to various antimicrobial agents in order to address the issue effectively.

Japan's AMR response has been conducted in coordination with international movements. Stronger international collaboration and a stronger approach from a One Health perspective will be key to the success of AMR control measures. In addition, it is important to strengthen educational and awareness-raising activities to raise awareness and encourage behavior change among the public, which has not been sufficiently effective;

disseminate guidelines to support the appropriate use of antimicrobial agents; and strengthen surveillance systems to measure and evaluate the effectiveness of AMR control measures.

In response to these challenges, the new Action Plan emphasizes collaboration with various stakeholders and cooperation within the international community. It is essential to build and strengthen these cooperative frameworks to achieve Japan's AMR control goals. The effective response to the AMR challenge by sharing knowledge and experience domestically and internationally, and by promoting research that can assess risks in humans, animals, and the environment in a cross-sectional manner, is critical to the future success of AMR control. These efforts will support effective responses to the AMR challenge both in Japan and overseas and could contribute to strengthening Japan's role in the international community. Efforts should be directed toward achieving a more comprehensive and effective approach to the AMR challenge, with the goal of improving the health and public health of the people. The new Action Plan continues to call for government-wide education and awareness-raising activities, but it is important to further explore effective methods are needed.

5. Outcome Indices for the Action Plan

Human-related indices for the Action Plan (2016-2020): proportion (%)* of specified antimicrobial-resistant bacteria

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2020 (target value [†])
Proportion of penicillin-non-susceptible <i>Streptococcus pneumoniae</i> , CSF specimens [§]	40.5	36.4	29.1	38.3	32.0	33.3	59.5	50.9	50.8	38.3	15% or lower
Proportion of penicillin-non-susceptible <i>Streptococcus pneumoniae</i> , non-CSF specimens [§]	2.7	2.1	2.1	2.2	2.2	3.5	3.4	3.8	3.7	3.6	
Proportion of fluoroquinolone-resistant <i>Escherichia coli</i>	38.0	39.3	40.1	40.9	41.4	41.5	40.4	39.6	38.7	38.1	25% or lower
Proportion of methicillin-resistant <i>Staphylococcus aureus</i>	48.5	47.7	47.7	47.5	47.7	47.5	46.0	45.5	45.2	44.4	20% or lower
Proportion of carbapenem-resistant <i>Pseudomonas aeruginosa</i> (Imipenem)	18.8	17.9	16.9	16.2	16.2	15.9	15.8	14.8	13.9	13.2	10% or lower
Proportion of carbapenem-resistant <i>Pseudomonas aeruginosa</i> (Meropenem)	13.1	12.3	11.4	10.9	10.6	10.5	10.3	9.5	8.8	8.3	10% or lower
Proportion of carbapenem-resistant <i>Escherichia coli</i> (Imipenem)	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.04	0.1	0.1	0.2% or lower (maintain at the same level) [¶]
Proportion of carbapenem-resistant <i>Escherichia coli</i> (Meropenem)	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2% or lower (maintain at the same level) [¶]
Proportion of carbapenem-resistant <i>Klebsiella pneumoniae</i> (Imipenem)	0.3	0.2	0.2	0.3	0.2	0.2	0.2	0.1	0.2	0.2	0.2% or lower (maintain at the same level) [¶]
Proportion of carbapenem-resistant <i>Klebsiella pneumoniae</i> (Meropenem)	0.6	0.5	0.4	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.2% or lower (maintain at the same level) [¶]

CSF, cerebrospinal fluid

* Prepared based on JANIS data. Data were provided every two years from 2013, but annual data have been provided since 2017.

[†] Target values were quoted from the National Action Plan on AMR.[1] Comparison to 2013

[§] The proportion of penicillin-non-susceptible *Streptococcus pneumoniae* in 2014, as indicated in the Action Plan, is based on the CLSI (2007) Criteria where those with penicillin MIC of 0.125 µg/mL or higher are considered resistant. The CLSI Criteria were revised in 2008, applying different standards to CSF and non-CSF specimens. Based on this revision, JANIS has divided data into CSF and non-CSF specimens since 2015. The number of specimens is around 100 (59 in 2023), therefore assessment of the resistance rate should be done with caution.

[¶] The National Action Plan on AMR [1] indicates that the respective proportion of carbapenem-resistant *Escherichia coli* and *Klebsiella pneumoniae* were at 0.1% and 0.2% in 2014, and the proportions should be maintained at the same level in 2020.

Human-related indices for the Action Plan (2023-2027): proportion (%) of specified antimicrobial-resistant bacteria*¹

	2020	2021	2022	2023	2024	2027 (target value [†])
Number of vancomycin-resistant <i>enterococci</i> infections	136	124	133	115	-	80 or less (maintained 2019 level)
Proportion of methicillin resistant <i>Staphylococcus aureus</i> (blood)* ²	35.9	35.1	33.9	32.5	32.7	20% or less
Proportion of fluoroquinolone resistant in <i>Escherichia coli</i> (urine)* ³	35.4	34.6	34.0	32.8	32.9	30% or less (maintained)
Proportion of carbapenem (meropenem) resistant <i>Pseudomonas aeruginosa</i> (blood)* ²	7.1	7.0	6.3	5.0	4.6	3% or less
Proportion of carbapenem (meropenem) resistant <i>Escherichia coli</i>	0.1	0.1	0.1	0.1	0.1	0.2% or less [§]
Proportion of carbapenem (meropenem) resistant <i>Klebsiella pneumoniae</i>	0.4	0.4	0.4	0.3	0.3	0.2% or less [§]

*1 Compiled from JANIS data (partly cited from AMED Research on Enhancing Surveillance of Antimicrobial Resistance and Promotion of Comprehensive Countermeasures against Antimicrobial Resistance) and from National Epidemiological Surveillance of Infectious Diseases.

[†]Target values are taken from AMR Action Plan Reference 7. Comparison to 2020.

²Bloodstream infections contribute significantly to the disease burden, and with the intent of excluding the effects of bacterial carriage, blood samples are taken.

³Urine specimens are used to target urinary tract infections in outpatient settings where drug-resistant bacteria are directly related to treatment.

[§] The AMR Action Plan (Ref. 1) states that the carbapenem resistance rates for *E. coli* and *Klebsiella pneumoniae* in 2014 were 0.1% and 0.2%, and that the resistance rates in 2020 will be maintained at the same level.

Human-related indices for the Action Plan (2016-2020): use of antimicrobials (DID) [†] (based on volume of sales)

	2013	2014	2015	2016	2017	2018	2019	2020	Change from 2013	2020 (Target*)
All antimicrobials	14.52	14.08	14.23	14.15	13.36	12.91	12.75	10.18	29.9% ↓	33% ↓
Oral cephalosporins	3.91	3.78	3.82	3.68	3.43	3.19	3.02	2.24	42.7% ↓	50% ↓
Oral fluoroquinolones	2.83	2.83	2.71	2.75	2.57	2.42	2.32	1.66	41.4% ↓	50% ↓
Oral macrolides	4.83	4.5	4.59	4.56	4.18	3.96	3.84	2.93	39.4% ↓	50% ↓
Intravenous antimicrobials	0.9	0.9	0.94	0.96	0.98	0.99	1.01	0.87	3.3% ↓	20% ↓

DID: Defined daily dose per 1,000 inhabitants per day

*Target values were quoted from [1].

[†] Prepared from [2] and [3].

Human-related indices for the Action Plan (2024-2027): use of antimicrobials (DID) [†] (based on volume of sales)

	2020	2021	2022	2023	2024	Change from 2020	2027 (Target*)
All antimicrobials	10.18	9.77	9.78	11.96	12.96	27.3% ↑	15% ↓
Oral third generation cephalosporins	1.85	1.70	1.63	1.94	1.81	2.5% ↓	40% ↓
Oral fluoroquinolones	1.66	1.48	1.52	2.07	2.42	46.2% ↑	30% ↓
Oral macrolides	2.93	2.72	2.66	3.45	3.95	35.1% ↑	25% ↓
Intravenous antimicrobials	0.07	0.07	0.07	0.06	0.06	9.0% ↓	20% ↓

DID: Defined daily dose per 1,000 inhabitants per day

*Target values were quoted from [7].

[†] Prepared from [2] and [3].

Animal-related indices for the Action Plan (2016-2020): proportion (%) of specified antimicrobial-resistant bacteria

		2014*	2015*	2016	2017	2018	2019	2020	2021	2020 (target value**)
Proportion of tetracycline-resistant <i>Escherichia coli</i> ****	(farms)	45.2	39.9							33% or lower
	(Animal slaughterhouses)		39.8	47.6	40.8	43.6	44.3	45.0	40.7	
Proportion of third generation cephalosporin-resistant <i>Escherichia coli</i> ****	(farms)	1.5	0.9							The same level as in other G7 nations***
	(Animal slaughterhouses)		0.7	2.4	2.1	1.1	2.1	1.4	1.4	
Proportion of fluoroquinolone-resistant <i>Escherichia coli</i> ****	(farms)	4.7	3.8							The same level as in other G7 nations
	(Animal slaughterhouses)		2.7	5.0	4.0	4.7	5.1	5.2	4.2	

* Prepared from [4] with partial modification. JVARM “Results of Monitoring of Antimicrobial Resistant Bacteria Isolated from Livestock Animals on Farms”

** Target values for 2020 were quoted from [1].

*** See [5] and [6].

**** MICs greater than 16 µg/mL for tetracyclines, 4 µg/mL for third generation cephalosporins, and 4 µg/mL for fluoroquinolones are considered resistant.

Animal-related indices for the Action Plan (2023-2027): proportion (%) of specified antimicrobial-resistant bacteria

		2020	2021	2022	2023	2027 (Target [§])
Proportion of tetracycline-resistant <i>Escherichia coli</i> *	Cattle	19.8	23.8	23.4	20.0	Cattle 20% or less Swine 50% or less Chicken 45% or less
	Swine	62.4	52.0	55.1	56.3	
	Chicken	52.9	46.2	43.0	53.5	
Proportion of third generation cephalosporin-resistant <i>Escherichia coli</i> *	Cattle	0.0	0.0	0.0	1.0	Cattle 1% or less Swine 1% or less Chicken 5% or less
	Swine	0.0	2.0	0.7	0.0	
	Chicken	4.1	2.1	0.7	3.9	
Proportion of fluoroquinolone-resistant <i>Escherichia coli</i> *	Cattle	0.4	0.0	1.0	0.5	Cattle 1% or less Swine 2% or less Chicken 15% or less
	Swine	1.1	2.0	3.7	0.7	
	Chicken	18.2	14.5	14.8	16.1	

[§]Target values for 2027 were quoted from [7].

*MICs greater than 16 µg/mL for tetracyclines, 4 µg/mL for third generation cephalosporins, and 1 µg/mL for fluoroquinolones are considered resistant.

Animal-related indices for the Action Plan (2023-2027): use of antimicrobials (t) (based on volume of sales)

	2020	2021	2022	2023	2027 (Target [†]) (Change from 2020)
Total use of veterinary antimicrobials in the livestock sector	626.8	598.1 (4.6% ↓)	568.0 (9.4% ↓)	559.4 (10.8% ↓)	15% ↓
Total use of second-line [※] veterinary antimicrobials in the livestock sector	26.7 t	27.6	27.0	23.5	Maintain below 27 t

[†] Target values for 2027 were quoted from [7].

※Third generation cephalosporins, 15-membered ring macrolides (tulathromycin, gamithromycin), fluoroquinolones, colistin

References

1. Ministerial Conference for the Control of Globally Threatening Infectious Diseases. “The National Action Plan on AMR 2016-2020.” 2016.
2. Muraki Y, *et al.* “Japanese antimicrobial consumption surveillance: first report on oral and parenteral antimicrobial consumption in Japan (2009–2013)” *J Glob Antimicrob Resist.* 2016 Aug 6; 7:19-23.
3. AMR Clinical Reference Center Japan Surveillance of Antimicrobial Consumption (JSAC): <https://amrrcc.ncgm.go.jp/surveillance/index.html>
4. National Veterinary Assay Laboratory, Ministry of Agriculture, Forestry and Fisheries. “Monitoring of AMR.” https://www.maff.go.jp/nval/yakuzai/yakuzai_p3.html
5. NARMS : <https://www.fda.gov/animal-veterinary/national-antimicrobial-resistance-monitoring-system/narms-now-integrated-data>
6. EFSA : <https://www.efsa.europa.eu/en>
7. Ministerial Conference on Measures for Strengthening Preparedness and Response to Internationally Threatening Infectious Diseases “AMR Action Plan (2023-2027)” 2023.

6. Current Status of Antimicrobial-resistant Bacteria in Japan

(1) Humans

1) Gram-negative bacteria

Source: JANIS

As for the recent status of gram-negative bacteria, despite recent global increase of carbapenem (imipenem (IPM) and meropenem (MEPM))-resistant *Enterobacteriales* such as *Escherichia coli* and *Klebsiella pneumoniae*, the proportion of carbapenem-resistant *Escherichia coli* and *Klebsiella pneumoniae* in Japan remained low at less than 1%, as in Tables 1 and 2.

The resistance rate of *E. coli* to third-generation cephalosporins, including cefotaxime (CTX), which had shown an increasing trend up to 2020, declined slightly for the first time in 2021 and remained stable or decreased in 2022; however, it has demonstrated an upward trend again since 2023. The resistance rate to fluoroquinolones, including levofloxacin (LVFX), has been declining since 2021. The rise in the rate of resistance to third generation cephalosporins would appear to reflect the increase in bacteria with ESBL genes. As such, there appears to be a particular need for measures targeted at the rise of these resistant bacteria. On the other hand, third generation cephalosporin-resistant *K. pneumoniae* continues to increase and behaves differently from third generation cephalosporin-resistant *E.coli*. Both species should continue to be monitored closely for future trend.

The proportion of carbapenem-resistant *Enterobacter cloacae* (Table 3) and *Klebsiella (Enterobacter) aerogenes* (Table 4) remained between around 1% and 2%; and the proportion of carbapenem-resistant *Pseudomonas aeruginosa* (Table 5) and *Acinetobacter* spp. (Table 6) remained at a level equivalent to or even lower than in other countries. In particular, the proportion of carbapenem-resistant *Acinetobacter* spp. remained low between around 1% and 3%.

i. Escherichia coli

Table 1. Resistance rates (%) of *Escherichia coli*

	BP (2014-)	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
ABPC	32	50.5 (257,065)	51.2 (288,052)	51.7 (307,143)	52.2 (325,553)	52.6 (336,351)	51.9 (337,433)	50.4 (340,248)	49.9 (358,902)	50.8 (390,307)	51.7 (409,378)
PIPC	128	44.1 (270,452)	44.9 (305,604)	45.2 (327,773)	46.0 (342,066)	46.4 (343,183)	45.6 (339,444)	44.0 (338,450)	43.5 (352,001)	44.7 (383,984)	46.1 (391,714)
TAZ/ PIPC	4/128	1.7 (179,722)	1.8 (218,008)	1.7 (241,519)	1.7 (263,131)	3.2 (285,685)	2.8 (290,567)	2.6 (303,907)	2.6 (326,287)	3.0 (366,049)	3.3 (391,125)
CEZ*	8	35.8 (268,898)	36.8 (303,608)	37.3 (324,109)	38.7 (347,491)	39.0 (361,167)	38.7 (360,415)	37.4 (363,330)	37.2 (379,774)	37.7 (419,588)	38.8 (440,960)
CMZ	64	0.9 (260,844)	1.0 (300,089)	0.9 (325,296)	0.9 (348,832)	0.9 (365,259)	0.8 (372,259)	0.8 (376,435)	0.7 (398,172)	0.8 (440,165)	0.8 (459,895)
CTX*	4	24.5 (209,404)	26.0 (230,911)	26.8 (241,843)	27.5 (251,068)	28.3 (257,856)	28.3 (257,134)	26.8 (251,869)	26.8 (258,317)	27.0 (266,719)	27.8 (266,530)
CTRX	4	-	-	-	-	-	-	-	-	30.0 (339,842)	31.5 (367,964)
CAZ*	16	10.8 (275,671)	11.6 (310,281)	12.0 (330,029)	12.4 (352,819)	14.0 (367,538)	13.9 (369,898)	13.0 (372,255)	12.8 (390,324)	13.4 (426,145)	14.2 (442,886)
CFPM	32	15.0 (236,705)	15.8 (273,587)	16.1 (296,143)	16.7 (321,745)	18.1 (337,526)	17.5 (341,664)	16.8 (344,555)	16.2 (362,758)	15.6 (403,673)	15.9 (430,563)
AZT*	16	17.6 (216,494)	18.4 (239,952)	18.7 (258,193)	19.3 (273,064)	21.0 (283,965)	20.4 (284,169)	19.2 (286,755)	19.1 (301,651)	19.3 (322,701)	19.9 (333,604)
IPM*	4	0.1 (251,050)	0.1 (284,316)	0.1 (304,633)	0.1 (321,043)	0.1 (328,665)	0.1 (328,031)	0.1 (330,003)	0.04 (342,379)	0.1 (361,944)	0.1 (368,437)
MEPM*	4	0.2 (269,893)	0.2 (317,987)	0.1 (340,687)	0.1 (365,600)	0.1 (379,637)	0.1 (383,513)	0.1 (387,094)	0.1 (407,162)	0.1 (449,222)	0.1 (468,774)
AMK	64	0.1 (281,641)	0.1 (317,913)	0.1 (339,871)	0.1 (362,591)	0.1 (374,518)	0.1 (378,104)	0.1 (380,774)	0.1 (400,312)	0.1 (438,273)	0.1 (457,400)
LVFX	8	38.0 (274,687)	39.3 (310,705)	40.1 (336,310)	40.9 (360,329)	41.4 (374,719)	41.5 (379,538)	40.4 (381,447)	39.6 (398,196)	38.7 (439,872)	38.1 (459,467)

The unit of BP is µg/mL. Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility. Data for ST were not calculated.

-: Not under surveillance

* CLSI (2012) (M100-S22) Criteria was applied to determine BP after 2014.

ii. *Klebsiella pneumoniae*

Table 2. Resistance rates (%) of *Klebsiella pneumoniae*

	BP (2014-)	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
ABPC	32	76.9 (131,700)	76.3 (147,500)	77.4 (152,477)	79.4 (158,654)	80.1 (159,790)	79.7 (157,459)	77.7 (160,188)	77.5 (174,552)	80.5 (199,842)	80.8 (215,228)
PIPC	128	21.1 (136,347)	21.8 (154,260)	21.8 (161,254)	22.9 (165,430)	24.5 (161,590)	25.1 (156,799)	26.7 (158,472)	27.6 (169,964)	30.2 (195,028)	30.9 (204,428)
TAZ/ PIPC	4/128	2.0 (91,503)	2.2 (110,189)	2.2 (118,796)	2.6 (127,778)	3.1 (135,732)	3.2 (136,696)	3.6 (145,033)	3.6 (160,489)	4.1 (187,961)	4.5 (205,598)
CEZ*	8	12.1 (135,486)	13.1 (152,973)	13.4 (157,849)	14.3 (166,906)	15.2 (170,001)	16.5 (166,842)	18.2 (170,103)	18.8 (183,757)	20.8 (213,723)	22.2 (230,809)
CMZ	64	1.9 (132,163)	1.7 (152,086)	1.5 (159,375)	1.6 (168,787)	1.5 (172,912)	1.5 (173,615)	1.5 (177,579)	1.4 (193,632)	1.5 (225,278)	1.4 (241,361)
CTX*	4	8.0 (107,409)	8.9 (118,057)	8.9 (119,672)	9.4 (122,459)	9.7 (122,241)	11.0 (119,269)	11.7 (117,676)	12.6 (124,914)	13.7 (135,436)	14.9 (138,565)
CTRX	4	-	-	-	-	-	-	-	-	17.2 (174,183)	18.7 (193,771)
CAZ*	16	4.0 (138,191)	4.6 (155,293)	5.0 (160,619)	5.7 (169,097)	6.9 (173,031)	8.6 (171,425)	9.5 (174,262)	10.3 (189,618)	11.7 (218,048)	12.7 (232,210)
CFPM	32	4.0 (119,563)	4.8 (138,737)	5.1 (145,745)	5.8 (156,485)	6.8 (160,502)	7.7 (160,138)	8.5 (163,139)	9.1 (177,866)	9.7 (207,945)	10.4 (226,964)
AZT*	16	5.3 (110,259)	5.9 (122,600)	6.2 (127,491)	6.7 (133,009)	8.0 (135,631)	9.1 (133,016)	10.2 (134,988)	11.0 (146,557)	12.5 (165,483)	13.5 (175,432)
IPM*	4	0.3 (126,997)	0.2 (143,813)	0.2 (149,546)	0.3 (154,879)	0.2 (155,242)	0.2 (151,882)	0.2 (154,691)	0.1 (165,377)	0.2 (183,217)	0.2 (191,649)
MEPM*	4	0.6 (135,930)	0.5 (159,623)	0.4 (166,298)	0.5 (175,408)	0.4 (179,042)	0.4 (178,240)	0.4 (182,018)	0.4 (197,801)	0.3 (229,357)	0.3 (245,546)
AMK	64	0.1 (141,710)	0.1 (159,871)	0.1 (166,081)	0.1 (174,259)	0.1 (176,609)	0.1 (175,742)	0.1 (179,422)	0.1 (194,640)	0.1 (224,579)	0.1 (240,340)
LVFX	8	2.6 (138,428)	2.7 (156,249)	2.8 (163,688)	3.1 (172,010)	3.4 (175,799)	4.2 (175,200)	4.6 (178,138)	5.2 (192,244)	5.7 (223,973)	6.1 (239,705)

The unit of BP is µg/mL.

Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.-: Not under surveillance

* CLSI (2007) (M100-S17) Criteria was applied to determine the BP up to 2013. CLSI (2012) (M100-S22) Criteria was applied to determine BP.

iii. *Enterobacter* spp.

Table 3. Resistance rates (%) of *Enterobacter cloacae*

	BP (2014-)	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
ABPC	32	80.2 (55,960)	79.3 (61,667)	79.8 (61,970)	81.2 (64,820)	81.3 (64,723)	81.4 (62,954)	80.4 (62,121)	82.0 (66,059)	82.9 (74,127)	83.0 (77,735)
PIPC	128	19.8 (58,039)	20.1 (63,580)	20.8 (64,217)	21.2 (66,020)	21.7 (62,798)	21.6 (60,369)	21.3 (58,758)	21.7 (61,527)	22.3 (67,672)	22.5 (69,485)
TAZ/ PIPC	4/128	8.9 (40,315)	8.9 (47,390)	9.4 (48,775)	9.8 (52,186)	10.5 (54,305)	10.3 (54,675)	10.1 (56,350)	10.6 (59,998)	10.8 (68,787)	10.7 (73,502)
CEZ*	8	98.3 (58,637)	98.3 (64,634)	98.3 (64,693)	98.3 (68,017)	98.2 (68,074)	98.2 (67,036)	98.2 (66,201)	98.3 (69,693)	98.2 (78,367)	98.4 (81,923)
CMZ**	64	85.4 (56,647)	85.5 (63,331)	86.1 (64,158)	88.0 (68,013)	87.4 (68,727)	88.1 (68,183)	87.9 (67,430)	88.1 (71,629)	87.6 (80,859)	87.7 (84,331)
CTX*	4	31.6 (46,727)	31.2 (50,311)	32.4 (50,022)	32.9 (51,470)	33.7 (50,606)	34.0 (49,402)	34.1 (47,591)	34.9 (48,848)	35.0 (51,214)	35.6 (51,084)
CTRX	4	-	-	-	-	-	-	-	-	35.8 (63,311)	35.9 (68,400)
CAZ*	16	25.0 (59,533)	24.9 (65,317)	25.8 (65,027)	26.3 (68,737)	26.8 (69,265)	27.4 (67,922)	27.7 (67,174)	28.5 (71,014)	29.0 (79,151)	29.3 (82,325)
CFPM	32	4.2 (52,218)	4.0 (58,298)	4.0 (59,398)	3.9 (64,337)	4.0 (65,211)	3.7 (65,110)	3.5 (64,286)	3.6 (67,964)	3.3 (76,726)	3.1 (81,634)
AZT*	16	24.0 (48,570)	23.9 (52,951)	24.3 (53,374)	24.9 (55,988)	26.1 (56,211)	26.3 (55,380)	26.5 (54,810)	27.4 (58,130)	27.6 (64,318)	27.7 (66,434)
IPM*	4	1.3 (54,926)	1.2 (60,602)	1.1 (60,689)	1.1 (63,611)	1.2 (61,918)	1.0 (61,234)	0.9 (59,721)	0.9 (62,027)	0.8 (66,680)	0.9 (68,128)
MEPM*	4	1.4 (59,009)	1.2 (67,250)	1.1 (67,392)	1.1 (71,119)	0.9 (71,548)	1.0 (70,910)	0.8 (70,077)	0.7 (74,210)	0.6 (83,317)	0.7 (86,989)
AMK	64	0.2 (61,086)	0.1 (67,133)	0.1 (67,125)	0.1 (70,659)	0.1 (70,392)	0.1 (69,812)	0.1 (68,955)	0.1 (73,178)	0.1 (81,661)	0.1 (84,925)
LVFX	8	3.7 (59,393)	3.4 (65,161)	3.5 (65,690)	3.2 (69,392)	3.1 (70,034)	2.9 (69,816)	2.6 (68,752)	2.5 (71,907)	2.3 (80,646)	2.2 (84,504)

The unit of BP is µg/mL. Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.

-: Not under surveillance

* CLSI (2007) (M100-S17) Criteria was applied to determine the BP up to 2013. CLSI (2012) (M100-S22) Criteria was applied to determine BP.

Table 4. Resistance rates (%) of *Klebsiella (Enterobacter)* aerogenes*

	BP (2014-)	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
ABPC	32	78.9 (26,680)	77.9 (29,228)	79.1 (30,844)	80.3 (32,746)	80.5 (33,621)	80.8 (33,862)	79.6 (35,315)	81.0 (38,564)	82.3 (42,088)	82.3 (44,252)
PIPC	128	14.2 (27,189)	15.8 (29,852)	17.1 (31,802)	17.4 (33,048)	18.9 (32,497)	18.6 (32,139)	17.5 (32,962)	17.5 (35,871)	18.4 (38,643)	18.5 (39,626)
TAZ/PIPC	4/128	4.8 (18,731)	4.8 (21,767)	5.7 (24,082)	6.9 (26,272)	6.9 (28,085)	7.2 (29,124)	7.0 (30,954)	7.4 (34,399)	7.6 (38,718)	7.6 (41,434)
CEZ**	8	93.7 (27,526)	94.2 (30,088)	94.5 (31,800)	95.0 (33,996)	94.7 (35,183)	95.1 (35,448)	95.0 (36,851)	94.8 (40,246)	94.8 (44,354)	94.6 (46,364)
CMZ	64	86.8 (26,739)	87.1 (29,681)	88.0 (31,915)	89.1 (34,051)	89.5 (35,408)	89.9 (36,068)	90.0 (37,881)	89.7 (41,502)	89.8 (45,944)	90.0 (47,827)
CTX**	4	30.7 (21,985)	31.1 (23,572)	32.9 (24,195)	33.4 (25,493)	34.2 (26,271)	35.4 (26,655)	35.2 (27,111)	35.9 (28,608)	37.5 (29,469)	37.3 (29,307)
CTRX	4	-	-	-	-	-	-	-	-	37.5 (35,448)	37.5 (38,707)
CAZ**	16	25.2 (27,886)	25.7 (30,388)	26.7 (32,030)	27.8 (34,142)	28.5 (35,487)	29.6 (35,985)	29.7 (37,638)	30.1 (41,161)	31.2 (45,029)	31.5 (46,855)
CFPM	32	1.1 (24,302)	1.1 (27,146)	1.3 (29,464)	1.4 (32,216)	1.5 (33,583)	1.4 (34,454)	1.5 (36,047)	1.6 (39,114)	1.5 (43,437)	1.6 (46,178)
AZT**	16	17.5 (23,225)	17.5 (25,023)	18.0 (26,772)	19.2 (28,281)	20.2 (29,397)	20.8 (30,056)	20.4 (31,103)	20.8 (34,014)	21.4 (36,517)	21.3 (38,228)
IPM**	4	1.9 (25,690)	1.9 (28,307)	1.9 (29,869)	2.6 (31,288)	2.3 (31,645)	2.2 (32,050)	1.7 (33,173)	1.3 (35,870)	1.4 (38,094)	1.4 (38,578)
MEPM**	4	0.8 (27,560)	0.8 (31,311)	0.8 (33,150)	0.8 (35,448)	0.8 (36,550)	0.9 (37,291)	0.9 (38,989)	0.9 (42,475)	0.7 (46,742)	0.8 (48,990)
AMK	64	0.1 (28,627)	0.1 (31,338)	0.1 (33,074)	0.1 (35,214)	0.1 (36,204)	0.05 (36,866)	0.05 (38,542)	0.04 (41,981)	0.04 (45,882)	0.1 (47,808)
LVFX	8	0.9 (28,012)	1.0 (30,451)	0.9 (32,503)	0.9 (34,383)	0.9 (35,735)	0.9 (36,768)	1.0 (38,092)	0.9 (41,329)	0.9 (45,227)	0.8 (47,491)

The unit of BP is µg/mL.

Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.

-: Not under surveillance

**Enterobacter aerogenes* has been renamed *Klebsiella aerogenes* (Int. J. Syst. Evol. Microbiol. 67, 502-504, 2017).

** CLSI (2007) (M100-S17) Criteria was applied to determine the BP up to 2013. CLSI (2012) (M100-S22) Criteria was applied to determine BP.

iv. *Pseudomonas aeruginosa*

Table 5. Resistance rates (%) of *Pseudomonas aeruginosa*

	BP (2014-)	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
PIPC	128	10.5 (181,977)	10.5 (201,764)	10.3 (205,165)	10.0 (206,858)	10.3 (214,513)	10.0 (211,455)	9.8 (214,729)	9.7 (223,807)	9.8 (252,866)	9.7 (265,617)
TAZ/ PIPC	4/128	8.8 (132,769)	8.4 (155,724)	8.3 (165,402)	8.1 (172,748)	8.4 (185,720)	7.8 (185,847)	7.8 (191,294)	7.8 (201,973)	8.0 (230,183)	7.9 (246,536)
CAZ	32	8.6 (180,479)	8.7 (199,597)	8.6 (202,025)	8.4 (203,554)	8.7 (210,892)	8.6 (207,738)	8.7 (211,983)	8.7 (221,033)	8.8 (246,519)	8.5 (259,223)
CFPM	32	6.6 (166,096)	6.5 (185,283)	6.3 (191,502)	6.0 (194,385)	5.9 (200,818)	5.7 (198,849)	5.5 (202,904)	5.3 (212,498)	5.0 (238,636)	4.9 (254,434)
AZT	32	14.0 (146,841)	13.8 (158,737)	13.7 (162,952)	13.1 (162,365)	13.3 (167,331)	13.6 (164,518)	13.4 (166,971)	13.0 (176,832)	12.3 (193,248)	11.8 (202,045)
IPM*	8	18.8 (168,471)	17.9 (186,380)	16.9 (188,981)	16.2 (188,778)	16.2 (195,183)	15.9 (191,793)	15.8 (194,826)	14.8 (202,639)	13.9 (225,975)	13.2 (237,300)
MEPM*	8	13.1 (180,850)	12.3 (201,991)	11.4 (206,368)	10.9 (209,149)	10.6 (217,161)	10.5 (214,691)	10.3 (218,610)	9.5 (228,253)	8.8 (257,396)	8.3 (272,658)
GM	16	4.5 (165,777)	4.1 (182,343)	3.3 (184,453)	2.9 (184,135)	3.1 (190,296)	3.0 (184,307)	2.8 (184,581)	2.5 (193,104)	2.4 (213,082)	2.4 (224,805)
AMK	64	1.5 (185,327)	1.3 (204,892)	1.1 (208,098)	0.9 (209,413)	0.9 (217,512)	0.8 (214,949)	0.7 (219,053)	0.6 (228,023)	0.6 (255,928)	0.5 (271,060)
LVFX	8	12.0 (174,301)	11.6 (193,366)	10.8 (197,890)	10.2 (199,760)	9.8 (207,963)	9.5 (204,829)	8.9 (207,311)	8.1 (216,226)	7.5 (244,553)	7.2 (260,140)

The unit of BP is µg/mL.

Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.

* CLSI (2007) (M100-S17) Criteria was applied to determine the BP up to 2013. CLSI (2012) (M100-S22) Criteria was applied to determine BP.

v. *Acinetobacter* spp.

Table 6. Resistance rates (%) of *Acinetobacter* spp.

	BP	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
PIPC	128	11.5 (27,887)	10.9 (29,776)	10.9 (27,468)	10.3 (27,905)	10.7 (26,237)	10.2 (23,018)	11.0 (22,399)	10.8 (22,002)	10.9 (24,924)	10.2 (25,195)
TAZ/ PIPC	4/128	8.1 (9,058)	8.6 (10,551)	9.0 (10,983)	9.4 (12,171)	9.0 (12,401)	8.2 (11,478)	9.5 (11,275)	9.0 (11,305)	8.2 (13,590)	8.5 (13,888)
SBT/ ABPC	16/32	4.8 (11,356)	5.4 (12,831)	4.7 (12,241)	4.4 (13,111)	4.3 (12,769)	3.4 (12,047)	3.6 (11,982)	4.3 (11,708)	4.2 (13,338)	3.4 (13,539)
CAZ	32	8.0 (28,166)	7.6 (29,844)	7.9 (27,308)	7.6 (28,077)	8.6 (26,614)	8.4 (23,626)	9.1 (23,064)	9.4 (22,645)	9.9 (25,633)	9.2 (25,593)
CFPM	32	7.2 (25,412)	7.4 (27,386)	7.6 (25,631)	6.8 (26,616)	6.8 (25,224)	7.0 (22,400))	7.2 (22,002)	6.9 (21,702)	6.7 (24,660)	6.1 (25,027)
IPM	16	3.2 (13,942)	3.1 (15,147)	2.5 (14,383)	2.0 (16,995)	1.8 (19,645)	1.1 (21,381))	1.1 (21,243)	1.0 (20,627)	0.9 (22,984)	0.7 (22,978)
MEPM	16	1.8 (28,227)	1.9 (30,489)	1.3 (28,064)	1.5 (29,024)	1.4 (27,418)	1.2 (24,163)	1.2 (23,500)	1.3 (23,196)	1.1 (26,234)	1.0 (26,479)
GM	16	8.5 (25,689)	8.5 (27,313)	8.2 (24,887)	7.8 (25,465)	8.0 (23,925)	7.7 (20,853)	8.6 (20,174)	8.1 (19,819)	7.7 (22,143)	7.8 (22,143)
AMK	64	3.1 (28,568)	2.3 (30,279)	2.3 (27,835)	2.0 (28,437)	2.1 (26,917)	2.0 (23,697)	2.4 (23,217)	2.4 (22,835)	1.6 (26,045)	1.6 (26,045)
LVFX	8	7.7 (27,858)	8.2 (29,702)	8.0 (27,360)	7.0 (28,209)	7.5 (26,898)	7.8 (23,650)	8.7 (22,998)	8.6 (22,546)	8.8 (26,041)	8.3 (26,041)

The unit of BP is µg/mL.

Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.

2) Gram-positive bacteria

Source: JANIS

Looking at the recent status of gram-positive bacteria, methicillin-resistant *Staphylococcus aureus* (MRSA) accounted for approximately 45% of all *S. aureus*. Although the proportion has been declining over the past few years, it remains higher than that seen in other countries. The proportion was higher among medical institutions with fewer than 200 beds than among those with 200 or more (Table 10). In the case of *enterococci*, rising vancomycin (VCM) resistance was a problem in many countries, but as shown in Tables 11 and 12, levels in Japan were comparatively low, at less than 0.05% in the case of *Enterococcus faecalis* and 2.0% in *Enterococcus faecium*. However, also in 2021, the VCM resistance rate among *E. faecium* significantly increased and widespread, nosocomial outbreaks of VCM-resistant *E. faecium* involving multiple facilities have been observed in some regions. Regional changes in resistance rates will need to be kept under close observation. The proportion of penicillin-resistant *Streptococcus pneumoniae* (PRSP) accounted for approximately 50% of all detected pneumococcus in cerebrospinal fluid (CSF) samples, though the figure varies from year to year, because only around 60 CSF samples were tested (Table 13). The proportion of PRSP was low for non-CSF samples at below 1% (Table 14), and below 4% even adding penicillin intermediate resistant bacteria.

i. *Staphylococcus aureus*

Table 7. Resistance rates (%) of total *Staphylococcus aureus**

	BP	2018	2019	2020	2021	2022	2023	2024
PCG	0.25	75.4 (287,805)	75.1 (295,031)	74.3 (281,583)	73.3 (277,317)	72.8 (288,253)	72.7 (303,146)	72.6 (309,086)
MPIPC	4	47.8 (266,047)	47.7 (265,763)	47.5 (243,162)	46.0 (237,103)	45.5 (243,386)	45.2 (250,974)	44.4 (252,258)
CFX	8	46.1 (57,604)	46.0 (64,239)	46.1 (61,811)	45.2 (62,331)	43.6 (65,031)	43.4 (68,107)	43.3 (69,115)
CEZ	32	20.7 (360,772)	19.7 (366,803)	19.3 (339,052)	17.8 (334,737)	16.2 (346,659)	16.5 (373,096)	15.6 (382,127)
GM	16	30.4 (345,964)	28.9 (350,425)	27.5 (325,197)	26.1 (317,744)	25.1 (330,361)	24.0 (347,757)	24.1 (356,400)
EM	8	51.7 (325,918)	51.2 (329,090)	50.5 (302,105)	48.4 (297,317)	46.6 (308,701)	46.7 (328,327)	46.6 (337,183)
CLDM	4	22.0 (340,953)	20.4 (350,136)	18.9 (325,568)	17.3 (319,298)	15.7 (331,565)	15.1 (356,345)	14.6 (366,648)
MINO	16	12.2 (377,507)	10.5 (385,264)	9.7 (360,076)	8.9 (353,680)	8.0 (365,963)	7.2 (396,719)	6.8 (408,847)
VCM	16	0.0 (374,982)	0.0 (382,254)	0.0 (356,747)	0.0 (347,976)	0.0 (358,032)	0.0 (388,557)	0.0 (400,244)
TEIC	32	<0.05 (336,502)	<0.05 (340,855)	<0.05 (314,742)	<0.05 (308,176)	<0.05 (318,317)	<0.05 (335,414)	<0.05 (340,109)
LVFX	4	50.4 (358,941)	51.7 (368,676)	52.3 (344,943)	51.3 (339,292)	51.3 (349,500)	52.3 (378,339)	53.1 (389,604)
LZD	8	<0.05 (286,366)	<0.05 (294,735)	<0.05 (276,069)	<0.05 (268,079)	<0.05 (277,713)	<0.05 (295,523)	<0.05 (305,491)
DAP	2	0.3 (72,401)	0.3 (98,366)	0.3 (108,416)	0.3 (116,811)	0.3 (128,962)	0.2 (142,755)	0.2 (158,398)

The unit of BP is µg/mL.

Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.

*Data collection began in 2018.

Table 8. Resistance rates (%) of Methicillin-susceptible *Staphylococcus aureus* (MSSA)

	BP	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
PCG	0.25	56.2 (119,343)	55.0 (126,394)	53.9 (129,943)	52.9 (135,360)	52.1 (138,818)	51.1 (133,767)	50.7 (135,944)	50.2 (143,105)	50.0 (150,674)	50.5 (155,307)
CEZ	32	0.1 (146,254)	<0.05 (157,917)	<0.05 (161,831)	<0.05 (164,909)	<0.05 (167,084)	<0.05 (155,735)	<0.05 (159,135)	<0.05 (167,376)	<0.05 (179,023)	<0.05 (185,300)
CVA/ AMPC	4/8	0.1 (19,163)	0.1 (21,783)	0.1 (24,713)	0.1 (26,376)	0.1 (25,258)	0.1 (24,967)	0.1 (26,846)	0.1 (28,097)	0.1 (29,323)	0.1 (31,360)
IPM	16	<0.05 (136,878)	<0.05 (146,433)	<0.05 (149,014)	<0.05 (149,454)	<0.05 (150,811)	<0.05 (138,998)	<0.05 (137,863)	<0.05 (141,411)	<0.05 (145,647)	<0.05 (147,246)
EM	8	22.9 (136,763)	23.3 (146,280)	23.5 (148,795)	23.1 (150,809)	22.7 (151,577)	22.6 (139,415)	21.5 (142,251)	20.5 (149,705)	20.3 (158,433)	20.3 (164,113)
CLDM	4	2.8 (136,292)	2.9 (148,439)	2.9 (151,841)	2.7 (155,141)	2.9 (157,700)	3.0 (147,257)	2.9 (150,416)	2.8 (158,285)	2.9 (170,182)	2.9 (176,267)
MINO	16	0.6 (151,493)	0.5 (163,214)	0.6 (167,178)	0.6 (169,953)	0.5 (171,857)	0.6 (161,001)	0.6 (164,230)	0.5 (172,471)	0.6 (186,197)	0.6 (193,380)
LVFX	4	11.6 (144,083)	12.3 (154,868)	13.1 (159,066)	13.8 (161,691)	14.7 (164,665)	15.5 (154,754)	15.9 (158,287)	16.4 (165,426)	17.3 (178,202)	18.4 (184,663)

The unit of BP is µg/mL.

Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.

Table 9. Resistance rates (%) of Methicillin-resistant *Staphylococcus aureus* (MRSA)

	BP (2014-)	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
EM	8	84.1 (149,851)	83.8 (155,587)	82.9 (157,708)	81.7 (159,215)	80.7 (161,613)	79.8 (147,736)	78.6 (140,331)	76.8 (143,415)	76.8 (153,672)	76.9 (156,518)
CLDM	4	56.0 (153,329)	51.6 (160,500)	46.3 (164,301)	41.7 (169,049)	37.9 (175,081)	35.1 (161,937)	33.1 (153,027)	30.2 (156,646)	28.7 (169,312)	27.6 (173,349)
MINO	16	31.7 (173,983)	29.1 (182,306)	27.1 (185,770)	23.7 (189,813)	20.1 (195,422)	18.7 (181,557)	17.7 (172,374)	16.0 (175,443)	14.3 (191,602)	13.4 (196,447)
VCM	16	0.0 (172,083)	0.0 (181,288)	0.0 (185,948)	0.0 (189,853)	0.0 (195,332)	0.0 (181,671)	0.0 (171,879)	0.0 (174,187)	0.0 (190,401)	0.0 (195,077)
TEIC	32	<0.05 (158,233)	<0.05 (165,213)	<0.05 (167,342)	<0.05 (169,651)	<0.05 (173,090)	<0.05 (158,930)	<0.05 (150,589)	<0.05 (153,290)	<0.05 (162,828)	<0.05 (163,581)
LVFX	4	85.2 (164,734)	85.8 (172,494)	86.5 (176,790)	86.8 (179,731)	87.8 (186,442)	88.5 (173,610)	88.9 (164,814)	89.4 (166,997)	90.0 (182,277)	90.7 (187,054)
LZD*	8	0.1 (127,278)	<0.05 (136,468)	<0.05 (139,785)	<0.05 (144,332)	<0.05 (149,340)	<0.05 (137,980)	<0.05 (129,420)	<0.05 (132,000)	<0.05 (141,211)	<0.05 (145,000)
DAP	2	0.9 (16,648)	0.8 (23,217)	0.7 (26,874)	0.5 (35,618)	0.4 (47,835)	0.5 (51,671)	0.5 (53,782)	0.5 (58,616)	0.4 (64,996)	0.3 (71,525)

The unit of BP is µg/mL.

Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.

* CLSI (2007) (M100-S17) Criteria was applied to determine the BP up to 2013. CLSI (2012) (M100-S22) Criteria was applied to determine BP.

Table 10. The proportion of (%) of patients with MRSA among all patients with *Staphylococcus aureus***Table 10-1. All participating medical institutions**

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Number of medical institutions	1,435	1,653	1,795	1,947	2,075	2,167	2,220	2,289	2,752	2,958
Number of patients with MRSA	169,528	177,768	182,619	185,709	192,320	176,848	167,858	168,718	183,743	189,919
Number of patients with <i>S. aureus</i>	349,743	372,787	383,006	391,316	400,094	367,976	360,912	370,067	400,620	415,207
MRSA (%)*	48.5	47.7	47.7	47.5	48.1	48.1	46.5	45.6	45.9	45.7

Table 10-2. Participating medical institutions with 200 or more beds

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Number of medical institutions	1,177	1,269	1,312	1,334	1,357	1,364	1,378	1,386	1,455	1,480
Number of patients with MRSA	157,419	160,060	160,714	159,054	161,159	144,828	135,984	135,670	139,030	139,376
Number of patients with <i>S. aureus</i>	328,540	341,822	344,543	344,156	345,447	312,738	305,116	311,251	320,112	323,417
MRSA (%)*	47.9	46.8	46.6	46.2	46.7	46.3	44.6	43.6	43.4	43.1

Table 10-3. Participating medical institutions with fewer than 200 beds

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Number of medical institutions	258	384	483	613	718	803	842	903	1,297	1,478
Number of patients with MRSA	12,109	17,708	21,905	26,655	31,161	32,020	31,874	33,048	44,713	50,543
Number of patients with <i>S. aureus</i>	21,203	30,965	38,463	47,160	54,647	55,238	55,796	58,816	80,508	91,790
MRSA (%)*	57.1	57.2	57.0	56.5	57.0	58.0	57.1	56.2	55.5	55.1

Those detected in selective media were also included.

* The number of patients with MRSA / The number of patients with *S. aureus*

ii. *Enterococcus* spp.

Table 11. Resistance rates (%) of *Enterococcus faecalis*

	BP	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
PCG	16	1.4 (92,132)	1.1 (98,465)	1.0 (98,478)	0.9 (104,023)	0.9 (107,021)	0.9 (111,226)	0.9 (114,014)	0.8 (117,159)	0.8 (124,597)	0.7 (126,005)
ABPC	16	0.3 (107,733)	0.2 (115,548)	0.2 (116,493)	0.2 (119,014)	0.2 (121,530)	0.2 (123,238)	0.2 (125,752)	0.2 (129,563)	0.2 (138,911)	0.2 (141,482)
EM	8	54.8 (95,409)	54.3 (101,036)	53.8 (101,379)	52.7 (102,496)	51.7 (102,871)	50.2 (103,067)	48.2 (105,505)	46.1 (108,619)	45.8 (118,552)	45.4 (121,310)
MINO	16	49.7 (115,648)	48.9 (123,860)	50.3 (125,728)	50.9 (128,160)	47.2 (130,729)	48.1 (133,174)	50.8 (135,820)	51.9 (139,723)	47.0 (153,581)	47.1 (157,728)
VCM	32	<0.05 (115,100)	<0.05 (124,305)	<0.05 (126,510)	<0.05 (129,545)	<0.05 (132,526)	<0.05 (135,184)	<0.05 (137,887)	<0.05 (142,316)	<0.05 (156,297)	<0.05 (160,728)
TEIC	32	<0.05 (105,403)	<0.05 (112,636)	<0.05 (113,501)	<0.05 (115,397)	<0.05 (117,097)	<0.05 (118,367)	<0.05 (120,564)	<0.05 (124,347)	<0.05 (132,251)	<0.05 (133,930)
LVFX	8	12.5 (109,160)	11.9 (117,297)	11.2 (120,136)	10.4 (122,551)	10.1 (125,836)	9.5 (128,449)	9.0 (131,088)	8.3 (134,507)	8.7 (147,680)	9.0 (151,558)

The unit of BP is µg/mL.

Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.

Table 12. Resistance rates (%) of *Enterococcus faecium*

	BP	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
PCG	16	87.6 (34,752)	88.2 (38,060)	87.8 (39,478)	87.5 (42,178)	87.4 (46,021)	86.9 (49,002)	87.1 (50,976)	87.1 (53,508)	87.4 (57,617)	87.3 (60,722)
ABPC	16	87.6 (41,459)	88.0 (45,069)	87.9 (47,046)	87.6 (49,207)	88.0 (52,929)	87.6 (54,632)	87.9 (56,395)	87.7 (59,105)	88.1 (63,880)	88.2 (67,351)
EM	8	84.5 (37,536)	84.0 (40,509)	83.1 (42,259)	83.0 (43,555)	83.1 (45,992)	83.1 (47,133)	80.0 (49,083)	79.5 (51,391)	81.5 (55,915)	83.0 (59,584)
MINO	16	35.1 (46,351)	34.7 (50,325)	36.2 (52,494)	38.3 (54,540)	33.0 (58,314)	31.7 (60,040)	30.2 (62,137)	31.5 (64,243)	28.8 (70,493)	25.4 (74,635)
VCM	32	0.7 (45,514)	0.9 (49,618)	0.8 (52,127)	0.9 (54,279)	1.5 (58,377)	1.4 (60,412)	2.6 (62,811)	2.6 (65,363)	1.9 (71,747)	2.0 (75,735)
TEIC	32	0.3 (41,905)	0.6 (45,388)	0.4 (47,321)	0.6 (48,991)	1.0 (52,502)	0.8 (54,125)	1.4 (55,948)	1.5 (58,342)	1.2 (63,085)	1.1 (66,513)
LVFX	8	85.8 (42,068)	86.6 (45,834)	86.5 (48,995)	86.7 (51,003)	87.6 (55,293)	86.9 (57,199)	87.2 (59,808)	86.9 (62,209)	86.9 (67,816)	87.6 (71,683)
LZD	8	0.1 (33,382)	0.1 (37,099)	<0.05 (39,584)	0.1 (41,596)	0.1 (44,887)	0.1 (46,611)	0.1 (47,809)	0.1 (49,958)	0.1 (55,010)	<0.05 (59,192)

The unit of BP is µg/mL.

Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.

iii. *Streptococcus pneumoniae*

Table 13. Resistance rates (%) of *Streptococcus pneumoniae* (spinal fluid specimens)

	BP	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
PCG	0.125	40.5 (126)	36.4 (140)	29.1 (117)	38.3 (94)	32.0 (100)	33.3 (57)	59.5 (42)	50.9 (57)	50.8 (59)	38.3 (60)
CTX	2	2.0 (100)	1.0 (105)	2.1 (97)	4.5 (88)	1.2 (85)	4.3 (47)	5.6 (36)	4.1 (49)	13.0 (54)	3.7 (54)
CTRX	2	-	-	-	-	-	-	-	-	11.1 (54)	4.8 (62)
MEPM	1	4.2 (119)	0.7 (134)	5.0 (120)	2.1 (95)	1.0 (99)	6.0 (50)	6.8 (44)	8.9 (56)	18.2 (55)	10.3 (58)
EM	1	84.9 (86)	75.5 (98)	82.4 (91)	75.0 (76)	84.8 (79)	76.7 (43)	86.5 (37)	77.8 (45)	70.8 (48)	76.6 (47)
CLDM	1	62.7 (83)	61.2 (98)	49.5 (91)	43.7 (71)	64.0 (75)	57.1 (42)	52.8 (36)	57.8 (45)	46.7 (45)	48.8 (43)
LVFX	8	0.0 (105)	0.0 (123)	0.9 (111)	2.3 (88)	0.0 (93)	0.0 (50)	0.0 (40)	1.9 (52)	0.0 (52)	2.1 (48)
VCM	2	0.0 (119)	0.0 (134)	0.0 (116)	0.0 (98)	0.0 (96)	0.0 (56)	0.0 (42)	0.0 (56)	0.0 (57)	0.0 (55)

The unit of BP is µg/mL.

Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.

CLSI (2012) (M100-S22) Criteria was applied to determine BP.

Table 14. Resistance rates (other than spinal fluid specimens) (%) of *Streptococcus pneumoniae*

	BP	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
PCG*	4	2.7 (36,475)	2.1 (35,960)	2.1 (34,415)	2.2 (33,483)	2.2 (31,506)	3.5 (16,056)	3.4 (16,526)	3.8 (14,510)	3.7 (17,727)	3.6 (18,414)
CTX	4	1.6 (30,734)	1.4 (29,405)	1.6 (27,773)	1.4 (27,004)	1.4 (26,040)	2.1 (13,140)	2.1 (13,878)	2.4 (12,372)	2.2 (15,330)	2.2 (16,053)
CTRX	4	-	-	-	-	-	-	-	-	2.6 (17,144)	2.2 (17,904)
MEPM	1	5.0 (34,461)	5.7 (34,885)	6.0 (34,011)	6.3 (33,115)	6.4 (31,489)	8.9 (16,152)	8.9 (16,479)	8.8 (14,452)	9.6 (17,827)	8.5 (18,561)
EM	1	85.5 (30,501)	84.4 (30,144)	82.4 (28,097)	81.3 (27,154)	81.5 (26,270)	80.4 (13,529)	80.5 (14,352)	82.0 (12,750)	81.4 (16,206)	80.6 (17,100)
CLDM	1	56.1 (27,555)	54.1 (28,541)	50.5 (27,536)	49.9 (26,459)	50.9 (25,404)	49.5 (13,651)	49.5 (14,047)	50.3 (12,386)	49.8 (15,506)	49.4 (16,390)
LVFX	8	3.5 (35,457)	4.1 (35,431)	4.3 (34,241)	4.4 (33,551)	4.7 (32,057)	6.4 (16,499)	6.0 (16,818)	6.4 (14,805)	6.9 (18,402)	7.6 (19,330)
VCM	2	0.0 (33,530)	0.0 (33,670)	0.0 (32,681)	0.0 (31,741)	0.0 (30,250)	0.0 (15,625)	0.0 (16,176)	0.0 (14,140)	0.0 (17,741)	0.0 (18,634)

The unit of BP is µg/mL.

Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.

* Each figure for PCG represents the sum of resistance (R: 8 µg/mL) and intermediate resistance (I: 4 µg/mL).

CLSI (2012) (M100-S22) Criteria was applied to determine BP.

3) Antimicrobial-resistant bacteria infection

Source: National Epidemiological Surveillance of Infectious Disease (NESID)

The numbers of cases reported under NESID each year through 2023 were publicized as confirmed reported data. Cases reported since 2013 are listed below. The scope of reporting was limited to cases where the isolated bacteria was regarded as the cause of an infectious disease, or cases where it was detected from specimens that normally should be aseptic. Colonization was excluded from the scope of reporting.

Among notifiable diseases (diseases that must be reported to the authorities in all cases), there have been around 80 reports of vancomycin-resistant enterococci (VRE) infection per year since 2017, representing a slight rise from the trend of 50 to 60 reports per year between 2013 and 2016. Since 2017, the number of cases has been increasing and in 2023, 115 cases were reported. No case of vancomycin-resistant *Staphylococcus aureus* (VRSA) infection has been reported since November 5, 2003, when this disease became notifiable. Carbapenem-resistant *Enterobacteriales* (CRE) infection became a notifiable disease on September 19, 2014, with 2,113 cases reported in 2023 and generally ranging from 2,000 to 2,300 cases since 2018. Surveillance for multidrug-resistant *Acinetobacter* (MDRA) infection was started in February 2011, with reporting of cases limited at first to designated sentinel sites. It subsequently became a notifiable disease on September 19, 2014, and reports ranged between 20 and 40 cases per year thereafter, with 15 cases reported in 2023.

Under a March 2017 notification issued by the Director of the Tuberculosis and Infectious Diseases Control Division, Health Service Bureau, MHLW, local public health institutes and other organizations have been using the PCR method to test strains isolated from notified cases of CRE infection for carbapenemase genes and other information. In 2022 results for 1,426 strains were reported. The major carbapenemase gene was detected in 212 (14.9%) isolates. Although IMP form the domestic carbapenemase genes accounted for the majority of isolates (173 strains, 81.6%), their proportion has been declining since 2019, particularly among IMP-positive *Klebsiella pneumoniae* and *Escherichia coli*. In 2023, results were reported for 1,620 isolates, of which 215 (13.3%) carried carbapenemase genes. By genotype, IMP-type isolates showed a decreasing trend, whereas the number of isolates carrying “foreign” carbapenemase genes—namely NDM, KPC, and OXA-48 types—exhibited an increasing trend.

Looking at antimicrobial-resistant infections notified by Japan’s designated sentinel sites (in principle medical institutions that have 300 or more beds, 500 institutions nationwide), both the number of reports of MRSA infections and the number of reports per sentinel site had decreased since 2011, with 15,531 cases (32.36 cases per designated sentinel site) reported in 2023. Multidrug-resistant *Pseudomonas aeruginosa* (MDRP) infections have generally declined since 2013, with 97 cases (0.20 cases per designated sentinel site) reported in 2023. The number of reported cases and the incidence per sentinel site of penicillin-resistant *Streptococcus pneumoniae* (PRSP) infections had been declining since 2011; however, in 2023, the number of reported cases increased to 1,011, corresponding to an incidence of 2.11 per sentinel site.

i. Diseases subject to notifiable disease surveillance

Table 15. Number of cases reported for diseases subject to notifiable disease surveillance (2013-2022)

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
VRE	56	66	61	83	80	80	136	124	133	115
VRSA	0	0	0	0	0	0	0	0	0	0
CRE	314*	1,671	1,573	1,660	2,289	2,333	1,956	2,066	2,015	2,113
MDRA	15*	38	33	28	24	24	10	6	13	15

* Reportable since September 19, 2014.

—: Not under surveillance

ii. Diseases reportable from designated sentinel sites

Table 16. Number of cases reported for diseases reportable from designated sentinel sites (2013-2022)

		2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
PRSP	Total	2,292	2,057	2,017	2,001	1,895	1,754	879	846	698	1,011
	Per site	4.79	4.29	4.21	4.18	3.94	3.65	1.84	1.77	1.46	2.11
MRSA	Total	18,082	17,057	16,338	16,551	16,311	16,241	14,940	14,516	14,694	15,531
	Per site	37.83	35.61	34.11	34.55	33.91	33.84	31.19	30.30	30.68	32.36
MDRA*	Total	4	-	-	-	-	-	-	-	-	-
	Per site	0.01	-	-	-	-	-	-	-	-	-
MDRP	Total	268	217	157	128	121	127	116	118	103	97
	Per site	0.56	0.45	0.33	0.27	0.25	0.26	0.24	0.25	0.22	0.20

* MDRA became reportable under notifiable disease surveillance on September 19, 2014.

—: Not under surveillance

4) Other antimicrobial-resistant bacteria

i. *Campylobacter* spp.

Source: Tokyo Metropolitan Institute of Public Health

Tokyo Metropolitan Institute of Public Health has conducted trend surveillance concerning the proportion of antimicrobial-resistant *Campylobacter* spp. Among the 114 outbreaks of food-borne illness that occurred in Tokyo in 2024, 26 outbreaks (22.8%) were caused by *Campylobacter* spp., being the largest cause of bacterial food-borne illness since 2005.[1] The strains provided for antimicrobial susceptibility tests were *Campylobacter jejuni* and *Campylobacter coli* isolated from sporadic diarrhea patients in Tokyo. Resistance rates for 2013-2023 are shown in the tables. Since the onset of the COVID-19 pandemic, the number of isolates has gradually increased; in 2023, 57 strains of *C. jejuni* and 3 strains of *C. coli* were reported. The resistance rate of *Campylobacter jejuni* (*C. jejuni*) to ciprofloxacin (CPFX) was 61.4%, which has increased as compared to 2022. The resistance rate of erythromycin (EM) was 3.5%, and the resistance rate of CPFX to *Campylobacter coli* was 33.3%. In both cases, the resistance rate has remained largely unchanged, although it has increased or decreased from year to year. However, the number of tested strains was smaller for *Campylobacter coli* and this should be taken into consideration upon interpretation of the result.

Table 17. Resistance rates (%) of *Campylobacter jejuni* * from sporadic diarrhea

(Number of samples)	2014 (125)	2015 (116)	2016 (113)	2017 (115)	2018 (110)	2019 (132)	2020 (86)	2021 (42)	2022 (49)	2023 (57)
EM	0.8	0.9	0.9	1.7	1.8	3.0	0.0	2.4	2.0	3.5
NA	50.4	37.1	53.1	46.1	51.7	54.5	31.4	31.0	53.1	61.4
CPFX	50.4	37.1	52.2	43.5	51.8	54.5	31.4	31.0	53.1	61.4

* Strains isolated from diarrhea cases in Tokyo.

Prepared from [5] with partial modification.

Table 18. Resistance rates (%) of *Campylobacter coli* * from sporadic diarrhea

(Number of samples)	2014 (7)	2015 (8)	2016 (14)	2017 (8)	2018 (8)	2019 (16)	2020 (7)	2021 (3)	2022 (2)	2023 (3)
EM	28.6	0.0	14.3	25.0	62.5	25.0	28.6	33.3	50.0	0.0
NA	57.1	50.0	50.0	62.5	50.0	68.8	57.1	100.0	100.0	33.3
CPFX	57.1	50.0	35.7	62.5	37.5	68.8	57.1	100.0	100.0	33.3

* Strains isolated from diarrhea cases in Tokyo.

Prepared from [5] with partial modification.

ii. Non-typhoidal *Salmonella* spp.

Source: Public Health Institutes

The 21-23 Public Health Institutes across Japan conducted research on the multidrug-resistant status of the 3,999 *Salmonella* spp. that were isolated between 2015 and 2024, using standardized methodology.[2] Table 19 lists the key serotypes of human-derived strains and food-derived strains.

In total, 38.7% of the 2,680 human-derived strains (from symptomatic humans) and 90.2% of the 1,319 food-derived strains indicated resistance to one or more of the 17 antimicrobials used in the study (Tables 20 and 21). Although this investigation was not conducted as a routine national surveillance operation conducted by public research institution, this was nationwide surveillance, and the resistance rates of the strains isolated between 2015 and 2024 are considered to reflect the current status in Japan. In this reporting period (2024), 67 (39.4%) of 170 human-derived strains and 118 (80.8%) of 146 food-derived strains were resistant to one or more agents, which did not differ significantly from the resistance rates of 2,510 human-derived strains (38.7%) and 1,173 food-derived strains (90.2%), which were isolated between 2015-2023. Over the past ten years, including the current period, annual trends indicate a slight decrease in human-derived strains between 2021 and 2022, followed by an increase in 2023-2024. In contrast, food-derived strains have remained largely stable during this period, although a slight decrease was observed in 2024. Forty-nine (1.8%) among 2,680 human-derived strains, and 75 (5.9%) among 1,319 food-derived strains, indicated multidrug resistance to as many as 6 to 13 agents. In addition, resistant strains to meropenem (MEPM) were detected for the first time in human-derived isolates in 2020 (Table 20). This isolated strain was *S. Heidelberg*, a multidrug-resistant strain resistant to eight agents, including MEPM. On the other hand, no MEPM-resistant strains have been detected in food-derived strains to date.

Tables 22 and 23 show antimicrobial resistance in the top two serotypes of food-derived strains (*S. Infantis* and *S. Schwarzengrund*), while Tables 24 to 28 show antimicrobial resistance in the top five serotypes of human-derived strains (*S. Infantis*, *S. Enteritidis*, *S. Thompson*, *S. 4: i:-*, and *S. Saintpaul*). Among food-derived strains, *S. Schwarzengrund* in particular accounted for a higher proportion of isolates in the recent period (2020-2024) than in 2015-2019, but the resistance trends were not significantly different. In human-derived strains, on the other hand, as resistance trends were observed characteristic to each serotype, the resistance rates were compared by stereotype over time and shown.

Three serotypes (*S. Schwarzengrund*, *S. Infantis* and *S. Manhattan*) were found commonly in both the top 10 human-derived and top 5 food-derived serotypes, and the antimicrobial resistance rates of these three serotypes were compared between human- and food-derived strains (Table 29). Clear similarities were observed in overall resistance trends to various antimicrobials, suggesting a strong association between human-derived resistant strains (approximately 40% of *S. Infantis* and the majority of *S. Schwarzengrund* and *S. Manhattan*) and food-derived resistant strains.

In addition to antimicrobial susceptibility tests, strains isolated between 2015 and 2023 (2,510 human-derived strains, 1,173 food-derived strains) that demonstrated resistance to one or more of the agents cefotaxime (CTX), ceftazidime (CAZ), and cefoxitin (CFX) (49 human-derived strains and 54 food-derived strains) underwent testing to detect extended-spectrum β -lactamase (ESBL) and AmpC β -lactamase (AmpC)

producing genes. The CTX-M-1 group was the most common genotype among the ESBL producing genes in human-derived and food-derived strains alike, followed by TEM. CIT was the most common genotype among the AmpC producing genes in human-derived and food-derived strains alike, followed by TEM. These results showed similarities in trends toward the detection of ESBL and AmpC producing genes in both human-derived and food-derived strains, while the CTX-M-9 group (ESBL-producing genes) was detected only in human-derived strains, and the EBC-type (AmpC genes) was detected only in food-derived strains. Strain characteristic detections were also observed.

Furthermore, to conduct detailed phylogenetic analysis between human-derived and food-derived strains, as well as to examine the genetic content of each strain, a total of 1,443 *Salmonella* strains (723 human-derived and 720 food-derived) isolated from 2015 to 2023 at regional public health institutes were subjected to whole genome sequencing using next-generation sequencing technologies in collaboration with the JIHS Antimicrobial Resistance Clinical Reference Center of the National Institute of Infectious Diseases.

Table 19. Serotypes of human- and food-derived non-typhoidal *Salmonella* spp. (2015-2024)

Human-derived strains (n=2,680)	%	Food-derived strains (n=1,319)	%
Enteritidis	14.1	Schwarzengrund	60.5
4:i:-	11.9	Infantis	17.0
Infantis	8.2	Manhattan	6.9
Thompson	8.1	Agona	1.6
Typhimurium	6.2	Heidelberg	1.4
Saintpaul	5.4	Others	12.6
Schwarzengrund	5.5	Total	100.0
Stanley	3.7		
Newport	3.1		
Manhattan	2.0		
Others	29.7		
Total	100.0		

Table 20. Resistance rates of human-derived non-typhoidal *Salmonella* spp. (2015-2024)

	2015 (n=387)	2016 (n=360)	2017 (n=393)	2018 (n=315)	2019 (n=265)	2020 (n=211)	2021 (n=146)	2022 (n=239)	2023 (n=194)	2024 (n=170)	SUM (n=2680)
ABPC	17.3	18.1	16.0	19.4	14.7	14.7	12.3	14.2	19.1	17.7	16.6
GM	0.3	0.6	0.8	0.6	1.5	0.5	0.7	0.4	0.5	1.2	0.7
KM	5.9	11.7	7.4	8.3	6.4	6.2	7.5	4.6	5.2	7.7	7.3
SM	27.4	30.0	26.2	29.2	23.8	25.6	22.6	19.3	22.2	17.7	25.3
TC	32.6	29.2	27.5	25.4	22.6	26.1	21.9	18.4	21.1	21.2	25.6
ST	4.4	6.7	8.1	6.4	3.8	9.0	4.8	2.9	8.3	5.9	6.0
CP	2.3	6.4	5.3	6.0	5.3	5.2	5.5	4.2	6.7	7.7	5.3
CTX	0.3	2.5	3.3	3.2	1.5	1.0	1.4	1.3	1.6	0.6	1.8
CAZ	0.3	2.2	1.8	1.9	0.8	1.0	1.4	0.8	1.0	0.0	1.2
CFX	0.0	1.4	0.5	0.6	0.0	1.0	1.4	0.8	0.5	0.0	0.6
FOM	0.0	0.0	0.3	0.0	0.4	0.5	0.0	0.0	0.0	0.0	0.1
NA	7.0	8.1	8.9	5.7	4.2	5.2	5.5	13.4	17.5	13.5	8.5
CPFEX	0.3	0.8	1.0	0.3	0.4	0.0	0.7	0.8	0.0	0.6	0.5
NFLX	0.0	0.8	0.5	0.0	0.8	0.0	0.0	0.8	0.0	0.6	0.4
AMK	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
IPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0
MEPM	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0
Number resistant to one or more antimicrobials	164	161	147	125	89	83	45	73	82	67	1036
Proportion resistant to one or more antimicrobials	42.4	44.7	37.4	39.7	33.6	39.3	30.8	30.5	42.3	39.4	38.7

Table 21. Resistance rates of food-derived non-typhoidal *Salmonella* spp.* (2015-2024) (%)

	2015 (n=156)	2016 (n=110)	2017 (n=86)	2018 (n=108)	2019 (n=126)	2020 (n=129)	2021 (n=140)	2022 (n=132)	2023 (n=186)	2024 (n=146)	SUM (n=1319)
ABPC	18.0	13.6	11.6	12.0	11.1	12.4	5.0	2.3	6.5	6.9	9.7
GM	0.0	0.9	1.2	0.0	0.0	0.0	0.7	0.0	0.5	0.0	0.3
KM	48.1	47.3	45.4	50.0	57.1	65.9	62.9	59.1	67.7	52.1	56.5
SM	82.7	70.9	69.8	77.8	64.3	70.5	71.4	81.1	69.9	65.1	72.4
TC	85.9	76.4	73.3	78.7	70.6	83.0	80.7	81.8	74.7	72.6	77.9
ST	19.9	16.4	12.8	38.0	25.4	24.8	14.3	22.0	47.3	21.2	25.3
CP	7.1	9.1	2.3	8.3	4.0	7.0	4.3	4.6	5.9	3.4	5.6
CTX	5.1	5.5	7.0	6.5	6.4	4.7	1.4	0.0	3.2	1.4	3.9
CAZ	4.5	6.4	7.0	6.5	4.8	3.9	0.0	0.0	2.7	1.4	3.4
CFX	2.6	3.6	7.0	4.6	5.6	5.4	1.4	0.0	2.2	1.4	3.1
FOM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1
NA	18.6	17.3	14.0	16.7	27.0	23.3	20.0	22.0	15.1	26.0	20.1
CPFX	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.5	0.7	0.2
NFLX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1
AMK	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
IPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MEPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Number resistant to one or more antimicrobials	143	96	77	98	113	124	121	120	166	118	1176
Proportion resistant to one or more	91.7	87.3	89.5	90.7	89.7	96.1	86.4	90.9	89.3	80.8	89.2

Table 22. Resistance rates of food-derived *S. Infantis* (2015-2024) (%)

	2015 (n=65)	2016 (n=33)	2017 (n=19)	2018 (n=27)	2019 (n=24)	2020 (n=8)	2021 (n=20)	2022 (n=10)	2023 (n=13)	2024 (n=5)	SUM (n=224)
ABPC	10.8	12.1	5.3	14.8	8.3	37.5	10.0	0.0	30.8	0.0	12.1
GM	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5
KM	46.2	42.4	15.8	33.3	37.5	62.5	35.0	60.0	23.1	20.0	38.8
SM	81.5	72.7	68.4	85.2	58.3	50.0	60.0	100.0	46.2	80.0	72.8
TC	89.2	81.8	68.4	85.2	58.3	37.5	70.0	100.0	53.8	80.0	77.2
ST	18.5	30.3	0.0	44.4	12.5	0.0	30.0	30.0	38.5	80.0	24.6
CP	3.1	3.0	0.0	0.0	0.0	12.5	5.0	0.0	0.0	0.0	2.2
CTX	4.6	6.1	5.3	11.1	8.3	12.5	0.0	0.0	23.1	0.0	6.7
CAZ	3.1	9.1	5.3	11.1	0.0	12.5	0.0	0.0	15.4	0.0	5.4
CFX	4.6	9.1	5.3	14.8	8.3	25.0	5.0	0.0	23.1	0.0	8.5
FOM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NA	3.1	9.1	0.0	3.7	16.7	0.0	15.0	0.0	0.0	0.0	5.8
CPFX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NFLX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AMK	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
IPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MEPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table 23. Resistance rates of food-derived *S. Schwarzengrund* (2015-2024) (%)

	2015 (n=47)	2016 (n=38)	2017 (n=45)	2018 (n=51)	2019 (n=66)	2020 (n=95)	2021 (n=107)	2022 (n=94)	2023 (n=147)	2024 (n=108)	SUM (n=798)
ABPC	17.0	5.3	0.0	7.8	3.0	5.3	1.9	0.0	2.7	5.6	4.1
GM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KM	85.1	86.8	77.8	80.4	92.4	73.7	72.0	71.3	79.6	61.1	76.1
SM	93.6	79.0	82.2	76.5	74.2	80.0	73.8	80.9	72.1	70.4	76.7
TC	95.7	84.2	80.0	86.3	81.8	93.7	83.2	85.1	78.2	78.7	83.8
ST	36.2	18.4	24.4	56.9	43.9	30.5	12.2	21.3	49.0	25.0	31.8
CP	19.2	10.5	4.4	9.8	6.1	5.3	4.7	6.4	4.8	4.6	6.5
CTX	0.0	0.0	0.0	0.0	0.0	1.1	0.9	0.0	0.7	0.0	0.4
CAZ	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.1
CFX	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.1
FOM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NA	25.5	18.4	6.7	23.5	27.3	20.0	18.7	22.3	13.6	29.6	20.6
CPFX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NFLX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AMK	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
IPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MEPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table 24. Resistance rates of human-derived *S. Infantis* (2015-2024) (%)

	2015 (n=34)	2016 (n=48)	2017 (n=47)	2018 (n=22)	2019 (n=16)	2020 (n=19)	2021 (n=9)	2022 (n=5)	2023 (n=10)	2024 (n=11)	SUM (n=221)
ABPC	0.0	2.1	0.0	9.1	6.3	5.3	0.0	0.0	0.0	0.0	2.3
GM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KM	20.6	14.6	6.4	22.7	12.5	5.3	11.1	0.0	0.0	0.0	11.8
SM	29.4	33.3	19.2	50.0	31.3	26.3	22.2	0.0	10.0	0.0	26.7
TC	47.1	33.3	21.3	54.6	37.5	47.4	22.2	20.0	0.0	0.0	32.6
ST	14.7	14.6	2.1	18.2	0.0	21.1	0.0	0.0	0.0	0.0	9.5
CP	0.0	0.0	0.0	9.1	6.3	5.3	0.0	0.0	0.0	0.0	1.8
CTX	0.0	0.0	0.0	4.6	6.3	5.3	0.0	0.0	0.0	0.0	1.4
CAZ	0.0	0.0	0.0	0.0	0.0	5.3	0.0	0.0	0.0	0.0	0.5
CFX	0.0	2.1	0.0	0.0	0.0	5.3	0.0	0.0	0.0	0.0	0.9
FOM	0.0	0.0	0.0	0.0	6.3	0.0	0.0	0.0	0.0	0.0	0.5
NA	8.8	4.2	8.5	0.0	12.5	5.3	11.1	0.0	0.0	0.0	5.9
CPFX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NFLX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AMK	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
IPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MEPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table 25. Resistance rates of human-derived *S. Enteritidis* (2015-2024) (%)

	2015 (n=39)	2016 (n=41)	2017 (n=47)	2018 (n=43)	2019 (n=37)	2020 (n=35)	2021 (n=20)	2022 (n=47)	2023 (n=43)	2024 (n=26)	SUM (n=378)
ABPC	5.1	19.5	4.3	7.0	5.4	0.0	0.0	23.4	2.3	3.9	7.9
GM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KM	2.6	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5
SM	12.8	12.2	10.6	14.0	5.4	2.9	0.0	23.4	0.0	0.0	9.3
TC	10.3	2.4	4.3	9.3	5.4	2.9	0.0	6.4	0.0	0.0	4.5
ST	5.1	0.0	0.0	0.0	0.0	5.7	0.0	0.0	4.7	0.0	1.6
CP	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3
CTX	0.0	2.4	0.0	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.3
CAZ	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3
CFX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FOM	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NA	10.3	26.8	12.8	25.6	10.8	14.3	15.0	44.7	55.8	23.1	25.1
CPFX	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.0
NFLX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AMK	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
IPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MEPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table 26. Resistance rates of human-derived *S. Saintpaul* (2015-2024) (%)

	2015 (n=27)	2016 (n=26)	2017 (n=41)	2018 (n=10)	2019 (n=8)	2020 (n=12)	2021 (n=7)	2022 (n=4)	2023 (n=2)	2024 (n=7)	SUM (n=144)
ABPC	7.4	7.7	14.6	10.0	0.0	8.3	0.0	0.0	0.0	0.0	8.3
GM	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7
KM	0.0	3.9	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1
SM	3.7	3.9	12.2	0.0	0.0	8.3	0.0	0.0	0.0	0.0	5.6
TC	40.7	15.4	22.0	10.0	12.5	25.0	14.3	25.0	0.0	28.6	22.9
ST	0.0	11.5	17.1	10.0	12.5	8.3	0.0	0.0	0.0	28.6	10.4
CP	3.7	0.0	14.6	0.0	12.5	0.0	0.0	0.0	0.0	0.0	5.6
CTX	0.0	0.0	12.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5
CAZ	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7
CFX	0.0	3.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7
FOM	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7
NA	7.4	3.9	19.5	0.0	0.0	0.0	0.0	25.0	0.0	57.1	11.1
CPFX	3.7	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4
NFLX	3.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AMK	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
IPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MEPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table 27. Resistance rates of human-derived *S. 4*: i:- (2015-2024) (%)

	2015 (n=60)	2016 (n=37)	2017 (n=36)	2018 (n=36)	2019 (n=23)	2020 (n=24)	2021 (n=17)	2022 (n=21)	2023 (n=36)	2024 (n=28)	SUM (n=318)
ABPC	71.7	64.9	77.8	86.1	82.6	79.2	76.5	71.4	66.7	60.7	73.3
GM	1.7	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.9
KM	3.3	5.4	2.8	8.3	4.4	4.2	11.8	0.0	5.6	10.7	5.4
SM	73.3	70.3	80.6	91.7	82.6	70.8	70.6	66.7	69.4	50.0	73.3
TC	85.0	62.2	77.8	80.6	65.2	50.0	76.5	66.7	61.1	50.0	69.5
ST	5.0	10.8	5.6	8.3	8.7	0.0	5.9	9.5	13.9	14.3	8.2
CP	3.3	10.8	8.3	13.9	8.7	4.2	11.8	9.5	13.9	17.9	9.8
CTX	0.0	2.7	2.8	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.9
CAZ	0.0	2.7	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6
CFX	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3
FOM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NA	1.7	2.7	5.6	0.0	0.0	0.0	0.0	0.0	8.3	3.6	2.5
CPFX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NFLX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AMK	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
IPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MEPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table 28. Resistance rates of human-derived *S. Thompson* (2015-2024) (%)

	2015 (n=28)	2016 (n=28)	2017 (n=29)	2018 (n=29)	2019 (n=27)	2020 (n=11)	2021 (n=14)	2022 (n=21)	2023 (n=17)	2024 (n=14)	SUM (n=218)
ABPC	0.0	10.7	0.0	0.0	7.4	0.0	0.0	0.0	0.0	0.0	2.3
GM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KM	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9
SM	7.1	7.1	3.5	6.9	0.0	0.0	7.1	0.0	0.0	0.0	3.7
TC	3.6	7.1	6.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3
ST	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9
CP	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9
CTX	0.0	10.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4
CAZ	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9
CFX	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9
FOM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NA	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.5
CPFX	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9
NFLX	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9
AMK	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
IPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MEPM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table 29. Resistance rates of *S. Infantis*, *S. Schwarzengrund*, and *S. Manhattan* detected in humans and food (2015-2024) (%)

	Infantis		Schwarzengrund		Manhattan	
	Human (n=221)	Food (n=224)	Human (n=148)	Food (n=798)	Human (n=54)	Food (n=91)
ABPC	2.3	12.1	2.7	4.1	1.9	13.2
GM	0.0	0.5	0.7	0.0	0.0	0.0
KM	11.8	38.8	62.8	76.1	0.0	0.0
SM	26.7	72.8	63.5	76.7	90.7	96.7
TC	32.6	77.2	64.9	83.8	87.0	78.0
ST	9.5	24.6	23.0	31.8	0.0	6.6
CP	1.8	2.2	3.4	6.5	0.0	0.0
CTX	1.4	6.7	2.7	0.4	0.0	7.7
CAZ	0.5	5.4	2.0	0.1	0.0	7.7
CFX	0.9	8.5	0.0	0.1	0.0	1.1
FOM	0.5	0.0	0.0	0.0	0.0	0.0
NA	5.9	5.8	15.5	20.6	9.3	18.7
CPFX	0.0	0.0	0.0	0.0	0.0	1.1
NFLX	0.0	0.0	0.0	0.0	0.0	0.0
AMK	0.0	0.0	0.0	0.0	0.0	0.0
IPM	0.0	0.0	0.0	0.0	0.0	0.0
MEPM	0.0	0.0	0.0	0.0	0.0	0.0

iii. *Neisseria gonorrhoeae*

Source: National Institute of Infectious Diseases

The 618, 675, 982, 1,167, and 1,023, 825, 698, 950, 1,134 and 788 *Neisseria gonorrhoeae* strains that were respectively isolated between 2015 and 2024 were tested for antimicrobial susceptibility (based on EUCAST breakpoints; Table 30). Ceftriaxone (CTRX)-resistant strains respectively accounted for 6.2%, 4.3%, 4.3%, 3.5%, 5.4%, 2.7%, 0.7, 1.9%, 1.8% and 0.6% since 2015. Strains assessed as resistant based on the CLSI Criteria (MIC ≥ 0.5 $\mu\text{g/mL}$) accounted for 0.6%, 0.4%, 0.5%, 0.3%, 0.4%, 0%, 0%, 0.1%, 0.1% and 0% since 2015. No spectinomycin (SPCM)-resistant strains were present. On the other hand, the resistance rate of azithromycin (AZM) was 13.0% in 2015 and shifted between 33% and 43.9% from 2016 to 2020, with 11.6%, 18.4%, 34.0% and 19.0% in 2021, 2022, 2023 and 2024, respectively.

The CLSI Criteria do not provide a resistance breakpoint for AZM, but, using the azithromycin (AZM) MIC distribution of strains with the 23S rRNA gene mutation as the basis, strains with a MIC of 2 $\mu\text{g/mL}$ or higher are referred to as “non-wild type.” When we investigated the resistance rate (see Reference (8)), albeit as a reference, we found that, between 2015 and 2024, 3.2%, 4.0%, 4.0%, 6.3%, 7.5%, 7.0%, 6.7, 9.8%, 13.1% of strains, and 10.8% respectively, had a MIC of 2 $\mu\text{g/mL}$ or higher. According to clinical assessments in Japan, strains indicating an AZM MIC of 1 $\mu\text{g/mL}$ or higher can reasonably be regarded as resistant. Under this criterion ($R \geq 1$ $\mu\text{g/mL}$), azithromycin-resistant strains accounted for 11.0%, 9.3%, 11.2%, 15.9%, 14.9%, 14.3%, 11.5%, 18.2%, 34.0% and 19.0% of strains respectively between 2015 and 2024. Among the other three antimicrobials, the proportion of cefixime (CFIX)- resistant strains accounted for approximately 20-40%, and that of CPFEX-resistant strains accounted for approximately 60-80%. Benzylpenicillin (PCG) would not have a therapeutic effect on more than 80% of strains.

Table 30. Resistance rates of *Neisseria gonorrhoeae* (%)

	2015 (618 strains)	2016 (675 strains)	2017 (982 strains)	2018 (1167strains)	2019 (1023strains)	2020 (825 strains)	2021 (698 strains)	2022 (950 strains)	2023 (1134strains)	2024 (788 strains)
PCG*	38.4 (96.6)	36.3 (96.9)	37.8 (99.0)	31.7 (82.5)	35.8 (88.5)	37.1 (98.9)	23.5 (92.7)	22.3 (98.7)	39.8 (99.4)	59.1 (99.2)
CFIX	36.2	43.2	31.0	28.4	33.4	33.1	21.9	25.9	22.2	24.3
CTRX	6.2	4.3	4.3	3.5	5.4	2.7	0.7	1.9	1.8	0.6
SPCM	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AZM	13.0	33.5	42.6	43.9	40.1	40.2	11.6	18.4	34.0	19.0
CPFEX	79.5	78.0	75.8	66.9	64.6	71.2	75.6	83.4	80.4	87.4

The EUCAST (Appendix 8) standards were used for susceptibility and resistance assessment.

* Figures in parentheses indicate the sum of resistance and intermediate resistance.

The EUCAST resistance breakpoints are as follows. CTRX (>0.125 $\mu\text{g/mL}$), SPCM (> 64 $\mu\text{g/mL}$), AZM (>0.5 $\mu\text{g/mL}$), PCG (> 1 $\mu\text{g/mL}$), CFIX (>0.125 $\mu\text{g/mL}$), CPFEX (> 0.06 $\mu\text{g/mL}$)

iv. *Salmonella* Typhi, *Salmonella* Paratyphi A, *Shigella* spp.

Source: National Institute of Infectious Diseases

The 14-46 *Salmonella* Typhi strains that were isolated between 2015 and 2024 were tested for antimicrobial susceptibility (Excluding the year 2021, which is estimated to have been significantly affected by the novel coronavirus pandemic. The same applies to *Salmonella* Paratyphi A and *Shigella* spp.). Ciprofloxacin (CPFX)-non-susceptible strains accounted for 60.7-86.5%, while strains with advanced resistance (MIC $\geq$ 4 μ g/mL) to ciprofloxacin accounted for 5.9-42.9%. During this period, 27 strains of multidrug-resistant *Salmonella* Typhi that indicated resistance to ampicillin (ABPC), chloramphenicol (CP) and sulfamethoxazole-trimethoprim (ST) were isolated, along with 10 strains of cefotaxime (CTX)-resistant *Salmonella* Typhi.

The 4-30 *S. Paratyphi* A strains isolated between 2015 and 2024 were tested for antimicrobial susceptibility. CPFX non-susceptible strains accounted for 76.9-100%. No strains with advanced CPFX or CTX resistance were isolated among the *Salmonella* Paratyphi A.

The 14-156 *Shigella* spp. strains that were isolated between 2015 and 2024 were tested for antimicrobial susceptibility. ST-resistant strains accounted for 71.4-91.9%; CPFX-resistant strains for 7.1-58.3%; and CTX-resistant strains for 0.0-33.0%.

Table 31. Resistance rates of *Salmonella* Typhi (%)

	2015 (32 strains)	2016 (46 strains)	2017 (31 strains)	2018 (34 strains)	2019 (28 strains)	2020 (20 strains)	2021 (3 strains)	2022 (14 strains)	2023 (40 strains)	2024 (37 strains)
ABPC	5.7	2.2	12.9	2.9	10.7	20.0	0.0	14.3	20.0	10.8
CP	5.7	2.2	12.9	5.9	10.7	25.0	0.0	14.3	15.0	10.8
ST	5.7	2.2	12.9	5.9	10.7	25.0	0.0	21.4	20.0	13.5
NA	68.8	63.0	83.9	61.7	57.1	55.0	66.7	57.1	82.5	83.8
CPFX	68.8(12.5*)	63.0(23.9*)	83.9(16.1*)	61.7(5.9*)	60.7(10.7*)	65.0(25.0*)	100.0(0.0*)	64.3 (42.9)	82.5(22.5)	86.5(21.6)
CTX	0.0	0.0	0.0	2.9	3.6	15.0	0.0	0.0	5.0	2.7

*Advanced resistance to fluoroquinolone

Table 32. Resistance rates of *Salmonella* Paratyphi A (%)

	2015 (30 strains)	2016 (20 strains)	2017 (13 strains)	2018 (21 strains)	2019 (16 strains)	2020 (5 strains)	2021 (0 strains)	2022 (10 strains)	2023 (4 strains)	2024 (6 strains)
ABPC	0.0	0.0	0.0	0.0	0.0	0.0	-	10.0	0.0	0.0
CP	0.0	0.0	0.0	0.0	0.0	0.0	-	0.0	0.0	0.0
ST	0.0	0.0	0.0	0.0	0.0	0.0	-	0.0	0.0	0.0
NA	80.0	80.0	76.9	100.0	87.5	100.0	-	70.0	75.0	83.3
CPFX	83.3	83.3	76.9	100.0	87.5	100.0	-	100.0	100.0	83.3
CTX	0.0	0.0	0.0	0.0	0.0	0.0	-	0.0	0.0	0.0

Table 33. Resistance rates of *Shigella* spp. (%)

	2015 (105 strains)	2016 (73 strains)	2017 (91 strains)	2018 (156 strains)	2019 (91 strains)	2020 (74 strains)	2021 (2 strains)	2022 (14 strains)	2023 (32 strains)	2024 (48 strains)
ABPC	21.9	42.5	31.9	19.2	14.3	41.9	50.0	14.3	56.3	58.3
CP	11.4	24.7	26.4	9.0	6.6	4.1	50.0	7.1	34.4	12.5
ST	81.0	80.8	73.6	76.9	76.9	91.9	50.0	71.4	84.4	79.2
NA	63.8	52.1	52.8	45.5	33.0	83.8	50.0	7.1	34.4	56.3
CPFX	45.7	35.6	35.2	21.2	14.3	35.1	0.0	7.1	28.1	58.3
CTX	5.7	16.4	13.2	5.1	3.3	27.0	0.0	0.0	12.5	33.3

5) *Candida auris*

Source: The National Institute of Infectious Diseases

The first case of invasive *Candida auris* bloodstream infection was reported in 2022, and surveillance commenced in December 2023. In addition to collecting bacterial strains through domestic medical institutions, public health centers, and local public health institutes, bacterial strains were also obtained in the form of isolated strains from four domestic private clinical laboratories.

As of August 2025, 146 cases had been confirmed, the majority of which were clade II strains derived from otorrhea. Although a few cases of colonization in the respiratory tract and wound sites were observed, no cases of invasive infections were identified.

However, a clade I strain isolated from otorrhea was confirmed in three cases, suggesting the need for caution regarding future isolation trends.

In terms of drug susceptibility, resistance to fluconazole was observed in slightly less than 24% of cases, and polyene-resistant isolates were observed in 2%; however no resistance was detected to echinocandin antifungal agents.

6) *Mycobacterium tuberculosis*

Source: The Research Institute of Tuberculosis, Japan Anti-tuberculosis Association

Looking at major antituberculosis antibiotics—isoniazid (INH), rifampicin (RFP), and ethambutol (EB)—among patients with culture-positive pulmonary tuberculosis who were newly notified between 2012 and 2022, resistance to INH has been on the rise in recent years, while RFP and EB resistance rates have remained mostly at the same level. Although a rise of up to 1.1 percentage points was seen in streptomycin (SM) resistance in 2017, it has mostly remained at the same level since 2018. The number of newly reported cases with multidrug-resistant tuberculosis that are resistant at least to both INH and RFP remained in the range of approximately 40 to 60 (0.4–0.9%) per year, decreasing to 26 by 2022.

Table 34. Newly Notified Patients with Culture-positive Pulmonary Tuberculosis: Trends in Agent Susceptibility at the Time of Notification

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Culture-positive patients, N	10,035	9,878	9,580	9,016	8,110	6,645	5,902	5,231	5,515	6,423
INH-resistant, n (%) [*]	372 (4.9)	369 (4.8)	383 (4.9)	377 (5.0)	359 (5.4)	297 (5.7)	221 (4.9)	200 (4.9)	254 (5.6)	264 (5.8)
RFP-resistant, n (%) [*]	77 (1.0)	74 (1.0)	80 (1.0)	87 (1.1)	65 (1.0)	60 (1.2)	56 (1.2)	41 (1.0)	52 (1.1)	55 (1.2)
INH & RFP-resistant [†] , n (%) [*]	48 (0.5)	49 (0.6)	52 (0.7)	55 (0.6)	44 (0.7)	46 (0.9)	41 (0.9)	26 (0.6)	35 (0.8)	45 (1.0)
SM-resistant, n (%) [§]	476 (6.3)	461 (6.0)	557 (7.1)	471 (6.3)	428 (6.5)	356 (6.9)	287 (6.4)	272 (6.7)	304 (6.7)	279 (6.3)
EB-resistant, n (%) [¶]	129 (1.7)	100 (1.3)	106 (1.3)	130 (1.7)	126 (1.9)	78 (1.5)	79 (1.9)	59 (1.4)	66 (1.5)	87 (1.9)

#. Up to 2023, the number represented newly registered pulmonary tuberculosis patients with positive results by *Mycobacterium tuberculosis* culture.

In 2024, the number represents the sum of the following: among newly registered pulmonary tuberculosis patients without a history of treatment or with an unknown treatment history, those with positive results by *M. tuberculosis* culture or other tuberculosis-specific tests; and among those with a history of treatment, those with positive results by *M. tuberculosis* culture

* The denominator was defined as the number of patients with recorded INH- and RFP-susceptibility testing results among all culture- positive patients: 8,046 patients in 2011, 8,347 in 2012, 7,701 in 2013, 7,645 in 2014, 7,630 in 2015, 7,732 in 2016, 7,891 in 2017, 7,570 in 2018, 6,658 in 2019, 5,209 in 2020, 4,551 in 2021, 4,086 in 2022, 4,526 in 2023, and 4,514 in 2024.

† INH- and RFP- resistant tuberculosis are referred to as "multidrug-resistant."

§ The proportion appeared here showed the share in patients with INH- and RFP-susceptibility testing results, excluding those who were not tested for SM-susceptibility or those with the unknown test result: 52 patients in 2014, 48 in 2015, 47 in 2016, 51 in 2017, 47 in 2018, 41 in 2019, 38 in 2020, 36 in 2021, 23 in 2022 77 in 2023, and 78 in 2024.

¶ The proportion appeared here showed the share in patients with INH- and RFP-susceptibility testing results, excluding those who were not tested for EB-susceptibility or those with the unknown test result: 13 patients in 2014, 19 in 2015, 17 in 2016, 14 in 2017,

13 in 2018, 8 in 2019, 14 in 2020, 9 in 2021, 11 in 2022, 18 in 2023, and 20 in 2024).

7) *Clostridioides difficile* infection

Clostridioides difficile is a spore-forming gram-positive anaerobic bacillus that colonizes the intestines of about 10% of healthy adults.[3] *C. difficile* infection (CDI) is a major healthcare-associated infection that causes diarrhea at hospitals and long-term care facilities for the elderly. In addition, CDI has been recognized as a cause of diarrhea even in the community.[4]

Existing observational studies in Japan indicate that the CDI incidence rate in Japan is 0.8-4.7 cases per 10,000 patient days, while prevalence is 0.3-5.5 cases per 1,000 admissions.[5] In a multi-institutional prospective study (20 wards at 12 institutions) using toxigenic cultures and nucleic acid amplification tests (NAAT), the CDI incidence rate was 7.4 cases per 10,000 patient days, rising to 22.2 in ICU wards, suggesting that the incidence rate is higher than indicated by existing reports, with a particularly high risk in ICU wards.[6] These comparisons of prevalence rates among hospitals and with other countries should take into account the influence of specimen collection wards, testing methods, definition of relapse, differences in average length of hospital stay, and other factors.

Since 2019, the AMR Clinical Reference Centre (AMRCRC) has been investigating CDI trends through operating the J-SIPHE and preparing annual reports. With regard to the incidence of CDI per 10,000 patient-days, facility-level data (median and interquartile range [IQR]) demonstrated a declining trend over time : in 2019, 1.38 (IQR: 0.56-2.43) in 276 facilities; in 2020, 1.20 (IQR: 0.45-2.13) in 347 facilities; in 2021, 0.96 (IQR: 0.32-1.97) in 470 facilities; in 2022, 0.82 (IQR: 0.14-1.66) in 1,241 facilities; in 2023, 0.72 (IQR: 0.00-1.64) in 1,796 facilities; and in 2024, 0.65(IQR : 0.00-1.52)in 2,422 facilities.

Table 35. Distribution of *Clostridioides difficile* outbreaks in hospitals (outbreaks per 10,000 patient hospital days)

	2019 (n=255)*	2020 (n=347)**	2021 (n=470) **	2022 (n=1,241)**	2023 (n=1,796)**	2024 (n=2,422)**
<i>C. difficile</i> (IQR)	1.38 (0.56-2.43)	1.20 (0.45-2.13)	0.96 (0.32-1.97)	0.82 (0.14-1.66)	0.72 (0.00-1.64)	0.65 (0.00-1.52)

n in the table indicates the number of facilities and the distribution of the number of occurrences per facility (number of occurrences/total number of patients in hospital x 10,000)

*2019 included 253 facilities for toxin testing using immunochromatography, 3 facilities for testing using NAAT, and 20 other facilities.

**2020: Only toxin is confirmed by immunochromatography and judged as CDI when positive, and the test is terminated when negative. 81 facilities in 2020, 65 in 2021, 194 in 2022, 246 in 2023, and 335 in 2024. If the test is negative, the test is terminated. 8 facilities in 2020, 2 in 2021, 5 in 2022, 6 in 2023, and 4 in 2024. Immunochromatography to confirm both GDH and toxin and determine CDI if GDH-positive and toxin-positive; if GDH-positive and toxin-negative, the test is completed without determining CDI. 115 facilities in 2020, 203 in 2021, 500 in 2022, 793 in 2023, and 1,108 in 2024. If both GDH and toxin are confirmed by immunochromatography and both GDH-positive and toxin-positive, the test is determined as CDI; if GDH-positive and toxin-negative, the test is determined for toxin using culture colonies and if both are negative, the test is terminated. 104 facilities in 2020, 110 in 2021, 226 in 2022, 262 in 2023, and 289 in 2024. Immunochromatography confirms both GDH and toxin and determines CDI if GDH positive and toxin positive; if GDH positive and toxin negative, determines toxin by toxin gene test in faces; if negative, test terminated. 36 facilities in 2020, 59 in 2021, 177 in 2022, and 288 in 2023. If the test is negative, the test is terminated. 3 facilities in 2020, 1 in 2021, 29 in 2022, 41 in 2023, and 48 in 2024. Others (other than above): 38 facilities in 2020, 45 in 2021, 136 in 2022, 175 in 2023, and 243 in 2024.

8) Antimicrobial resistance surveillance linked to JANIS

The Japan Antimicrobial Resistant Bacterial Surveillance (JARBS) program, a nationwide surveillance initiative in Japan linked to the Ministry of Health, Labour and Welfare's Nosocomial Infection Surveillance program (JANIS), is being implemented by the Antimicrobial Resistance Research Center of the National Institute of Infectious Diseases with support from Japan Agency for Medical Research and Development (AMED) (<https://jarbs.net/>). In 2019 JARBS initially began collecting primarily gram-negative bacteria with reduced susceptibility to carbapenems and resistance to third-generation cephalosporins (with participation from 196 medical institutions), as well as *Staphylococcus aureus* isolates derived from blood specimens (from 63 hospitals within the National Hospital Organization). Through whole-genome sequencing, the program comprehensively identifies antimicrobial resistance genes and virulence-associated genes and performs high-resolution strain typing. These genomic analysis results of provided isolates are returned to individual institutions, while national trends in antimicrobial-resistant bacteria are monitored at the genomic and genic levels across Japan. Building on the experience of the first phase of JARBS (2019–2020) (Kayama*, Yahara*, Sugawara* et al., 2023, *Nature Communications*; Yano et al., 2024, *Antimicrobial Agents and Chemotherapy*; Hisatsune et al., 2025, *Nature Communications*), the second phase, JARBS-GNR/VRE 2.0, was launched in 2023 with substantial operational enhancements. These improvements include streamlining isolate data entry at participating medical institutions through integration with the JANIS database; implementing a web-based system that enables the upload of isolate data and the download of feedback reports; narrowing the scope of target organisms while establishing a framework to perform whole-genome sequencing of all eligible isolates and to provide rapid feedback of results. As of September 2025, 136 medical institutions are participating. In this report, we present the analysis of 898 Enterobacterales isolates with reduced susceptibility to carbapenems (defined as a MIC of ≥ 0.25 $\mu\text{g/mL}$ for meropenem [MEPM]) that were collected and subjected to whole-genome sequencing in 2023.

Whole-genome sequencing of 898 isolates identified 101 isolates (11%) harboring carbapenemase genes. All 101 isolates carried a single carbapenemase gene. The *bla*_{IMP} gene was the most predominant (85%, 86/101 isolates), particularly *bla*_{IMP-1} (68%, 69/101 isolates), followed by *bla*_{NDM} (9%, 9/101 isolates) and *bla*_{GES} (3%, 3/101 isolates) (Table 36). The major species among the 101 isolates were *K. pneumoniae* (35%, 35/101), *Enterobacter* spp. (34%, 34/101), *E. coli* (12%, 12/101), and *Citrobacter* spp. (8%, 8/101). Among these predominant species, *bla*_{IMP} was the most common carbapenemase gene (*K. pneumoniae*: 89% [31/35]; *Enterobacter* spp.: 88% [30/34]; *E. coli*: 67% [8/12]; *Citrobacter* spp.: 88% [7/8]) (Figure 1). Among the *bla*_{IMP} variants, *bla*_{IMP-1} accounted for 80% (69/86), followed by *bla*_{IMP-6} (17%, 15/86) and *bla*_{IMP-11} (2%, 2/86) (Table 36). Within *Enterobacter* spp. and *Citrobacter* spp., *bla*_{IMP-1} was particularly dominant among *bla*_{IMP}-positive isolates (93% [28/30] and 100% [7/7], respectively), whereas *bla*_{IMP-1} accounted for 77% (24/31) in *K. pneumoniae* and 38% (3/8) in *E. coli*.

Table 36. Breakdown of Carbapenemase genes identified among the 101 isolates

Subtype	<i>bla</i> _{IMP}			<i>bla</i> _{NDM}				<i>bla</i> _{GES}		<i>bla</i> _{KPC}	<i>bla</i> _{IMI}	<i>bla</i> _{OXA}	Total
	1	6	11	5	1	4	69	24	5	2	1	181	
Number of isolates	69	15	2	6	1	1	1	2	1	1	1	1	101
Rate (%)	68	15	2	6	1	1	1	2	1	1	1	1	




Figure 1. Breakdown of Carbapenemase genes by bacterial taxon among the 101 isolates

Next, using these carbapenemase-producing isolates, antimicrobial susceptibility testing was performed for seven new agents (either approved or unapproved in Japan) as well as MEPM. Minimum inhibitory concentrations (MICs) were determined over a wide low-concentration range using a microdilution method with customized frozen plates. Details of the drugs and interpretive criteria are provided in Table 37. Figure 2 shows the susceptibility rates for each drug stratified by the type of β -lactamase (β -lactamase family) encoded by the carbapenemase gene. Across all six β -lactamase types, the isolates showed high susceptibility rates to four agents—CFDC, CFPM/NAC, AZT/NAC, and AZT/AVI—with susceptibility rates of $\geq 78\%$. Among the 86 isolates carrying *bla*_{IMP}, which is the predominant carbapenemase gene detected in Japan, susceptibility rates of $\geq 98\%$ were observed for all of CFDC, CFPM/NAC, AZT/NAC, and AZT/AVI. For the nine isolates carrying *bla*_{NDM}, susceptibility rates were 78% and 89% for CFDC and CFPM/NAC, respectively, and 100% for both AZT/NAC and AZT/AVI. CFDC and AZT/AVI have been reported to be effective against class B carbapenemases (Ambler classification), which include *bla*_{IMP} and *bla*_{NDM}. AZT/NAC and CFPM/NAC are novel agents that combine NAC, a β -lactamase inhibitor similar to AVI with intrinsic antibacterial activity. The efficacy of these four agents was confirmed against Japanese clinical isolates harboring carbapenemase genes. In contrast, the agents showing lower susceptibility rates among isolates carrying *bla*_{IMP} or *bla*_{NDM} were three combination drugs (CAZ/AVI, CFPM/EMT, IPM/REL) known to have limited activity against class B carbapenemases, as well as MEPM. Among the 101 isolates, 13 (13%) remained susceptible to MEPM (MIC ≤ 1 $\mu\text{g/mL}$), indicating the presence of “stealth isolates” that carry resistance genes yet display susceptibility.

Table 37. Details of antimicrobial agents and susceptibility testing

Drugs (Abbreviation)	Approved in Japan	BL inhibitor concentration or mixing ratio	Interpretive criteria
Cefiderocol (CFDC)	Approved	—	CLSI (2025)
Cefepime / nacubactam (CFPM/NAC)	Unapproved ^{*1}	1:1 Blend	S: ≤ 8 , R: ≥ 16 ^{*2}
Aztreonam / nacubactam (AZT/NAC)	Unapproved ^{*1}	1:1 Blend	In accordance with CLSI (2025) criteria for AZT monotherapy
Aztreonam / avibactam (AZT/AVI)	Unapproved ^{*3}	AVI 4 $\mu\text{g/mL}$	EUCAST (v 15.0)
Ceftazidime / avibactam (CAZ/AVI)	Approved	AVI 4 $\mu\text{g/mL}$	CLSI (2025)
Cefepime / enmetazobactam (CFPM/EMT)	Unapproved ^{*4}	EMT 8 $\mu\text{g/mL}$	EUCAST (v 15.0)
Imipenem / relebactam (IPM/REL)	Approved	REL 4 $\mu\text{g/mL}$	CLSI (2025)
Meropenem (MEPM)	Approved	—	CLSI (2025)

^{*1} In clinical trials

^{*2} Considered susceptible up to the CLSI (2025) SDD (susceptible-dose dependent) upper limit of 8 for CFPM

^{*3} Approved in the EU, UK, and US

*4 Approved in the EU and US

The MIC measurement range for each agent is shown on the x-axis of Figure 3

Ambler's class	β -lactamase family	Number of isolates	CFDC ≤ 4	CFPM/ NAC ≤ 8	AZT/ NAC ≤ 4	AZT/ AVI ≤ 4	CAZ/ AVI ≤ 8	CFPM/ EMT ≤ 4	IPM/ REL ≤ 1	MEPM ≤ 1
B	IMP	86	98%	98%	100%	100%	8%	29%	29%	13%
	NDM	9	78%	89%	100%	100%	0%	0%	11%	11%
A	GES	3	100%	100%	100%	100%	100%	67%	33%	0%
	KPC	1	100%	100%	100%	100%	100%	0%	100%	0%
	IMI	1	100%	100%	100%	100%	100%	100%	0%	0%
D	OXA	1	100%	100%	100%	100%	100%	100%	100%	100%

Figure 2. Susceptibility rates of isolates classified by β -lactamase family of the Carbapenemase gene

The MIC distributions of seven novel agents and MEPM against 95 isolates carrying class B carbapenemase genes are shown in Figure 3. The upper panels of Figure 3 present results for the four agents that generally exhibited high susceptibility rates against class B carbapenemase-producing isolates (see Figure 2), while the lower panels show results for the four agents with lower susceptibility rates. For CFDC, two *bla*_{NDM}-carrying isolates were resistant and two *bla*_{IMP}-carrying isolates showed intermediate susceptibility. For CFPM/NAC, two *bla*_{IMP}-carrying isolates and one *bla*_{NDM}-carrying isolate were resistant. Across all eight agents, the MIC distributions of *bla*_{IMP}- and *bla*_{NDM}-carrying isolates overlapped, and no significant association was observed between the type of carbapenemase gene (*bla*_{IMP} or *bla*_{NDM}) and susceptibility.

The susceptibility profiles of the four CFDC-non-susceptible isolates (MIC ≥ 8 µg/mL) against all eight agents are summarized in Table 38. All four isolates were confirmed to be susceptible to CFPM/NAC, AZT/NAC, and AZT/AVI.




Figure 3. MIC distributions of eight antimicrobial agents against 95 isolates carrying class B β-lactamases

Table 38. MICs and susceptibility results for eight antimicrobial agents against four CFDC-non-susceptible isolates

Species	Carbapenemase gene possession	MIC (S, I, R)							
		CFDC	CFPM/NAC	AZT/NAC	AZT/AVI	CAZ/AVI	CFPM/EMT	IPM/REL	MEPM
<i>E. coli</i>	<i>bla</i> _{NDM-1}	64 (R)	2 (S)	0.25 (S)	0.25 (S)	>64 (R)	>64 (R)	16 (R)	8 (R)
<i>E. coli</i>	<i>bla</i> _{NDM-5}	16 (R)	2 (S)	0.12 (S)	0.06 (S)	>64 (R)	64 (R)	16 (R)	16 (R)
<i>E. kobei</i>	<i>bla</i> _{IMP-1}	8 (I)	2 (S)	0.25 (S)	0.12 (S)	>64 (R)	>64 (R)	4 (R)	4 (R)
<i>E. roggenkampii</i>	<i>bla</i> _{IMP-1}	8 (I)	2 (S)	1 (S)	0.06 (S)	64 (R)	32 (R)	2 (I)	2 (I)

These results indicate that, among Japanese clinical isolates carrying carbapenemase genes in 2023, AZT/NAC (susceptibility rate 100%), AZT/AVI (100%), CFPM/NAC (97%), and CFDC (96%) were highly effective. Furthermore, isolates exhibiting reduced susceptibility to CFDC were confirmed to remain susceptible to CFPM/NAC, AZT/NAC, and AZT/AVI. Considering the presence of “stealth” isolates, ongoing monitoring is warranted to track resistance patterns among carbapenemase-producing strains, as well as the types and distribution of carbapenemase genes.

9) Status of health care associated infection

Source: Japan Nosocomial Infections Surveillance (JANIS)

In the surgical site infection (SSI) division of JANIS, among 407,650 surgeries reported from 903 institutions in 2024, 15,274 surgical site infections (SSIs) were recorded, corresponding to an incidence rate of 3.7%. The SSI rate, which had shown a declining trend since 2011, plateaued in 2021 and 2022 but has shown a renewed decrease since 2023.

In the intensive care unit (ICU) division of JANIS, the incidence of ventilator-associated pneumonia has been 1.2-1.8 per 1,000 days of ICU stay over the past 10 years, with a rate of 1.2 per 1,000 days of ICU stay recorded in 2024. While the incidence of urinary tract infection was around 0.5-0.8 per 1,000 days of ICU stay, the incidence of catheter related bloodstream infection was around 0.6-0.8 per 1,000 days of ICU stay. Both of these rates have been fluctuating slightly. JANIS monitors cases of infections that occurred between 48 hours after admission to ICU and discharge from ICU.

i. Surgical site infection

Table 39. The trend (%) of reported SSI cases

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total SSI cases per total surgical operations (%)*	5.8	5.7	5.4	5.1	4.6	4.4	4.2	4.2	4.0	3.7
Participated medical institutions	671	730	772	802	785	786	768	814	825	903
Total surgical operations	251,832	274,132	292,031	305,960	307,052	290,795	291,958	313,110	348,567	407,650
Total SSI cases	14,701	15,674	15,889	15,566	14,226	12,696	12,227	12,998	14,033	15,274

*Total SSI cases per total surgical operations (%) = (Total SSI cases at medical facilities participated in JANIS) / (Total surgical operations at medical facilities participated in JANIS) ×100

Prepared from annual reports of the SSI division, JANIS.[7]

ii. Infections at Intensive Care Unit (ICU)

Table 40. Incidence rates of infection at ICU

		2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Ventilator-associated pneumonia	Total infection incidence rate*	1.5	1.5	1.3	1.3	1.3	1.2	1.8	1.4	1.4	1.2
	Total infections at monitored medical institutions	522	499	405	409	387	333	508	421	417	378
Urinary tract infection	Total infection incidence rate*	0.5	0.6	0.7	0.8	0.6	0.7	0.5	0.6	0.7	0.6
	Total infections at monitored medical institutions	190	219	213	244	174	183	157	184	211	201
Catheter-related bloodstream infection	Total infection incidence rate*	0.7	0.8	0.7	0.6	0.6	0.7	0.7	0.8	0.7	0.7
	Total infections at monitored medical institutions	240	263	213	190	177	193	214	229	224	224

*Total infection incidence rate = (Total infections among applicable patients at medial facilities participated in JANIS) / (Total days of ICU stay of applicable patients medial facilities participated in JANIS) ×1,000

Prepared from annual reports of the ICU division, JANIS.[8]

10) Survey of infection treatment and control and the disease burden at hospitals

Source: J-SIPHE, AMR Clinical Reference Center (AMRCRC)

The AMR Clinical Reference Center (AMRCRC) operates the J-SIPHE system, which can be used for AMR measures at hospitals as well as for promoting regional cooperation. The J-SIPHE 2024 Annual Report covers a total of 3,471 participating medical institutions (344 institutions calculating Infection Prevention and Control Premium 1, 1,005 calculating Premium 2, 1,037 calculating Premium 3, and 95 calculating no premium). Registration information was optional for each participating facility. The median number of blood cultures submitted at hospitals (n=2,071) was 14.0/1,000 patient days (IQR: 3.3-31.4), while the median rate of multiple sets (n=902, counting facilities submitting 20 or more) for patients aged 15 and older was 90.4% (IQR: 78.5-96.4). The median positive rate (n=902, counting facilities submitting 20 or more) was 16.6% (IRQ: 13.0-21.9).

In 2024, the number of outbreaks of bacteria detected in blood samples per 10,000 patient days was the highest for *Escherichia coli* with a median of 1.8 (IQR: 0.6-2.9), followed by *Staphylococcus aureus* with 1.1 (IQR: 0.4-2.1), *Klebsiella pneumoniae* at 0.6 (IQR: 0.0-1.2), showing a slight decrease compared to the previous year.

The overall hand hygiene compliance rate (n=134) was 64.2%, while the breakdown of the figures by ward function showed that wards categorized in “others” (n=70) had a higher rate of compliance, at 71.5% compared to the other wards.

The amount of hand sanitizer consumed per 1,000 patient days for the period 2019–2021 represents a combined figure of both usage and dispensing, whereas from 2022 onward, due to differing trends, the dispensing quantity is treated separately, and only the usage amount is presented here. In 2024, the total usage across all units (n=1,476) was 10.1 L (IQR: 6.1-14.8), with the critical care area (n=493) using 39.7 L (IQR: 25.1-63.3), which was higher compared to general wards. The use of hand hygiene products had been on an increasing trend from 2019 to 2022; however, it then exhibited a slight downward trend in 2023 and 2024.

The estimated number of deaths in patients with bloodstream infections was also published after a study of JANIS data carried out with a Health, Labour and Welfare Policy Research Grants. (Tsuzuki et al. J Infect Chemother 2019. doi: 10.1016/j.jiac.2019.10.017). This report presents the estimated annual number of deaths due to bloodstream infections using a similar methodology. Aside from a temporary decline observed in 2020, the number of deaths from bacteremia has shown a gradual increasing trend. While deaths from bacteremia caused by major antimicrobial-resistant pathogens have also risen gradually, this appears to reflect an overall increase in reported cases of bacteremia rather than a proportional rise in antimicrobial-resistant infections.

DALYs, an indicator of burden of disease that includes losses due to factors other than death (e.g. sequelae), were published (Tsuzuki et al. Int J Infect Dis 2021. doi: 10.1016/j.ijid.2021.05.018). Some of the parameters used in the estimation of both the number of deaths and DALYs were borrowed from previous studies overseas.

Table 41. Basic information on medical institutions participating in J-SIPHE for annual report

	2019	2020	2021	2022	2023	2024
Number of participating facilities	581	778	818	1,876	2,534	3,471
(Premium 1)	(449)	(539)	(547)	(868)	(1,057)	(1,334)
(Premium 2)	(127)	(232)	(263)	(493)	(668)	(1,005)
(Premium 3)	-	-	-	(487)	(751)	(1,037)
(without Premium)	(5)	(7)	(8)	(28)	(58)	(95)
Number of beds, median (IQR)	340.5 (221.3-525.3)	308.1 (196.0-498.3)	301 (184-480)	214 (129.8-382.2)	199 (120.8-356.2)	195 (114-327)
Average hospital days, median (IQR)	13.6 (11.7-17.1)	14.4 (12.0-19.0)	14.0 (11.8-19.7)	16.9 (12.3-34.7)	19.7 (12.7-43.1)	22.5 (13.3-49.9)

IQR (Interquartile range)

*Premium 3 was newly established in April 2022.

Table 42. Distribution of multiple sets of blood culture at hospitals (%)

	2019	2020	2021	2022	2023	2024
All patients, median (IQR)	90.6(83.6-95.4) (n=276)	92.8(87.9-96.1) (n=326)	93.1(88.0-96.7) (n=401)	93.1(87.1-96.4) (n=960)	92.8(86.1-96.6) (n=1,408)	87.3(76.4-94.7) (n=1,897)
Patients aged 15 years and older, median (IQR)	95.0(90.8-97.2) (n=276)	95.7(92.3-97.5) (n=326)	96.0(92.8-97.7) (n=401)	95.6(91.2-97.6) (n=960)	95.7(90.6-97.8) (n=1,407)	90.5(78.5-96.4) (n=1,897)
Patients aged under 15 years, median (IQR)	4.9(0.9-16.8) (n=178)	5.2(0.0-21.7) (n=211)	7.9(1.4-26.7) (n=261)	7.6(0.7-22.5) (n=510)	6.2(2.0-18.4) (n=559)	5.6(1.7-16.7) (n=673)

*Share of submissions of 2 sets or more of blood culture among blood culture submissions

2020: Data from facilities with 20 or more blood culture submissions during the period of interest.

(n in the table indicates the number of facilities, the distribution of blood culture set rates per facility)

Table 43. Distribution of occurrences of bloodstream infections at hospitals (total number per 10,000 patient days)

	Median (IQR)*					
	2019 (n=253)	2020 (n=329)	2021 (n=329)	2022 (n=1,030)	2023 (n=1,520)	2024 (n=2,070)
<i>S. aureus</i>	1.61 (0.86-2.17)	1.38 (0.75-2.21)	1.53 (0.80-2.27)	1.50 (0.63-2.27)	1.38 (0.48-2.21)	1.14 (0.39-2.09)
<i>Enterococcus faecalis</i>)	0.37 (0.12-0.65)	0.38 (0.07-0.65)	0.39 (0.12-0.67)	0.31 (0.00-0.59)	0.29 (0.00-0.58)	0.23 (0.00-0.51)
<i>Escherichia coli</i>	2.20 (1.40-3.37)	2.13 (1.23-3.26)	2.21 (1.42-3.25)	2.07 (1.01-3.14)	2.00 (0.89-3.16)	1.81 (0.60-2.86)
<i>Klebsiella pneumoniae</i>	0.83 (0.43-1.29)	0.77 (0.32-1.26)	0.83 (0.36-1.29)	0.72 (0.22-1.27)	0.69 (0.20-1.31)	0.62 (0.00-1.18)
<i>Klebsiella aerogenes</i> †	-	-	-	0.00 (0.00-0.20)	0.00 (0.00-0.21)	0.00 (0.00-0.18)
<i>Enterobacter</i> spp.	0.32 (0.08-0.61)	0.31 (0.00-0.67)	0.34 (0.03-0.67)	-	-	-
<i>Enterobacter cloacae</i> complex†	-	-	-	0.15 (0.00-0.40)	0.10 (0.00-0.37)	0.00 (0.00-0.33)
<i>Streptococcus pneumoniae</i>	0.00 (0.00-0.15)	0.00 (0.00-0.08)	0.00 (0.00-0.07)	0.00 (0.00-0.00)	0.00 (0.00-0.00)	0.00 (0.00-0.00)
MRSA	0.59 (0.26-0.94)	0.56 (0.24-0.89)	0.56 (0.26-0.96)	0.56 (0.15-0.97)	0.50 (0.14-0.95)	0.45 (0.00-0.88)
3CREC	0.42 (0.16-0.84)	0.50 (0.14-0.83)	0.49 (0.21-0.85)	0.46 (0.00-0.81)	0.44 (0.00-0.84)	0.39 (0.00-0.79)
FQREC	0.64 (0.27-1.18)	0.66 (0.28-1.11)	0.69 (0.35-1.13)	0.64 (0.18-1.07)	0.55 (0.09-1.06)	0.45 (0.00-0.95)
3CRKP	0.00 (0.00-0.09)	0.00 (0.00-0.12)	0.00 (0.00-0.11)	0.00 (0.00-0.12)	0.00 (0.00-0.15)	0.00 (0.00-0.14)
PRSP	0.00 (0.00-0.00)	0.00 (0.00-0.00)	0.00 (0.00-0.00)	0.00 (0.00-0.00)	0.00 (0.00-0.00)	0.00 (0.00-0.00)

MRSA; methicillin resistant *S. aureus*, 3 CREC; 3rd generation Cephalosporine resistant *E. coli*, FQREC; fluoroquinolone resistant *E. coli*, 3CRKP; 3rd generation Cephalosporine resistant *K. pneumoniae*, PRSP; penicillin resistant *S. pneumoniae*

* The tabulation includes MRSA for *S. aureus*, FQREC or 3CREC for *E. coli*, 3CRKP for *Klebsiella pneumoniae*, and PRSP for *S. pneumoniae*.

† *Enterobacter* spp. are counted by dividing them into *Enterobacter cloacae* complex and *Klebsiella aerogenes* starting in January 2022.

(n in the table indicates the maximum number of facilities that participated in the tally by bacterium, the distribution of bloodstream infections per facility)

Table 44. Distribution of hand hygiene compliance rate at hospitals (%)

	Median (IQR)					
	2019	2020	2021	2022	2023	2024
Overall	57.5(45.0-68.3) (n=45)	62.6(50.3-75.1) (n=47)	68.4(50.9-78.0) (n=50)	67.0(49.0-78.9) (n=110)	66.5(49.9-77.1) (n=126)	64.2(51.4-78.3) (n=134)
Critical Care Area	67.0(55.8-75.2) (n=22)	68.9(52.9-78.3) (n=22)	75.6(51.6-83.4) (n=26)	72.2(57.8-81.6) (n=45)	67.8(57.5-77.4) (n=49)	66.2(55.5-72.3) (n=51)
General wards	56.9(42.6-68.0) (n=44)	62.8(48.4-75.1) (n=41)	67.9(48.4-78.6) (n=48)	67.6(47.2-77.2) (n=93)	66.2(49.5-76.7) (n=111)	63.0(48.7-76.0) (n=110)
Other wards*	59.1(39.0-75.2) (n=22)	68.3(42.6-82.6) (n=26)	64.0(52.0-75.4) (n=26)	65.0(49.8-79.7) (n=55)	69.1(53.5-82.5) (n=68)	71.5(47.9-83.8) (n=70)

(n in the table indicates the number of facilities, the distribution of hygiene compliance rate per facility)

* Other wards include psychiatric wards, palliative care wards, convalescent rehabilitation wards, and long-term care wards that are not classified as critical care or general wards.

Table 45. Distribution of total amount of hand sanitizer consumed at hospitals (L/1,000 patient days)

		Median (IQR)					
		2019	2020	2021	2022	2023	2024
Overall		7.41 (4.21-11.42) (n=198)	9.63 (5.69-14.48) (n=245)	10.39 (6.66-16.50) (n=321)	11.31 (7.05-17.19) (n=677)	10.41(6.36-15.48) (n=1,055)	10.09(6.12-14.84) (n=1,476)
Category of addition	Premium 1			12.06(7.85-18.91) (n=239)	14.04 (9.68-20.58) (n=371)	13.26(9.35-19.30) (n=483)	12.62(8.92-18.34) (n=659)
	Premium 2			6.32(3.71-10.51) (n=79)	8.27 (5.52-12.34) (n=214)	8.81(5.31-12.99) (n=269)	8.88(5.71-12.54) (n=403)
	Premium 3				8.06 (4.55-12.80) (n=185)	7.35(4.60-11.10) (n=314)	6.73(4.23-11.25) (n=382)
Ward function	Critical Care Area	33.61 (18.51-58.52) (n=111)	41.15 (28.67-76.19) (n=120)	52.43 (28.85-86.57) (n=159)	46.55 (28.40-73.69) (n=272)	42.10(26.73-66.10) (n=382)	39.74(25.13-63.31) (n=493)
	General wards	7.35 (4.71-12.16) (n=184)	9.12 (6.36-14.83) (n=219)	9.85 (6.70-15.58) (n=290)	11.20 (7.46-16.42) (n=576)	10.17(6.66-15.01) (n=879)	10.24(6.41-14.73) (n=1,214)
	Other wards*	6.31 (3.98-12.84) (n=125)	8.95 (4.91-15.57) (n=168)	10.12 (5.71-17.53) (n=227)	10.50 (6.23-17.40) (n=496)	9.30(5.69-15.44) (n=784)	9.33(5.71-13.92) (n=1,119)

(n in the table indicates the number of facilities, the distribution of hand sanitizer consumed per facility)

* Other wards include psychiatric wards, palliative care wards, convalescent rehabilitation wards, and long-term care wards that are not classified as critical care or general wards.

Table 46. Estimated number of deaths from bloodstream infection (patients)

Patients (95% CI) *										
	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
<i>S. aureus</i> *	7,372 (5,721-9,047)	7,935 (6,172-9,725)	8,070 (6,271-9,885)	8,187 (6,361-10,034)	8,732 (6,793-10,693)	7,510 (5,399-9,624)	8,039 (5,776-10,316)	9,528 (7,387-11,620)	10,439 (8,097-12,770)	11,388 (8,958-13,904)
MRSA	3,608 (2,357-4,873)	3,758 (2,453-5,078)	3,716 (2,428-5,029)	3,690 (2,411-4,979)	3,966 (2,590-5,363)	3,633 (2,516-4,901)	3,917 (2,715-5,288)	3,938 (2,602-5,386)	4,505 (2,952-6,266)	5,314 (3,463-7,359)
<i>S. pneumoniae</i> *	480 (160-879)	430 (144-787)	447 (149-818)	463 (154-846)	410 (137-750)	247 (82-453)	204 (68-374)	198 (66-363)	220 (73-370)	259 (86-473)
PRSP	126 (42-231)	108 (36-198)	94 (31-173)	113 (38-206)	106 (35-194)	77 (26-141)	74 (25-136)	60 (20-101]	99 (33-168)	82 (27-150)
<i>E. coli</i> *	7,130 (5,701-8,643)	7,636 (6,111-9,251)	8,001 (6,404-9,688)	8,154 (6,523-9,890)	8,666 (6,921-10,506)	8,527 (6,829-10,240)	8,713 (6,983-10,481)	8,542 (6,843-10,311)	9,992 (7,937-12,006)	10,635 (8,475-12,897)
FQREC	2,889 (2,715-3,071)	3,310 (3,113-3,528)	3,376 (3,173-3,591)	3,753 (3,534-3,994)	4,201 (3,955-4,467)	4,118 (3,876-4,394)	4,170 (3,920-4,445)	4,172 (3,930-4,434)	4,827 (4,530-5,145)	4,832 (4,543-5,138)
3CREC	2,146 (1,155-3,300)	2,252 (1,212-3,462)	2,377 (1,280-3,660)	2,647 (1,425-4,074)	3,009 (1,620-4,625)	2,890 (1,559-4,245)	3,028 (1,635-4,445)	2,970 (1,601-4,565)	3,810 (2,048-5,590)	4,259 (2,302-6,574)
<i>Klebsiella pneumoniae</i> *	4,167 (3,171-5,276)	4,218 (3,207-5,318)	4,311 (3,275-5,437)	4,561 (3,466-5,755)	4,506 (3,424-5,704)	4,484 (3,405-5,668)	4,529 (3,444-5,727)	4,659 (3,453-5,840)	5,640 (4,268-7,188)	6,015 (4,567-7,530)
3CRKP	474 (344-608)	492 (359-633)	461 (334-592)	533 (386-685)	530 (385-680)	597 (432-761)	682 (495-870)	762 (572-974)	1,120 (838-1,427)	1,404 (1,017-1,781)
<i>Pseudomonas aeruginosa</i> *	2,036 (1,320-2,855)	2,109 (1,369-2,957)	2,074 (1,345-2,909)	2,188 (1,418-3,069)	2,243 (1,455-3,148)	2,139 (1,385-2,996)	2,344 (1,516-3,282)	2,282 (1,373-3,197)	2,598 (1,563-3,637)	3,020 (1,817-4,234))
CRPA	343 (296-388)	369 (318-418)	303 (263-343)	318 (275-360)	324 (280-367)	344 (297-388)	399 (345-448)	323 (281-366)	294 (257-334)	397 (344-450)

MRSA; methicillin resistant *S. aureus*, PRSP; penicillin resistant *S. pneumoniae*, FQREC; fluoroquinolone resistant *E. Coli*, 3CREC; 3rd generation Cephalosporine resistant *E. coli*, 3CRKP; 3rd generation Cephalosporine resistant *K. pneumoniae*, CRPA; Carbapenem resistant *P. aeruginosa*,

[†]The method for calculating the estimated number of deaths followed that reported by Tsuzuki et al (Tsuzuki S et al. IJID 2021. DOI: 10.1016/j.ijid.2021.05.018). The total number of bacteremia cases was estimated from the number of beds at participating facilities and the actual number of beds in each year based on JANIS data. The estimated number of deaths was then multiplied by the mortality rate per microorganism obtained from previous studies. Mortality rates due to bacteremia per microorganism are in the appendix to the above literature ([https://www.ijidonline.com/article/S1201-9712\(21\)00419-7/fulltext#supplementaryMaterial](https://www.ijidonline.com/article/S1201-9712(21)00419-7/fulltext#supplementaryMaterial)).

**S. aureus* includes MRSA, *S. pneumoniae* includes PRSP, *E. coli* includes FQREC or 3CREC (FQREC and 3CREC are calculated independently for bacteria that are resistant to each drug), *K. pneumoniae* includes 3CRKP, and *P. aeruginosa* includes CRPA. Figures in parentheses represent 95% confidence intervals.

11) Survey of infections and antimicrobial use at facilities for the elderly

Source: AMRCRC

Funded by a Health and Labor Sciences Research Grant and Health, Labour and Welfare Policy Research Grants, the AMRCRC conducted a survey of healthcare-associated infections and antimicrobial use at facilities for the elderly. [9-12]

i Medical long-term care wards/hospitals

A Point Prevalence Survey (PPS) was conducted by randomly selecting 1,175 facilities with medical long-term care wards from members of the Japan Association of Medical and Care Facilities (January 2020 survey). Eighty facilities (7.8% response rate) responded. The median patient age was 84.0 years (78, 90). The antimicrobial use rate was 9.4% (630 patients receiving antimicrobials out of a total of 6,729 inpatients). The median age of male patients was 82.0 years (IQR: 75–87.8), and that of female patients was 87.0 years (IQR: 80.8–92). The top infections were "pneumonia" in 199 patients (39.5%), "urinary tract infection" in 135 patients (26.8%), and "bronchitis" in 19 patients (3.8%). The main antimicrobial agents used were injectable third generation cephalosporins, penicillin beta-lactamase inhibitor combinations, and carbapenems.

ii Long-term care facilities for the elderly

The center randomly selected facilities from among the members of the Japan Association of Geriatric Health Services Facilities and conducted a PPS. In the 1st PPS (conducted in February 2019, 1,500 facilities), responses were received from 134 facilities (a response rate of 8.9%), in the 2nd PPS (conducted in February 2022, 1,000 facilities), responses were received from 100 facilities (a response rate of 10.0%)

The antimicrobial use rate in the 1st PPS was 1.7% (172 antimicrobial users, total 10,148 residents). The median age of male patients was 84.0 years (IQR: 75-89), and that of female patients was 87.0 years (IQR: 83-92). The top infections were urinary tract infections, affecting 70 people (46.1%); pneumonia, affecting 29 people (19.1%); and upper respiratory tract infections, affecting 11 people (7.2%). The main antimicrobials used to treat urinary tract infections were fluoroquinolones, while the antimicrobials primarily used for pneumonia were injectable third generation cephalosporins.

The antimicrobial use rate in the 2nd PPS was 1.3% (110 antimicrobial users, total 8,291 residents). The median age of male patients was 85.0 years (IQR: 80.5-89.5) and, that of female patients was 89.0 years (IQR: 86.5-94.0). The top infections were urinary tract infections, affecting 47 people (51.6%); pneumonia, affecting 14 people (15.4%); and cellulitis, affecting 7 people (7.7%). The main antimicrobials used to treat urinary tract infections and were fluoroquinolones while the antimicrobials primarily used for pneumonia were injectable third generation cephalosporins.

iii Welfare facilities for the elderly requiring long-term care (special nursing homes for the aged)

The center randomly selected 1,500 welfare facilities for the elderly requiring long-term care from among the members of the Japanese Council of Senior Citizens Welfare Service and conducted a point prevalence survey (PPS). Responses were received from 139 facilities (a response rate of 9.3%). The median age of the patients was 90.0 years (IQR: 85, 93), while the median age of male patients was 80.5 years (IQR: 76, 90) and that of female patients was 92.0 years (IQR: 87, 93).

For the first PPS (February 2019 survey; 1,500 facilities sampled), responses were obtained from 134 facilities (response rate: 8.9%). For the second PPS (February 2022 survey; 1,000 facilities sampled), responses were obtained from 100 facilities (response rate: 10.0%).

The top focuses of infection were urinary tract infections, affecting 23 people (31.5%); pneumonia, affecting 11 people (15.1 %); and upper respiratory tract infections, affecting 9 people (12.3%). The main antimicrobials used to treat urinary tract infections were fluoroquinolones, while the main ones used for pneumonia were injectable third generation cephalosporins. The antimicrobial use rate in the 2nd point prevalence survey (PPS) was 1.1% (108 antimicrobial users among a total of 10,225 residents). The median age was 85.5 years for males (IQR: 82–89) and 89.0 years for females (IQR: 84–93). The most common infections were urinary tract infections (42 cases, 48.3%), pneumonia (11 cases, 12.6%), and upper respiratory tract infections (8 cases, 9.2%). Fluoroquinolones were the antimicrobial agents most commonly used for the treatment of urinary tract infections and pneumonia.

Table 47. Use of antimicrobial agents in long-term care wards/hospitals and elderly care facilities

facility [Number of facilities responding]	Antimicrobial use rate (Antimicrobial users/residents on survey date)	Major infections for which antimicrobial agents were used	Major antimicrobial classes (All infectious diseases)
Medical long-term care (Medical institutions) [82]	9.4% (630/6,729)	Pneumonia (39.5%) Urinary tract infections (26.8%) Bronchitis (3.8%)	Injectable 3rd gen cephalosporins Combinations of penicillins, including beta lactamase inhibitors Carbapenems
Medical and rehabilitation facilities (Geriatric health care) 1st PPS [126]	1.7% (172/10,148)	Urinary tract infection (46.1%) Pneumonia (19.1%) Upper respiratory tract infections (7.2%)	Fluoroquinolones Third generation cephalosporins Combinations of penicillins, including beta lactamase inhibitors
2nd PPS [98]	1.3% (110/8,291)	Urinary tract infection (51.6%) Pneumonia (15.4%) Cellulitis (7.7%)	Fluoroquinolones 3rd gen cephalosporins Oral fluoroquinolones Broad-spectrum penicillins
Nursing care and welfare (Special nursing homes) 1st PPS [137]	1.0% (94/9,044)	Urinary tract infection (31.1%) Pneumonia (14.9%) Upper respiratory tract infection (12.2%)	Fluoroquinolones 3rd generation cephalosporins Macrolide
2nd PPS[157]	1.1% (108/10,225)	Urinary tract infection (48.3%) Pneumonia (12.6%) Upper respiratory tract infection (9.2%)	Fluoroquinolones 3rd generation cephalosporins 2nd generation cephalosporins

Reference

- Konishi N. et al. "Epidemiological Studies of Drug Resistance in Human and Foodborne Enterobacteria," Shared Research under 'Research on Trends in Outbreaks of Foodborne Drug-Resistant Bacteria and Sanitary Measures,' Shared Research Report, Grants for Research from the Ministry of Health, Labour and Welfare of Japan(Research Project. 2018
- Shinomiya, H. et al. "Construction of Information Collection System for Drug-Resistant Bacteria Isolated at Regional Public Health Laboratories in Japan," Shared Research under 'Research on Trends in Outbreaks of Foodborne Drug-Resistant Bacteria and Sanitary Measures,' Shared Research Report, Grants for Research from the Ministry of Health, Labour and Welfare of Japan(Research Project. 2018
- Galdys AL, et al. "Prevalence and duration of asymptomatic *Clostridium difficile* carriage among healthy subjects in Pittsburgh, Pennsylvania." J Clin Microbiol. 2014;52(7): 2406-9.
- Evans CT, et al. "Current Trends in the Epidemiology and Outcomes of *Clostridium difficile* Infection" Clin Infect Dis 2015; 60 (suppl_2): S66-S71.
- T. V. Riley, T. Kimura. "The Epidemiology of *Clostridium difficile* Infection in Japan: A Systematic Review" Infect Dis Ther. 2018;7: 39–70.
- Kato H, Senoh M, Honda H, et al. "*Clostridioides (Clostridium) difficile* infection burden in Japan: A multicenter prospective study." Anaerobe 2019.
- Nosocomial Control Surveillance Project, Ministry of Health, Labour and Welfare, "SSI Division JANIS (for the general public) Periodic and Annual Report."Available at: <https://janis.mhlw.go.jp/report/ssi.html>
- Surveillance of Nosocomial Measures Project, Ministry of Health, Labour and Welfare, "ICU JANIS (for the general public) periodic and annual reports," Available at: <https://janis.mhlw.go.jp/report/icu.html>
- Suzuki, K. et al. "Study on the Implementation of the Drug Resistance (AMR) Action Plan (FY17-Emerging Administration-Designation-005)" of the Research Project to Promote Emerging and Re-emerging Infectious Diseases and Immunization Policy Funded by the Health and Labour Administration, Research on Healthcare-Associated Infections and Antimicrobial Use in Nursing and Geriatric Care Facilities, 2019.
- Ohmagari N, et al. "Research on the Implementation of the Antimicrobial Resistance (AMR) Action Plan: A Survey on Infectious Disease Management, Antimicrobial Usage, and Infection Control Practices in Long-Term Care Facilities for the Elderly - Point prevalence survey" 2023, Grants for Health, Labour and Welfare Policy Research (Research Project concerning Emerging and Re-emerging Infectious Diseases and Vaccination Policies)
- Ohmagari N, et al. "Research on the Implementation of the Antimicrobial Resistance (AMR) Action Plan: A Survey on Infectious Disease Management and Infection Control Practices in Welfare Facilities for the Elderly Requiring Long-Term Care - Point prevalence survey" 2021, Grants for Health and Labor Sciences Research (Research Project concerning Emerging and Re-emerging Infectious Diseases and Vaccination Policies)
- Ohmagari N, et al. "Grant for the Promotion of Health and Labor Administration Research Projects (Research Project on Emerging and Re-emerging Infectious Diseases and Vaccination Policy Promotion): 'Research to Address Challenges in Implementing the Antimicrobial Resistance (AMR) Action Plan 2023–2027'—Survey on the Current Status of Infectious Disease Diagnosis and Infection Control Measures in Welfare facilities for the elderly requiring long-term care (special nursing homes for the aged): Point Prevalence Survey." 2026.

(2) Animals

1) Livestock animals

Source: Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM)

Under the JVARM, antimicrobial susceptibility tests were performed using the broth microdilution method according to the CLSI guidelines to determine the MICs of antimicrobial agents for various strains collected.

For agents with a breakpoint (BP) established by the CLSI, susceptibility was interpreted using the CLSI Criteria. For agents without CLSI-defined breakpoints, values defined by EUCAST (epidemiological cut-off values, ECOFFs) or epidemiological cut-off values calculated based on the MIC distributions in JVARM were used. Antimicrobial agents for which breakpoints could not be established using these methods were not included in the table because resistance rates could not be calculated. In addition, resistance rates were not published when the number of tested isolates was fewer than 20.

Bacteria derived from diseased animals

Surveys of bacteria derived from diseased animals were carried out using bacteria isolated from livestock animals which were subjected to pathological appraisal by prefectural livestock hygiene service centers. With regard to the site of bacterial isolation, *Salmonella* spp. were mainly isolated from feces, gastrointestinal tract and liver, *Staphylococcus* spp. mainly from milk and udder, and *Escherichia coli* mainly from feces, gastrointestinal tract and lungs.

i. *Salmonella* spp.

Monitoring of antimicrobial resistance had been carried out on 11 agents until 2018, and from 2019 onward, 12 agents were surveyed with meropenem (MEPM) added. For resistance rates in cattle- and swine-derived strains were collected in 2023, more than 50% were resistant to tetracycline (TC). In contrast, the resistance rates of cefotaxime (CTX) and ciprofloxacin (CPFX), important antimicrobial agents in human medicine, were less than 5% in swine-derived strains, 21.2% for CTX and 16.2% for CPFX in cattle-derived strains, and 0.0% for MEPM in both cattle and swine.

The most common *Salmonella* serotypes isolated from diseased livestock animals from 2014 to 2023 were *S. Typhimurium* and its monophasic variant *S. 4: i:-* among cattle-derived strains; *S. Typhimurium*, *S. 4:i:-*, and *S. Choleraesuis* among swine-derived strains; and *S. Schwarzengrund*, *S. Infantis*, and *S. Enteritidis* among chicken-derived strains. In the strains collected in 2023, the isolation rate of *S. Dublin* increased in cattle, all except one of which were CTX and CL resistant. Regarding the resistance rates by serotype among isolates obtained from 2014 to 2023, *S. Choleraesuis* from swine exhibited high resistance, with 60.9% resistance to Ampicillin (ABPC) and 67.4% resistance to TC. Resistance greater than 70% was observed for ABPC and TC in cattle- and swine-derived *S. 4: i:-*, for TC in chicken-derived *S. Infantis*, and for kanamycin (KM) and TC in chicken-derived *S. Schwarzengrund*. On the other hand, the resistance rates to CTX and CPFX, important antimicrobial agents in human medicine, were less than 10% for both serotypes.

Table 48. The resistance rates (%) of *Salmonella* spp. isolated from diseased animals

Agent	BP	Animal species	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
ABPC	32*	Cattle	61.9	56.6	50.0	40.7	36.8	61.4	39.2	42.9	55.4	69.7
		Swine	41.4	46.9	41.1	40.9	50.0	44.9	37.7	25.8	51.7	21.7
		Chickens	3.9	-	-	-	4.5	-	-	-	-	-
CEZ	8* (-2015:32*)	Cattle	7.9	7.9	22.9	5.1	3.5	21.1	19.6	38.8	33.7	47.5
		Swine	0.0	6.1	23.2	6.8	9.4	17.4	13.2	0.0	20.7	4.3
		Chickens	0.0	-	-	-	0.0	-	-	-	-	-
CTX	4*	Cattle	7.9	7.9	4.3	1.7	0.0	1.8	0.0	26.5	16.9	21.2
		Swine	0.0	4.1	0.0	0.0	0.0	0.0	1.9	0.0	3.4	0.0
		Chickens	0.0	-	-	-	0.0	-	-	-	-	-
MEPM	4*	Cattle	-	-	-	-	-	0.0	0.0	0.0	0.0	0.0
		Swine	-	-	-	-	-	0.0	0.0	0.0	0.0	0.0
		Chickens	-	-	-	-	-	-	-	-	-	-
SM	32†	Cattle	60.3	67.1	41.4	39.0	42.1	64.9	49.0	44.9	54.2	75.8
		Swine	82.8	67.3	57.1	59.1	60.9	55.1	62.3	58.1	69.0	65.2
		Chickens	39.2	-	-	-	68.2	-	-	-	-	-
GM	16*	Cattle	3.2	7.9	4.3	1.7	1.8	7.0	17.6	14.3	12.0	5.1
		Swine	15.5	8.2	17.9	15.9	4.7	5.8	15.1	0.0	6.9	4.3
		Chickens	0.0	-	-	-	0.0	-	-	-	-	-
KM	64*	Cattle	14.3	21.1	25.7	5.1	0.0	12.3	3.9	4.1	10.8	9.1
		Swine	8.6	6.1	10.7	13.6	4.7	14.5	13.2	3.2	10.3	4.3
		Chickens	29.4	-	-	-	63.6	-	-	-	-	-
TC	16*	Cattle	50.8	55.3	42.9	39.0	33.3	63.2	43.1	44.9	53.0	73.7
		Swine	60.3	61.2	58.9	50.0	50.0	37.7	43.4	48.4	51.7	52.2
		Chickens	39.2	-	-	-	77.3	-	-	-	-	-
NA	32*	Cattle	3.2	11.8	5.7	5.1	1.8	3.5	25.5	38.8	21.7	33.3
		Swine	15.5	6.1	7.1	9.1	20.3	21.7	20.8	16.1	17.2	21.7
		Chickens	3.9	-	-	-	0.0	-	-	-	-	-
CPFX	1* (-2017:4*)	Cattle	0.0	0.0	0.0	0.0	1.8	1.8	0.0	2.0	8.4	16.2
		Swine	0.0	0.0	0.0	0.0	4.7	1.4	0.0	3.2	3.4	0.0
		Chickens	0.0	-	-	-	0.0	-	-	-	-	-
CL	4* (-2015:16*)	Cattle	0.0	0.0	1.4	5.1	0.0	1.8	0.0	12.2	7.2	17.2
		Swine	0.0	0.0	3.6	4.5	4.7	8.7	5.7	3.2	10.3	0.0
		Chickens	0.0	-	-	-	18.2	-	-	-	-	-
CP	32*	Cattle	17.5	22.4	12.9	3.4	3.5	29.8	2.0	26.5	41.0	62.6
		Swine	25.9	12.2	8.9	18.2	21.9	8.7	17.0	9.7	0.0	30.4
		Chickens	3.9	-	-	-	0.0	-	-	-	-	-
ST (-2017: TMP)	(-2017)TMP:16* (2018-)ST:76/4*	Cattle	6.3	13.2	4.3	3.4	1.8	29.8	3.9	6.1	26.5	40.4
		Swine	32.8	22.4	21.4	25.0	12.5	18.8	20.8	3.2	6.9	34.8
		Chickens	29.4	-	-	-	59.1	-	-	-	-	-
Number of isolates tested (n)		Cattle	63	76	70	59	57	57	51	49	83	99
		Swine	58	49	56	44	64	69	53	31	29	23
		Chickens	51	7	-	-	22	16	16	7	6	14

The unit of BP is µg/mL.

* BP follows CLSI Criteria. † BP set based on the EUCAST ECOFF.

For GM, when the interpretive criterion used prior to 2022 (16) was applied, the resistance rates in 2023 were 5.1% in cattle and 4.3% in swine.

Resistance rates were not reported when the number of tested isolates was fewer than 20.

Table 49. Number of strains of *Salmonella* spp. isolated from diseased livestock animals by serotype (2014-2023)

Serotypes	Cattle	Swine	Chickens	Total	(%)
4:i:-	237	114	0	351	27.4
Typhimurium	148	185	3	336	26.3
Schwarzengrund	6	4	63	73	5.6
Infantis	19	8	21	48	3.8
Choleraesuis	0	46	0	46	3.6
Dublin	42	0	0	42	3.3
Stanley	31	1	0	32	2.5
Thompson	28	2	2	32	2.5
Newport	20	6	3	29	2.3
Derby	2	20	0	22	1.7
Rissen	2	16	0	18	1.4
Choleraesuis var. Kunzendorf	0	17	0	17	1.3
Mbandaka	10	1	5	16	1.3
Enteritidis	2	1	12	15	1.2
Braenderup	5	2	6	13	1.0
Others	112	53	24	189	14.8
Total	664	476	139	1279	100.0

Table 50. Resistance rates (%) of *Salmonella* spp. from diseased animals by serotype (2014-2023)

Agents	BP	Typhimurium		4:i:-		Choleraesuis	Infantis	Schwarzengrund
		Cattle (n=148)	Swine (n=185)	Cattle (n=237)	Swine (n=114)	Swine (n=46)	Chickens (n=21)	Chickens (n=63)
ABPC	32	46.6	28.1	94.1	71.9	60.9	4.8	4.8
CEZ	8	20.3	9.7	33.3	21.9	15.2	4.8	0.0
CTX	4	9.5	0.0	3.4	0.9	4.3	4.8	0.0
GM	16	1.4	5.4	11.8	13.2	32.6	0.0	0.0
KM	64	23.0	4.3	6.8	7.0	43.5	52.4	79.4
TC	16	40.5	36.2	91.1	85.1	67.4	85.7	88.9
NA	32	11.5	14.1	12.2	17.5	34.8	4.8	23.8
CPFX	1	0.7	3.8	16.2	2.6	0.0	0.0	0.0
CL	4	0.7	4.9	4.1	7.9	0.0	4.8	3.2
CP	32	22.3	24.3	33.8	13.2	8.7	0.0	3.2
ST(-2017: TMP)	(-2017) TMP:16* (2018-) ST:76/4*	7.4	21.6	32.1	7.9	56.5	57.1	57.1

The unit of BP is µg/ml.* BP follows CLSI Criteria.

ii. *Staphylococcus aureus*

Monitoring of antimicrobial resistance was carried out on 7 agents until 2018. Starting from 2019, 8 agents were surveyed, including Oxacillin (MIPIC). Resistance rates to TC in swine-derived strains were observed to exceed 40% in 2023. Resistance rates to all antimicrobials, except GM, were observed to be higher in swine-derived strains than in those derived from cattle. The resistance rate to CPFEX, an antimicrobial agent important in human medicine, was 1.3% in isolates from cattle and 12.5% in isolates from swine.

Table 51. Resistance rates (%) of *Staphylococcus aureus* isolated from disease appraisal samples

Agents*	BP	Animal species	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
ABPC (PCG since 2019)	(-2018) ABPC:0.5 [†] (2019-) PCG:0.25*	Cattle	5.3	21.3	7.8	7.5	9.3	6.4	7.0	2.0	9.1	6.5
		Swine	-	-	75.6	71.4	82.4	87.5	81.0	81.8	-	70.8
		Chickens	-	-	3.7	22.6	8.0	-	12.5	0.0	0.0	-
MIPIC	4 [†]	Cattle	-	-	-	-	-	2.4	0.8	0.0	0.0	0.0
		Swine	-	-	-	-	-	15.0	4.8	22.7	-	16.7
		Chickens	-	-	-	-	-	-	0.0	0.0	0.0	-
SM	64 [†] (2023-: 32 [†])	Cattle	1.3	2.7	1.4	3.4	5.8	8.0	4.7	5.9	4.0	18.2
		Swine	-	-	33.3	20.4	39.2	17.5	19.0	31.8	-	25.0
		Chickens	-	-	3.7	0.0	0.0	-	0.0	15.0	14.3	-
GM	16*	Cattle	0.0	1.3	0.0	0.6	0.0	0.0	0.8	0.0	2.0	0.0
		Swine	-	-	2.2	14.3	11.8	7.5	4.8	4.5	-	0.0
		Chickens	-	-	3.7	9.7	4.0	-	0.0	0.0	9.5	-
EM	8*	Cattle	0.0	6.7	2.8	1.7	5.8	4.8	3.9	1.0	3.0	1.3
		Swine	-	-	37.8	38.8	52.9	52.5	33.3	18.2	-	33.3
		Chickens	-	-	22.2	6.5	4.0	-	4.2	5.0	4.8	-
TC	16*	Cattle	6.6	6.7	0.0	0.0	0.6	2.4	0.8	2.0	5.1	3.9
		Swine	-	-	57.8	53.1	60.8	77.5	57.1	54.5	-	41.7
		Chickens	-	-	33.3	19.4	20.0	-	20.8	5.0	9.5	-
CP	32*	Cattle	0.0	1.3	0.0	0.6	0.6	1.6	0.0	5.9	2.0	0.0
		Swine	-	-	22.2	30.6	43.1	37.5	28.6	22.7	-	12.5
		Chickens	-	-	3.7	3.2	8.0	-	12.5	5.0	4.8	-
CPFEX	4*	Cattle	0.0	1.3	0.7	0.6	0.0	1.6	1.6	1.0	3.0	1.3
		Swine	-	-	11.1	8.2	23.5	5.0	23.8	13.6	-	12.5
		Chickens	-	-	3.7	3.2	28.0	-	16.7	0.0	0.0	-
Number of isolates tested (n)		Cattle	76	75	141	174	172	125	128	101	99	77
		Swine	3	2	45	49	51	40	21	22	16	24
		Chickens	12	6	27	31	25	17	24	20	21	19

Units of BP are in µg/ml. * BP follows CLSI Criteria. † BP set based on the EUCAST ECOFF.

For SM, when the interpretive criterion used prior to 2022 (64) was applied, the resistance rates in 2023 were 5.2% in cattle and 8.3% in swine.

Resistance rates were not reported when the number of tested isolates was fewer than 20.

iii. *Escherichia coli*

Monitoring of antimicrobial resistance was carried out on 12 agents until 2018 and on 13 agents with the addition of MEPM from 2019 onward. In 2023, an antimicrobial resistance rate exceeding 50% was observed to TC in both cattle- and swine-derived isolates, to SM in cattle-derived isolates, and to ABPC in swine-derived isolates. Resistance to CTX, CPFX, and CL, which are critically important antimicrobials for human medicine, was in the ranges 0.0 to 8.8%, 12.8 to 23.1%, and 0.0 to 7.7%, respectively, while the resistance rate to MEPM was 0.0% in any animal species. For CL, in 2018 its designation as a feed additive was revoked and its use was prohibited, and it was positioned as a second-line agents for veterinary use and its use is restricted. The resistance rate to CL showed more than 50% for swine-derived strains in 2017, but it decreased to 7.7% in 2023. It will be necessary to continue to monitor future trends in the resistance rate due to the strengthening of these risk management measures.

Table 52. Resistance rates (%) of *Escherichia coli* isolated from disease appraisal material

Agent	BP	Animal species	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
ABPC	32*	Cattle	57.8	63.8	37.7	50.0	51.7	62.8	63.8	52.8	50.0	48.4
		Swine	50.4	57.9	74.5	70.7	62.8	67.6	61.2	63.6	76.0	69.2
		Chickens	-	60.4	43.5	33.3	52.9	47.5	56.8	55.0	61.2	43.6
CEZ	8*(-2015: BP 32*)	Cattle	6.7	14.9	15.6	15.6	17.2	28.7	27.7	18.5	28.4	13.2
		Swine	6.1	9.3	34.3	35.0	21.5	23.5	17.6	21.6	28.0	17.9
		Chickens	-	14.6	15.2	11.1	17.6	20.0	13.5	13.3	20.4	2.6
CTX	4*	Cattle	6.7	8.5	7.8	8.9	9.2	14.9	22.3	13.9	17.6	8.8
		Swine	0.0	3.7	2.9	3.3	3.3	4.9	2.4	8.0	6.0	5.1
		Chickens	-	10.4	6.5	5.6	11.8	7.5	8.1	11.7	6.1	0.0
SM	32†	Cattle	68.9	78.7	49.4	61.1	57.5	63.8	63.8	61.1	61.8	59.3
		Swine	64.3	66.4	74.5	72.4	54.5	64.7	61.2	62.5	72.0	46.2
		Chickens	-	60.4	56.5	38.9	51.0	65.0	67.6	61.7	40.8	35.9
GM	16*(2024-:BP 8*)	Cattle	6.7	12.8	10.4	8.9	10.3	8.5	11.7	7.4	8.8	6.6
		Swine	8.7	19.6	21.6	22.8	13.2	12.7	14.1	22.7	20.0	10.3
		Chickens	-	2.1	10.9	5.6	2.0	5.0	10.8	0.0	4.1	7.7
KM	64*	Cattle	26.7	29.8	16.9	26.7	28.7	31.9	29.8	22.2	27.5	24.2
		Swine	33.9	30.8	46.1	39.0	32.2	27.5	24.7	25.0	20.0	20.5
		Chickens	-	39.6	50.0	36.1	27.5	25.0	37.8	33.3	38.8	20.5
TC	16*	Cattle	66.7	66.0	54.5	62.2	58.6	66.0	66.0	63.0	66.7	64.8
		Swine	75.7	75.7	87.3	78.9	70.2	68.6	69.4	80.7	72.0	64.1
		Chickens	-	70.8	78.3	55.6	72.5	60.0	70.3	63.3	57.1	38.5
MEPM	4*	Cattle	-	-	-	-	-	0.0	0.0	0.0	0.0	0.0
		Swine	-	-	-	-	-	0.0	0.0	0.0	0.0	0.0
		Chickens	-	-	-	-	-	0.0	0.0	0.0	0.0	0.0
NA	32*	Cattle	33.3	36.2	18.2	33.3	33.3	36.2	34.0	28.7	38.2	28.6
		Swine	52.2	49.5	48.0	50.4	33.1	27.5	32.9	38.6	38.0	20.5
		Chickens	-	52.1	56.5	55.6	35.3	60.0	32.4	61.7	28.6	35.9
CPFX	1* (-2017:4*)	Cattle	24.4	34.0	11.7	17.8	21.8	28.7	28.7	25.0	31.4	23.1
		Swine	23.5	31.8	24.5	28.5	22.3	15.7	20.0	21.6	18.0	17.9
		Chickens	-	8.3	8.7	11.1	5.9	35.0	18.9	31.7	10.2	12.8
CL	4* (-2015:16*)	Cattle	6.7	0.0	10.4	20.0	11.5	11.7	1.1	0.9	1.0	2.2
		Swine	0.0	2.8	56.9	52.0	35.5	27.5	27.1	23.9	16.0	7.7
		Chickens	-	0.0	8.7	0.0	2.0	10.0	0.0	0.0	0.0	0.0
CP	32*	Cattle	28.9	46.8	19.5	28.9	31.0	38.3	40.4	35.2	51.0	44
		Swine	64.3	60.7	69.6	59.3	57.0	54.9	57.6	61.4	50.0	38.5
		Chickens	-	16.7	21.7	11.1	21.6	15.0	32.4	18.3	24.5	7.7
ST(-2017: TMP)	(-2017)TMP:16* (2018-)ST:76/4*	Cattle	33.3	44.7	23.4	35.6	42.5	41.5	40.4	33.3	32.4	29.7
		Swine	59.1	64.5	62.7	56.9	52.9	56.9	51.8	53.4	50.0	35.9
		Chickens	-	33.3	23.9	13.9	19.6	35.0	24.3	31.7	32.7	20.5
Strains tested (n)		Cattle	45	47	77	90	87	94	94	108	102	91
		Swine	115	107	102	123	121	102	85	88	50	39
		Chickens	-	48	46	36	51	40	37	60	49	39

The unit of BP is µg/mL.

* BP follows CLSI Criteria. Resistance rates for years prior to the change are based on BP before the change. † BP set based on the EUCAST ECOFF.

For GM, when the interpretive criterion used prior to 2022 (16) was applied, the resistance rates in 2023 were 6.6% in cattle, 10.3% in swine, and 7.7% in chickens.

Bacteria derived from healthy livestock animals

Surveillance of food-borne pathogenic bacteria and indicator bacteria from healthy livestock animals was carried out using samples of rectal feces and cecal feces collected at animal and poultry slaughterhouses. When JVARM first began, surveillance was carried out using samples of feces from livestock animals collected at farms by livestock hygiene service centers. Surveillance at animal and poultry slaughterhouses was parallelly launched in FY2012, as this facilitated more intensive sampling at a stage closer to the final food product. In FY2016, there was confirmed to be no major difference in the findings of both surveys, so JVARM shifted to surveillance at animal and poultry slaughterhouses for bacteria derived from healthy livestock animals.

i. *Escherichia coli*

Monitoring of antimicrobial resistance was carried out on 12 agents until 2017, and on 13 agents adding MEPM from 2018 onward. In 2023, resistance to TC in swine- and chicken-derived strains, SM and KM in chicken-derived strains was observed to exceed 40%. The rates of resistance to critically important antimicrobials for human medicine CTX and CL were less than 5%, and the resistance rate to CPFY was less than 1% in cattle and swine, and 16.1% in chickens. The resistance rate to MEPM was 0.0%, in any animal species.

Table 53. Resistance rates (%) of *Escherichia coli* from animal slaughterhouses and poultry slaughterhouses

Agent	BP	Animal species	2014 [†]	2015	2016	2017	2018	2019	2020	2021	2022	2023
ABPC	32*	Cattle	3.2	5.5	7.4	4.8	11.6	5.9	5.1	5.0	7.3	4.3
		Swine	40.9	34.4	36.7	33.7	34.9	32.5	44.1	33.3	37.5	39.6
		Chickens	40.1	43.5	36.1	39.3	36.1	36.7	30.6	40.7	23.9	38.7
CEZ	8*(-2015:32*)	Cattle	0.0	0.0	1.9	0.8	0.5	0.7	0.4	1.1	0.3	1.4
		Swine	1.1	1.0	6.7	1.2	2.4	3.8	1.1	2.0	1.5	9.0
		Chickens	5.8	3.8	10.8	6.7	7.7	4.7	6.6	3.4	2.1	10.3
CTX	4*	Cattle	0.0	0.0	0.4	0.4	0.0	0.3	0.0	0.0	0.0	1.0
		Swine	0.0	0.0	1.1	1.2	0.0	2.5	0.0	2.0	0.7	0.0
		Chickens	4.1	2.2	5.7	4.7	3.2	3.1	4.1	2.1	0.7	3.9
MEPM	4*	Cattle	—	—	—	—	0.0	0.0	0.0	0.0	0.0	0.0
		Swine	—	—	—	—	0.0	0.0	0.0	0.0	0.0	0.0
		Chickens	—	—	—	—	0.0	0.0	0.0	0.0	0.0	0.0
SM	32 [†]	Cattle	16.7	12.4	22.1	19.0	18.5	19.8	14.6	18.0	18.5	13.8
		Swine	51.1	39.6	50.0	41.0	49.4	41.3	45.2	24.5	31.6	36.1
		Chickens	44.8	41.8	51.3	41.3	48.4	40.6	47.1	48.3	45.8	54.8
GM	16*(2023-: 8*)	Cattle	0.0	0.0	0.8	0.0	0.0	0.0	0.4	0.4	0.3	0.0
		Swine	6.8	2.1	3.3	3.6	3.6	2.5	1.1	1.0	2.9	1.4
		Chickens	2.9	2.2	5.1	6.0	5.2	6.3	3.3	1.4	2.1	4.5
KM	64*	Cattle	0.4	0.7	4.3	1.2	0.0	0.7	0.4	0.8	1.4	1.9
		Swine	10.2	8.3	10.0	10.8	8.4	10.0	5.4	8.8	5.9	5.6
		Chickens	33.1	37.5	43.7	36.7	43.9	37.5	31.4	44.8	44.4	41.3
TC	16*	Cattle	19.0	18.6	29.8	21.0	26.5	22.6	19.8	23.8	23.4	20.0
		Swine	58.0	45.8	56.7	55.4	55.4	47.5	62.4	52.0	55.1	56.3
		Chickens	43.6	54.9	56.3	46.0	49.0	62.5	52.9	46.2	43.0	53.5
NA	32*	Cattle	2.4	2.6	2.3	2.0	2.1	1.0	3.2	1.9	2.1	1.4
		Swine	9.1	5.2	15.6	12.0	12.0	11.3	8.6	9.8	8.1	5.6
		Chickens	45.3	35.9	35.4	39.3	40.6	36.7	48.8	37.2	33.1	36.1
CPFX	1*(-2017:4*)	Cattle	0.8	0.0	0.4	0.0	0.5	0.0	0.4	0.0	1.0	0.5
		Swine	2.3	3.1	4.4	0.0	1.2	3.8	2.2	2.0	3.7	0.7
		Chickens	9.9	4.9	10.1	12.0	18.1	16.4	18.2	14.5	14.8	16.1
CL	4*(-2015:16*)	Cattle	0.8	0.0	0.4	1.2	0.0	0.3	0.0	0.0	0.0	0.0
		Swine	0.0	0.0	4.4	2.4	6.0	2.5	4.3	2.0	2.2	2.1
		Chickens	0.0	0.5	2.5	3.3	0.0	0.0	0.8	0.0	0.0	0.0
CP	32*	Cattle	3.6	2.9	2.3	2.8	4.8	3.8	5.9	6.5	7.3	7.1
		Swine	34.1	25.0	25.6	21.7	25.3	22.5	30.1	26.5	33.1	36.1
		Chickens	15.1	9.8	19.6	11.3	17.4	15.6	20.7	9.7	12.0	21.3
ST	76/4*	Cattle	5.2	2.9	5.4	2.0	5.3	2.4	2.8	3.4	3.8	2.9
		Swine	34.1	30.2	28.9	26.5	32.5	23.8	25.8	30.4	30.1	31.9
		Chickens	30.2	28.3	28.5	34.7	33.5	30.5	22.3	23.4	19.7	28.4
Number of isolates tested (n)		Cattle	252	274	258	252	189	288	253	261	286	210
		Swine	88	96	90	83	83	80	93	102	136	144
		Chickens	172	184	158	150	155	128	121	145	142	155

The unit of BP is µg/mL.

* BP follows CLSI Criteria. † BP set based on the EUCAST ECOFF.

For GM, when the interpretive criterion used prior to 2022 (16) was applied, the resistance rates in 2023 were 0.0% in cattle, 1.4% in swine, and 4.5% in chickens.

ii. *Campylobacter jejuni*

Monitoring of antimicrobial resistance was carried out on 7 agents until 2016, and on 8 agents, adding azithromycin (AZM) from 2017 onward.

In 2023, resistance to TC, NA, and CPFX in cattle-derived strains exceeded 60%. On the other hand, resistance to CP in cattle- and chicken-derived strains and to EM in chicken-derived strains were 0%. Resistance to CPFX and AZM, which are critically important antimicrobials for human medicine, were 67.9% and 7.7% in cattle-derived strains, respectively, and 21.1% and 0.0% in chicken-derived strains, respectively.

Table 54. Resistance rates (%) of *Campylobacter jejuni* from animal and poultry slaughterhouses

Agents*	BP	Animal species	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
ABPC	32 [†]	Cattle	12.9	8.9	7.4	8.2	8.6	11.4	8.3	10.5	10.1	14.3
		Chickens	17.5	18.6	16.2	28.4	14.9	14.3	22.4	15.3	22.0	19.3
SM	32 [†] (2023-: BP 8 [†])	Cattle	3.8	3.2	6.2	4.1	8.6	1.8	3.7	4.4	3.9	6.5
		Chickens	3.5	2.1	11.8	1.5	0.0	0.0	2.0	0.0	0.0	7.0
EM	32*	Cattle	0.0	1.3	0.0	0.0	5.7	0.0	2.8	0.9	1.6	5.4
		Chickens	0.0	0.0	0.0	1.5	0.0	0.0	4.1	0.0	0.0	0.0
AZM	4 [†] (2023-: 5)	Cattle	—	—	—	0.0	5.7	0.0	2.8	0.9	1.6	7.7
		Chickens	—	—	—	1.5	0.0	0.0	4.1	0.0	0.0	0.0
TC	16*	Cattle	49.2	52.2	63.0	72.2	65.7	67.5	69.7	62.3	65.1	70.8
		Chickens	38.6	27.8	33.8	46.3	23.4	34.3	22.4	28.8	20.0	12.3
CP	16 [†] (2023-: 32 [†])	Cattle	0.0	1.3	3.7	6.2	2.9	6.1	0.0	6.1	0.8	0.0
		Chickens	1.8	0.0	2.9	0.0	2.1	0.0	0.0	0.0	0.0	0.0
NA	16 [†] (2023-: 32 [†])	Cattle	66.7	42.7	46.9	57.7	37.1	60.5	62.4	64.9	57.4	69.6
		Chickens	36.8	27.8	64.7	46.3	34.0	37.1	32.7	44.1	34.0	21.1
CPFX	4*	Cattle	49.2	40.8	44.4	50.5	31.4	59.6	62.4	60.5	54.3	67.9
		Chickens	29.8	25.8	51.5	44.8	29.8	34.3	32.7	33.9	34.0	21.1
Strains tested (n)		Cattle	132	157	81	97	35	114	109	114	129	168
		Chickens	57	97	68	67	47	35	49	59	50	57

The unit of BP is µg/mL.

[†] BP follows CLSI Criteria. [†] BP set based on the EUCAST ECOFF

For SM, when the interpretive criterion used prior to 2022 (32) was applied, the resistance rates in 2023 were 4.8% in cattle and 7.0% in chickens.

For AZM, when the interpretive criterion used prior to 2022 (4) was applied, the resistance rates in 2023 were 5.4% in cattle and 0.0% in chickens.

For CP, when the interpretive criterion used prior to 2022 (16) was applied, the resistance rates in 2023 were 1.2% in cattle and 0.0% in chickens.

For NA, when the interpretive criterion used prior to 2022 (16) was applied, the resistance rates in 2023 were 69.6% in cattle and 21.1% in chickens.

iii. *Campylobacter coli*

Monitoring of antimicrobial resistance was carried out on 7 agents until 2016, and on 8 agents, adding AZM from 2017 onward. In 2023, swine-derived strains exhibited resistance rates exceeding 60% to SM, TC, and CPFX and over 50% to NA.

On the other hand, CP resistance was less than 3%. Resistance to CPFX, which is a critically important antimicrobial for human medicine, was 61.2%, while the AZM resistance rate was 31.0%.

Table 55. Resistance rates (%) of slaughterhouse-derived *Campylobacter coli*

Agent*	BP	Animal species	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
ABPC	32 [†]	Swine	36.6	24.6	15.4	29.5	17.2	26.7	21.4	23.9	13.3	30.2
SM	32 [†] (2023-: 8 [†])	Swine	69.9	72.3	64.1	68.9	69.0	68.3	71.4	64.8	62.7	92.2
EM	32*	Swine	43.0	26.2	38.5	31.1	20.7	33.3	21.4	33.8	20.5	31.0
AZM	4 [†] (2023-: 1 [†])	Swine	—	—	—	31.1	20.7	31.7	21.4	33.8	20.5	31.0
TC	16*	Swine	80.6	87.7	89.7	83.6	86.2	78.3	73.8	76.1	65.1	69.8
CP	16 [†] (2023-: 32 [†])	Swine	7.5	9.2	15.4	1.6	3.4	3.3	2.4	2.8	2.4	1.7
NA	32 [†] (2023-: 64 [†])	Swine	52.7	47.7	61.5	50.8	58.6	45.0	50.0	54.9	49.4	58.6
CPFX	4*	Swine	50.5	47.7	59.0	54.1	58.6	40.0	50.0	54.9	50.6	61.2
Strains tested (n)		Swine	93	65	39	61	29	60	42	71	83	116

The unit of BP is µg/mL.

.[†] BP follows CLSI Criteria. † BP set based on the EUCAST ECOFF

For SM, when the interpretive criterion used prior to 2022 (32) was applied, the resistance rate in 2023 was 71.6% in swine.

For AZM, when the interpretive criterion used prior to 2022 (4) was applied, the resistance rate in 2023 was 31.0% in swine.

For CP, when the interpretive criterion used prior to 2022 (16) was applied, the resistance rate in 2023 was 3.4% in swine.

For NA, when the interpretive criterion used prior to 2022 (32) was applied, the resistance rate in 2023 was 61.2% in swine.

iv. *Enterococcus* spp.

Monitoring of antimicrobial resistance was carried out on 10 agents until 2014, and 11 agents from 2015 onward with vancomycin (VCM) added. From 2018, dihydrostreptomycin (DSM), oxytetracycline (OTC) and enrofloxacin (ERFX) were changed to SM, TC and CPF, respectively, of which resistance rates were investigated for 10 agents excepting SM as no BPs were established for it.

In 2023, the resistance rate of *Enterococcus* spp. exceeded 40% to KM, EM, and TS in chicken-derived strains and to TC and LCM in both swine- and chicken-derived strains. In contrast, resistance rates to ABPC were 0% in any animal species. Resistance rates to CPF, which belongs to the fluoroquinolone class of antibiotics important in human medicine, ranged from 0.4 to 7.2%. The resistance rate to VCM was 0.0%.

In 2023, among *Enterococcus* spp., *E. hirae* was the most prevalent species in cattle and swine, accounting for 88.3% (197 of 223 isolates) and 59.3% (80 of 135 isolates), respectively. In contrast, *E. faecalis* was the most prevalent species in chickens, representing 71.7% (109 of 152 isolates). The proportion of *E. faecalis* among isolates from cattle and swine was 3.1% (7 of 223 isolates) and 20.7% (28 of 135 isolates), respectively. The proportions of *E. faecium* among isolates from cattle, swine, and chickens were 1.8% (4 of 223 isolates), 6.7% (9 of 135 isolates), and 6.6% (10 of 152 isolates), respectively.

Among chicken-derived *E. faecalis* isolates with ≥ 30 samples, resistance rates exceeded 40% for KM, TC, EM, LCM, and TS. In contrast, The resistance rate to CPF-one of the fluoroquinolones which are critically important antimicrobials for human medicine-was 6.4%, while resistance to VCM was 0.0%.




Figure 4. Proportion of *Enterococcus* spp. species from slaughterhouses and poultry processing plants

Table 56. Resistance rates (%) of *Enterococcus* spp. from animal and poultry slaughterhouses

Agent*	BP	Animal species	2014†	2015	2016	2017	2018	2019	2020	2021	2022	2023
ABPC	16*	Cattle	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
		Swine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
		Chickens	0.6	0.0	0.0	0.0	0.0	0.8	0.5	0.5	0.9	0.0
DSM	128§	Cattle	31.2	14.9	2.9	0.8	-	-	-	-	-	-
		Swine	55.7	34.4	29.7	28.0	-	-	-	-	-	-
		Chickens	30.9	49.2	30.6	27.0	-	-	-	-	-	-
GM	32*(2023-: 500*)	Cattle	4.2	2.2	0.8	0.0	13.5	3.1	8.6	2.2	2.1	0.0
		Swine	3.4	3.1	4.4	1.2	19.0	10.0	6.5	2.6	2.8	2.2
		Chickens	5.5	9.4	4.5	3.4	12.6	9.5	6.2	3.2	6.1	11.2
KM	128§(2023 -: 512‡)	Cattle	5.0	4.1	1.3	0.8	15.9	6.3	15.7	13.9	12.2	1.3
		Swine	20.5	31.3	17.6	22.0	35.4	21.3	33.1	19.7	26.0	9.6
		Chickens	37.0	47.0	41.4	41.9	61.6	49.2	48.2	40.6	45.9	49.3
OTC	16§	Cattle	21.2	27.1	27.6	26.4	-	-	-	-	-	-
		Swine	54.5	59.4	64.8	58.5	-	-	-	-	-	-
		Chickens	58.0	63.0	66.2	52.0	-	-	-	-	-	-
TC	16*	Cattle	-	-	-	-	24.7	24.3	20.6	25.1	26.0	24.2
		Swine	-	-	-	-	58.2	55.0	59.7	48.7	63.3	54.8
		Chickens	-	-	-	-	64.2	54.8	59.6	41.9	48.5	60.5
CP	32*	Cattle	0.0	0.0	0.4	0.4	0.6	0.4	0.4	0.4	0.0	0.0
		Swine	17.0	10.4	15.4	14.6	15.2	11.3	16.1	10.3	14.1	14.1
		Chickens	8.8	7.2	10.2	8.8	9.3	12.7	9.8	6.9	7.8	11.2
EM	8*	Cattle	3.8	1.5	2.5	2.1	1.8	2.4	3.7	4.3	2.1	4.5
		Swine	28.4	30.2	34.1	26.8	27.8	23.8	31.5	22.2	30.5	35.6
		Chickens	43.1	42.5	45.2	41.2	36.4	34.9	36.8	26.3	25.1	44.1
LCM	128§(2023 -: 256‡)	Cattle	3.1	0.7	2.5	2.1	1.8	2.0	2.2	3.9	1.7	2.7
		Swine	50.0	34.4	37.4	35.4	36.7	41.3	39.5	29.1	39.0	40.0
		Chickens	34.3	43.1	47.1	40.5	37.7	41.3	40.9	34.6	32.5	41.4
ERFX	4‡	Cattle	1.2	0.4	0.8	0.0	-	-	-	-	-	-
		Swine	5.7	2.1	1.1	3.7	-	-	-	-	-	-
		Chickens	3.9	13.3	3.8	2.7	-	-	-	-	-	-
CPFX	4*	Cattle	-	-	-	-	2.4	1.6	0.4	1.3	0.3	0.4
		Swine	-	-	-	-	17.7	7.5	4.8	5.1	8.5	1.5
		Chickens	-	-	-	-	6.6	11.1	7.3	8.8	11.7	7.2
TS	64§(2023-: 16‡)	Cattle	2.3	0.7	2.1	2.5	1.8	2.4	2.2	4.3	1.4	3.1
		Swine	21.6	19.8	28.6	24.4	26.6	23.8	29.8	17.9	24.3	25.2
		Chickens	42.0	35.9	42.7	41.2	34.4	34.1	30.6	24.0	19.0	42.1
VCM	32*	Cattle	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
		Swine	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
		Chickens	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Number of isolates tested (n)		Cattle	260	269	239	242	170	255	267	231	288	223
		Swine	88	96	91	82	79	80	124	117	177	135
		Chickens	181	181	157	148	151	126	193	217	231	152

The unit of BP is µg/ml.

* BP follows CLSI Criteria. † BP set based on the EUCAST ECOFF. ‡ BP set based on epidemiological cut-off values calculated from the MIC distributions in JVARM.

§ Intermediate value of the bimodal MIC distribution from JVARM.

For GM, when the interpretive criterion used prior to 2022 (32) was applied, the resistance rates in 2023 were 6.3% in cattle, 3.7% in swine, and 16.4% in chickens.

For KM, when the interpretive criterion used prior to 2022 (32) was applied, the resistance rates in 2023 were 10.3% in cattle, 24.4% in swine, and 61.8% in chickens.

For LCM, when the interpretive criterion used prior to 2022 (128) was applied, the resistance rates in 2023 were 2.7% in cattle, 41.5% in swine, and 44.7% in chickens.

For TS, when the interpretive criterion used prior to 2022 (64) was applied, the resistance rates in 2023 were 2.7% in cattle, 25.2% in swine, and 41.4% in chickens.

Table 57. Resistance rates (%) of *Enterococcus faecalis* from poultry slaughterhouses

Agent	BP	Animal species	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
ABPC	16*	Chickens	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DSM	128§	Chickens	53.8	72.4	40.6	38.8	-	-	-	-	-	-
GM	32*(2023-: 500*)	Chickens	9.9	14.3	6.3	3.5	15.1	15.0	7.0	4.9	9.1	14.7
KM	128§(2023 -: 512‡)	Chickens	57.1	66.3	55.2	58.8	66.0	51.7	47.7	51.9	57.1	60.6
OTC	16§	Chickens	67.0	70.4	83.3	65.9	-	-	-	-	-	-
TC	16*	Chickens	-	-	-	-	70.8	66.7	77.9	59.3	64.9	70.6
CP	32*	Chickens	13.2	9.2	15.6	12.9	11.3	20.0	14.0	12.3	14.3	13.8
EM	8*	Chickens	64.8	60.2	59.4	58.8	43.4	53.3	44.2	40.7	33.8	49.5
LCM	128§(2023 -: 256‡)	Chickens	45.1	54.1	59.4	55.3	43.4	55.0	43.0	40.7	35.1	45.9
ERFX	4‡	Chickens	1.1	0.0	2.1	0.0	-	-	-	-	-	-
CPFX	4*	Chickens	-	-	-	-	2.8	3.3	0.0	4.9	5.2	6.4
TS	64§(2023-: 16‡)	Chickens	65.9	53.1	59.4	60.0	43.4	55.0	44.2	40.7	29.9	50.5
VCM	32*	Chickens	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Strains tested (n)		Chickens	91	98	96	85	106	60	86	81	77	109

The unit of BP is µg/ml.

* BP follows CLSI Criteria. † BP set based on the EUCAST ECOFF. ‡ BP set based on epidemiological cut-off values calculated from the MIC distributions in JVARM.

§ Intermediate value of the bimodal MIC distribution from JVARM.

For GM, when the interpretive criterion used prior to 2022 (32) was applied, the resistance rates in 2023 were 21.1% in chickens.

For KM, when the interpretive criterion used prior to 2022 (32) was applied, the resistance rates in 2023 were 67.9% in chickens.

For LCM, when the interpretive criterion used prior to 2022 (128) was applied, the resistance rates in 2023 were 48.6% in chickens.

For TS, when the interpretive criterion used prior to 2022 (64) was applied, the resistance rates in 2023 were 49.5% in chickens.

v. *Salmonella* spp.

Monitoring of 12 agents in chicken-derived strains was carried out until 2017, and on 13 agents adding MEPM from 2018 onward. Among chicken-derived strains in 2023 resistance of approximately 60% was observed for KM, TC, and SM. On the other hand, resistance to CEZ was 5%, and resistance to GM was 0%. In the realm of critically important antimicrobials for human medicine, the rates of resistance to CTX and CPFX were 0.7% and 1.5%, respectively, and resistance to CL or MEPM was 0.0%.

The *Salmonella* serotypes most commonly isolated from poultry slaughterhouses from 2015 to 2023 were *S. Schwarzengrund* and *S. Infantis*. In comparison of *Salmonella* serotypes isolated from poultry slaughterhouses with those isolated from food and from humans (source: Nippon AMR One Health Report 2024: Table 19) (Table 60, Figure 5), the same trends were observed in *Salmonella* serotypes isolated from poultry slaughterhouses as in those isolated from food. The top two serotypes isolated from poultry slaughterhouses were the same as those isolated from food, respectively accounting for 89.4% and 77.5% of all serotypes from those sources, which suggested a relationship between them. On the other hand, the serotypes isolated from humans were more diverse than those isolated from poultry slaughterhouses and food, with the top two serotypes isolated from poultry slaughterhouses accounting for 13.9% of human-derived strains, which suggested the possibility that there are variety of origin other than poultry or their food products. Comparison of the resistance rates of the top two serotypes *S. Schwarzengrund* and *S. Infantis*, which account for the majority of the poultry slaughterhouse-derived strains, between poultry slaughterhouse-derived and food-derived strains and human strains (Table 60, Fig. 6) (source: Nippon AMR One Health Report 2024: Table 29) showed that KM, SM, and TC resistance rates were similar between food- and poultry slaughterhouse-derived strains.

In *S. Schwarzengrund*, similarities were observed in the resistance rates of human-derived strains as well as those of poultry slaughterhouse- and food-derived strains. On the other hand, the human-derived *S. Infantis* strains showed different resistance rates compared to the strains other isolates, suggesting that the human-derived *S. Infantis* may have originated from sources other than chickens and foods.

Table 58. Resistance rates (%) of *Salmonella* spp. from poultry slaughterhouses

Agent	BP	Animal species	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
ABPC	32*	Chickens	17.2	13.0	13.5	8.0	6.8	5.6	1.8	1.6	0.7	4.5
CEZ	8*(- 2015:32*)	Chickens	3.1	1.6	7.7	3.6	3.4	3.7	1.8	0.8	0.7	1.5
CTX	4*	Chickens	2.3	1.6	1.9	1.8	2.6	1.9	0.9	0.0	0.7	0.7
MEPM	4*	Chickens	—	—	—	—	0.0	0.0	0.0	0.0	0.0	0.0
SM	32†	Chickens	85.9	76.4	77.9	60.7	73.5	33.6	48.6	71.3	49.3	59.7
GM	16*(2023:- 8*)	Chickens	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KM	64*	Chickens	57.8	69.1	72.1	73.2	68.4	75.7	68.8	70.5	73.5	66.4
TC	16*	Chickens	85.2	83.7	82.7	77.7	76.9	69.2	73.4	74.4	64.0	61.2
CP	32*	Chickens	1.6	1.6	0.0	0.9	1.7	0.9	0.0	0.0	0.0	0.0
CL	4*(- 2015:16*)	Chickens	0.0	0.0	0.0	0.0	0.9	1.9	0.0	0.0	0.0	0.0
NA	32*	Chickens	17.2	15.4	12.5	17.0	18.8	8.4	11.9	19.4	14.7	24.6
CPFX	1*(- 2017:4*)	Chickens	0.0	0.0	0.0	0.0	0.9	0.9	0.9	0.8	0.7	1.5
ST	76/4*	Chickens	51.6	57.7	56.7	55.4	53.0	52.3	45.9	40.3	39.0	41.0
Strains tested (n)		Chickens	128	123	104	112	117	107	109	129	136	134

The unit of BP is µg/ml.

* BP follows CLSI Criteria. . † BP set based on the EUCAST ECOFF.

For GM, when the interpretive criterion used prior to 2022 (16) was applied, the resistance rate in 2023 was 0.0% in chickens.

Table 59. Serotypes of *Salmonella* spp. derived from chickens at poultry slaughterhouses (2015-2023)

Serotypes	Number of strains isolated	(%)
Schwarzengrund	779	72.7
Infantis	179	16.7
Manhattan	37	3.5
Typhimurium	37	3.5
Agona	13	1.2
Others	26	2.4
Total	1071	100.0

Table 60. Serotypes of *Salmonella* spp. derived from chickens at poultry slaughterhouses, food, and humans (2015-2023)

From chickens at poultry slaughterhouses (n=1071)	%	From food (n=1,173)	%	From humans (n=2,510)	%
Schwarzengrund	72.7	Schwarzengrund	58.8	Schwarzengrund	5.5
Infantis	16.7	Infantis	18.7	Infantis	8.4
Manhattan	3.5	Manhattan	7.2	Manhattan	2.2
Typhimurium	3.5	Agona	1.7	Typhimurium	6.1
Agona	1.2	Heidelberg	1.5	Enteritidis	14.0
Others	2.4	Others	12.0	4:i:-	11.6
Total	100.0	Total	100.0	Thompson	8.1
				Saintpaul	5.5
				Stanley	3.5
				Newport	3.1
				Others	32.0
				Total	100.0

*Source: Nippon AMR One Health Report 2024: Table 19




Figure 5. Proportions of the top 2 serotypes of *Salmonella* spp. derived from chickens at poultry slaughterhouses isolated in food and humans (2015-2023)

(figures for proportions in human-derived and food-derived strains are quoted from Nippon AMR One Health Report 2024: Table 19)

Table 61. Resistance rates (%) of *S. Infantis* and *S. Schwarzengrund* strains isolated from poultry slaughterhouses (chickens), food, and humans (2015-2023)

	Infantis			Schwarzengrund		
	Chicken (n=179)	Food (n=219)*	Humans (n=210)*	Chicken (n=779)	Food (n=690)*	Humans (n=139)*
ABPC	6.1	12.3	2.4	1.0	3.9	2.9
GM	0.0	0.5	0.0	0.0	0.0	0.7
KM	47.5	39.3	12.4	82.9	78.4	61.9
SM	65.9	72.6	28.1	59.8	77.7	64.7
TC	75.4	77.2	34.3	73.9	84.6	64.7
CP	1.1	2.3	1.9	0.5	7.0	3.6
CTX	4.5	6.8	1.4	0.6	0.4	2.9
NA	6.1	5.9	6.2	16.3	19.3	14.4
CPFX	0.0	0.0	0.0	0.9	0.1	0.0

*Source: Nippon AMR One Health Report 2024: Table 22, 23, 24, 29




Figure 6. Resistance rates of *S. Infantis* and *S. Schwarzengrund* strains derived from humans, food, and poultry slaughterhouses (2015-2023)

(figures for resistance rates in human-derived and food-derived strains are quoted from Nippon AMR One Health Report 2024: Table 22, 23, 24, 29)

2) Farm-raised aquatic animals

Source: Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM)

For the monitoring and surveillance of antimicrobial resistance in aquaculture sector under the JVARM, antimicrobial susceptibility monitoring was conducted focusing on causative agents of α -hemolytic lactococcosis*, and *Vibrio* spp. that were derived from diseased fish.

The test strains were obtained from farmed fish isolates that had undergone pathogenicity testing at prefectural fisheries experiment stations and other facilities. Until 2016, the survey was limited to isolates from farmed amberjack species, but from 2017 onward, it was expanded to include isolates from all farmed fish species.

Additionally, since 2021, a pilot study has been conducted on the antimicrobial susceptibility of causative agents of α -hemolytic lactococcosis (*) and *Vibrio* spp. derived from healthy fish (yellowtail). Test strains were obtained from farmed yellowtail harvested for market.

In antimicrobial susceptibility tests, MIC values were measured using a broth microdilution method or an agar plate dilution method compliant with the CLSI Guidelines. For antimicrobial agents with a BP established by the CLSI, susceptibility was interpreted using the CLSI Criteria. The BPs of the other antimicrobial agents were determined microbiologically (intermediate value of a bimodal MIC distribution).

* Causative agents of α -hemolytic lactococcosis had previously been identified as *Lactococcus garvieae*; however, around 2013, strains with a different serotype, distinct from the conventional serotype (serotype I), began to emerge. These strains, previously classified as serotype II, were reclassified in 2023 as *Lactococcus formosensis* (hereafter referred to as serotype II for convenience). Furthermore, since around 2021, α -hemolytic lactococcosis caused by another serotype (serotype III) has also emerged.

Bacteria derived from diseased fish

i. Causative agents of α -hemolytic lactococcosis derived from diseased fish

The monitoring of antimicrobial resistance has been conducted since 2011 on four agents approved as veterinary medicinal products for aquatic animals for the treatment of α -hemolytic lactococcosis. From 2011 to 2016, test strains were provided annually by 4–6 prefectures; in 2017 by 7 prefectures; in 2018 by 11 prefectures; in 2019 by 7 prefectures; in 2020 by 10 prefectures; in 2021 by 6 prefectures; and in 2022 and 2023 by 10 prefectures each year, through prefectural fisheries experiment stations and other facilities.

As an overall trend, the resistance rate of LCM exhibits significant fluctuations compared to the relatively stable resistance rates of EM and OTC, suggesting the potential influence of serotypes II and III. Resistance rate to LCM was 82.6% (37.5% for serotype I, 85.5% for serotype II, and 100% for serotype III (in 2022, 82.3% (43.5% for serotype I, 90.8% for serotype II, and 98.7% for serotype III))). Resistance rate to EM was 3.0% (2.5% for serotype I, 5.5% for serotype II, and 0% for serotype III (in 2022, 5.2% (0% for serotype I, 10.8% for serotype II, and 0% for serotype III))), a decrease compared to the previous year's rate of 5.2%. The resistance rate to OTC was maintained at a low level of 0.4% (2.5% for serotype I, 0% for serotype II, 0% for serotype III (in 2022, 0% (0% for serotype I, 0% for serotype II, 0% for serotype III))). As the MIC distribution of FF was not bimodal, the BP could not be established, and the resistance rate could therefore not be calculated. However, all strains had MICs within the range of 0.5–16 $\mu\text{g/mL}$, and most isolates (209 strains) exhibited MICs of 2–4 $\mu\text{g/mL}$ (Table 62).

Table 62. Resistance rates (%) of is in the past 10 years

Agent* ¹	BP (-2019)	BP (2020-)	2014	2015	2016	2017* ^{2,3}	2018	2019	2020	2021	2022	2023
EM	8	16	0.0	2.2	1.7	1.9	0.0	3.1	0.6	14.1	5.2	3.0
LCM	8	16	40.0	53.3	58.3	61.0	31.5	54.6	53.8	66.0	82.3	82.6
OTC	8	16	0.0	2.2	1.7	0.0	0.0	2.6	0.6	0.5	0.0	0.4
Strains tested (n)			25	45	60	105	149	194	158	206	271	235

The unit of BP is $\mu\text{g/mL}$.

*¹: While FF was also included in the scope of survey, the proportion of FF-resistant strains was not listed because BP could not be established.

*²: Monitoring focused only on farmed yellowtail until 2016 but was expanded in 2017 to include strains derived from all farmed fish species.

*³: An agar plate dilution method was used in monitoring until 2016, but the broth microdilution method has been used since 2017.

ii. *Vibrio* spp.

Since 2017, the monitoring of antimicrobial resistance has been conducted on four agents approved as veterinary medicinal products for aquatic animals for the treatment of vibriosis using isolates from diseased fish. Test strains were provided by prefectural fisheries experiment stations and other facilities from six prefectures in 2017, nine in 2018, ten in 2019, eight in 2020, eleven in 2021, eight in 2022, and ten in 2023.

In 2023, the resistance rate to OTC was 11.8%. For FF, OA, and SMMX, resistance rates could not be determined because the MIC distributions did not show a bimodal pattern, preventing breakpoint (BP) setting. For FF and OA, MICs for all isolates ranged from 0.25 to 2 µg/mL and ≤0.12 to 0.5 µg/mL, respectively. For SMMX, 27 of 34 isolates had MICs >64 µg/mL, while the remaining seven isolates had MICs in the range of 1–16 µg/mL. (Table 63).

Table 63. Trends in resistance rates (%) of *Vibrio* spp.

Agent*	BP (-2019)	BP (2020-)	2017	2018	2019	2020	2021	2022	2023
OTC	8	16	12.8	15.7	0.0	11.9	4.2	7.4	11.8
Strains tested (n)			39	51	40	42	71	54	34

The unit of BP is µg/mL.

* While FF, OA and SMMX were also included in the scope of survey, their resistance proportion were not listed because BP could not be established.

Bacteria derived from healthy fish

Monitoring of the bacteria derived from healthy fish (causative agents of α-hemolytic lactococcosis and *Vibrio* spp.) was initiated in 2021 on a trial basis. From 2021 to 2023, 100 fish were examined each year. The number of fish farms sampled was 10 in 5 prefectures, and each farm sampled 10 fish. The protocol will undergo continuous review and revision as necessary, in parallel with the ongoing accumulation of data.

Furthermore, due to the limited number of isolates, calculating the resistance rates proved challenging, and as a result, the resistance rate is not provided.

i. Causative agents of α-hemolytic lactococcosis from healthy farmed yellowtail

Among strains obtained from healthy farmed yellowtail harvested in 2023, the isolation rate (number of fish with isolates/number of fish examined) was 14%, and bacteria were isolated from three of the ten aquaculture facilities. Antimicrobial susceptibility was investigated for four agents approved for the treatment of α-hemolytic lactococcosis in aquaculture. For EM and FF, MICs for all isolates ranged from ≤0.12–0.5 µg/mL and 2–4 µg/mL, respectively. For OTC, MICs were ≤0.12 µg/mL for all isolates except two strains (16 µg/mL) obtained from two fish originating from the same aquaculture facility. In contrast, for LCM, MICs for all isolates ranged from 64 to 128 µg/mL.

ii. *Vibrio* spp. from healthy farmed yellowtail

Among isolates obtained from healthy farmed yellowtail harvested in 2023, the isolation rate (number of fish with isolates/number of fish examined) was 60%, and bacteria were isolated from all ten aquaculture facilities. As this bacterium is ubiquitous in the marine environment, a high isolation frequency is expected.

Antimicrobial susceptibility was examined for four agents approved for the treatment of vibriosis in aquaculture. For OA and FF, MICs for all isolates ranged from ≤0.12–1 µg/mL and 0.5–2 µg/mL, respectively. For OTC, MICs ranged from 0.25–1 µg/mL for all isolates except one strain (>64 µg/mL) isolated from a single fish. For SMMX, isolates from 25 fish originating from all facilities (33 of 112 isolates) showed MICs >64 µg/mL. The remaining isolates (79 strains) had MICs ranging from 4 to 64 µg/mL, with the majority (66 strains) showing MICs of 8–16 µg/mL.

3) Companion animals

Source: Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM)

Routine monitoring of antimicrobial resistance in bacteria derived from diseased dogs and cats was launched in 2017, as part of efforts to strengthen monitoring under the AMR Action Plan. Monitoring of antimicrobial resistance in bacteria derived from diseased animals, unlikely from healthy animals, has the potential to be affected using antimicrobials in treatment or by the incidence of diseases. As with livestock animals, obtaining information about antimicrobial resistance trends in healthy companion animals to serve as a baseline is considered important. Accordingly, as well as ongoing monitoring of diseased animals, surveillance of healthy dogs and cats was launched in 2018.

Antimicrobial susceptibility tests measured the MIC values of antimicrobials in respect of the bacterial strains collected, using a broth microdilution method compliant with the CLSI criteria.

For agents with a BP indicated by the CLSI, susceptibility was interpreted using the CLSI criteria. The BPs of the other antimicrobial agents used EUCAST values (ECOFF) or epidemiological cut-off values calculated based on the MIC distributions in JVARM were used.

Although no combination products with β -lactamase inhibitors had been approved as veterinary medicinal products, a combination of amoxicillin and the β -lactamase inhibitor clavulanic acid (CVA/AMPC) was approved for use in dogs and cats in 2021. Accordingly, this drug is included in the monitoring program from 2024. As a result, several antimicrobial agents included in the survey were modified.

For *E. coli* and *Klebsiella* spp., CVA/AMPC was added to the panel of antimicrobials tested, and nalidixic acid (NA) was removed.

For *Staphylococcus* spp., CVA/AMPC was also added, and vancomycin (VCM), clindamycin (CLDM), and the sulfamethoxazole-trimethoprim combination (ST) were additionally included, while cefoxitin (CFX), cefotaxime (CTX), and azithromycin (AZM) were removed.

For *Enterococcus* spp., minocycline (MINO) was added.

Bacterial strains from diseased dogs and cats

Bacterial strains from diseased dogs and cats were collected from small-animal clinical laboratories. The country was divided into six regional blocks-Hokkaido and Tohoku, Kanto, Chubu, Kinki, Chugoku and Shikoku, and Kyushu and Okinawa-and the number of strains allocated on the basis of the number of notifications of veterinary clinic (small animal and other animals) establishment received.

Samples of *Escherichia coli* and *Klebsiella* spp. were collected from urine and reproductive organs, samples of coagulase-positive *Staphylococcus* spp. from urine and skin, and samples of *Enterococcus* spp. from urine and ears.

i. *Escherichia coli*

The resistance rate to the newly added CVA/AMPC was 21.4% in dog-derived strains and 21.0% in cat-derived strains. As in the years before, the rate of resistance to ABPC was the highest, exceeding 50%, among the agents surveyed. On the other hand, the rates of resistance to SM, GM, KM, and CP in strains isolated from both dogs and cats, as well as to TC and ST in strains isolated from cats, were less than 20%. The rates of resistance to critically important antimicrobials for human medicine in dog- and cat-derived strains respectively were as follows: 20.9% and 25.0% to CTX, 39.0% and 26.1% to CPF, 0.5% and 1.1% to CL, and both 0.0% to MEP.

Table 64. Resistance rates (%) of *Escherichia coli* derived from diseased dogs and cats

Agent	BP	Animal species	2017	2018	2019	2020	2021	2022	2023	2024
ABPC	32*	Dog	55.3	63.0	51.1	50.3	54.4	53.5	48.3	50.8
		Cat	64.0	65.6	60.2	56.5	59.4	47.9	56.2	50.0
CVA/AMPC	16/8*	Dog	-	-	-	-	-	-	-	21.4
		Cat	-	-	-	-	-	-	-	21.0
CEZ	32*(2024-: 8*)	Dog	31.2	44.2	30.3	31.1	32.8	30.3	30.2	35.8
		Cat	37.5	44.1	32.0	29.8	33.5	32.0	38.0	36.4
CEX	32†(2024-: 64†)	Dog	31.7	42.9	31.5	32.8	32.8	32.4	29.5	26.7
		Cat	41.9	47.3	31.3	31.7	37.1	32.5	39.4	30.1
CTX	4*	Dog	26.1	41.6	26.4	27.1	27.8	25.9	26.8	20.9
		Cat	33.8	39.8	26.6	26.1	29.4	24.3	27.7	25.0
MEPM	4*	Dog	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
		Cat	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SM	32†	Dog	29.6	29.9	20.2	27.1	25.6	20.5	16.8	22.5
		Cat	32.4	34.4	28.9	19.3	23.5	17.8	21.9	18.8
GM	16*(2024-: 8*)	Dog	14.1	18.8	12.9	13.0	12.2	11.9	10.1	9.6
		Cat	12.5	15.1	9.4	9.9	17.1	10.7	13.9	8.0
KM	64*	Dog	6.5	7.8	5.1	5.6	5.6	7.6	4.7	5.3
		Cat	8.1	12.9	7.0	3.7	6.5	4.1	5.1	2.8
TC	16*	Dog	28.1	27.9	21.3	23.2	20.6	20.0	18.1	20.9
		Cat	24.3	29.0	26.6	16.8	24.1	23.1	23.4	18.8
CP	32*	Dog	12.6	16.2	11.8	7.9	12.8	5.4	9.4	8.6
		Cat	13.2	15.1	7.8	5.0	8.2	8.3	13.1	6.3
CL	4*	Dog	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5
		Cat	0.0	1.1	0.0	0.6	0.6	0.0	0.7	1.1
NA	32*	Dog	61.8	72.7	56.2	58.8	56.1	55.1	51.0	-
		Cat	58.8	68.8	46.9	55.9	54.7	53.3	58.4	-
CPFX	1*(- 2017:4*)	Dog	43.2	55.2	38.8	42.4	40.6	37.3	38.3	39.0
		Cat	39.0	50.5	37.5	38.5	41.2	29.6	34.3	26.1
Strains tested (n)		Dog	199	154	178	177	180	185	149	187
		Cat	136	93	128	161	170	169	137	176

The unit of BP is µg/ml.

* BP follows CLSI Criteria. † BP set based on the EUCAST ECOFF.

For CEZ, when the interpretive criterion used prior to 2023 (32) was applied, the resistance rates in 2024 were 25.1% in dogs and 28.4% in cats.

For CEX, when the interpretive criterion used prior to 2023 (32) was applied, the resistance rates in 2024 were 29.4% in dogs and 33.3% in cats.

For GM, when the interpretive criterion used prior to 2022 (16) was applied, the resistance rates in 2024 were 9.6% in dogs and 7.4% in cats.

ii. *Klebsiella* spp.

Among *Klebsiella* spp., *K. pneumoniae* was the most prevalent, with *K. oxytoca*, *K. aerogenes*, and *K. variicola* also collected. In 2024, as with *Escherichia coli*, NA was removed from the tested antimicrobials, and measurement of CVA/AMPC was newly initiated. Resistance rates exceeding 40% were observed for CEZ in isolates from both dogs and cats, and for CVA/AMPC, cephalexin (CEX), CTX, SM, CPFX, and ST in isolates from cats. In contrast, resistance rates below 20% were maintained for KM in isolates from both dogs and cats, and for SM and TC in isolates from dogs. For clinically important antimicrobials for human medicine, resistance rates in dog and cat isolates were as follows: CTX, 26.3% and 44.1%; CPFX, 33.7% and 55.9%; CL, 1.1% and 3.4%; and MEPM, 1.1% and 0.0%, respectively.

Table 65. Trends in resistance rates (%) of *Klebsiella* spp. derived from diseased dogs and cats

Agent	BP	Animal species	2017	2018	2019	2020	2021	2022	2023	2024
CVA/AMPC	16/8*	Dog	-	-	-	-	-	-	-	35.8
		Cat	-	-	-	-	-	-	-	50.8
CEZ	32*(8*from 2024)	Dog	49.3	48.0	42.0	45.8	44.0	39.3	30.9	41.1
		Cat	85.2	85.0	67.6	61.3	69.3	68.1	69.2	66.1
CEX	32†	Dog	46.7	48.0	42.0	45.8	44.0	36.0	32.1	36.8
		Cat	85.2	80.0	62.2	58.1	64.0	68.1	69.2	57.6
CTX	4*	Dog	41.3	40.0	34.6	34.9	37.4	33.7	23.5	26.3
		Cat	77.8	80.0	56.8	48.4	56.0	62.3	65.4	44.1
MEPM	4*	Dog	0.0	0.0	0.0	0.0	0.0	0.0	1.2	1.1
		Cat	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SM	32†	Dog	25.3	34.0	29.6	31.3	30.8	32.6	19.8	17.9
		Cat	55.6	55.0	59.5	41.9	52.0	46.4	42.3	42.4
GM	16*(8*from 2024)	Dog	25.3	28.0	21.0	28.9	24.2	30.3	14.8	21.1
		Cat	59.3	55.0	40.5	33.9	44.0	49.3	32.7	30.5
KM	64*	Dog	8.0	12.0	6.2	10.8	9.9	9.0	3.7	5.3
		Cat	22.2	20.0	13.5	12.9	9.3	18.8	11.5	11.9
TC	16*	Dog	32.0	44.0	30.9	33.7	26.4	30.3	19.8	18.9
		Cat	55.6	65.0	48.6	40.3	56.0	52.2	44.2	33.9
CP	32*	Dog	24.0	32.0	19.8	25.3	20.9	21.3	19.8	20.0
		Cat	25.9	45.0	16.2	25.8	26.7	27.5	13.5	27.1
CL	4*	Dog	1.3	0.0	0.0	0.0	0.0	0.0	4.9	1.1
		Cat	3.7	0.0	0.0	1.6	4.0	2.9	0.0	3.4
NA	32*		49.3	60.0	46.9	48.2	54.9	48.3	29.6	-
			81.5	95.0	81.1	54.8	77.3	79.7	59.6	-
CPFX	1*(-2017:4*)	Dog	42.7	56.0	46.9	44.6	49.5	43.8	24.7	33.7
		Cat	81.5	90.0	75.7	56.5	73.3	72.5	59.6	55.9
ST	76/4*	Dog	40.0	46.0	37.0	39.8	38.5	37.1	27.2	23.2
		Cat	74.1	70.0	56.8	43.5	54.7	60.9	57.7	45.8
Strains tested (n)		Dog	75	50	81	83	91	89	81	95
		Cat	27	20	37	62	75	69	52	59

The unit of BP is µg/mL.

* BP follows CLSI Criteria. ‡ BP set based on the EUCAST ECOFF.

For CEZ, when the interpretive criterion used prior to 2023 (32) was applied, the resistance rates in 2024 were 37.9% in dogs and 61.0% in cats.

iii. Coagulase-positive *Staphylococcus* spp.

The most common coagulase-positive *Staphylococcus* spp. in both dogs and cats was *S. pseudintermedius*. *S. aureus* was also collected.

For *S. pseudintermedius* in 2024, resistance rates exceeded 50% for all tested antimicrobials except GM, MINO, and ST in both dog- and cat-derived strains, and CVA/AMPC, MPIPC, and CP in dog-derived strains. For clinically important antimicrobials for human medicine, resistance to CPFX was 63.4% in dog-derived strains and 88.9% in cat-derived strains, whereas resistance rate to VCM was 0.0% in strains derived from both species.

In *S. aureus* isolated from cats, resistance to CVA/AMPC and CPFX was observed to exceed 50% in 2024. On the other hand, the resistance rates to SM, MINO, and ST were low (<10%) and that to CP was 0.0%. For critically important antimicrobials for human medicine, the resistance rate to CPFX was 64.1%, while resistance to VCM was 0.0%.

Table 66. Resistance rates (%) of *Staphylococcus pseudintermedius* derived from diseased dogs and cats

Agent*	BP	Animal species	2017	2018	2019	2020	2021	2022	2023	2024
PCG	0.25*	Dog	-	-	97.4	95.9	97.4	98.9	92.6	87.8
		Cat	-	-	97.6	98.0	98.4	95.7	96.3	95.6
CVA/AMPC	1/0.5*	Dog	-	-	-	-	-	-	-	42.7
		Cat	-	-	-	-	-	-	-	66.7
MPIPC	1*(-2020:0.5*)	Dog	58.7	56.6	62.8	51.4	56.6	60.2	50.6	48.8
		Cat	68.6	81.8	81.0	77.6	78.7	76.1	81.5	73.3
GM	16*	Dog	24.0	54.2	64.1	25.7	40.8	44.3	45.7	40.2
		Cat	13.7	63.6	52.4	44.9	50.8	63.0	48.1	26.7
TC	16*	Dog	62.0	67.5	66.7	73.0	71.1	65.9	84.0	-
		Cat	52.9	81.8	85.7	71.4	85.2	73.9	66.7	-
MINO	16*	Dog	-	-	-	-	-	-	-	0.0
		Cat	-	-	-	-	-	-	-	2.2
CP	32*	Dog	43.0	49.4	60.3	58.1	55.3	59.1	65.4	45.1
		Cat	64.7	72.7	83.3	67.3	82.0	65.2	66.7	64.4
EM	8*	Dog	66.9	74.7	79.5	77.0	71.1	77.3	82.7	62.2
		Cat	70.6	86.4	95.2	79.6	91.8	89.1	88.9	80.0
AZM	8*	Dog	66.9	74.7	79.5	77.0	71.1	77.3	81.5	-
		Cat	66.7	86.4	95.2	79.6	91.8	91.3	88.9	-
CLDM	4*	Dog	-	-	-	-	-	-	-	63.4
		Cat	-	-	-	-	-	-	-	77.8
VCM	32*	Dog	-	-	-	-	-	-	-	0.0
		Cat	-	-	-	-	-	-	-	0.0
CPFX	4*	Dog	64.5	75.9	75.6	74.3	73.7	79.5	77.8	63.4
		Cat	88.2	100.0	97.6	93.9	91.8	97.8	100.0	88.9
ST	76/4*	Dog	-	-	-	-	-	-	-	34.1
		Cat	-	-	-	-	-	-	-	40.0
Strains tested (n)		Dog	Dog	83	78	74	76	88	81	82
		Cat	Cat	22	42	49	61	46	27	45

The unit of BP is µg/mL.

† BP follows CLSI Criteria.

Table 67. Resistance rates (%) of *Staphylococcus aureus* derived from diseased cats

Agent	BP	Animal species	2017	2018	2019	2020	2021	2022	2023	2024
PCG	0.25*	Cat	-	-	90.0	84.6	96.3	81.0	71.0	82.1
CVA/AMPC	1/0.5*	Cat	-	-	-	-	-	-	-	66.7
MPIPC	4*	Cat	61.9	-	70.0	65.4	51.9	50.0	35.5	41.0
CEZ	4†	Cat	61.9	-	66.7	57.7	44.4	47.6	38.7	41.0
CEX	32‡	Cat	61.9	-	70.0	61.5	59.3	52.4	38.7	41.0
CFX	8*	Cat	61.9	-	70.0	61.5	51.9	50.0	41.9	-
CTX	8†	Cat	61.9	-	70.0	61.5	55.6	47.6	38.7	-
SM	32†	Cat	4.8	-	0.0	3.8	3.7	4.8	6.5	5.1
GM	16*	Cat	47.6	-	36.7	57.7	22.2	31.0	22.6	38.5
TC	16*	Cat	14.3	-	43.3	38.5	14.8	21.4	16.1	-
MINO	16*	Cat	-	-	-	-	-	-	-	7.7
CP	32*	Cat	0.0	-	0.0	0.0	3.7	0.0	0.0	0.0
EM	8*	Cat	66.7	-	70.0	61.5	70.4	52.4	48.4	48.7
AZM	8*	Cat	66.7	-	70.0	61.5	70.4	52.4	51.6	-
CLDM	4*	Cat	-	-	-	-	-	-	-	10.3
VCM	16*	Cat	-	-	-	-	-	-	-	0.0
CPFEX	4*	Cat	61.9	-	83.3	73.1	63.0	59.5	58.1	64.1
ST	76/4*	Cat	-	-	-	-	-	-	-	2.6
Strains tested (n)		Cat	21	17	30	26	27	42	31	39

The unit of BP is µg/mL.

† BP follows CLSI Criteria. † BP set based on the EUCAST ECOFF. ‡ BP set based on epidemiological cut-off values calculated from the MIC distributions in JVARM.

Resistance rates were not published when the number of tested isolates was fewer than 20.

iv. *Enterococcus* spp.

The most common *Enterococcus* spp. in both dogs and cats was *E. faecalis*, followed by *E. faecium*.

In 2024, rates of resistance to TC were the highest in both dog- and cat-derived strains (62.8% in dogs and 64.9% in cats), followed by MINO (50.67% in dogs and 50.9% in cats) and EM (34.4% in dogs and 42.7% in cats), and the resistance rates to ABPC, GM, and CP in dog- and cat-derived strains were less than 20%. From 2024 onward, the CLSI-defined high-level resistance breakpoint of 500 µg/mL was adopted when determining GM resistance rates. For CPFX, an important antimicrobial agent in human medicine, 28.3% and 31.0% of dog- and cat-derived strains were found to be resistant, respectively. As to the measurement of VCM which began in 2019 as a test agent, the resistance rates of both dog- and cat-derived strains were 0.0%.

Table 68. Resistance rates (%) of *Enterococcus* spp. derived from diseased dogs and cats

Agent*	BP	Animal species	2017	2018	2019	2020	2021	2022	2023	2024
ABPC	16*	Dog	26.7	20.5	20.0	14.6	13.3	14.8	16.2	11.7
		Cat	17.3	31.6	33.0	26.4	24.1	24.5	30.4	15.8
GM	32§(2024-: 500*)	Dog	22.9	15.4	25.2	25.7	27.8	33.0	18.5	10.0
		Cat	19.4	24.6	25.2	25.7	27.1	20.9	33.0	14.6
TC	16*	Dog	65.6	67.9	68.9	64.9	63.9	65.9	59.2	62.8
		Cat	70.4	73.7	64.1	68.2	65.9	66.9	73.2	64.9
MINO	16*	Dog	-	-	-	-	-	-	-	50.6
		Cat	-	-	-	-	-	-	-	50.9
CP	32*	Dog	20.6	14.1	18.5	14.6	13.3	14.8	14.6	10.0
		Cat	20.4	15.8	8.7	18.2	15.3	12.3	17.0	9.9
EM	8*	Dog	61.8	39.7	43.0	45.0	46.1	43.4	37.7	34.4
		Cat	41.8	54.4	39.8	48.0	45.9	38.0	50.0	42.7
CPFX	4*	Dog	42.7	28.2	31.1	25.1	27.8	34.1	28.5	28.3
		Cat	34.7	49.1	43.7	40.5	40.6	40.5	43.8	31.0
VCM	32*	Dog	-	-	0.0	0.0	0.0	0.0	0.0	0.0
		Cat	-	-	0.0	0.0	0.0	0.0	0.0	0.0
Strain tested (n)		Dog	131	78	135	171	180	182	130	180
		Cat	98	57	103	148	170	163	112	171

The unit of BP is µg/mL.

† BP follows CLSI Criteria. ‡ BP set based on the EUCAST ECOFF. § Intermediate value of the bimodal MC distribution obtained in FY 2002.

For GM, when the interpretive criterion used prior to 2023 (32) was applied, the resistance rate in 2024 was 16.7% in dogs and 19.9% in cats.

Bacterial strains from healthy dogs and cats

Bacterial strains from healthy dogs and cats were collected from veterinary clinics across the country with the cooperation of the Japan Veterinary Medical Association, with the number of strains allocated on the basis of the number of notifications of veterinary clinic (small animals and other animals) establishment received by each prefecture. Rectal swabs were taken from healthy dogs and cats brought to veterinary clinics for health checkups and vaccination. *Escherichia coli* and *Enterococcus* spp. were then isolated from the samples, identified, and antimicrobial susceptibility tests.

i. *Escherichia coli*

In 2024, as with *E. coli* from diseased dogs and cats, NA was removed from the panel of tested antimicrobials, and measurement of CVA/AMPC was newly initiated. The resistance rate to CVA/AMPC was 11.8% in dog-derived strains and 9.9% in cat-derived strains. As in previous surveys, showed a trend toward higher resistance rates to ABPC and NA among the agents surveyed than to the other agents, while resistance rates to the other agents (see Table 68) were all less than 20%. The rates of resistance to critically important antimicrobials for human medicine in dog- and cat-derived strains were 9.1% and 9.9% to CPFX, while the resistance rates to CL and MEPM were both 0.0%. In all agents which resistant strains had been found, resistance rates of *Escherichia coli* derived from healthy dogs and cats were lower than that from diseased dogs and cats collected in same year.

Table 69. Resistance rates (%) of *Escherichia coli* derived from healthy dogs and cats

Agent	BP	Animal species	2018	2019	2020	2021	2022	2023	2024
ABPC	32*	Dog	33.8	22.9	29.5	17.5	28.1	21.5	21.8
		Cat	28.5	27.1	18.5	21.7	25.4	20.6	25.2
CVA/AMPC	16/8*	Dog	-	-	-	-	-	-	11.8
		Cat	-	-	-	-	-	-	9.9
CEZ	32*(2024-: 8*)	Dog	17.2	10.9	17.8	10.4	14.6	13.1	16.4
		Cat	17.1	11.7	7.5	9.9	13.6	11.2	12.6
CEX	32†(2024-: 64†)	Dog	17.9	10.9	17.1	9.7	14.0	14.0	13.6
		Cat	18.4	13.3	8.9	10.6	14.8	11.2	12.6
CTX	4*	Dog	13.2	8.9	13.0	7.8	8.8	11.2	9.1
		Cat	10.8	6.4	2.7	7.5	7.1	3.7	7.2
MEPM	4*	Dog	0.0	0.0	0.0	0.0	0.0	0.0	0.0
		Cat	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SM	32†	Dog	19.2	13.0	14.4	8.4	13.5	10.3	9.1
		Cat	11.4	11.7	8.9	11.2	7.7	5.6	7.2
GM	16*(2024-: 8*)	Dog	3.3	2.6	8.2	1.9	3.5	1.9	6.4
		Cat	2.5	4.3	3.4	4.3	2.4	0.9	3.6
KM	64*	Dog	5.3	3.6	4.1	2.6	2.9	3.7	1.8
		Cat	1.9	3.2	3.4	3.1	2.4	2.8	3.6
TC	16*	Dog	16.6	13.0	12.3	8.4	11.1	9.3	6.4
		Cat	10.8	10.1	8.2	8.1	3.6	4.7	8.1
CP	32*	Dog	4.6	5.7	5.5	3.2	4.7	1.9	2.7
		Cat	1.3	3.7	1.4	2.5	1.2	3.7	2.7
CL	4*	Dog	0.0	0.5	0.0	0.0	0.0	0.0	0.0
		Cat	0.0	0.0	0.0	0.0	0.6	0.0	0.0
NA	32*	Dog	27.8	20.8	22.6	10.4	19.3	14.0	-
		Cat	24.7	28.7	17.8	17.4	20.1	23.4	-
CPFX	1*(-2017:4*)	Dog	18.5	8.9	12.3	7.1	10.5	5.6	9.1
		Cat	12.0	13.3	4.8	7.5	7.1	7.5	9.9
ST	76/4*	Dog	13.2	7.8	11.6	5.8	11.1	3.7	10.0
		Cat	12.0	9.6	5.5	7.5	6.5	5.6	8.1
Strains tested (n)		Dog	151	192	146	154	171	107	110
		Cat	158	188	146	161	169	107	111

The unit of BP is µg/mL.

*BP follows CLSI Criteria. †BP set based on the EUCAST ECOFF.

For CEZ, when the interpretive criterion used prior to 2023 (32) was applied, the resistance rate in 2024 was 12.7% in dogs and 11.7% in cats.

For CEX, when the interpretive criterion used prior to 2023 (32) was applied, the resistance rate in 2024 was 13.6% in dogs and 12.6% in cats.

For GM, when the interpretive criterion used prior to 2023 (16) was applied, the resistance rate in 2024 was 5.5% in dogs and 3.6% in cats.

ii. *Enterococcus* spp.

The most common *Enterococcus* spp. in both dogs and cats were *E. faecalis*. *E. faecium*, *E. durans*, *E. gallinarum*, *E. hirae*, *E. avium*, and *E. casseliflavus* were also collected.

In strains isolated from dogs and cats in 2023, the highest rate of resistance was to TC, followed by EM, while rates of resistance to the other antimicrobials were all less than 20%.

As with *Enterococcus* spp. isolated from diseased dogs and cats, MINO was newly added to the panel of tested antimicrobials in 2024. Resistance rates to all other agents were below 20%, except for TC and EM in isolates from both dogs and cats, MINO in isolates from dogs, and GM in isolates from cats. From 2024 onward, the CLSI-defined high-level resistance breakpoint of 500 µg/mL was adopted when determining GM resistance rates. The rates of resistance to critically important antimicrobial for human medicine CPFX in dog- and cat-derived strains were 9.4 and 9.5%, and both 0.0% to VCM.

Table 70. Resistance rates (%) of *Enterococcus* spp. derived from healthy dogs and cats

Agent*	BP	Animal species	2018	2019	2020	2021	2022	2023	2024
ABPC	16*	Dog	6.9	1.9	5.4	0.0	2.3	3.3	2.1
		Cat	2.2	3.4	1.3	1.2	3.4	0.0	2.4
GM	32§(2024-: 500*)	Dog	12.4	7.0	14.0	10.2	9.9	6.7	7.3
		Cat	11.1	15.7	22.1	11.9	6.9	12.3	21.4
TC	16*	Dog	55.9	41.8	43.4	47.7	45.6	45.6	46.9
		Cat	48.9	61.8	44.2	58.3	45.7	49.1	57.1
MINO	16*	Dog	-	-	-	-	-	-	30.2
		Cat	-	-	-	-	-	-	19.1
CP	32*	Dog	15.9	10.1	10.1	11.7	11.1	6.7	6.3
		Cat	11.1	14.6	14.3	15.5	6.0	8.8	16.7
EM	8*	Dog	32.4	23.4	27.9	23.4	27.5	27.8	20.8
		Cat	34.4	34.8	32.5	38.1	29.3	29.8	45.2
CPFX	4*	Dog	13.8	5.7	10.1	5.5	15.8	8.9	9.4
		Cat	14.4	13.5	10.4	4.8	8.6	8.8	9.5
VCM	32*	Dog	0.0	0.0	0.0	0.0	0.0	0.0	0.0
		Cat	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Strains tested (n)		Dog	145	158	129	128	171	90	96
		Cat	90	89	77	84	116	57	42

The unit of BP is µg/mL.

*† BP follows CLSI Criteria. † BP set based on the EUCAST ECOFF.

§ Intermediate value of the bimodal MC distribution from JVARM.

For GM, when the interpretive criterion used prior to 2023 (32) was applied, the resistance rate in 2024 was 16.7% in dogs and 28.6% in cats.

4) Wild animals

Antimicrobial susceptibility tests were conducted on 963 strains of *Escherichia coli* isolated from 475 wild animals (525 strains from 242 deer; 224 strains from 112 wild boar; 199 strains from 113 small mammals (including brown rats, black rats, large Japanese field mice, and Japanese shrew moles); 10 strains from 4 badgers; 3 strains from 2 feral cattle (Japanese native cattle Kuchinouchi cattle); and 2 strains from 2 Amami rabbits) within Japan between 2013 and 2017 (Table 71). Strains isolated from deer and wild boar demonstrated resistance to eight antimicrobials, while those isolated from small mammals showed resistance to 10 antimicrobials. Antimicrobial resistance was observed in 5.9% of *E. coli* strains isolated from deer, with resistance to tetracycline (TC, 4.4%) highest, followed by CL (1.5%), ABPC, and sulfamethoxazole-trimethoprim (ST, 0.8%). Resistance was observed in 8.0% of strains isolated from wild boar, with resistance to TC (4.0%) highest, followed by ABPC (3.6%), and CP (1.8%). Resistant strains accounted for 18.1% of strains isolated from small mammals, with resistance to ABPC and TC (12.6% in both cases) highest, followed by ST (11.6%). In particular, in the case of small mammals, most of antimicrobial-resistant strains were observed in strains from facilities related to livestock animals, with resistance to ABPC, ST, TC, and NA observed to be in excess of 10%. However, resistance to only two antimicrobials (TC and ST) was found in strains isolated from urban areas and no resistance to any of the 12 agents monitored was found in strains isolated from mountainous areas. Bacteria producing extended-spectrum β -lactamase (ESBL) were observed in 1 strain isolated from small mammals (livestock facility) and the ESBL was found to be CTX-M-1.

While the effects of antimicrobial-resistant bacteria on habitat contamination can be seen in the distribution of resistant bacteria in land-dwelling wild animals, the rates are low compared with livestock animals and companion animals. 848 *E. coli* isolates from wild deer from 2016 to 2019 also showed a low rate of antimicrobial resistance (9 isolates, 1.1%), although the antimicrobials tested varied (Table 72). Thus, antimicrobial-resistant bacterial contamination of the mountainous areas that form the main habitat of the deer and wild boar covered by this study appeared to be low.

In addition, 135 strains of *E. coli* from the Amami rabbit inhabiting a remote island (Amami Oshima) from 2017 to 2020 were susceptible to the antimicrobials tested. The Amami rabbit, which feeds primarily on grasses and woody plants, has limited opportunities to acquire antimicrobial-resistant bacteria from humans, livestock, or other wild animals. Continued monitoring is therefore expected to clarify whether the carriage (or isolation) of resistant bacteria remains low in this species.

Among 144 *E. coli* strains isolated from great cormorants caught in Gunma, Gifu, Shiga, and Oita prefectures from 2018 to 2019, 5.6% were resistant, and resistance were observed to ABPC (3.5%), TC (2.8%), NA (1.4%), CPFX (0.7%), CL (0.7%), CP (1.4%), and ST (1.4%) (Table 72). In 110 *E. coli* isolates from white-fronted goose feces collected in Miyajima-numa (Hokkaido, Japan) in 2019, one (0.9%) was resistant (ABPC-CEZ resistant) and carried a plasmid-mediated AmpC β -lactamase gene (*bla_{ACC}*) (Table 72). Although it must be taken into account that the fact that the great cormorant is a resident bird and the white-fronted goose is a migratory bird affects the distribution of resistant strains, attention must be paid to the spread of resistant bacteria and contamination of the aquatic environment through wild waterfowl, as fluoroquinolone-resistant and transmissible β -lactamase-producing strains were isolated from wild waterfowl.

Seven-hundred fifty *E. coli* strains isolated from the feces of 274 (75%) of 366 wild animals in Japan between 2018 and 2021 (517 isolates from 189 of 243 deer, 33 isolates from 12 of 43 nutria, 61 isolates from 22 of 22 masked palm civets, 54 isolates from 18 of 18 wild boars, 24 isolates from 8 of 8 Japanese raccoon dogs, 9 isolates from 5 of 5 badgers, 11 isolates from 4 of 4 weasels, 11 isolates from 4 of 4 foxes, 7 isolates from 4 of 4 small Japanese field mouse, 9 isolates from 3 of 3 Japanese macaques, 2 isolates from 1 of 2 raccoons, 6 isolates from 2 of 2 wild cats, 3 isolates from 1 of 1 bear, 3 isolates from 1 of 1 marten) were tested for drug susceptibility.

Antimicrobial resistance was found in *E. coli* from deer (5.4%, 28/517), masked palm civet (1.6%, 1/61), wild boar (7.4%, 4/54), badger (11%, 1/9), fox (9.1%, 1/11), Japanese macaque (11.1%, 1/9) and raccoon (50%, 1/2). Resistance was observed to five agents in the fox-derived strain, four drugs in the deer-derived strain and one drug in the masked palm civet, wild boar, Japanese macaque and raccoon-derived strains (Table 73). Overall, TC (5.4%) resistance was the highest, and resistance to six other drugs was observed. The CIP-resistant strains found in foxes were multidrug-resistant strains to ABPC, TC and CP.

CTX-resistant and quinolone-resistant *E. coli* were isolated on DHL agar medium containing antimicrobials (Table 74). CTX-resistant *E. coli* isolated on cephalosporin (CEZ, cephalixin or CTX)-containing media were isolated from 5 of 366 (1.4%, 14 strains). Isolates were from 2 of 243 deer (0.8%, 6 strains), 1 of 6 badgers (16.7%, 2 strains), 1 of 4 foxes (25%, 3 strains) and 1 of 2 raccoons (50%, 2 strains). One strain from foxes was a AmpC β -lactamase-producing strain (CMY-2), while the others were ESBL-producing strains (CTX-M-27, CTX-M-55 and CTX-M-1). Thirty-five strains of quinolone-resistant *E. coli* were isolated from 17 of 366 (4.6%) specimens on NA-containing media and the animals were deer (10, 4.1%), masked palm civet (1, 13.6%), Japanese raccoon dog (1, 12.5%), fox (2, 50%) and raccoon (1, 50%). Quinolone-resistant strains showed mutations in the quinolone resistance-determining region (QRDR) of DNA gyrase or topoisomerase IV, and some strains (1 deer, 2 foxes) carried a plasmid mediated quinolone resistance gene (*qnrB19*).

Recently, a study using an antimicrobial-containing isolation medium for wildlife in urban areas was reported (Table 74): 20 strains of CTX-resistant *E. coli* were isolated on CTX-containing medium from 20 of 80 (25%) Japanese raccoon dogs captured in Kanagawa Prefecture in 2016-2017. The breakdown of β -lactamases produced was 18 isolates had CMY-2 (n=7), CTX-M-14 (n=5), CTX-M-2 (n=2), CTX-M-1 (n=1), CTX-M-55 (n=1), DHA-1 (n=1), 1 isolate had CMY-2 and CTX-M-14, and 1 was unknown. In 2018, quinolone-resistant *E. coli* were isolated using NA-containing media from deer faecal samples in urban areas, mainly in Nara Park. NA-resistant *E. coli* were isolated from 41 of 59 (69.5%) deer, and NA-resistant *E. coli* isolated from 22 of them were also resistant to fluoroquinolones. In this area, antimicrobial-resistant *E. coli* with similar genotypes were observed in several deer species, suggesting a high distribution rate of resistant bacteria through deer-deer transmission (intra-species transmission). Resistant *E. coli* were also isolated from deer feces collected in urban areas, primarily Nara Park in 2019-2020, rural area neighboring Nara Park around urban areas in 2018-2021, and mountainous areas in the prefecture in 2019, using cephalexin-containing and NA-containing media. CTX-resistant *E. coli* were isolated from deer in urban areas (24.3%, 35/ 144) and deer in rural area (4.3%, 1/23), but not from deer in mountainous areas (0/30). Regarding quinolone-resistant *E. coli*, CPMX-resistant *E. coli* were isolated from deer in urban areas (11.1%, 16/144) and rural area (4.3%, 1/23), but not from deer in mountain areas (0/30). The genotypes of resistant *E. coli* carried by multiple deer in urban areas and deer in rural area were different, and no dissemination of resistant *E. coli* from deer in urban area to those in rural area was observed.

Genetic analysis of resistant *E. coli* isolated from wildlife in Japan has revealed the distribution of the pandemic clone ST131 [1-3]. Phylogenetic analysis using whole genome data from these wildlife-derived strains, as well as from aquatic environments and human patients, showed the following: (i) Domestic ST131 strains have low genetic similarity to ST131 strains foreign obtained from public databases, (ii) ST131 strains isolated from domestic wildlife can be classified into a common cluster based on the accessory genome of human-derived domestic strains, and (iii) Core genome SNP analysis indicates that some wildlife-derived ST131 strains are genetically similar to human-derived ST131 strains. These findings suggest that domestic ST131 has spread from human society into natural environments, including wildlife [4].

Among 252 fecal samples collected from 11 wild bird species between 2021 and 2024, *E. coli* strains were isolated from 70 samples (27.8%) representing six species, yielding a total of 159 strains. By species, strains were recovered from great cormorants in 56 of 184 samples (30.4%, 123 strains), mallards in 2 of 20 samples (10%, 4 strains), common teal in 1 of 12 samples (8.3%, 3 strains), copper pheasants in 6 of 8 samples (75%, 18 strains), spot-billed ducks in 3 of 5 samples (60%, 5 strains), and Japanese pheasants in 2 of 3 samples (66.7%, 6 strains). Of the 159 *E. coli* strains, 7 (5.7%) exhibited resistance to the tested antimicrobials. Among the 123 strains from cormorants, 6 (4.9%) were resistant to AMP. Of the three strains from common teal, one (33.3%) displayed multidrug resistance to AMP, CFZ, TET, and CIP, while the remaining two (66.7%) were resistant to CHL and SXT (Table 75). All other strains were susceptible to the tested antimicrobials.

Using isolation media containing NA and CTX, NA-resistant strains were isolated from cormorants (8 samples, 4.3%) and spot-billed ducks (1 sample, 20%), with resistance associated with amino acid substitutions in the QRDR and acquisition of the plasmid-mediated quinolone resistance gene *qnrS*. CTX-resistant strains were isolated from cormorants (7 samples, 3.8%) and carried CTX-M-14 (3 strains), CTX-M-15, CTX-M-55, MOX-4, and CMY-2 (1 strain each). Overall, these results indicate a low prevalence of antimicrobial resistance among *E. coli* from wild birds, suggesting limited exposure to antimicrobials and resistant bacteria [5].

References

1. Asai T, Usui M, Sugiyama M, Andoh M. A survey of antimicrobial-resistant *Escherichia coli* prevalence in wild mammals in Japan using antimicrobial-containing media. *J Vet Med Sci.* 84(12): 1645-1652, 2022.
2. Shimizu T, Kido N, Miyashita N, Tanaka S, Omiya T, Morikaku K, Kawahara M, Harada K. Antimicrobial resistance in *Escherichia coli* isolates from Japanese raccoon dogs (*Nyctereutes viverrinus*) in Kanagawa Prefecture, Japan: Emergence of extended-spectrum cephalosporin-resistant human-related clones. *J Med Microbiol.* 71(12) 001631, 2022.
3. Asai T, Sugiyama M, Omatsu T, Yoshikawa M, Minamoto T. Isolation of extended-spectrum β -lactamase-producing *Escherichia coli* from Japanese red fox (*Vulpes vulpes japonica*). *Microbiologyopen.* 11(5):e1317, 2022.
4. Sato T, Uemura K, Yasuda M, Maeda A, Minamoto T, Harada K, Sugiyama M, Ikushima S, Yokota SI, Horiuchi M, Takahashi S, Asai T. Traces of pandemic fluoroquinolone-resistant *Escherichia coli* clone ST131 transmitted from human society to aquatic environments and wildlife in Japan. *One Health.* 18:100715, 2024.
5. Asai T, Sugiyama M, Morimoto T, Sudo A, Moribe J, Usui M. Prevalence and genetic characteristics of antimicrobial-resistant *Escherichia coli* in wild birds in Japan. *J Vet Med Sci.* 87(11):1266-1273, 2025.

Table 71. Resistance rates (%) of *Escherichia coli* derived from wild animals from 2013 to 2017

	Deer				Wild boar		Small mammals			Other		
	Mountains	Shrines	Parks	Subtotal	Mountains	Livestock facilities	Urban areas	Mountains	Subtotal	Badgers	Kuchinoshima cattle	Amami rabbits
Number of strains	327	102	96	525	224	106	47	46	199	10	3	2
Number of resistant	15	5	11	31	18	30	6	0	36	4	2	1
Resistance rate (%)	4.6	4.9	11.5	5.9	8.0	28.3	14.0	0.0	18.1	40.0	66.7	50.0
ABPC (32)	0.6	2.0	0.0	0.8	3.6	23.6	0.0	0.0	12.6	10.0	0.0	0.0
CEZ (32)	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	1.5	0.0	0.0	0.0
CTX (4)	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	1.0	0.0	0.0	0.0
MEPM (2)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GM (16)	0.3	0.0	0.0	0.2	0.4	2.8	0.0	0.0	1.5	0.0	0.0	0.0
KM (64)	0.9	0.0	0.0	0.6	1.3	5.7	0.0	0.0	3.0	20.0	0.0	0.0
TC (16)	3.1	2.0	11.5	4.4	4.0	17.9	12.8	0.0	12.6	20.0	33.3	0.0
NA (32)	0.9	0.0	0.0	0.6	0.9	11.3	0.0	0.0	6.0	0.0	0.0	0.0
CPFX (2)	0.3	0.0	0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CL (4)	1.2	2.9	1.0	1.5	1.3	3.8	0.0	0.0	2.0	10.0	33.3	50.0

BP units are in µg/mL.* Number of strains resistant to at least one agent.

Source: Asai T, Usui M, Sugiyama M, Izumi K, Ikeda T, Andoh M. Antimicrobial susceptibility of *Escherichia coli* isolates obtained from wild mammals between 2013 and 2017 in Japan. J Vet Med Sci. 82(3):345-349, 2020.

Table 72. Resistance rates (%) of *Escherichia coli* from wild animals

Agent (BP)	Deer (2016-2019)	Amami rabbit (2017-2020)	Great cormorant (2018-2019)	White-fronted goose (2019)
		Amami Oshima	Gunma, Gifu, Shiga, Oita	Miyajima swamp, Hokkaido
Number of strains	848	135	144	110
Number of resistant	9	0	8	1
Resistance rate (%)	1.1	0.0	5.6	0.9
ABPC (32)	0.1	0.0	3.5	0.9
CEZ (32)	0.1	0.0	0.0	0.9
CTX (4)	0.0	0.0	0.0	0.0
MEPM (2)	Not implemented	0.0	0.0	0.0
GM (16)	0.0	0.0	0.0	0.0
KM (64)	0.0	0.0	0.0	0.0
TC (16)	0.0	0.0	2.8	0.0
NA (16)	0.0	0.0	1.4	0.0
CPFX (2)	0.0	0.0	0.7	0.0
CL (4)	Not implemented	0.0	0.7	0.0
CP (32)	0.1	0.0	1.4	0.0
ST (76/4)	0.6	0.0	1.4	0.0

BP units are in µg/mL.* Number of strains resistant to at least one agent.

Source:

Deer: Tamamura-Andoh Y, Tanaka N, Sato K, Mizuno Y, Arai N, Watanabe-Yanai A, Akiba M, Kusumoto M. A survey of antimicrobial resistance in *Escherichia coli* J Vet Med Sci. 83(5):754-758, 2021.

Amami rabbit: Matsunaga N, Suzuki M, Andoh M, Ijiri M, Ishikawa K, Obi T, Chuma T, Fujimoto Y. Analysis of fecal samples from Amami rabbits (*Pentalagus furnessi*) indicates low levels of antimicrobial resistance in *Escherichia coli*. Eur J Wildl Res 66: 84, 2020.

Great cormorant: Odoi JO, Sugiyama M, Kitamura Y, Sudo A, Omatsu T, Asai T. Prevalence of antimicrobial resistance in bacteria isolated from Great Cormorants (*Phalacrocorax carbo hanedae*) in Japan. J Vet Med Sci. 83(8):1191-1195, 2021.

White-fronted goose: Fukuda A, Usui M, Ushiyama K, Shrestha D, Hashimoto N, Sakata MK, Minamoto T, Yoshida O, Murakami K, Tamura Y, Asai T. Prevalence of antimicrobial-resistant *Escherichia coli* in migratory Greater White-fronted Goose (*Anser albifrons*) and their habitat in Miyajimanuma, Japan. Wildl Dis. 57(4): 954-958, 2021.

Table 73. Resistance rates of *Escherichia coli* isolated from wild animals from 2018 to 2021 (%)

Agent (BP)	Deer	Masked palm civet	Wild boar	Nutria	Japanese raccoon dog	Fox	Weasel	Badger	Japanese macaque	Small Japanese field mouse	Wild cat	Bear	Marten	Raccoon
Number of strains	517	61	54	33	24	11	11	9	9	7	6	3	3	2
Number of resistant*	28	1	4	0	0	1	0	1	1	0	0	0	0	1
Resistance rate (%)	5.4	1.6	7.4	0.0	0.0	9.1	0.0	11.1	11.1	0.0	0.0	0.0	0.0	50.0
ABPC (32)	0.4	1.6	0.0	0.0	0.0	9.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CEZ (32)	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CTX (4)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MEPM (2)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GM (16)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KM (64)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TC (16)	4.1	0.0	7.4	0.0	0.0	9.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NA (16)	0.0	0.0	0.0	0.0	0.0	9.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CPFEX (2)	0.0	0.0	0.0	0.0	0.0	9.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CL (4)	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.1	0.0	0.0	0.0	0.0	50.0
CP (32)	0.0	0.0	0.0	0.0	0.0	9.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ST (76/4)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

BP units are in µg/mL.* Number of strains resistant to at least one agent.

Source: Asai T, Usui M, Sugiyama M, Andoh M. A survey of antimicrobial-resistant *Escherichia coli* prevalence in wild mammals in Japan using antimicrobial-containing media. J Vet Med Sci. 84(12):1645-1652, 2022.

Table 74. Survey of distribution of antimicrobial-resistant *Escherichia coli* in wild animals using antimicrobial-containing media

Surveyed area	Surveyed year	Animal species	CTX-resistant <i>E. coli</i>	CPFEX-resistant <i>E. coli</i>	Author
Gifu, Wakayama, Kagoshima	2018-2021	Deer	2/243 (0.8%)	2/243 (0.8%)	Asai et al., 2022
Gifu	2018-2021	Masked palm civet	0/22 (0%)	1/22 (4.5%)	
Gifu, Yamaguchi	2018-2021	Badger	1/6 (16.7)	0/6 (0%)	
Gifu	2018-2021	Fox	1/4 (25%)	2/4 (50%)	
Gifu	2018-2021	Raccoon	1/2 (50%)	1/2 (50%)	
Kanagawa - Urban area	2016-2017	Japanese raccoon dog	20/80 (25%)	Not implemented	Shimizu et al., 2023
Nara - Urban area	2018	Deer	Not implemented	22/59(37.3%)	Ikushima et al., 2021
Nara - Urban area	2019-2020	Deer	35/144 (24.3%)	16/144 (11.1%)	Ikushima et al., 2023
Naara – rural area	2018-2021	Deer	1/23 (4.3%)	1/23 (4.3%)	
Nara - Mountain area	2019	Deer	0/30 (0%)	0/30 (0%)	

Asai T, Usui M, Sugiyama M, Andoh M. A survey of antimicrobial-resistant *Escherichia coli* prevalence in wild mammals in Japan using antimicrobial-containing media. J Vet Med Sci. 84(12): 1645-1652, 2022.

Shimizu T, Kido N, Miyashita N, Tanaka S, Omiya T, Morikaku K, Kawahara M, Harada K. Antimicrobial resistance in *Escherichia coli* isolates from Japanese raccoon dogs

(*Nyctereutes viverrinus*) in Kanagawa Prefecture, Japan: Emergence of extended-spectrum cephalosporin-resistant human-related clones. J Med Microbiol. 71(12) 001631, 2022.

Ikushima S, Torii H, Asano M, Suzuki M, Asai T. Clonal Spread of Quinolone-Resistant *Escherichia coli* among Sika Deer (*Cervus nippon*) Inhabiting an Urban City Park in Japan. J Wildl Dis. 57(1): 172-177, 2021.

Ikushima S, Torii H, Sugiyama M, Asai T. Characterization of quinolone-resistant and extended-spectrum β-lactamase-producing *Escherichia coli* derived from sika deer populations of the Nara Prefecture, Japan. J Vet Med Sci. 85(9): 937-941, 2023.

Table 75. Resistance rates (%) of *Escherichia coli* isolated from wild birds from 2021 to 2024

Agent (BP)	Great cormorant	Copper pheasant	Pheasant	Spot-billed Duck	Mallard	Common Teal
Number of strains	123	18	6	5	4	3
Number of resistant*	6	0	0	0	0	3
Resistance rate (%)	4.9	0	0	0	0	100
AMP (32)	4.9	0	0	0	0	33.3
CFZ (8)	0	0	0	0	0	33.3
CTX (4)	0	0	0	0	0	0
MEM (4)	0	0	0	0	0	0
GEN (16)	0	0	0	0	0	0
KAN (64)	0	0	0	0	0	0
TET (16)	0	0	0	0	0	33.3
NAL (32)	0	0	0	0	0	0
CIP (1)	0	0	0	0	0	33.3
CST (4)	0	0	0	0	0	0
CHL (32)	0	0	0	0	0	66.7
SXT (76/4)	0	0	0	0	0	66.7

BP units are in µg/mL.* Number of strains resistant to at least one agent

Source: Asai T, Sugiyama M, Morimoto T, Sudo A, Moribe J, Usui M. Prevalence and genetic characteristics of antimicrobial-resistant *Escherichia coli* in wild birds in Japan. J Vet Med Sci. 87(11):1266-1273, 2025.

(3) Food

The status of foodborne resistant bacteria is based on the results of a research project (2023 Health and Labour Sciences Research Grant General Report on the Research Project to Promote Food Safety: “Study on Surveillance and Transmission Mechanisms of Foodborne Antimicrobial-Resistant Bacteria Based on a One Health Approach” Principal Investigator Motoyuki Sugai).

Surveillance of Antimicrobial Resistance Trends in *Salmonella*, *Escherichia coli*, *Campylobacter*, and Other Bacteria Isolated from Food and Humans Based on the National Network of Local Public Health Institutes

After each local public health institute (CHIKEN, 23 CHIKEN participating voluntarily) purchased commercial meat from the relevant region, *Salmonella*, *Campylobacter*, *E. coli*, and other bacteria contaminating the meat were cultured and isolated using selective media according to the protocols established thus far. Antimicrobial susceptibility of the isolated strains were tested for 12 agents by the CLSI disk diffusion method. The emergence of agent-resistant strains of *Salmonella* is summarized in section (iv) ii, Non-typhoidal *Salmonella*, (local public health institutes) (see p. 34-40). Among *Salmonella* isolates, 67 of 170 human-derived strains (39.4%) and 118 of 146 food-derived strains (80.8%) exhibited resistance to at least one of 17 tested antimicrobials. These rates are comparable to those observed in isolates from 2015–2023, in which 972 of 2,510 human-derived strains (38.7%) and 1,058 of 1,173 food-derived strains (90.2%) were resistant, although a slightly lower trend was noted in food-derived strains. Serotype-specific analysis of 2024 isolates showed that the proportion of *S. Schwarzengrund* among food-derived strains was higher than in 2015–2023, but overall resistance trends were largely unchanged. In human-derived strains, resistance patterns were serotype-specific; therefore, serotype-specific resistance rates were compared over time. Among human-derived strains, the serotypes *S. Infantis*, *S. Schwarzengrund*, and *S. Manhattan*—which were also isolated from food—showed strong similarity in resistance patterns between human- and food-derived strains, consistent with isolates from 2015–2023, strongly suggesting a close association between antimicrobial-resistant strains from food and those from humans.

The emergence of agent-resistant strains of *Campylobacter*: For *Campylobacter*, the 2024 isolates of *C. jejuni* (200 strains) and *C. coli* (18 strains) showed strong similarity in resistance patterns between human- and food-derived strains, strongly suggesting a close association between antimicrobial-resistant strains from food and those from humans.

The emergence of agent-resistant strains of *E. coli*: Among *E. coli* isolates in 2024, 148 of 389 human-derived strains (38.0%) and 32 of 46 food-derived strains (69.6%) exhibited resistance to at least one antimicrobial, comparable to the results from isolates collected between 2015 and 2023. Other *E. coli* strains, including those lacking virulence factors, frequently displayed multidrug resistance to six or more antimicrobials and exhibited higher levels of multidrug resistance than diarrheagenic *E. coli*.

Surveillance of Foodborne Antimicrobial-Resistant Bacteria (*Salmonella*, *Campylobacter*, and ESBL-Producing *E. coli*)

For *Salmonella*, a survey was conducted using 200 samples of commercially available domestic chicken meat and 76 samples of packaged products from poultry processing plants. Clear regional differences were observed in both the prevalence of *Salmonella* and antimicrobial resistance patterns, suggesting that a clone of *Salmonella Schwarzengrund* with susceptibility may be maintained in certain regions of eastern Japan.

For *Campylobacter* and ESBL-producing *E. coli*, a survey was conducted using 110 samples of commercially available domestic chicken meat, the same samples used in the *Salmonella* survey. The isolation rate of *Campylobacter* was significantly higher in samples from western Japan than in those from eastern Japan, opposite to the pattern observed for *Salmonella*. Antimicrobial resistance remained consistent with previous findings; approximately half of the isolates (47.5%) were resistant to fluoroquinolones, whereas no resistance to macrolides was detected. Genome analysis of isolates from the previous year revealed that chicken-derived isolates contained clonal complexes (CCs) frequently observed in human-derived strains, and that susceptible and resistant strains were located in different clusters within the same CC. The isolation rate of ESBL-producing *E. coli* was also significantly higher in samples from western Japan compared to eastern Japan, similar to *Campylobacter*. Genome analysis of ESBL-producing *E. coli* from the previous year indicated that the pandemic clone ST131 was not detected; however, ST4649 and ST69 complexes, which frequently carry CTX-M-type ESBL in human-derived strains, were identified. Within the same ST, isolates carried the same CTX-M-type ESBL, suggesting the possible dissemination of specific clones.

Trends in Antimicrobial Resistance of Meat-Derived Bacteria (Enterobacterales and Enterococci)

In isolates collected in 2024, ESBL- and AmpC-producing Enterobacterales were detected in domestic chicken meat in 67 samples (27.7%) and 48 samples (19.8%), respectively, and in imported chicken meat in 32 samples (26.2%) and 14 samples (11.5%), respectively. The predominant ESBL type was CTX-M. Among domestic chicken-derived strains, the M2 group was most frequent, followed by the M1 and M9 groups, whereas imported chicken-derived strains were dominated by M1 and M8 groups. For AmpC, FOX- and CIT-type resistance was

common in domestic chicken-derived strains, while CIT-type predominated in imported chicken-derived strains. No CRE were detected. Colistin-resistant strains were detected in 7 imported chicken samples (2 from Brazil, 2 from Thailand, 2 from France, and 1 from New Zealand; 5.7%) but were not detected in domestic chicken. Regarding antimicrobial-resistant *enterococci*, VanN-type vancomycin-resistant *enterococci* (VRE) were detected in 4 domestic chicken samples from 3 regions (1.7%). OptrA-positive linezolid-resistant *enterococci* were detected in 2 domestic chicken samples from 2 regions (0.8%) and 2 Brazilian chicken samples (1.6%), while poxtA-positive linezolid-resistant *enterococci* were detected in 2 domestic chicken samples from 2 regions (0.8%). High-level bacitracin-resistant *enterococci* (bcr-positive) were found in 65 domestic chicken samples from 13 regions (26.9%) and in 34 imported chicken samples from Brazil, Thailand, New Zealand, and France (27.9%).

Investigation of Antimicrobial-Resistant Bacteria in the Food Chain

To investigate the current status of antimicrobial-resistant bacteria in the food chain and to clarify factors influencing their distribution, a survey was conducted targeting methicillin-resistant *Staphylococcus aureus* (MRSA), cefotaxime (CTX)-resistant *E. coli*, and *Salmonella* in retail meat. In addition, the relationship with antimicrobial use at breeder farms and hatcheries was examined. In a survey conducted in the Chubu region this year, the MRSA-positive rate in pork was low (3.5%, 2/57). MRSA was also isolated from chicken meat (2.3%, 1/44) but not from beef. Contamination of domestic chicken meat with CTX-resistant *E. coli* was 54.1% overall (46/85 samples). The prevalence was lower in Hokkaido–Tohoku (23.3%, 7/30) than in Chubu (68.1%, 30/44) and Kyushu (75.0%, 9/12), demonstrating a clear west–east gradient, with higher rates in western Japan. Antimicrobial susceptibility testing of CTX-resistant *E. coli* further showed that kanamycin resistance was more frequent in Chubu (78.9%, 30/38 isolates) and Kyushu (100%, 9/9 isolates) than in Hokkaido–Tohoku (12.5%, 1/8 isolates). Furthermore, a survey of *Salmonella* contamination in retail pork liver conducted in Hokkaido revealed that *Salmonella* was isolated from 26.8% of samples including the liver surface (62/231) and from 19.5% of internal liver samples (45/231). Contamination in either sample type showed seasonal variation, peaking in autumn (September–November) at 37.8% (28/74 samples).

In the farm survey, most *Salmonella* isolates from eight flocks in which antimicrobials were not used for the prevention of bacterial infections at breeder farms or hatcheries were susceptible to all tested antimicrobials (only one flock showed SM resistance). In contrast, among 14 flocks in which OTC was used at breeder farms and DSM at hatcheries, the isolated *Salmonella* showed resistance to SM and TC (in 13 and 14 flocks, respectively). Furthermore, among 17 flocks in which OTC was used at breeder farms and KM at hatcheries, the isolated *Salmonella* exhibited resistance to KM and TC (in 15 and 17 flocks, respectively). These findings suggest that antimicrobial resistance in *Salmonella* is associated with resistance to antimicrobials routinely used at breeder farms and hatcheries. In contrast, in surveys conducted on farms where antimicrobials were not used, the proportion of ESBL-producing *E. coli* among total *E. coli* in fecal samples was less than 1% in three flocks (one flock at 4 days of age and two flocks at 21 days of age) among six flocks examined. However, higher proportions were observed in one flock at 4 days of age (6.0%) and in two flocks at 17 days of age (1.3% and 3.5%). These findings suggest that the distribution of antimicrobial-resistant bacteria on farms cannot be explained solely by antimicrobial use.

Monitoring of Antimicrobial Resistance in Bacteria from Animals (Livestock): Collaboration with JVARM

Within the framework of the antimicrobial resistance monitoring program for animal-derived bacteria (JVARM), *Salmonella* isolates obtained from slaughterhouses and poultry processing plants (isolated in FY2022) were compared with human-, food-, and chicken-derived isolates in terms of serotypes and resistance rates. When resistance rates of the predominant serotypes in chicken and food isolates, *S. Schwarzengrund* and *S. Infantis*, were compared, similar resistance patterns were observed between food- and chicken-derived isolates for both serotypes. However, human-derived *S. Infantis* showed resistance patterns that differed from those of chicken- and food-derived isolates, suggesting that sources other than chicken and food. Regarding colistin, an antimicrobial agent important in human medicine, *E. coli* and *Salmonella* isolates obtained from slaughterhouses and poultry processing plants in FY2022 with a colistin MIC of ≥ 2 $\mu\text{g/mL}$ were examined for the presence of colistin resistance genes (*mcr-1* to *mcr-10*). The *mcr-1* gene was detected in *E. coli* isolates from cattle and swine, although at a low frequency ($\leq 3\%$). Although the current prevalence of the *mcr-1* gene is low, genome analysis suggested that the gene may be disseminating among swine via IncI2-type plasmids. These findings indicate that continued adherence to the use of colistin as a second-line antimicrobial is necessary. In addition, genome sequencing was performed for MRSA isolates obtained from swine raised in Japan and transported to slaughterhouses (isolated in FY2023) to determine genotypes and detect antimicrobial resistance genes. The results showed that ST398/t034 was the predominant type, which is a typical livestock-associated MRSA (LA-MRSA) lineage. Because MRSA frequently harbors multiple antimicrobial resistance genes, including those conferring resistance to tetracyclines and aminoglycosides, strict implementation of prudent antimicrobial use on farms is considered essential to avoid selection of MRSA.

Antimicrobial Resistance Trends in *Escherichia coli* Isolated from Feces of Healthy Individuals

A survey of antimicrobial resistance in *E. coli* isolated from fecal samples of healthy individuals showed that 81 isolates (36.5%) were resistant to at least one of the 18 antimicrobials tested. Since surveillance began in 2015, this proportion has remained relatively stable. Antimicrobials with relatively high resistance rates included ABPC, NA, TC, the ST combination, and SM, showing a pattern similar to that observed in previous years. Resistance to fluoroquinolones (FQ) was 9.0%, while resistance to CTX was 5.0%.

(4) Environment

In general, waste resulting from human activities is discharged into the environment (rivers or oceans) after being treated at sewage treatment plants or other household wastewater treatment facilities until it meets effluent standards. Attention to environmental AMR based on the One Health approach focuses on evaluating the risks posed by antimicrobial-resistant bacteria (genes) by determining which antimicrobial-resistant bacteria (genes) exist in treated environmental water discharged into the environment (rivers and oceans) and considering how those antimicrobial-resistant bacteria (genes) could circulate into our daily lives and pose a risk to human health.

1) Results of the Ministry of Health, Labor and Welfare Scientific Research Grant Project Survey Methods and Continuation of Fact-Finding Surveys in Japan

Currently, there are only a few quantitative reports on how many drug-resistant bacteria (AMR bacteria: ARB) and their derived drug-resistant genes (AMR genes: ARG) are released into the environment, and how much they continue to burden the environment. With only a few quantitative reports available at present concerning how many antimicrobial-resistant bacteria (AMR bacteria: ARB) and the antimicrobial-resistance genes (AMR genes: ARGs) that stem from them are being released into the environment and continuing to impose a burden on the environment, a systematic nationwide survey is regarded as important. Accordingly, Ministry of Health, Labour and Welfare research "Research for establishment of survey method of drug-resistant bacteria and antimicrobial agents in the environment. Principal Investigator: Hajime Kanamori H30-R02, R03-R05, R06-R08" has been formed for the purpose of conducting ongoing environmental AMR surveillance. Led by Hajime Kanamori, the research group (hereinafter referred to as "Kanamori's group") is conducting a study entitled "Research to Establish Methods of Surveying Antimicrobial-resistant Bacteria and Antimicrobials in the Environment" for three years from 2018 to 2020. In FY 2008 - FY 2020, this research group prepared a procedure manual contributing to environmental AMR monitoring and conducted research to establish a method for investigating agent-resistant bacteria and residual antimicrobial agents in environmental water. A system was established by this research to develop a nationwide environmental AMR monitoring survey of discharged treated water, and the actual environmental burden of local governments was elucidated at the genetic level. In addition, a domestic and international literature review was conducted to clarify the current status and issues related to agent resistance in the environment. Since fiscal year 2024, our research group has been conducting the following studies as part of a data infrastructure on environmental AMR (resistome): (1) risk assessment of environmental antimicrobial resistance in relation to human infectious diseases; (2) risk assessment based on comparative analysis of antimicrobial resistance One Health data and literature reviews; (3) investigation methods for antimicrobial resistance in the environment and genomic analysis of antimicrobial-resistant microorganisms; (4) investigation methods for environmental antimicrobial resistance in large metropolitan areas; (5) development of policies for the testing and evaluation of antimicrobials in the environment; and (6) methods for investigating antimicrobials in the environment and assessing their risk for antimicrobial resistance.

Regarding investigation methods for antimicrobial resistance in the environment and genomic analysis of antimicrobial-resistant microorganisms, the comprehensive sequencing of antimicrobial resistance genes (ARGs) and related elements from environmental water using next-generation sequencing (metagenomic analysis), which had been conducted by our research group from fiscal year 2018 to 2023 (the Pathogen Genomics Center, National Institute of Infectious Diseases), was resumed in fiscal year 2024 (AMR Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security). Metagenomic analyses were conducted in both summer and winter on a total of 49 effluent samples from wastewater treatment plants provided by 31 local governments. The abundance of resistance genes for each antimicrobial class showed results generally consistent with those obtained in previous analyses; however, a marked increase in rifampicin- and vancomycin-resistance genes was detected. The significance of this finding is currently unclear, and continued monitoring will be necessary. With the continued cooperation of local governments, nationwide surveys will be conducted twice a year (summer and winter) in order to establish a foundational dataset on the environmental AMR (resistome) in Japan. In addition, we attempted to utilize sewage AMR monitoring for outbreak detection. Since 2018, outbreaks of vancomycin-resistant *enterococci* (VRE) have been increasingly reported in multiple medical institutions in regional areas of Japan (Infectious Diseases Weekly Report, IDWR) (<https://idinfo.jihs.go.jp/surveillance/iasr/44/518/article/060/index.html>). During a VRE outbreak in Hiroshima beginning in 2021, VRE were isolated from influent samples at several wastewater treatment plants, and monitoring surveys were conducted. As a result, the same clone as the hospital strain was continuously detected. Based on these findings, our research group initiated a nationwide survey in fiscal year 2024,

in which influent wastewater samples are newly collected by local public health institutes to investigate the status of sewage-derived VRE in the environment. In the analysis conducted in August 2024 (summer survey), influent wastewater from treatment plants in 23 municipalities was collected, and 29 VRE isolates were obtained using VR E-selective media. In regions without a history of VRE outbreaks, VRE tended not to be isolated from sewage, whereas in regions with a history of VRE outbreaks, VRE were more likely to be detected. We will continue conducting nationwide monitoring surveys and plan to develop rapid detection methods optimized for environmental sewage VRE surveillance.

In addition to ARG in discharged treated water, it is vital to identify the presence of ARB that could potentially exist and proliferate in the environment. Kanamori's group has reported that at a water reclamation center in Tokyo Bay, a KPC-2-producing *Klebsiella pneumoniae* (Sequence type 11: ST11) strain rarely found in clinical isolates, had been isolated from the environmental water, that ST11 was the same type as clinical isolates widely isolated in East Asia [1], that KPC-2 was found in *Aeromonas* spp. rarely isolated in wound infections,[2] and that *E. coli* with NDM-5 carbapenemase, which has acquired broader-spectrum activity than NDM-1, had been isolated,[3] and information on the situation within Japan is gradually becoming increasingly clear. A report has also been published on a comprehensive AMR study carried out on hospital wastewater, inlet and treated outlet water from sewage treatment plants, and river water in the Yodo River basin in Osaka. Its estimates suggest that a diverse array of ARB are isolated from non-ozone treated outlet water from sewage treatment plants and that hospital wastewater imposes an environmental AMR burden.[4] The reality is that, as in the case of the situation overseas, no small number of ARBs are isolated in environmental water in Japan.

In addition to metagenomic analysis, conventional culture methods were also important, and not only the detection of resistance genes, but also the analysis of the characteristics of live antimicrobial resistant bacteria in sewage was conducted. It is hoped that conducting both the metagenomic analysis and the culture method approaches will lead to a better understanding of the overall picture of drug resistance in environmental waters. As establishing surveillance techniques for monitoring environmental AMR and residual antimicrobials, and actually conducting fact-finding studies are important, a procedure for metagenomic analysis of treated effluent from sewage treatment plants was developed as a method for investigating drug resistance in environmental water. In metagenomic analysis of effluent wastewater, an average of only 104 RPKM reads were obtained. However, by utilizing a hybrid capture-based metagenomic analysis technique (xHYB), the RPKM was concentrated to 601,576 reads, enabling the comprehensive detection of ARGs that could not be detected using conventional metagenomic methods. [15] In hospital wastewater from adult patients, the average RPKM value of ARGs detected by xHYB was significantly higher compared to mDNA-seq. [16]

In addition to a nationwide environmental water AMR survey, Kanamori's group also conducted a survey of the status of environmental AMR of local hospital effluent and the sewage from a local pig farm and a measurement of antimicrobial residue in local sewage treatment water in Japan. Risk assessment should be based on the findings from these studies and the results of the literature review on environmental AMR. To set out the evidence concerning the environmental AMR from overseas, the research group published a translation of Initiatives for Addressing Antimicrobial Resistance in the Environment: Current Situation and Challenges. 2018 [7].

Important issues for environmental AMR control include: 1) the environment can be contaminated with antimicrobial agents and resistant bacteria if wastes are not appropriately treated; 2) the impact of environmental contamination of antimicrobial agents and resistant bacteria in wastes on human health is not fully understood; 3) to understand the risk of resistant bacteria to human health, it is important to assess where and how many resistant bacteria are present in environmental water; and 4) to evaluate sampling and testing methods and standardize practices to measure resistant bacteria in environmental water.

A Japanese literature review reported that a considerable amount of resistant bacteria and resistant genes remain in effluent water after treatment and in the river water that receives it, placing a concern for the environmental contamination; resistant bacteria (such as KPC-2 and NDM-5-producing bacteria), which are rarely isolated clinically in Japan, have been detected in sewage, and suggesting sewage is useful for monitoring in the city. Although the existence of drug resistance in the environment has been proven in this way in Japan and overseas, the reality is that there is insufficient evidence on the risks to humans and animals due to the lack of established survey methods and assessment criteria for environmental AMR.

A literature review was conducted on sewage AMR in Japan. [8] As a result, of 37 eligible papers from 1991-2021, 26 reported on AMR, 10 on antimicrobial agents and one on both AMR and antimicrobial agents. The presence of clinically important ARBs, ARGs and residual antimicrobials such as ESBL-producing bacteria, CRE, MDRP, MDRA, MRSA and VRE in Japanese sewage was observed. Hospital drainage may be a reservoir of clinically important resistant bacteria, but the direct risk to humans of ARBs in hospital drainage is not clear. In addition, antimicrobials commonly used in Japan may create an environment conducive to the growth of AMR in sewage and may further contribute to the dissemination of AMR through proliferation. While promotion of AMR control in humans, animals and the environment are necessary, knowledge on AMR in the environment is still limited compared to humans and animals. Progress in surveys and research on environmental AMR in Japan is anticipated.

From fiscal years 2023 to 2024, a high-throughput analysis system for residual antibiotics in environmental waters was developed by Osaka Medical and Pharmaceutical University, utilizing a combination of an automated dispensing device (pipetting robot) and an automated solid-phase extraction pre-treatment system. Using this system, monitoring surveys of residual antibiotics were conducted on effluent from water reclamation centers (sewage treatment plants) provided by 43 municipalities nationwide in the summer of 2024 (August) and winter of 2025 (January). The survey results showed that clarithromycin, levofloxacin, azithromycin, and vancomycin were detected in 98%, 96%, 42%, and 31% of samples, respectively, with mean concentrations of 301 ng/L, 741 ng/L, 177 ng/L, and 40 ng/L. Comparisons between the summer and winter surveys indicated that the concentrations of clarithromycin and levofloxacin in winter 2025 were 2-3 times higher than those measured in summer 2024. Case studies assessing nationwide residual antibiotics in environmental waters remain scarce globally. Continued monitoring is essential to establish a domestic foundation for environmental AMR, while comparative analyses with reports from other countries will be important.

Although efforts have been made to assess the risk of infection transmission and the health effects in cases of nosocomial infection based on the results of field epidemiology and molecular epidemiological analysis of isolates, as described above, research findings indicating that antimicrobial-resistant bacteria derived from the environment affect human and animal health are scarce. Overseas, as the contamination of vegetables believed to result from the use of river water for irrigation [7] and assessments of the risk of exposure to AMR through water-based recreation [8] are starting to be reported, albeit only little by little, a certain degree of a risk cycle is being calculated. At this point, it is difficult to set definite standards for discussing environmental risk. However, it is vital to quantitatively monitor and evaluate environmental AMR, conduct research that could assist in appraising health risks, and undertake risk assessments and reviews of major literature from both within Japan and overseas, as shedding light on the major factors contributing to the environmental AMR load and investigating whether it is developing into a risk to human and animal health are matters of urgency. A multidisciplinary One Health approach at the human-animal-environment interface to infectious diseases is essential to assess the risk to humans and animals of agent resistance in the environment [9].

2) Results of the Environment Research and Technology Development Fund

It has been pointed out that the aquatic environment, where wastewater containing various antimicrobial agents and resistant bacteria ultimately flows into, may be a reservoir for the dissemination of resistant bacteria. To control the dissemination of resistant bacteria, it is important to clarify the mechanism of drug-resistant gene dissemination in the aquatic environment. Therefore, the "Elucidation of Transmission Potential and Transmission Mechanism of Drug Resistance Genes in the Environment" project funded by the Environment Research and Technology Development Fund (FY2020-2022), a survey of the distribution of resistant bacteria in major rivers in Japan and an evaluation experiment of the transmission potential of drug resistance genes using an *in vitro* transmission experiment were conducted. [12]

In the distribution survey of resistant bacteria, eight rivers in the Tohoku region (Aka, Mogami, Omono, Iwaki, Mabuchi, Kitakami, Natori, and Abukuma Rivers) were surveyed. In all rivers, the concentration of *E. coli* in river water was determined to be low in terms of *E. coli* contamination, meeting the environmental standard for Type A on the day of water sampling. The detected *E. coli* was isolated and identified, and their drug susceptibilities to 18 antimicrobial agents were evaluated. As a result, 26.8% of *E. coli* were detected to be resistant to one or more of the tested antimicrobial agents, and the largest number of 178 isolates (24.2%) were resistant to ampicillin. [11] Of the strains resistant to ABPC, 23 (3.5%) and 1 (0.2%) strains were detected to be resistant to cefotaxime and cefazolin, respectively. Of all *E. coli* isolates, 10% were multidrug-resistant (ampicillin, amoxicillin/clavulanic acid, tetracyclines, quinolones (ciprofloxacin, levofloxacin). ESBL-producing *E. coli*, which are positioned as having increased concerns by WHO, were also detected. Since a one-year river monitoring of the Akagawa and Mogami Rivers enabled the isolation of ESBL-producing *E. coli*, the ESBL-producing genes (*bla*) of the isolates were characterized. Of the 21 types of *bla* tested, 17 types were detected, with *bla*_{CTX-M-1-group} being the most abundant. It is noteworthy that not only *bla*_{IMP}, a domestic-type carbapenemase, but *bla*_{KPC}, *bla*_{OXA-48}, *bla*_{VIM}, and *bla*_{NDM}, which are considered foreign types because there are few cases detected in Japan, were also detected. Comparing the number of *bla* detected at each location, the highest number of 15 types of *bla* was detected in the strains isolated directly under the sewage treatment plant. The results indicate that healthy people living in the city as well as in clinical care settings are also a source of resistant bacteria in rivers.

In an experimental evaluation of the transmission potential of drug resistance genes using *in vitro* transmission experiments, *in vitro* transmission experiments were conducted using *enterococci* and *E. coli* as model bacteria to simulate the environment. As a result, only *vanA* was confirmed to be transmitted in *enterococci*, and the transmission potential was confirmed to be in the range of 10⁻³ to 10⁻⁷ depending on the combination of donor and recipient bacteria. In addition, no transmission was observed in the liquid phase of river water, and transmission was observed in activated sludge, an environment in which bacteria accumulate, although at a low probability (10⁻⁷). On the other hand, when *Enterobacteriales* harboring *bla*_{CTX-M} were used, transmission was confirmed (10⁻⁴ to 10⁻⁸) under conditions simulating any of the environments. Furthermore, Gram-negative bacteria showed higher potential for a field (transmission field) to transmit drug resistance genes compared to Gram-positive bacteria. It was suggested that the dissemination of drug resistance genes in the environment is highly possible, and that intensive treatment is necessary, especially in areas where bacterial density is assumed to be high. It was highlighted that drug-resistant and ESBL-producing *E. coli* are already dispersed in the river water in Japan. On the other hand, the origin of these environmental AMRs and the extent of their impact on humans and animals are unknown. There is no doubt that drug-resistant bacteria are released into the environment from their human and animal origins; however, the active accumulation of information in the environmental field is needed to clarify the effects of these bacteria from the environment on humans and animals.

Starting from the 2023 fiscal year, research was conducted under the Environmental Research and Technology Development Fund project titled "Comprehensive Genomic Analysis of Antimicrobial-Resistant Bacteria in Environmental Water" (continuing until the 2025 fiscal year) on extended-spectrum β -lactamase (ESBL)-producing *E. coli* and carbapenem-resistant *Enterobacteriaceae* (CRE). This research focuses on the investigation of antimicrobial-resistant bacteria concentrations in rivers and lakes nationwide, as well as the genomic analysis of these resistant bacteria. [14]

In the fiscal year 2023, water samples were collected from 17 locations across seven prefectures in the Kansai region, including rivers and lakes, for the cultivation and detection of ESBL-producing *E. coli* and CRE. Regarding CRE, due to the frequent detection of false-positive colonies, enumeration was not performed, and only the preservation of strains for genomic analysis was carried out. The results showed significant variation in the concentration of ESBL-producing *E. coli* across different locations. At sites considered to be heavily influenced by anthropogenic contamination, higher concentrations of ESBL-producing *E. coli* and a higher proportion of ESBL-producing *E. coli* relative to total *E. coli* were observed. Additionally, whole-genome sequencing was performed on 26 ESBL-producing *E. coli* strains and 25 CRE strains that were isolated and preserved during the cultivation and detection process. The analysis of the obtained genome sequences revealed that the ESBL-producing *E. coli* strains exhibited a high degree of similarity with clinical isolates in terms of phylogeny and the antimicrobial resistance genes they carried. On the other hand, although the CRE strains were classified into general commonly found in clinical isolates, the carbapenemase genes (genes encoding carbapenem-degrading enzymes) detected in

the CRE strains showed limited similarity to those found in clinical isolates.

In fiscal year 2024, river water sampling was conducted outside the Kansai region, specifically at four sites in Kyushu, two sites in Shikoku, two sites in Chugoku, six sites in Chubu, three sites in Kanto, and one site in Tohoku. As a result, an additional 37 ESBL-producing *E. coli* strains and 11 carbapenem-resistant Enterobacterales strains were isolated, totaling 48 antimicrobial-resistant strains. Combined with the results from fiscal year 2023, ESBL-producing *E. coli* were detected at 22 of 35 sites nationwide (62.9%), and carbapenem-resistant Enterobacterales were detected at 18 sites (51.4%). Among sites where resistant bacteria were detected, substantial variability in concentrations was observed between locations. Furthermore, genome analysis of river-derived *E. coli* revealed plasmid-mediated quinolone resistance (PMQR) genes present in structural contexts not previously reported, suggesting potential dissemination [5].

Furthermore, since fiscal year 2024, under the Environment Research and Technology Development Fund project “Emergence Trends and Assessment Methods for Novel Infectious Microorganisms in the Environment and Wildlife toward a One Health Approach” (through fiscal year 2026), investigations have been conducted on the occurrence and trends of emerging infectious microorganisms in riverine environments and wildlife. The research aims to clarify the transmission pathways from the environment and wildlife to livestock and humans, develop methods for evaluating antimicrobial-resistant bacteria and associated resistance genes, and elucidate the routes and mechanisms of resistant bacteria dissemination in environmental and wildlife contexts. These findings are intended to inform guidelines for environmental standards and strategies to prevent the spread of resistant bacteria.

From April 2025, the Environment Research and Technology Development Fund Strategic Research and Development project, “Research toward the Establishment of a Framework for Surveillance of Antimicrobial Resistance and Antimicrobial Agents in the Environment,” will be launched. This project aims to advance the accumulation of data on antimicrobial resistance (AMR) in domestic environmental settings.




Figure 7. Metagenomic analysis (Metagenomic DNA-Seq) of wastewater discharged from Japanese sewage treatment plants (water reclamation centers)

Comprehensive sequencing (metagenomic analysis) of various categories of antimicrobial resistance genes (ARGs) detected in treated effluent provided by municipalities was performed 13 times from summer 2018 (18S) to winter 2025 (25W) (summer and winter each year). ARGs were normalized using RPKM (Reads Per Kilobase of gene per Million mapped reads) with ARGs_OAP v3.2.25. Note that the figure's visualization method differs from that used last year; therefore, some data for years up to 2023 may appear differently from the corresponding figure in last year's report.




Figure 8. Analysis of Residual Antimicrobials in Effluent from Wastewater Treatment Plants (Water Reclamation Centers) in Japan

Concentrations of residual antimicrobials detected in treated effluent provided by municipalities during summer 2024 and winter 2025 are summarized. Data points not shown indicate concentrations below the detection limit of the analytical system.

3) A Study on the Quantitative Evaluation of Vegetable Contamination through Aquatic and Soil Environments Infected by Livestock-Derived Antimicrobial-Resistant Bacteria and Its Transmission to Humans (Results from the Food Safety Impact Assessment Technology Research (FY2020–FY2021)) [19]

An examination was conducted with the aim of evaluating the risk of contamination of vegetables by livestock-derived antimicrobial-resistant bacteria through aquatic and soil environments and their potential transmission to humans.

Using university-affiliated farms and others as a model, the extent of transmission of livestock-derived antimicrobial-resistant bacteria to crops was investigated. The study identified, strains closely related to antimicrobial-resistant bacteria found in livestock waste in the soil and crops on the farm, while the transmission of livestock-derived antimicrobial-resistant bacteria to vegetables through soil cannot be ruled out, it was confirmed that the transmission from livestock waste to crops was extremely limited.

In addition, a comparative analysis was conducted on the genomes of ampicillin-resistant bacteria (primarily *E. coli*) isolated from livestock (rectal feces, farm soil, etc.), aquatic environments (wastewater before and after treatment), vegetables, and human clinical cases from fiscal year 2020 to 2021. The genomic analysis revealed that the phylogenetic classification of resistant bacteria from livestock, aquatic environments, vegetables, and human clinical sources was diverse, and no clear relationships were found between the isolates from these different sources. On the other hand, among 332 strains harboring the *bla*_{TEM} gene isolated from livestock, aquatic environments, vegetables, and humans, NGS analysis revealed that 47 strains possessed structures including *IS26* in the *bla*_{TEM} gene and its surrounding regions. Sequence comparison of 19 of these strains were identified to have similar gene sequences. While the epidemiological relationships and transmission routes of these strains remain unclear, it is suggested that resistance genes and their surrounding structures may be transmitted and disseminated across different sources, potentially via plasmids. However, as the genomic comparison focuses on identical structures, there is a possibility that the frequency of dissemination or transmission may have been overestimated.

Table 76. Detection results of β -lactamase genes in ampicillin-resistant bacteria

Origin	Number of strains	TEM	SHV	CTX-M1	CTX-M9
Livestock (rectal feces, farm soil, etc)	33	21	ND	5	7
Livestock (feces from healthy animals and sick animals)	247	224	2	3	9
Aquatic environments (wastewater before and after treatment)	106	70	4	19**+3	19**
Retail vegetables*	148	19	5	76**	76**
Human clinical cases	205	121	1	10	48

ND, not detected.

* Many of the bacteria derived from vegetables were not *E. coli*.

**For some wastewater samples and isolates derived from retail vegetables, *bla* typing confirmed that they belonged to the CTX group; however, differentiation between the M1 group and M9 group was not performed.

Table 77. Results of the phylogenetic classification (Phylogenetic group) of isolated ampicillin-resistant *Escherichia coli* strains

Origin	Number of strains	A	B1	B2	C	D	E	F
Livestock (rectal feces, farm soil, etc)	247	62	123	3	9	10	10	7
Aquatic environments (wastewater before and after treatment)	39	28	15	0	0	6	0	0
Retail vegetables*	11	1	4	3	0	0	3	0
Human clinical cases	205	4	13	157	3	20	2	6

Table 78. List of *bla*_{TEM} gene-positive strains analyzed by NGS

Origin	ampicillin-resistant bacteria	<i>bla</i> _{TEM} gene	NGS analysis	including <i>IS26</i> , has been determined
Livestock (rectal feces, farm soil, etc)	33	21	19	7
Aquatic environments (wastewater before and after treatment)	247	224	182	18
Aquatic environments (wastewater before and after treatment)	106	70	48	6
Retail vegetables*	148	19	5+2*	0
Human clinical cases	205	121	76	16

*Two vegetable-derived isolates that were TEM-positive in another project were additionally analyzed.

References

1. Sekizuka T, Yatsu K, Inamine Y, et al. Complete Genome Sequence of a blaKPC-2-Positive *Klebsiella pneumoniae* Strain Isolated from the Effluent of an Urban Sewage Treatment Plant in Japan. *mSphere* 2018;3.
2. Sekizuka T, Inamine Y, Segawa T, Hashino M, Yatsu K, Kuroda M. Potential KPC-2 carbapenemase reservoir of environmental *Aeromonas hydrophila* and *Aeromonas caviae* isolates from the effluent of an urban wastewater treatment plant in Japan. *Environ Microbiol Rep* 2019; 11:589-97.
3. Sekizuka T, Inamine Y, Segawa T, Kuroda M. Characterization of NDM-5- and CTX-M-55-coproducing *Escherichia coli* GSH8M-2 isolated from the effluent of a wastewater treatment plant in Tokyo Bay. *Infect Agent Resist* 2019; 12:2243-9.
4. Azuma T, Otomo K, Kunitou M, et al. Environmental fate of pharmaceutical compounds and antimicrobial-resistant bacteria in hospital effluents, and contributions to pollutant loads in the surface waters in Japan. *Sci Total Environ* 2019; 657:476-84.
5. Sekizuka T, Yamaguchi N, Kanamori H, Kuroda M. Multiplex Hybrid Capture Improves the Deep Detection of Antimicrobial Resistance Genes from Wastewater Treatment Plant Effluents to Assess Environmental Issues. *Microb Drug Resist*. 2023;29:510-515.
6. Baba H, Kuroda M, Sekizuka T, Kanamori H. Highly sensitive detection of antimicrobial resistance genes in hospital wastewater using the multiplex hybrid capture target enrichment. *mSphere*. 2023;8:e0010023Initiatives for Addressing Antimicrobial Resistance in the Environment: Current Situation and Challenges (<http://amr.ncgm.go.jp/medics/2-8-1.html#sonota>)
7. Initiatives for Addressing Antimicrobial Resistance in the Environment - Current Situation and Challenges (<https://amr.jihs.go.jp/medics/2-8-1.html#sonota>)
8. Baba H, Nishiyama M, Watanabe T, Kanamori H. Review of Antimicrobial Resistance in Wastewater in Japan: Current Challenges and Future Perspectives. *Antibiotics (Basel)*. 2022; 11:849.
9. Van Hoek AH, Veenman C, van Overbeek WM, Lynch G, de Roda Husman AM, Blaak H. Prevalence and characterization of ESBL- and AmpC-producing Enterobacteriaceae on retail vegetables. *Int J Food Microbiol* 2015; 204: 1-8.
10. Leonard AFC, Zhang L, Balfour AJ, et al. Exposure to and colonisation by antibiotic-resistant *E. coli* in UK coastal water users: Environmental surveillance, exposure assessment, and epidemiological study (Beach Bum Survey). *Environ Int* 2018; 114:326-33.
11. Kanamori H, Baba H, Weber DJ. Rethinking One Health approach in the challenging era of COVID-19 pandemic and natural disasters. *Infect Ecol Epidemiol*. 2020; 11:1852681.
12. Completed research report of Environment Research and Technology Development Fund project 5RF-2005 Antibiotic Resistance in Water Environments: Gene Transfer Potential and Mechanisms (JPMEERF20205R05) 2020-2022 (https://www.erca.go.jp/suishinhi/seika/db/pdf/end_houkoku/5RF-2005.pdf)
13. Masaya M, Masateru N, Ichiro Y, Toru W. Classification of Phylogenetic Groups and Antibiotic Resistance of *Escherichia Coli* Isolated from Akagawa River System, Yamagata, JAPAN. January 2022 *Journal of Japan Society of Civil Engineers Ser G (Environmental Research)* 78(7): III_307-III_316
14. Interim Report of 5RF-2301 Genomic Analysis of Antimicrobial-Resistant Bacteria in Environmental Waters in Japan [JPMEERF20235R01] 2023-2025 funded by the Environment Research and Technology Development Fund (https://www.erca.go.jp/suishinhi/seika/db/pdf/end_houkoku/5RF2005.pdf)
15. Research Report on the Research Program for Risk Assessment Study on Food Safety “A Study on the Quantitative Evaluation of Vegetable Contamination through Aquatic and Soil Environments Infected by Livestock-Derived Antimicrobial-Resistant Bacteria and Its Transmission to Humans” [JPCAFSC20202002] 2020–2021

(5) Genome comparison of Antimicrobial-resistant Bacteria: Exploring the relationships between humans, animals, food, and the environment

The Action Plan on Antimicrobial Resistance (AMR) (2016-2020) clearly stated the implementation of an integrated One Health trend survey on antimicrobial-resistant (AMR) bacteria isolated from humans, animals, food, and the environment. Since 2017, the Nippon AMR One Health Report has provided year-on-year data on the antimicrobial susceptibility of bacterial species of concern in relation to antimicrobial resistance in each of these sectors. The Nippon AMR One Health Report has played a critical role in enabling a comprehensive overview of data from various sectors in a one-stop format. The Action Plan on AMR (2016-2020) also outlined efforts to establish an integrated One Health trend surveillance system, which included analysis of antimicrobial resistance transfer factors present in humans, animals, food, and the environment, and research on the relationships between transmission processes. This initiative has been carried over into the new Action Plan (2023-2027). This paper presents the results of a study examining the relationships of AMR bacteria from various fields based on genomic comparisons of resistant strains.

1) Comparative genomics of antimicrobial-resistant bacteria derived from humans, food, and animals

In the Nippon AMR One Health Report, we have previously reported on the annual trends in antibiotic susceptibility data for bacterial species that are of concern due to antibiotic resistance. In particular, for non-typhoidal *Salmonella* spp., we have presented data for both human-derived and food-derived strains, highlighting similarities between the two. However, it is not possible to determine the extent of transmission of antibiotic-resistant bacteria between humans, food, and animals solely based on antibiotic susceptibility data. To address this knowledge gap, a research team funded by the Ministry of Health, Labour and Welfare's Health and Labour Sciences Research Grant (Research on Food Safety) has conducted genomic analysis of the strains shown in Table 79. Specifically, in addition to non-typhoidal *Salmonella* spp., *Campylobacter* spp. and *Enterococcus* spp. were also included. The study aims to investigate, through comparison of genome sequence data, how similar human-derived resistant strains are to food- and animal-derived strains at the genomic level, and whether instances can be found that suggest transmission of resistant bacteria between food, animals, and humans.

Table 79. Strains subjected to genomic analysis

Class	Derived from	Year of isolation	Number of strains (min-max per year)	Collecting Institution
<i>Salmonella</i> spp. (non-typhoidal)	Food	2017-2022	563 (74-111)	Public Health Institutes
	Humans	2017-2022	623 (90-126)	Public Health Institutes
	Animals	2019-2022	427 (96-129)	National Veterinary Assay Laboratory
<i>Campylobacter</i> spp.	Food	2024	57	National Institute of Health Sciences
	Humans	2018, 2021-2023	261 (45-106)	Tokyo Metropolitan Institute of Public Health
	Animals	2018-2021	364 (18-146)	National Veterinary Assay Laboratory
<i>Enterococcus</i> spp.	Food	2016-2019, 2021	38 (8-11)	Gunma University
	Humans	2020	34	National Institute of Infectious Diseases

non-typhoidal *Salmonella* spp.

Genomic analysis was conducted on 1,613 strains of non-typhoidal *Salmonella* spp. accepted by the National Institute of Infectious Diseases between 2021 and 2024. A phylogenetic tree was constructed based on the single nucleotide polymorphisms (SNPs) of the core genome (the nucleotide sequences formed by extracting and concatenating genes that are common to all analysed strains without using specific reference strain). The right side of the phylogenetic tree displays, information on each strain's serotype, origin (human, food, animal), and testing material by origin, as well as the types of ESBL or AmpC genes (usually located on plasmids) and their presence or absence, were displayed, along with the presence or absence of genes conferring resistance to fosfomycin, tetracycline, trimethoprim, kanamycin, and macrolides (Figure 9). The non-typhoidal *Salmonella* spp. strains used in this genomic analysis were isolated and preserved by regional public health institutes between 2017 and 2022 and underwent antibiotic susceptibility testing (see p.34, ii. non-typhoidal *Salmonella* spp.). Human-derived strains were isolated from patient samples of infectious gastroenteritis or food poisoning, while food-derived strains were isolated from various foods, primarily domestic and imported chicken. These included strains collected through

foodborne pathogen contamination surveys or local government collection inspections, as well as those isolated from food poisoning cases. These strains were randomly provided. The animal-derived strains were those isolated between 2019 and 2022, for which antimicrobial susceptibility testing was conducted under the JVARM program, and the strains were stored at National veterinary Assay Laboratory (see p.68, v. *Salmonella* spp.). The animal-derived strains were isolated from the cecal contents of chickens at 15 poultry slaughterhouses across the country. Many serotypes formed distinct clusters on the core genome phylogenetic tree, with each serotype clustering independently from others (Figure 9).

In the core genome phylogenetic tree, many strains harboring tetracycline, trimethoprim, or kanamycin resistance genes were found within the Infantis cluster located at the upper part of the tree and the Schwarzengrund cluster located at the lower part. Strains harboring ESBL or AmpC genes accounted for only 3% of the total and were scattered across multiple lineages (it should be noted that while ESBL or AmpC genes, typically located on plasmids, may be present, it was not possible to determine from this genomic analysis whether all of these genes are actually located on plasmids). Macrolide resistance genes were present in 1% of the strains and were detected across several lineages; of the 12 strains harboring the *mph(A)* gene, 8 strains (67%) were included in the Blockley cluster.

The complete dataset comprised 75 serotypes, with a balanced distribution of major serotypes observed in both food-derived and animal-derived strains (see Figure 10). Notably, the two most prevalent serotypes in both origins were Schwarzengrund (62% of food-derived strains and 72% of animal-derived strains) and Infantis (13% and 19%, respectively), accounting for over 75% of each origin group. However, divergence in serotype distribution was observed between these two origins and human-derived strains. In human-derived strains, Enteritidis (20% of human-derived strains, with the primary source being poultry eggs and related products, though eggs were not included in the food samples handled by the regional public health institutes mentioned above), 4:i:- (10%), and Thompson (8%) were most prevalent, but the overall distribution was highly diverse.

The distribution of detected resistance genes was compared among three groups: human-derived strains, food-derived strains, and animal-derived strains. For the kanamycin resistance gene, the proportion of *aph(3')-Ia* was over 98% in all three groups (see Figure 9). However, for the tetracycline resistance gene, the proportion of *tet(A)* was over 97% in food-derived and animal-derived strains, while in human-derived strains it was 61% with *tet(B)* detected at a rate of 28%. Similarly, for the trimethoprim resistance gene, the proportion of *dfrA14* was over 96% in food-derived and animal-derived strains, while in human-derived strains it was 58%, with *dfrA12* and *dfrA27* detected at rates of 18% and 11%, respectively. The data indicates that while the patterns of tetracycline and trimethoprim resistance gene possession were clearly similar between food- and animal-derived strains, they differed significantly among human-derived strains. This discrepancy can be attributed to the variation in serotype distribution observed among the different sources.

With regard to the fosfomycin resistance gene, it was detected at a low frequency in 43 out of 1,613 strains, and 39 strains out of 43 harbored *fosA7* or *fosA7.2*. The distribution of the detected genes by source showed that the proportion of *fosA7.2* was 100% (5/5 strains) in animal-derived strains, 65% (13/20 strains) in human-derived strains, in contrast, food-derived strains exhibited a *fosA7.2* proportion of 17% (3/18 strains), highlighting a disparity between food- and animal-derived strains, with the former predominantly containing *fosA7.2*. Notably, 13 out of the 18 food-derived strains originated from imported chicken meat. Phylogenetic analysis revealed that *fosA7* was present in 83% (15/18) of food-derived strains, forming a closely adjacent cluster. Notably, 13 of these strains were derived from imported chicken meat, which may have contributed to the observed differences in the fosfomycin resistance gene patterns between food-derived and animal-derived strains.

Next, the potential for the transmission of strains with resistance genes from food to humans was investigated. Among the ESBL genes, *bla_{CTX-M-15}* was the only gene found in both human-derived and food or animal-derived strains. Within a cluster formed by the Blockley serotype (three human strains and six food strains), the gene was present in three human-derived strains and two food-derived strains. The core genome phylogenetic tree of the Blockley strains is shown at the top of Figure 11. The five strains harboring *bla_{CTX-M-15}* exhibited concordance in the presence of other resistance genes, and these human-derived and food-derived strains were isolated in 2017–2019 and 2018, respectively (within the two rectangular boxes in the Blockley phylogenetic tree in Figure 11). In the small number of Blockley strains that were subjected to genomic analysis, highly closely related (6–10 SNPs) pairs of human-derived and food-derived strains were revealed (A cluster in Figure 11), strongly suggesting that the human-derived strains harboring *bla_{CTX-M-15}* may have been transmitted from food-derived strains. Although many of the human- and food-derived non-typhoidal *Salmonella* spp. strains isolated and stored by the regional public health laboratories in this study were not from the same foodborne outbreak case, there observed human-derived and food-derived strains with a similarity close to that used in the United Kingdom as the standard for the same foodborne outbreak strains of non-typhoidal *Salmonella* spp. (SNP count of 5 or fewer [1]).

Among the AmpC genes, *bla_{CMY-2}* was the only one found in both human-derived and food or animal-derived strains. The human-derived and food-derived strains with identical resistance gene profiles were isolated 4 years apart, suggesting that investigating the potential transmission of strains with resistance genes from food to humans would be inappropriate in this case.

A similar investigation was conducted regarding fosfomycin resistance genes, and it was found that human- and food-derived strains closely adjacent within Agona cluster in the tree had an identical resistance gene profile, including the *fosA7.2* gene possession. Thus, a core genome phylogenetic tree was constructed using Agona human-derived strains (13 strains) and food-derived strains (3 strains) (Figure 11, lower part). Genomic analysis of a small number of Agona strains revealed highly closely related (13-15 SNPs) pairs of human-derived and food-derived strains (B cluster in Figure 11), strongly suggesting that the human-derived strains harboring *fosA7.2* may have been transmitted from food-derived strains.

Next, core genome phylogenetic trees were constructed for each of the two major serotypes in food-derived strains, Schwarzengrund and Infantis. The results showed that human-derived strains were often found adjacent to either food-derived or animal-derived strains on the phylogenetic trees (Figures 12 and 13). For further investigation, the number of single nucleotide polymorphism (SNPs) was calculated for the following comparisons: between human-derived strains. It should be noted, however, that strains belonging to distinct phylogenetic lineages diverging significantly from the main lineages (as shown in Figures 12 and 13) were excluded from this analysis). The distribution of SNP counts between human-derived strains, human-derived versus food-derived strains, and human-derived versus animal-derived strains largely overlapped (Figures 14 and 15). In the case of Schwarzengrund (Figure 14), there was no significant difference in the frequency distribution of SNPs (with a p-value of 0.92 for the comparison between the differences among human-derived strains and the differences between human-derived and food-derived strains, and a p-value of 0.096 for the comparison between the differences among human-derived strains and the differences between human-derived and animal-derived strains, as indicated by the Wilcoxon rank-sum test). In the case of Infantis (Figure 15), the median number of SNPs (131), between human-derived and food-derived strains as well as between human-derived and animal-derived strains, was smaller than the median number of SNPs among human-derived strains (142). The p-values for these comparisons were 0.019 for the comparison between the differences among human-derived strains and the differences between human-derived and food-derived strains and 0.0066 for the comparison between the differences among human-derived strains and the differences between human-derived and animal-derived strains, indicating that the differences in core genomes between human-derived strains and food- or animal-derived strains were comparable to or smaller than those observed among human-derived strains. The human-derived *S. Schwarzengrund* and *S. Infantis* strains isolated from patients with infectious enteritis or food poisoning in this study were generally considered to have likely been transmitted to humans through animals or food. Notably, closely related pairs of human-derived and food-derived strains with an SNP count of 15 or under were detected, with 57 pairs in Schwarzengrund and 1 pair in Infantis. However, these strains did not harbor the ESBL, AmpC, or fosfomycin resistance genes.




Figure 9. Core genome phylogenetic tree of 1613 non-typhoidal *Salmonella* spp. strains, along with the serotype, origin (human, food, animal), sample type by origin, and the presence or absence of key resistance genes, including ESBL or AmpC genes (typically located on plasmids), fosfomycin resistance genes, tetracycline resistance genes, trimethoprim resistance genes, kanamycin resistance genes, and macrolide resistance genes.




Figure 10. Serotype distribution (percentage) of human-derived strains (left), food-derived strains (middle), and animal-derived strains (right) used in the genomic analysis of non-typhoidal *Salmonella* spp.

Note: Food-derived strains are colored according to the top 8 most frequent serotypes, while human- and animal-derived strains are colored for these serotypes as well as those with a frequency exceeding 3%. All other serotypes are shown in dark gray.




Figure 11. Core genome phylogenetic tree of Blockley strain (upper) and core genome phylogenetic tree of human-derived and food-derived strains of serotype Agona (lower)

The two boxes in the Blockley phylogenetic tree indicate strains that carry the *bla*_{CTX-M-15} gene and share the same resistance gene profile. The two boxes in the Agona phylogenetic tree indicate closely related human- and food-derived strains that carry the *fosA7.2* gene and have the same resistance gene profile.




Figure 12. Core genome phylogenetic tree of *Salmonella* Schwarzengrund strains




Figure 13. Core genome phylogenetic tree of *Salmonella* Infantis strains




Figure 14. Distribution of SNP counts among human-derived strains, between human-derived and food-derived strains, and between human-derived and animal-derived strains of *Salmonella* Schwarzengrund

The light blue represents the overlap between blue (human-derived and animal-derived strains) and green (human-derived and food-derived strains).




Figure 15. Distribution of SNP counts among human-derived strains, between human-derived and food-derived strains, and between human-derived and animal-derived strains of *Salmonella Infantis*

The light blue represents the overlap between blue (human-derived and animal-derived strains) and green (human-derived and food-derived strains).

***Campylobacter* spp.**

From the genomic data of 682 *Campylobacter* spp. strains accepted for genome analysis by the National Institute of Infectious Diseases between 2021 and 2024 (57 strains from food sources, specifically chicken meat distributed in the Tokyo metropolitan area; 364 strains from animal sources, including rectal feces from cattle and swine at slaughterhouses and cecal feces from chickens at poultry slaughterhouses; and 261 human-derived strains), core genome phylogenetic trees were constructed for *Campylobacter jejuni* (635 strains) and *Campylobacter coli* (47 strains) (Figures 16, 17). The trees indicate the Clonal Complex (CC), source of origin, and the presence or absence of resistance genes or mutations contributing to resistance against tetracycline, fluoroquinolones, macrolides, and aminoglycosides. The most prevalent CC in *C. jejuni* was the ST-21 complex (232/635 = 37%), while in *C. coli*, the most frequent was the ST-828 complex (32/47 = 68%). Among the resistance genes, the most prevalent tetracycline resistance genes were *tet(O)* and *tet(O/M/O)*. In *C. jejuni*, the proportions of strains harboring *tet(O)* among those with tetracycline resistance genes were 52% for human-derived strains, 45% for food-derived strains, and 44% for animal-derived strains, with no significant differences between the groups. The factors contributing to macrolide resistance detected were amino acid substitutions in the 50S ribosomal protein L22 and base substitutions in the 23S rRNA gene, while *erm(B)* was not detected. The proportion of strains harboring amino acid substitutions in the 50S ribosomal protein L22 or base substitutions in the 23S rRNA gene was 43% in *C. coli* and 15% in *C. jejuni*.

With regard to the source of isolation of the bacteria, *C. jejuni* was most frequently derived from sources other than swine (humans, chickens, cattle) (Figures 16, 18), whereas *C. coli* was predominantly derived from swine (Figures 17, 19). When comparing the breakdown of CCs (or STs) between different sources for *C. jejuni* and *C. coli*, no clear similarities in the CC breakdown between sources were observed for either species (Figures 18, 19). Furthermore, *C. coli* exhibited a higher proportion of strains harboring genes contributing to tetracycline resistance, mutations contributing to macrolide resistance, and genes contributing to aminoglycoside resistance compared to *C. jejuni* (Figure 20). When defining multidrug resistance as the presence of three or more genes or mutations contributing to resistance against tetracycline, fluoroquinolones, macrolides, or aminoglycosides, the proportion was 45% for *C. coli* and 5% for *C. jejuni*. No strains harboring ESBL genes were found in either *C. jejuni* or *C. coli*.

Furthermore, among the human- and food-derived *C. jejuni* strains that are adjacent on the phylogenetic tree,

combinations with short branch lengths (indicated by fewer SNPs in the comparison of core genome sequences) and with the isolation year of the human-derived strains relatively close to that of food-derived strains (2022 and 2023, compared to 2024 for food-derived strains) are shown in Figure 21. The combinations of these strains belonged to either the ST-21 complex, ST-48 complex, or ST-22 (among these, ST-22 is known for its higher risk of causing Guillain-Barré syndrome). For each pair of human-derived and food-derived strains, SNPs on the core genome were detected, with at least 23 SNPs identified. The human-derived and food-derived strains analyzed in this study were not isolated from the same foodborne outbreak involving humans and the implicated food. In this analysis, pairs of strains that were closely related to the level detected in *Salmonella* were not found in *C. jejuni*. In contrast, in *C. coli*, no combinations with short branch lengths between human-derived and food-derived strains, similar to those found in *C. jejuni*, were observed. In *C. jejuni* used for this analysis, the number of food-derived strains was approximately one-fifth that of human-derived strains. To further investigate the potential for *C. jejuni* transmission from food to humans, expanding the dataset of food-derived strains is recommended.




Figure 16. The phylogenetic tree constructed from the genomic data of 249 human-derived *C. jejuni* strains, 48 food (chicken)-derived strains, and 338 animal-derived strains, each strain's CC and origin, and the presence or absence of *tet* genes contributing to tetracycline resistance, amino acid substitutions in GyrA (mutation located in the quinolone resistance-determining region of the DNA gyrase A gene) contributing to fluoroquinolone resistance, amino acid substitutions in the 50S ribosomal protein L22 and base substitutions in the 23S rRNA gene contributing to macrolide resistance, and genes contributing to aminoglycoside resistance (primarily *aph(3')-IIIa* and amino acid substitutions in the ribosomal protein S12, encoded by the *rpsL* gene)




Figure 17. The phylogenetic tree constructed from the genomic data of 12 human-derived *C. coli* strains, 9 food (chicken)-derived strains, and 26 animal-derived strains, each strain's CC and origin, and the presence or absence of *tet* genes contributing to tetracycline resistance, amino acid substitutions at T86I in GyrA (mutation located in the quinolone resistance-determining region of the DNA gyrase A gene) contributing to fluoroquinolone resistance, amino acid substitutions in the 50S ribosomal protein L22 and base substitutions in the 23S rRNA gene contributing to macrolide resistance, and genes contributing to aminoglycoside resistance (primarily *aadECc* and amino acid substitutions in the ribosomal protein S12)




Figure 18. The breakdown of CC (or ST) by the source of *C. jejuni* (human, poultry meat, cattle rectal feces, and chicken cecal feces)

Note: All groups representing more than 5% of each source were highlighted, while the remaining strains, including those without assigned types, were colored gray. "Others (ST-21 complex)" refers to STs that account for less than 5%.




Figure 19. The breakdown of CC (or ST) by the source of *C. coli* (human, poultry meat, and swine rectal feces)

Note: "Others" (gray) refers to strains with no assigned ST, and "Others (ST-828 complex)" refers to STs that account for less than 5%.




Figure 20. Proportions of major resistance genes in three different sources (human, food [chicken], and animals [rectal feces from cattle and swine at slaughterhouses, cecal feces from poultry slaughterhouses]) in two major CCs and other strains (strains outside the *C. jejuni* ST-21 complex and *C. coli* ST-828 complex). (Top: Two major CCs, Bottom: Other strains)




Figure 21. The expanded view (right) of the core genome phylogenetic tree (left) shown in Figure 16, highlighting the adjacent and closely related regions between food-derived strains (isolates from 2024) and human-derived strains (isolates from 2022 or 2023) within the ST-21 complex, ST-48 complex, and ST-22 complex

The rectangular frame in the expanded view indicates information on closely related food-derived strains and human-derived strains.

Enterococcus spp.

Figure 22 shows a core-genome phylogenetic tree constructed from genome data of 38 *Enterococcus* spp. isolates obtained from foods (chicken samples from meat hygiene inspection centers and quarantine stations) that were received and subjected to genome analysis by the National Institute of Infectious Diseases in 2021 and were originally isolated between 2016 and 2021, together with 34 vancomycin-resistant *Enterococcus* (VRE) isolates collected from hospitals across Japan during 2019–2020 by the Antimicrobial Resistance Research Center of the National Institute of Infectious Diseases. The species composition included one human-derived strain of *Enterococcus gallinarum*, 42 strains of *Enterococcus faecium*, and 29 strains of *Enterococcus faecalis*. Both *E. faecium* and *E. faecalis* were isolated from both food and human sources (Figures 22 and 23). In *E. faecium*, all human-derived VRE strains were classified into CC17, while none of the food-derived strains belonged to CC17, indicating a phylogenetic separation between human-derived VRE and food-derived strains. Similarly, in *E. faecalis*, human-derived VRE strains were classified into either ST6 or ST179, while none of the food-derived strains belonged to ST6 or ST179, indicating that human-derived and food-derived strains of *Enterococcus* spp. are phylogenetically distinct.




Figure 22. The phylogenetic tree constructed from the genome data of 38 food-derived and 34 human-derived *Enterococcus* spp. strains, along with information on the origin of each strain (human or food), species, ST, CC, and the types of van genes present




Figure 23. The proportion of the two *Enterococcus* species in food-derived and human-derived strains

2) The Antimicrobial Resistance (AMR) One Health Surveillance in coordination with the WHO surveillance (Tricycle Project)

This section presents an overview of the Tricycle Surveillance (Japanese name: SANRINSHA (tricycle) Project) using ESBL-producing *Escherichia coli* (ESBL-Ec), along with the results obtained thus far in Japan.

1. Background

At the G7 Elmau Summit in June 2015, antimicrobial resistance (AMR) was addressed as one of the key issues, and a policy was presented to develop and promote an integrated approach (One Health approach) involving humans, animals, food, and the environment. In 2017, the WHO Food Safety and Zoonoses Department, along with its advisory body AGISAR (the Advisory Group on Integrated Surveillance on Antimicrobial Resistance), proposed the Tricycle Surveillance using ESBL-producing *Escherichia coli* (ESBL-Ec) (<https://www.who.int/publications/i/item/9789240021402>), allowing participation by member countries. This initiative focuses on ESBL-Ec as a key indicator, and like the three wheels of a tricycle, it follows a common protocol across countries to calculate the proportion of ESBL-Ec among *Escherichia coli* from three sectors: human-derived, food-derived, and environment-derived. In addition to this, molecular characterization of the isolated strains and epidemiological analyses are conducted. By leveraging collaboration with GLASS, comparisons between regions and links with antimicrobial consumption are also explored. In Japan, surveys on antimicrobial-resistant bacteria in humans, food, and the environment have been conducted sporadically or as isolated studies across various fields and regions.

For example, it has been reported that 26% of *E. coli* cases resulting in community-acquired infections in humans carry ESBL [2]. The carriage rate of ESBL-producing Enterobacteriaceae in infants is 19.3%, with all but one case involved *E. coli* [3]. In the food sector, *K. pneumoniae* carrying *bla*_{NDM-1}, *bla*_{VIM-1}, and *mcr-9* was isolated from Japanese chicken meat obtained from grocery stores [4]. Furthermore, studies have identified minor carbapenemases such as *bla*_{GES-5}, *bla*_{FRI}, and *bla*_{IMI} from *Enterobacter* spp. and other bacteria in river and lake samples in Japan, suggesting that the environment may function as a potential reservoir for these resistance genes [5]. Although such sporadic reports exist, in Japan, nationwide surveillance over the long term based on a unified protocol, such as the WHO Tricycle Project, has not been conducted to date, and no data has been available to provide an overview of the current situation. In light of the need for continuous surveillance of antimicrobial-resistant bacteria in humans, food, and the environment in Japan, a research group was established for the study titled "Research on Antimicrobial-Resistant Bacteria One Health Trend Survey, Coordinated with WHO Surveillance" (Principal Investigator: Motoyuki Sugai, from April 1, 2020, to March 31, 2023) [6] as part of the Japan Agency for Medical Research and Development's (AMED) initiative for Research Program on Emerging and Re-emerging Infectious Diseases. Through these efforts, the results of the WHO Tricycle Project in Japan were included in the Nippon AMR One Health Report (2024 edition), and the present report represents the second publication of these findings.

2. Objectives

The objective of this research group is to establish a system to accurately implement a protocol in accordance with the Tricycle Project. The aim is to establish a surveillance system capable of national-level comparisons by analyzing collected *E. coli* and ESBL-Ec strains, determining the antimicrobial resistance rates of *E. coli* in humans, food, and the environment, identifying trends in resistance development within each sector, and examining the transmission of resistance genes between sectors.

3. Samples and Methods

The isolation of *E. coli* and ESBL-Ec was conducted as follows:

(1) Human-derived samples

a) Prevalence of ESBL-Ec in patients (Blood culture origin, single institution)

- The rate of ESBL-Ec/Ec using *E. coli* counts from blood cultures obtained from a university hospital in A Prefecture was calculated.

b) Prevalence of ESBL-Ec in patients (Blood culture origin, nationwide)

- The rate of CTX resistant Ec/Ec using *E. coli* counts from blood cultures obtained from JANIS (hospitalization).

c) Prevalence of ESBL-Ec in healthy individuals (Rectal swabs from pregnant women)

- The rate of ESBL-Ec-positive pregnant women/total pregnant women was calculated using rectal swabs collected from healthy pregnant women in their third trimester (35–37 weeks) who visited outpatient clinics and university hospitals for prenatal checkups. ESBL-producing *E. coli* (ESBL-Ec) was identified from isolates grown on CTX-containing MacConkey agar.

d) Prevalence of ESBL-Ec in healthy individuals (Fecal samples from food service workers)

- The rate of ESBL-Ec/Ec was calculated using *E. coli* isolated from fecal samples of food service workers, and samples themselves.
- (2) Samples from chicken cecal feces at poultry processing plants (as an index for food-derived)
- The rate of ESBL-Ec/Ec was calculated for *E. coli* collected by the Ministry of Agriculture, Forestry and Fisheries' National Veterinary Assay Laboratory for the Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM) The isolates were derived from broiler chicken cecal feces collected at poultry processing plants.
- (3) Environmental-derived samples
- The presence of *E. coli* and ESBL was confirmed from isolates obtained on TBX agar, which is designed for *E. coli* isolation. The rate of ESBL-Ec/Ec was calculated using sewage inflow water from wastewater treatment plants and river water, in specific regions (including Hokkaido, Saitama, Nagano, Okayama, Hiroshima, and Tokushima).

4. Results and discussion

The proportion of ESBL-Ec was determined for each of the human, environmental and food sectors by implementing and analyzing the collection of bacterial strains in humans, the environment, and food in Japan (Figure 24).

With regard to the proportion of ESBL-Ec among *E. coli* isolates in the human sector, a study conducted from 2019 to 2022 on blood culture-derived *E. coli* at a university hospital in A Prefecture revealed that ESBL-Ec accounted for 27.8% of *E. coli* isolates. Meanwhile, the nationwide statistics for blood culture-derived *E. coli* from hospitalized patients as reported by JANIS, indicated that the proportion of CTX-resistant strains from 2019 to 2023 was 23.6%. It should be noted that, as JANIS does not collect bacterial strains but instead gathers phenotypic data based on antimicrobial susceptibility test results, CTX-resistant strains were considered to be ESBL-producing strains. Consequently, the ESBL *E. coli* prevalence among patients with underlying conditions was found to be 20–30%. In contrast, for healthy individuals, the proportion of ESBL-Ec among *E. coli* isolated from rectal swabs of pregnant women in a specific region from 2022 to 2023 was 12.0%, and from fecal samples of food service workers from 2019 to 2020, it was 4.0%. Both of these values were lower than the ESBL prevalence in *E. coli* isolates from patient samples. Meanwhile, results based on protocols aligned with the Tricycle Project have increasingly been reported from various countries. The proportion of ESBL-Ec among *E. coli* isolates has been reported as 11% in human fecal samples in the United Kingdom [7], 57.7% in blood cultures and 40% in pregnant women in Indonesia [8], 22.3% in pregnant women in Benin [9], 39% in blood cultures and 30% in pregnant women in Madagascar [10], and 49% in blood cultures and 15% in pregnant women in Nepal [11].

The proportion of ESBL-Ec isolated from the cecal feces of chickens collected at poultry processing plants, which serve as indicators for food (2019–2023 strains collected by JVARM), was 1.88 (with 2.75% of the strains exhibiting resistance to CTX). In Japan, third-generation cephalosporins are used as a second-line drugs for cattle and swine but sales are low (1.07 t, 0.17% in 2021) [12] Cephalosporins are not approved for use in chickens. Prior to 2012, some off-label use in chickens was conducted, but this practice has since been discontinued. Furthermore, in the case of swine, where the sales volume of third-generation cephalosporins is highest, the resistance rate of *E. coli* from healthy swine to cefotaxime, a third-generation cephalosporin, is low at 2.1%. The proportion of ESBL-Ec in poultry reported from various countries based on protocols aligned with the Tricycle Project has been reported as 65% in the United Kingdom (retail poultry) [7], 67.1% in Indonesia [8], 39% in Vietnam [13], 57% in Madagascar [10], and 38.6% in Nepal [11].

With regard to environmental-derived samples, a survey conducted from 2020 to 2023 revealed that the proportion of ESBL-Ec was 1.17% in upstream river water, 0.41% in downstream river water, 3.27% in sewage inflow water, and 1.06% in wastewater from poultry and other animal slaughterhouses. The proportion of ESBL-Ec among *E. coli* isolates from environmental water, based on protocols aligned with the Tricycle Project, has been reported as 12.8% in Indonesia [8], 2.79% in Ghana (urban average) [14], 19% in Vietnam (slaughterhouses) [13], and 8.7% in Nepal (downstream river water) [11].




Figure 24. The proportion of ESBL-Ec among the total *E. coli* isolates

The proportion of ESBL-producing *E. coli* among the total *E. coli* isolates is shown [6]. The years of analysis are indicated below the bar graph for each sample.

7. Current Volume of Use of Antimicrobials in Japan

(1) Antimicrobials for humans

1) Usage of antimicrobials in Japan

Source: Japan Surveillance of Antimicrobial Consumption (JSAC)

Antimicrobial use based on sales volume in Japan from 2015 to 2024 is shown in Table 80 (oral agents), Table 81 (injectable agents), and Table 82 (total of oral and injectable antimicrobial agents). Overall use of antimicrobials in Japan in 2024 amounted to 12.96 DID. A comparison with DID in major countries in 2020 shows that this was lower than France (21.5 DID), Italy (17.5 DID), and Sweden (10.1 DID), but higher than the Netherlands (8.5 DID) and Austria (8.8 DID) [1]. Looking at changes over time, no significant changes in antimicrobial use were observed from 2013 to 2016, but the decline began in 2017, with the decrease becoming smaller. During such a trend, there was an epidemic of COVID-19 infections, and overall antimicrobial use in 2020 declined more sharply compared to the previous years. The years 2021 and 2022 exhibited a flat trend, with a 3.9% decrease in 2022 compared to 2020. However, in 2023 and in 2024, the overall figure was 11.96 DID and 12.96 DID, respectively, representing a 27.3% increase compared to 2020 and 2024.

The use of oral agents in 2024 (Table 80) as a percentage of total antimicrobial use is 11.91 DID (91.9%), of which oral third generation cephalosporins (1.94 DID) which are targeted to be reduced by 40% in the Nippon AMR Action Plan, oral fluoroquinolones (2.42 DID), which are targeted for a 30% reduction, and oral macrolides (3.95 DID), which are targeted for a 25% reduction, together accounted for 63.1% of all oral antimicrobial agents. While this trend has not changed since 2013, compared with 2020, the use of oral third-generation cephalosporins decreased by 2.2%, whereas the use of oral fluoroquinolones and oral macrolides increased by 45.8% and 34.8%, respectively, in 2024. The use of parenteral carbapenems decreased by 9.0% between 2020 and 2024 (Table 81). It was thought that 2019 may have seen a decrease in first-generation cephalosporins and an increase in narrow-range penicillins, penicillin with β -lactamase inhibitors, second- and third generation cephalosporins, and carbapenems, especially due to cephazolin supply shortage issues. [2] Overall antimicrobial use decreased since 2020, which may be due not only to the promotion of appropriate antimicrobial use, but also to the impact of COVID-19 (e.g., fewer patients seen with infections other than new coronavirus infections). A similar trend was seen to continue until 2022 also due to the continuing pandemic.

Table 83 shows antimicrobial use based on the AWARe classification recommended by the WHO as an indicator of antimicrobial stewardship. Carried in the 20th edition of the WHO Model Lists of Essential Medicines, the AWARe classification is an antimicrobial classification system that is applied as an indicator of antimicrobial stewardship. It classifies antimicrobials into four categories: Access (first- or second-choice antimicrobials used for treating common infections, regarding whose resistance potential there is little concern, and which should be made widely available by all countries in high-quality formulations at a reasonable cost. Examples include ampicillin and cephalexin), Watch (antimicrobials that should be used only for a limited number of conditions or applications, as their resistance potential is a source of concern. Examples include vancomycin, meropenem, levofloxacin, and ceftriaxone), Reserve (antimicrobials that should be used as the last resort when no other alternatives can be used. Examples include tigecycline, colistin, and daptomycin), and Unclassified. This classification was amended in 2019 to add the new category of “discouraged antibiotics,” consisting of antimicrobials whose clinical use the WHO does not recommend (for example, cefoperazone-sulbactam). The WHO has set a target of at least 60% of antimicrobial consumption being from medicines classified as the Access Group. While consumption of antimicrobials classified as the Access Group as a proportion of total use tends to be lower in Japan than other countries,[3] the figure has risen gradually over the years since 2014 from 11.8% to 23.2% in 2024, with the percentage of antimicrobials classified as the Watch Group falling from 86.7% to 75.7%, which can mean that Japan is on its way towards the actions recommended in the Action Plan (2023-2027).

However, various factors, such as the problem of antimicrobial supply shortages and the impact of new coronavirus infections and lifting of restrictions on activities, are also of concern and require continued close monitoring.

A survey of oral and parenteral antimicrobial use in terms of potency by weight from a One Health perspective (Table 84) also confirmed an increase since 2023 in overall use, which had been showing a decrease. While the use of Access-category antimicrobials, such as penicillins, first-generation cephalosporins, and trimethoprim-sulfamethoxazole, has increased, the use of quinolones and macrolides—antimicrobials with relatively high usage in Japan—has also increased, indicating the need for close monitoring of future trends. The largest proportional decrease was observed in the use of oral third generation cephalosporins, fluoroquinolones, and macrolides, and it is necessary to clarify the factors from the viewpoint of appropriate use, considering the impact of COVID-19 infection, the subsequent lifting of restrictions on activities, the emergence of various infectious diseases, and limitations in the supply of antibiotics. Since there may be a future impact of the incentives for appropriate use of antibiotics, continuous monitoring of future trends in antimicrobial use is deemed essential.

Furthermore, in recent years, it has become possible to analyze antibiotic prescription rates using NDB data. The target conditions included major infections: acute respiratory infections, diarrhea, otitis media, pneumonia, and

urinary tract infections, and analyses focused on whether antibiotics were prescribed at the initial consultation (Tables 82 and 83). For upper respiratory infections and diarrhea, for which appropriate antibiotic use has been identified as a challenge in the AMR Action Plan, prescription rates have shown a declining trend. Between the implementation of the AMR Action Plan and 2020, prescription rates decreased from 54.2% to 38.2% for upper respiratory infections and from 35.5% to 30.3% for diarrhea. These findings indicate that not only antibiotic consumption but also prescription patterns for these conditions have undergone significant changes. Given changes in circumstances such as the COVID-19 pandemic, subsequent environmental shifts, and instability in pharmaceutical supply, continued monitoring of prescription rates will remain necessary.

The establishment of a surveillance system, which was one of the goals of the Action Plan for AMR control, made it possible to assess the use of antimicrobial agents in Japan over time. In addition to the various influencing factors mentioned above, the impact of the increasing elderly population should also be considered, necessitating closer attention. In 2020, however, oral agents declined further, and parenteral antimicrobial agents also began to decline. One reason for the decrease may be the various effects associated with the new coronavirus infections, and although there has not been another increase at this time, it is necessary to understand future trends. Furthermore, the purpose of antimicrobial use needs to be clarified and its appropriateness evaluated by continuing surveillance of antimicrobial use, based not only on sales volume data but also on the National Database for Prescription and National Health Checkups (NDB).

Table 80. Trends in oral antimicrobial use in Japan based on the volume of sales

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Tetracyclines	0.77	0.80	0.81	0.88	0.96	1.10	1.18	1.18	1.28	1.51
Amphenicols	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Penicillins with extended spectrum	0.68	0.66	0.65	0.69	0.77	0.61	0.59	0.60	0.83	0.84
Beta Lactamase-sensitive penicillins	0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Combinations of penicillins, including beta lactamase inhibitors	0.17	0.18	0.19	0.20	0.23	0.18	0.19	0.19	0.23	0.26
1st generation cephalosporins	0.07	0.07	0.07	0.08	0.09	0.09	0.10	0.11	0.13	0.13
2nd generation cephalosporins	0.29	0.29	0.28	0.28	0.30	0.29	0.31	0.32	0.37	0.28
3rd generation cephalosporins	3.46	3.32	3.08	2.83	2.63	1.85	1.70	1.63	1.94	1.81
Carbapenems	0.02	0.02	0.01	0.01	0.01	0.01	0.01	0.00	0.01	0.01
Other cephalosporins and penems	0.13	0.12	0.12	0.11	0.10	0.09	0.09	0.08	0.09	0.09
Combinations of sulfonamides and trimethoprim, including derivatives	0.29	0.31	0.33	0.36	0.38	0.41	0.44	0.46	0.48	0.50
Macrolides	4.59	4.56	4.18	3.96	3.84	2.93	2.72	2.66	3.45	3.95
Lincosamides	0.02	0.01	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.03
Fluoroquinolones	2.71	2.75	2.57	2.42	2.32	1.66	1.48	1.52	2.07	2.42
Other quinolones	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Other antibacterials	0.10	0.10	0.09	0.08	0.08	0.06	0.06	0.06	0.06	0.07
Total	13.30	13.19	12.38	11.92	11.74	9.31	8.88	8.84	10.96	11.91

* As a unit, DIDs (DDDs/1,000 inhabitants/day) is used.

* Figures for DDD (defined daily dose) are those for January 1, 2025.

Table 81. Trends in parenteral antimicrobial use in Japan based on the volume of sales

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Tetracyclines	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.01
Amphenicols	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Penicillins with extended spectrum	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
Beta-lactamase sensitive penicillins	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Combinations of penicillins, incl. beta-lactamase inhibitors	0.16	0.18	0.19	0.21	0.22	0.18	0.20	0.23	0.26	0.28
First-generation cephalosporins	0.14	0.14	0.15	0.15	0.12	0.13	0.14	0.15	0.15	0.16
Second-generation cephalosporins	0.10	0.10	0.10	0.09	0.10	0.08	0.08	0.09	0.09	0.08
Third-generation cephalosporins	0.21	0.22	0.23	0.24	0.27	0.22	0.21	0.22	0.24	0.26
Fourth-generation cephalosporins	0.03	0.03	0.03	0.03	0.02	0.02	0.02	0.02	0.03	0.03
Monobactams	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Carbapenems	0.08	0.08	0.08	0.08	0.08	0.07	0.07	0.07	0.06	0.06
Other cephalosporins and penems	-	-	-	-	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Combinations of sulfonamides and trimethoprim, incl. derivatives	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Macrolides	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Lincosamides	0.02	0.02	0.02	0.02	0.02	0.01	0.01	0.01	0.01	0.01
Streptogramins	< 0.01	< 0.01	< 0.01	< 0.01	-	-	-	-	-	-
Streptomycins	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Other aminoglycosides	0.05	0.04	0.04	0.03	0.03	0.03	0.02	0.02	0.02	0.02
Fluoroquinolones	0.03	0.04	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.04
Glycopeptide antibacterials	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.04	0.04
Polymyxins	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Imidazole derivatives	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Other antibacterials	0.02	0.02	0.02	0.02	0.02	0.01	0.01	0.01	0.01	0.01
Total	0.94	0.96	0.98	0.99	1.01	0.87	0.89	0.94	1.00	1.05

* As a unit, DID (DDDs/1,000 inhabitants/day) is used.

* Figures for DDD (defined daily dose) are those for January 1, 2025.

Table 82. Trends in oral and parenteral antimicrobial use in Japan based on the volume of sales

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Tetracyclines	0.79	0.82	0.83	0.90	0.98	1.12	1.19	1.19	1.30	1.52
Amphenicols	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Penicillins with extended spectrum	0.70	0.68	0.67	0.71	0.79	0.63	0.61	0.62	0.85	0.86
Beta-lactamase sensitive penicillins	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.01	0.01
Combinations of penicillins, incl. beta-lactamase inhibitors	0.34	0.36	0.38	0.41	0.45	0.36	0.38	0.42	0.48	0.54
First-generation cephalosporins	0.20	0.21	0.22	0.23	0.21	0.22	0.24	0.26	0.29	0.30
Second-generation cephalosporins	0.39	0.39	0.37	0.38	0.41	0.38	0.39	0.41	0.45	0.37
Third-generation cephalosporins	3.67	3.54	3.31	3.07	2.90	2.07	1.91	1.85	2.18	2.07
Fourth-generation cephalosporins	0.03	0.03	0.03	0.03	0.02	0.02	0.02	0.02	0.03	0.03
Monobactams	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Carbapenems	0.10	0.10	0.09	0.09	0.09	0.07	0.08	0.07	0.07	0.07
Other cephalosporins and penems	0.13	0.12	0.12	0.11	0.10	0.09	0.09	0.08	0.09	0.10
Combinations of sulfonamides and trimethoprim, incl. derivatives	0.29	0.32	0.34	0.36	0.39	0.41	0.44	0.46	0.48	0.50
Macrolides	4.59	4.56	4.18	3.96	3.84	2.93	2.73	2.66	3.45	3.96
Lincosamides	0.04	0.04	0.03	0.03	0.04	0.03	0.03	0.03	0.04	0.05
Streptogramins	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	-	-	-	-	-
Streptomycins	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Other aminoglycosides	0.05	0.04	0.04	0.03	0.03	0.03	0.02	0.02	0.02	0.02
Fluoroquinolones	2.74	2.78	2.60	2.45	2.35	1.69	1.51	1.55	2.10	2.46
Other quinolones	< 0.02	< 0.03	< 0.04	< 0.05	< 0.06	< 0.07	< 0.08	< 0.09	< 0.10	< 0.01
Glycopeptide antibacterials	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.04	0.04
Polymyxins	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Imidazole derivatives	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Other antibacterials	0.12	0.12	0.10	0.10	0.10	0.08	0.07	0.07	0.08	0.08
Total	14.23	14.15	13.36	12.91	12.75	10.18	9.77	9.78	11.96	12.96

* As a unit, DID (DDDs/1,000 inhabitants/day) is used.

* Figures for DDD (defined daily dose) are those for January 1, 2025.

Table 83. Trends in antimicrobial use in Japan by AWaRe classification

AWaRe Classification	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Access (%)	1.79 (12.49)	1.84 (12.92)	1.90 (14.16)	2.06 (15.90)	2.25 (17.57)	2.17 (20.91)	2.29 (22.85)	2.39 (23.79)	2.80 (22.94)	3.08 (23.22)
Watch (%)	12.31 (86.07)	12.18 (85.70)	11.33 (84.47)	10.72 (82.76)	10.38 (81.11)	8.07 (77.67)	7.58 (75.77)	7.52 (74.90)	9.29 (75.98)	10.04 (75.72)
Reserve (%)	0.18 (1.27)	0.17 (1.22)	0.16 (1.20)	0.15 (1.18)	0.15 (1.16)	0.13 (1.25)	0.12 (1.22)	0.12 (1.15)	0.12 (0.99)	0.13 (0.97)
Non-recommended (%)	0.02 (0.15)	0.02 (0.15)	0.02 (0.16)	0.02 (0.16)	0.02 (0.16)	0.02 (0.17)	0.02 (0.16)	0.02 (0.16)	0.01 (0.09)	0.01 (0.08)
Unclassified (%)	0.00 (0.01)	0.00 (0.01)	0.00 (0.01)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)
Total	14.30	14.21	13.41	12.96	12.79	10.39	10.01	10.03	12.23	13.25

* As a unit, DID (DDDs/1,000 inhabitants/day) is used.

* Figures for DDD (defined daily dose) are those for January 1, 2023. AWaRe classification 2023 edition was used.

* The above follows the WHO's AWaRe classification and corresponds to the medications included in the GLASS Report.

Table 84. Antimicrobial consumption by weight based on sales volume in Japan, converted to potency (t)

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Tetracyclines	7.1	7.2	7.0	7.3	7.7	8.4	8.7	8.5	9.0	10.2
Amphenicols	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0
Penicillins with extended spectrum	57.6	56.3	54.5	57.3	62.6	49.3	47.9	48.5	64.3	65.0
Beta Lactamase-sensitive penicillins	1.7	1.5	1.4	1.3	1.8	1.3	1.1	1.1	1.3	1.3
Combinations of penicillins, including beta lactamase inhibitors	106.1	114.9	124.4	132.2	146.0	118.0	129.2	146.4	163.3	177.6
1st generation cephalosporins	25.2	26.3	27.2	28.4	24.9	26.5	28.9	30.2	33.1	34.1
2nd generation cephalosporins	27.0	26.7	25.9	26.0	28.6	25.5	26.5	27.7	29.5	25.2
3rd generation cephalosporins	97.8	95.9	91.2	86.6	85.3	64.0	59.8	58.8	65.1	63.6
4th generation cephalosporins	6.0	5.7	5.5	4.8	4.5	4.3	4.2	4.4	4.7	4.7
Monobactams	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Carbapenems	10.1	10.2	10.1	9.8	10.0	8.8	9.1	9.1	8.2	8.1
Other cephalosporins and penems	4.6	4.3	4.0	3.8	3.6	3.3	3.0	2.9	3.2	3.5
Combinations of sulfonamides and trimethoprim including derivatives	53.7	58.6	62.1	65.7	71.0	75.7	81.2	84.6	87.5	91.4
Macrolides	103.4	102.9	94.5	89.7	87.2	67.8	63.4	61.9	79.0	89.5
Lincosamides	2.6	2.5	2.4	2.4	2.7	2.1	2.1	2.2	2.4	2.8
Streptogramins	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1
Streptomycin	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0
Other aminoglycosides	0.9	0.8	0.8	0.7	0.7	0.5	0.5	0.5	0.5	0.5
Fluoroquinolones	56.6	57.4	53.2	50.1	47.7	33.0	29.2	29.1	36.9	40.9
Other quinolones	0.3	0.3	0.2	0.1	0.1	0.1	0.0	0.0	0.0	0.0
Glycopeptides	2.3	2.4	2.5	2.4	2.6	2.7	2.4	2.6	2.8	2.9
Polymyxins	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1
Imidazole derivatives (parenteral)	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3
Other antibacterials	16.6	16.7	14.3	13.8	13.1	10.3	9.3	8.9	9.8	10.5
Total	580.1	591.4	581.6	582.9	600.2	501.9	507.0	527.8	601.1	632.2

Table 85. Trends in the use of total oral and parenteral antimicrobial agents in Japan based on NDB

	2013	2014	2015	2016	2017	2018	2019	2020	2021
Tetracyclines	0.75	0.74	0.75	0.78	0.79	0.85	0.93	1.06	1.13
Amphenicols	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01
Penicillins with extended spectrum	0.53	0.56	0.64	0.64	0.63	0.67	0.76	0.61	0.61
Beta-lactamase sensitive penicillins	0.01	0.01	0.01	0.01	<0.01	<0.01	0.01	0.01	<0.01
Combinations of penicillins, incl. beta-lactamase inhibitors	0.25	0.27	0.29	0.31	0.33	0.35	0.38	0.31	0.33
First-generation cephalosporins	0.14	0.15	0.16	0.16	0.17	0.18	0.17	0.19	0.22
Second-generation cephalosporins	0.34	0.35	0.36	0.35	0.34	0.34	0.37	0.35	0.36
Third generation cephalosporins	3.47	3.54	3.69	3.57	3.34	3.11	2.94	2.10	1.91
Fourth generation cephalosporins	0.03	0.03	0.03	0.03	0.02	0.02	0.02	0.02	0.02
Monobactams	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01
Carbapenems	0.08	0.08	0.08	0.08	0.08	0.07	0.07	0.06	0.06
Other cephalosporins and penems	0.12	0.12	0.12	0.11	0.11	0.10	0.10	0.09	0.08
Combinations of sulfonamides and trimethoprim, incl. derivatives	0.23	0.25	0.27	0.29	0.31	0.33	0.36	0.38	0.42
Macrolides	4.97	4.93	5.07	5.03	4.64	4.44	4.37	3.30	3.04
Lincosamides	0.04	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Streptogramins	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	-
streptomycins	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01
Other aminoglycosides	0.05	0.05	0.05	0.04	0.04	0.03	0.03	0.02	0.02
Fluoroquinolones	2.78	2.74	2.93	2.93	2.74	2.61	2.51	1.78	1.63
Other quinolones	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01
Glycopeptide antibacterials	0.02	0.02	0.02	0.02	0.02	0.02	0.03	0.03	0.03
Polymyxins	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01
Imidazole derivatives	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01
Other antibacterial agents	0.11	0.11	0.11	0.11	0.09	0.09	0.09	0.07	0.06
Total	13.93	13.99	14.63	14.51	13.70	13.28	13.15	10.41	9.96

* As a unit, DID (DDDs/1,000 inhabitants/day) is used.

* Figures for DDD (defined daily dose) are those for January 1, 2024.

Table 86. Trends in antibiotic prescription rates for various infectious diseases based on NDB in Japan

	2013	2014	2015	2016	2017	2018	2019	2020
Acute respiratory infections	57.8	56.1	56.5	54.2	50.9	45.8	43.0	38.2
Diarrhea	35.5	35.4	36.2	34.5	33.7	31.1	30.1	30.3
Otitis media	71.6	71.8	72.4	72.3	70.6	69.0	67.7	60.4
Pneumonia	82.9	82.4	83.0	83.5	81.6	80.5	79.8	74.2
Urinary tract infections	77.6	77.3	77.0	77.2	76.5	76.2	75.9	76.4
Skin and soft tissue infections	52.9	52.1	51.0	49.9	48.6	48.2	47.7	46.6
Sexually transmitted infections	49.1	49.3	49.4	49.8	50.0	51.1	52.0	52.3

* All values are expressed as percentages.

* Cited from the Japan Surveillance of Antimicrobial Consumption.

* Acute respiratory infections are defined to include both acute upper respiratory infections and acute bronchitis.

2) Usage of parenteral antimicrobials in hospitals

Source: J-SIPHE

J-SIPHE, operated by AMRCRC, uses an integrated inpatient EF file* to survey antimicrobial use in participating facilities and publishes the annual reports.[4] In 2024, overall, in-hospital use of intravenous antimicrobial agents followed a similar trend to the previous year. Penicillins (AUD 3.80, DOT 5.76) were the most commonly used, followed by 3rd generation cephalosporins (AUD 3.12, DOT 3.90), 1st generation cephalosporins (AUD 1.93, DOT 2.59), cephamycins (AUD 0.86, DOT 1.64), and carbapenems (AUD 0.64, DOT 1.27). It is necessary to continuously monitor the trend in the future.

*E file: An information file for details about medical services; *F file: A claims file for medical service fees for inpatients that integrates procedural detail information

Table 87. Use of parenteral antimicrobials at medical institutions (AUD, DOT)

	2019		2020		2021		2022		2023		2024	
	AUD (IQR)	DOT (IQR)	AUD (IQR)	DOT (IQR)	AUD (IQR)	DOT (IQR)	AUD (IQR)	DOT (IQR)	AUD (IQR)	DOT (IQR)	AUD (IQR)	DOT (IQR)
Penicillin	3.92 (2.75-5.12)	5.96 (4.23-7.82)	3.48 (2.15-4.82)	5.19 (3.53-7.01)	3.92 (2.32-5.32)	5.77 (3.70-7.35)	3.86 (1.85-5.75)	5.64 (3.20-7.99)	3.95 (1.87-6.38)	6.02 (3.19-8.88)	3.80 (1.78-6.39)	5.76 (3.02-8.79)
1st generation cephalosporins	1.71 (0.83-2.86)	2.24 (1.23-3.94)	2.28 (1.15-3.27)	3.11 (1.58-4.36)	2.52 (1.22-3.62)	3.40 (1.72-4.73)	2.21 (0.79-3.62)	3.02 (1.08-4.75)	2.10 (0.74-3.70)	2.88 (1.03-4.85)	1.93 (0.62-3.71)	2.59 (0.91-4.76)
2nd generation cephalosporins	0.19 (0.09-0.41)	0.37 (0.19-0.83)	0.15 (0.06-0.35)	0.29 (0.13-0.69)	0.14 (0.06-0.29)	0.27 (0.12-0.60)	0.15 (0.07-0.32)	0.31 (0.14-0.66)	0.14 (0.06-0.31)	0.30 (0.13-0.62)	0.09 (0.03-0.19)	0.18 (0.07-0.40)
3rd generation cephalosporins	3.35 (2.24-4.73)	4.63 (3.10-6.30)	3.00 (1.95-4.32)	4.04 (2.87-5.60)	2.91 (1.90-4.32)	4.02 (2.68-5.42)	2.84 (1.74-4.17)	3.91 (2.52-5.36)	2.99 (1.69-4.35)	3.86 (2.35-5.40)	3.12 (1.62-4.61)	3.90 (2.19-5.49)
4th generation cephalosporins	0.34 (0.14-0.70)	0.53 (0.26-1.02)	0.31 (0.14-0.76)	0.49 (0.26-1.05)	0.32 (0.16-0.74)	0.55 (0.28-1.02)	0.27 (0.14-0.62)	0.46 (0.25-0.97)	0.27 (0.14-0.62)	0.48 (0.26-0.97)	0.24 (0.13-0.54)	0.44 (0.23-0.83)
Oxacefemes	0.30 (0.11-0.70)	0.32 (0.12-0.76)	0.26 (0.11-0.61)	0.27 (0.11-0.64)	0.20 (0.09-0.54)	0.20 (0.10-0.55)	0.22 (0.10-0.46)	0.22 (0.10-0.48)	0.22 (0.10-0.49)	0.23 (0.10-0.52)	0.22 (0.10-0.54)	0.23 (0.10-0.53)
Cephamycins	0.90 (0.52-1.42)	1.73 (1.01-2.63)	0.91 (0.47-1.42)	1.67 (0.93-2.62)	1.01 (0.53-1.52)	1.87 (1.04-2.76)	0.94 (0.43-1.55)	1.76 (0.84-2.78)	0.91 (0.36-1.58)	1.69 (0.74-2.84)	0.86 (0.34-1.59)	1.64 (0.67-2.92)
Cephalosporins with beta-lactamase inhibitors	0.06 (0.03-0.10)	0.07 (0.05-0.13)	0.09 (0.06-0.14)	0.09 (0.06-0.13)	0.00 (0.00-0.00)	0.00 (0.00-0.00)	0.10 (0.06-0.18)	0.10 (0.06-0.14)	0.12 (0.07-0.23)	0.10 (0.06-0.18)	0.12 (0.07-0.21)	0.11 (0.07-0.17)
Siderophore Cephalosporin class	-	-	-	-	-	-	-	-	-	-	0.06 (0.04-0.10)	0.09 (0.05-0.14)
Carbapenems	1.23 (0.63-1.79)	2.06 (1.16-3.02)	1.09 (0.55-1.87)	1.95 (1.04-2.90)	1.12 (0.56-1.91)	2.04 (1.09-3.05)	0.88 (0.43-1.71)	1.71 (0.89-2.83)	0.71 (0.32-1.43)	1.42 (0.70-2.50)	0.64 (0.31-1.25)	1.27 (0.66-2.26)
Monobactams	0.04 (0.02-0.09)	0.07 (0.03-0.11)	0.04 (0.02-0.09)	0.07 (0.04-0.10)	0.05 (0.03-0.07)	0.07 (0.05-0.11)	0.06 (0.03-0.11)	0.07 (0.05-0.14)	0.06 (0.03-0.09)	0.07 (0.05-0.13)	0.05 (0.03-0.09)	0.08 (0.05-0.13)
Glycopeptides	0.56 (0.27-0.93)	0.81 (0.47-1.32)	0.48 (0.25-0.92)	0.77 (0.40-1.30)	0.50 (0.26-0.95)	0.77 (0.43-1.32)	0.42 (0.22-0.79)	0.70 (0.38-1.20)	0.40 (0.21-0.77)	0.66 (0.39-1.19)	0.37 (0.19-0.70)	0.62 (0.34-1.09)
Oxazolidinones	0.11 (0.07-0.16)	0.11 (0.07-0.17)	0.11 (0.07-0.18)	0.12 (0.08-0.20)	0.12 (0.07-0.19)	0.13 (0.08-0.21)	0.12 (0.07-0.20)	0.13 (0.08-0.22)	0.13 (0.07-0.21)	0.14 (0.08-0.23)	0.13 (0.07-0.21)	0.14 (0.09-0.23)
Arbekacine	0.07 (0.04-0.13)	0.07 (0.04-0.12)	0.08 (0.04-0.14)	0.08 (0.04-0.15)	0.08 (0.04-0.16)	0.08 (0.04-0.16)	-	-	-	-	-	-
Lipopeptides	0.25 (0.14-0.38)	0.17 (0.11-0.28)	0.24 (0.14-0.39)	0.16 (0.11-0.26)	0.26 (0.15-0.44)	0.18 (0.11-0.30)	0.26 (0.15-0.43)	0.18 (0.11-0.29)	0.25 (0.15-0.40)	0.17 (0.11-0.28)	0.23 (0.14-0.40)	0.17 (0.11-0.27)
Quinolones	0.39 (0.21-0.61)	0.41 (0.24-0.64)	0.37 (0.22-0.59)	0.40 (0.25-0.63)	0.35 (0.22-0.59)	0.38 (0.24-0.63)	0.35 (0.21-0.59)	0.38 (0.23-0.62)	0.37 (0.22-0.60)	0.39 (0.24-0.64)	0.38 (0.22-0.62)	0.40 (0.24-0.66)
Aminoglycosides	0.10 (0.06-0.18)	0.23 (0.14-0.46)	0.10 (0.05-0.17)	0.24 (0.14-0.43)	0.10 (0.05-0.20)	0.25 (0.15-0.49)	0.11 (0.06-0.21)	0.27 (0.15-0.49)	0.11 (0.06-0.21)	0.27 (0.14-0.48)	0.11 (0.05-0.20)	0.26 (0.15-0.47)
Streptomycins	-	-	-	-	-	-	0.05 (0.03-0.09)	0.06 (0.03-0.10)	0.05 (0.03-0.12)	0.06 (0.03-0.12)	0.06 (0.03-0.11)	0.07 (0.03-0.12)
Tetracyclines	0.14 (0.09-0.26)	0.17 (0.10-0.29)	0.15 (0.09-0.27)	0.17 (0.10-0.33)	0.15 (0.09-0.30)	0.17 (0.10-0.32)	0.18 (0.11-0.34)	0.21 (0.12-0.39)	0.19 (0.11-0.35)	0.22 (0.12-0.40)	0.20 (0.12-0.36)	0.23 (0.13-0.41)
Lincosamides	0.22 (0.13-0.39)	0.32 (0.19-0.55)	0.20 (0.13-0.33)	0.28 (0.18-0.46)	0.19 (0.12-0.32)	0.27 (0.18-0.43)	0.20 (0.12-0.32)	0.28 (0.18-0.43)	0.20 (0.12-0.32)	0.28 (0.17-0.44)	0.19 (0.11-0.32)	0.27 (0.16-0.43)
Macrolides	0.07 (0.04-0.10)	0.07 (0.04-0.10)	0.07 (0.05-0.11)	0.07 (0.05-0.12)	0.07 (0.04-0.11)	0.07 (0.05-0.11)	0.08 (0.05-0.13)	0.08 (0.05-0.13)	0.08 (0.05-0.14)	0.08 (0.05-0.14)	0.09 (0.06-0.14)	0.09 (0.06-0.14)
ST	0.07 (0.03-0.11)	0.06 (0.03-0.09)	0.07 (0.03-0.14)	0.06 (0.03-0.11)	0.08 (0.04-0.14)	0.07 (0.04-0.11)	0.08 (0.05-0.15)	0.07 (0.04-0.12)	0.08 (0.04-0.14)	0.07 (0.05-0.11)	0.08 (0.04-0.15)	0.07 (0.05-0.12)
Imidazole derivatives	0.10 (0.07-0.17)	0.11 (0.08-0.19)	0.11 (0.06-0.17)	0.12 (0.07-0.19)	0.12 (0.08-0.18)	0.14 (0.09-0.21)	0.14 (0.09-0.22)	0.15 (0.10-0.24)	0.15 (0.09-0.24)	0.16 (0.10-0.25)	0.14 (0.09-0.22)	0.16 (0.10-0.24)

AUD: Antimicrobial Use Density, DOT: Days of Therapy, tabulated by DDDs/100 patient-days

DOT: Days of Therapy, tabulated by DOTs/100 patient-days

*Note: Cephalosporin/a beta-lactamase inhibitor combination is not used in 2021 due to supply disruptions.

*Note: Benzylpenicillin benzathine has been classified as a penicillin, with data collection starting in September 2022.

*Note: Imipenem/cilastatin/relebactam has been classified as a carbapenems, with data collection starting in September 2022.

*Note: Ceftiderocol has been classified as a siderophore cephalosporin, with data collection starting in February 2024

*Note: Ceftazidime/avibactam has been classified as a third-generation cephalosporin, with data collection starting in November 2024

*Tabulation definitions have changed since 2022.

- Arbekacin and spectinomycin are counted as aminoglycosides.
- Streptomycin is counted as streptomycin instead of aminoglycoside.
- Change of class names: Ceftarosan/tazobactam is changed to cephalosporin with beta-lactamase inhibitor, daptomycin to lipopeptide, lincomycin to lincosamide, sulfamethoxazole/trimethoprim to ST.
- * Tabulation definitions have changed since 2023.
- Metronidazole is counted as imidazole.

References

1. European Centre for Disease Prevention and Control An agency of the European Union. "Antimicrobial consumption in the EU Annual Epidemiological Report 2019". Available from: <https://www.ecdc.europa.eu/sites/default/files/documents/Antimicrobial-consumption-in-the-EU-Annual-Epidemiological-Report-2019.pdf>
2. Koizumi R, Kusama Y, Asai Y, Gu Y, Muraki Y, Ohmagari N. "Effects of the cefazolin shortage on the sales, cost, and appropriate use of other antimicrobials". BMC Health Serv Res. 2021 Oct 19;21(1):1118.
3. Ono A, Koizumi R, Tsuzuki S, Asai Y, Ishikane M, Kusama Y, Ohmagari N. Int J Infect Dis. 2022 Jun;119:13-17.
4. J-SIPHE Annual Report 2019, 2020, 2021, 2022, 2023, 2024

(2) Veterinary agents

Source: Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM)

Based on the same volumes of sales of antibiotics and synthesized antimicrobials, as reported under Article 71-2 of the Regulatory Rules for Veterinary Medicinal Products, the amounts of veterinary antimicrobials were calculated in terms of active ingredients (metric tons (t)). In the period from 2014 to 2023 the volume of sales of veterinary antimicrobials ranged between 717.54 to 858.09 t. The total volume of sales in 2023 decreased by approx. 59 t since 2022. Antimicrobials reduced their sales including tetracyclines (approx. 17 t) and macrolides (approx. 16 t), with the decrease in tetracyclines primarily due to a reduction of 7 tons in livestock animals and 10 tons in aquatic animals. Tetracyclines represented the largest share of antimicrobial sales volume over the period monitored, accounting for between 36.1% and 43.3%, which, however, have fallen below 40% in recent years.

On the other hand, third generation cephalosporins and fluoroquinolones, which are important antimicrobials for human medicine, accounted for approx. 0.2% and 1.0% of overall volume of sales, respectively.

Table 88. Amounts of veterinary antimicrobials in terms of active ingredients by class (t)

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Penicillins	77.96	83.73	90.01	88.08	88.99	92.41	96.97	89.02	91.15	83.46
Cephalosporins(total)	5.50	5.89	6.45	6.65	7.06	8.02	7.72	8.03	7.37	7.47
1st generation cephalosporins	(4.58)	(4.98)	(5.41)	(5.50)	(5.67)	(6.62)	(6.40)	(6.61)	(5.96)	6.04
2nd generation cephalosporins	(0.20)	(0.12)	(0.16)	(0.18)	(0.22)	(0.14)	(0.15)	(0.13)	(0.13)	0.12
3rd generation cephalosporins	(0.71)	(0.79)	(0.88)	(0.96)	(1.18)	(1.26)	(1.16)	(1.28)	(1.27)	1.30
Aminoglycosides	40.64	35.47	47.86	44.76	35.61	35.17	36.89	29.84	31.31	27.30
Macrolides	70.43	98.41	134.12	140.83	154.72	180.71	173.72	157.72	134.69	118.27
Lincosamides	43.26	28.66	21.87	25.26	22.76	21.29	21.45	22.45	23.70	20.93
Tetracyclines	324.85	333.86	331.55	347.05	311.18	313.03	304.38	305.75	300.41	283.19
Peptides	9.98	14.54	14.02	19.99	12.34	19.56	19.06	18.40	18.55	15.61
Other antibiotics	28.85	32.39	31.96	36.19	37.50	35.96	36.34	37.45	35.92	33.61
Sulfonamides	97.57	96.67	95.85	99.06	88.77	84.69	98.53	81.96	84.37	78.52
Quinolones	1.91	1.71	1.74	1.84	1.48	2.57	2.34	1.72	2.29	1.54
Fluoroquinolones	5.63	7.35	6.08	6.83	6.65	7.53	7.06	8.39	7.54	6.97
Amphenicols	26.15	29.73	26.49	27.11	24.82	27.38	25.55	27.02	28.28	29.22
Furan and derivatives	1.76	1.24	1.57	1.36	1.34	1.35	1.23	1.55	1.45	1.46
Other synthetic antibacterials	13.97	13.35	12.12	13.09	11.98	11.71	11.68	11.57	9.88	10.00
Total	748.44	782.98	821.70	858.09	805.19	841.37	842.92	800.87	776.90	717.54

* The figures in parentheses are included in the Cephalosporins (total).

The marketing authorization holders also submit the percentage of sales for each species of domestic animal estimated from information on the distributors, so the estimated volumes for each species sold are calculated based on those estimated percentages. In terms of active ingredients, swine accounted for the largest amount, followed by seawater fish. Since 2018, sales have decreased in swine, with the decrease in livestock possibly due to increased awareness of the need for prudent use and improved rearing hygiene management due to outbreaks of classical swine fever and highly pathogenic avian influenza.

In order to conduct comparisons of usage by animal species, the number of heads and weight per head of the animal should be taken into account. Accordingly, there is a comparison method which involves using animal weights and numbers to calculate biomass weight (total weight of animals) and expressing figures for antimicrobial use as usage per unit of biomass weight. The WOA has recently set out a method for calculating biomass weight as part of its data collection of veterinary antimicrobial usage data and published data on use per biomass weight (sales volume) by region, but this is a summary of all livestock and does not allow trends to be assessed by species. Therefore, we are currently considering specific calculation methods, taking cues from the WOA methodology.

Table 89. Estimated amounts of veterinary antimicrobials in terms of active ingredients by animal species (t)

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Beef cattle	20.35	23.77	25.00	25.92	33.17	33.40	58.33	59.27	58.00	54.48
Dairy cow	30.45	32.48	35.10	34.55	41.01	36.79	48.71	47.97	45.34	45.21
Horse	2.01	2.10	2.31	2.17	3.90	3.49	3.84	1.84	1.87	1.95
Swine	490.42	503.13	513.86	541.61	471.36	450.24	421.27	410.52	391.57	385.04
Broiler	70.14	62.36	63.81	61.74	62.79	69.81	77.53	69.14	61.53	65.13
Layer	23.67	19.36	19.78	15.32	15.86	17.56	17.13	9.32	9.68	7.56
Seawater fish	93.41	123.02	143.03	159.07	164.00	217.66	204.15	190.56	197.26	146.60
Freshwater fish	5.61	7.28	10.10	9.07	2.91	2.74	2.27	2.03	2.15	2.19
Ornamental fish	1.07	1.60	1.95	1.74	1.63	1.64	1.56	2.14	2.09	1.66
Dog/Cat	8.10	7.78	6.67	6.90	8.56	8.03	8.11	8.08	7.40	7.72
Other	3.22	0.09	0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total	748.44	782.96	821.70	858.09	805.19	841.37	842.92	800.87	776.90	717.54

1) Livestock animals

The estimated volumes of veterinary antimicrobials sold for livestock animals (cattle, swine, horses, chickens, and others) in terms of active ingredients are listed in Table 90. In the period from 2014 to 2023, the estimated volume of sales ranged between 559.37 t and 681.31 t, with sales in 2023 being the lowest volume since 2014. The most common antimicrobials were tetracyclines (213.90 t to 286.01 t), which accounted for 38.2% to 43.1% of the antimicrobials for livestock animals, but in 2023 they were at their lowest volume (213.90 t) since 2014. This is largely due to the decreased use in swine. In contrast, third generation cephalosporins and fluoroquinolones, which are critically important antimicrobials for human medicine, each accounted for approximately from 0.1% to 0.2% and 1% of the antimicrobial agents for livestock animals, respectively.

Table 90. The estimated volumes of sales of veterinary antimicrobials for livestock animals (cattle, swine, horses, chickens, and others) in terms of active ingredients (t)

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Penicillins	61.96	67.25	73.82	71.75	74.48	73.76	76.22	72.44	72.88	69.81
Cephalosporins (total)	3.06	3.22	3.34	3.44	3.91	4.11	3.79	4.05	3.99	4.04
1st generation cephalosporins	(2.34)	(2.52)	(2.52)	(2.51)	(2.73)	(2.93)	(2.68)	(2.85)	(2.77)	(2.79)
2nd generation cephalosporins	(0.20)	(0.12)	(0.16)	(0.18)	(0.22)	(0.14)	(0.15)	(0.13)	(0.13)	(0.12)
3rd generation cephalosporins	(0.51)	(0.58)	(0.65)	(0.74)	(0.96)	(1.04)	(0.95)	(1.07)	(1.08)	(1.12)
Aminoglycosides	38.66	34.07	47.46	44.37	34.69	34.77	36.52	29.75	31.22	26.97
Macrolides	53.30	60.36	72.68	71.96	72.09	73.29	72.71	73.03	61.00	74.58
Lincosamides	36.61	23.65	15.62	19.39	16.72	16.26	17.48	19.11	19.60	18.82
Tetracyclines	275.83	276.24	280.66	286.01	257.36	242.93	240.12	236.49	220.70	213.90
Peptides	9.97	14.54	14.01	19.98	12.34	19.56	19.05	18.39	18.54	15.61
Other antibiotics	28.43	32.23	31.55	35.72	36.87	35.64	35.54	37.30	35.61	33.45
Sulfonamides	88.43	84.40	78.57	84.10	78.59	68.64	84.38	64.16	62.53	61.63
Quinolones	0.20	0.20	0.16	0.31	0.01	0.11	0.18	0.16	0.26	0.18
Fluoroquinolones	4.73	6.41	5.19	5.93	5.80	6.66	6.18	7.54	6.70	6.12
Amphenicols	25.14	27.39	24.82	25.34	23.28	23.89	23.11	24.23	25.27	24.47
Furan and derivatives	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other synthetic antibacterials	13.92	13.32	12.07	13.02	11.96	11.68	11.53	11.41	9.70	9.80
Total	640.25	643.28	659.95	681.31	628.09	611.29	626.83	598.07	567.99	559.37

* The figures in parentheses are included in the Cephalosporins (total).

2) Aquatic animals

The estimated volumes of veterinary antimicrobials sold for aquatic animals (seawater fish, freshwater fish, and ornamental fish) in terms of active ingredients are summarized in the table. In the period from 2014 to 2023, the estimated volume of sales ranged between 100.09 t (2014) to 222.05 t (2019). In 2023, the volume was 150.45 t (74.7% of the previous year), representing the lowest level since 2016, with a particularly marked decrease observed in seawater fish (74.3% of the previous year).

From 2015 to 2019, sales volumes increased primarily due to a rise in macrolide use. The antimicrobial with the highest sales volume was tetracyclines until 2015, but from 2016 to 2021, macrolides exceeded tetracyclines, before reversing again in 2022. The substantial increase in macrolide use is likely associated with the occurrence of serotype II α -hemolytic lactococcosis in seawater fish—where aquaculture production is high—detected around 2013, against which conventional vaccines proved ineffective, necessitating antimicrobial treatment.

In 2020, sales volumes began to decline, which may reflect the successful development, improvement, and dissemination of vaccines targeting serotype II α -hemolytic lactococcosis, as well as renewed efforts since 2021 to promote the appropriate use of antimicrobials. Since around 2021, occurrences of serotype III α -hemolytic lactococcosis have been reported, and in 2025, a vaccine covering serotypes I–III α -hemolytic lactococcosis was released. Continued monitoring of trends remains necessary.

Third generation cephalosporins and fluoroquinolones that are important for human health are not approved for aquatic animal use.

Table 91. The estimated volumes of sales of veterinary antimicrobials for aquatic animals (seawater fish, freshwater fish, and ornamental fish) in terms of active ingredients (t)

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Penicillins	13.87	14.38	14.62	14.66	12.85	17.01	19.21	14.29	16.16	11.44
Cephalosporins (total)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
1st generation cephalosporins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
2nd generation cephalosporins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
3rd generation cephalosporins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Aminoglycosides	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Macrolides	17.13	38.05	61.44	68.87	82.61	107.40	101.01	84.69	73.68	43.68
Lincosamides	6.56	4.90	6.12	5.73	5.91	4.88	3.82	3.19	3.94	2.01
Tetracyclines	49.01	57.62	50.89	61.05	52.55	69.57	63.84	68.84	79.28	68.88
Peptides	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other antibiotics	0.42	0.16	0.42	0.47	0.63	0.32	0.80	0.16	0.31	0.16
Sulfonamides	8.59	11.71	16.74	14.39	9.64	15.56	13.36	17.53	21.49	16.55
Quinolones	1.71	1.51	1.58	1.53	1.47	2.45	2.15	1.56	2.03	1.36
Fluoroquinolones	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Amphenicols	1.01	2.33	1.67	1.77	1.53	3.48	2.43	2.78	2.99	4.74
Furan and derivatives	1.76	1.24	1.57	1.36	1.34	1.35	1.23	1.55	1.45	1.46
Other synthetic antibacterials	0.04	0.02	0.04	0.06	0.02	0.02	0.12	0.13	0.16	0.18
Total	100.09	131.91	155.08	169.88	168.54	222.05	207.98	194.72	201.50	150.45

3) Companion animals

The estimated volumes of veterinary antimicrobials sold for companion animals (dogs and cats) in terms of active ingredients are summarized in Table 92. In the period from 2014 to 2023, the estimated volume of sales ranged between 6.67 to 8.56 t, with 7.72 t in 2023, marking an increase of 0.31 t from 2022. Sales volume of human antimicrobials in companion animals was not originally monitored under JVARM and is therefore excluded from the values in the table for 2015 and earlier. Accordingly, with the full cooperation of the Japan Animal Agents & Instruments Dealers Association and Federation of Japan Pharmaceutical Wholesalers Association, the Ministry of Agriculture, Forestry and Fisheries began monitoring the actual usage of human antimicrobials in 2016. The results of its surveillance revealed that the volume of human antimicrobials sold for use in companion animals is less than the volume of veterinary antimicrobials sold for that purpose. Including those for human antimicrobials, the most commonly sold antimicrobials were first-generation cephalosporins and penicillins.

Table 92. The estimated volumes of sales of veterinary and human antimicrobials for companion animals (dogs and cats) in terms of active ingredients (t) (1/2)

	2014	2015	2016		2017		2018	
	Veterinary	Veterinary	Veterinary	Human	Veterinary	Human	Veterinary	Human
Penicillins	2.13	2.08	1.57	1.93	1.68	1.75	1.66	2.14
Cephalosporins(total)	2.44	2.67	3.12	3.23	3.21	2.39	3.16	1.98
1st generation cephalosporins	(2.23)	(2.46)	(2.89)	(3.08)	(2.99)	(2.27)	(2.93)	(1.86)
2nd generation cephalosporins	(0.00)	(0.00)	(0.00)	(0.04)	(0.00)	(0.03)	(0.00)	(0.03)
3rd generation cephalosporins	(0.20)	(0.21)	(0.23)	(0.11)	(0.22)	(0.09)	(0.22)	(0.09)
Aminoglycosides	1.97	1.40	0.41	0.02	0.39	0.01	0.91	0.01
Macrolides	0.00	0.00	0.00	0.17	0.00	0.16	0.02	0.17
Lincosamides	0.09	0.11	0.13	0.10	0.13	0.10	0.14	0.10
Tetracyclines	0.00	0.00	0.00	0.28	0.00	0.31	1.27	0.33
Peptides	0.01	0.01	0.01	0.00	0.01	0.00	0.01	0.00
Other antibiotics**	0.00	0.00	0.00	0.22	0.00	0.21	0.00	0.22
Sulfonamides	0.55	0.56	0.53	0.19	0.57	0.19	0.53	0.22
Quinolones	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fluoroquinolones	0.90	0.94	0.89	0.11	0.90	0.11	0.84	0.12
Amphenicols	0.00	0.00	0.00	0.12	0.01	0.10	0.01	0.11
Furan and derivatives	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other synthetic antibacterials***.	0.01	0.01	0.01	0.08	0.01	0.10	0.01	0.10
Total	8.10	7.78	6.67	6.48	6.90	5.43	8.56	5.51

Table 92. The estimated volumes of sales of veterinary and human antimicrobials for companion animals (dogs and cats) in terms of active ingredients (t) (2/2)

	2019		2020		2021		2022		2023	
	Veterinary	Human	Veterinary	Human	Veterinary	Human	Veterinary	Human	Veterinary	Human
Penicillins	1.64	1.98	1.54	1.56	2.29	1.88	2.11	1.80	2.21	1.55
Cephalosporins(total)	3.91	2.04	3.93	1.62	3.97	1.50	3.38	1.15	3.43	1.08
1st generation cephalosporins	(3.69)	(1.90)	(3.72)	(1.49)	(3.76)	(1.39)	(3.19)	(1.06)	(3.25)	(0.97)
2nd generation cephalosporins	(0.00)	(0.03)	(0.00)	(0.03)	(0.00)	(0.03)	(0.00)	(0.03)	(0.00)	(0.02)
3rd generation cephalosporins	(0.22)	(0.11)	(0.21)	(0.10)	(0.21)	(0.08)	(0.19)	(0.07)	(0.18)	(0.08)
Aminoglycosides	0.40	0.02	0.37	0.02	0.09	0.01	0.10	0.01	0.33	0.01
Macrolides	0.02	0.18	0.00	0.18	0.00	0.15	0.00	0.15	0.00	0.16
Lincosamides	0.15	0.09	0.15	0.08	0.15	0.07	0.16	0.06	0.10	0.06
Tetracyclines	0.53	0.35	0.42	0.34	0.42	0.31	0.43	0.33	0.42	0.38
Peptides	0.01	0.00	0.01	0.00	0.01	0.00	0.01	0.00	0.01	0.00
Other antibiotics**	0.00	0.22	0.00	0.23	0.00	0.18	0.00	0.18	0.00	0.25
Sulfonamides	0.50	0.25	0.78	0.25	0.26	0.25	0.36	0.26	0.33	0.27
Quinolones	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fluoroquinolones	0.87	0.16	0.88	0.11	0.85	0.08	0.84	0.08	0.85	0.07
Amphenicols	0.01	0.12	0.01	0.11	0.01	0.09	0.01	0.09	0.01	0.10
Furan and derivatives	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other synthetic antibacterials***	0.00	0.13	0.02	0.11	0.02	0.09	0.02	0.09	0.02	0.10
Total	8.03	5.53	8.11	4.60	8.08	4.61	7.40	4.21	7.72	4.04

The figures in parentheses are included in the Cephalosporins (total).

** Includes fosfomycin and rifamycin, etc. (vancomycin for human was 0.0006 t in 2016, 0.0005 t in 2017, 0.0006 t in 2018, 0.0006 t in 2019, 0.0006 t in 2020, 0.0004 t in 2021, 0.0005 t in 2022, 0.0006 t in 2023)

*** Includes trimethoprim, penems, carbapenems, etc. (carbapenems for human was 0.0066 t in 2016, 0.0057 t in 2017, 0.0062 t in 2018, 0.0083 t in 2020, 0.0070 t in 2021, 0.0060 t in 2022, 0.0065 t in 2023)

References

1. Gochez D., Raicek M., Ferreira J. P., Jeannin M., Moulin G., Erlacher-Vindel E. OIE annual report on antimicrobial agents intended for use in animals: methods used. *Frontiers in Vet. Sci.* 2019. 6. doi: 10.3389/fvets.2019.00317

(3) Antimicrobial feed additives

Source: Food and Agricultural Materials Inspection Center (FAMIC) and Japan Scientific Feeds Association

The volumes of distribution of antimicrobial feed additives, based on surveys by the Food and Agricultural Materials Inspection Center and by the Japan Scientific Feeds Association, are indicated in the table. While the volume of such additives distributed showed a slight increase in the period 2022 to 2023, from 203.3 t to 219.2 t. The designation of the polypeptide colistin as a feed additive was revoked in July 2018, followed by the macrolide tylosin in May 2019 and two tetracyclines in December 2019. Distribution of these antimicrobials ceased from the time their designation was revoked.

Table 93. Volume of distribution of antibiotic feed additives in terms of effective value (t)

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Aminoglycosides	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Polypeptides	28.3	29.6	32.1	15.2	9.4	6.4	7.1	10.4	4.7	11.2
Tetracyclines	2.2	2.6	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Macrolides	5.3	5.5	1.4	3.5	0.0	0.0	0.0	0.0	0.0	0.0
Polysaccharides	0.0	0.1	0.1	0.1	0.0	2.3	3.4	1.4	1.3	4.8
Polyethers	142.5	141.7	159.9	165.5	161.0	174.1	192.5	169.7	166.8	173.4
Other antimicrobials	18.3	12.5	14.6	19.8	26.2	17.6	11.9	12.5	13.4	12.6
Synthetic antimicrobials	29.3	24.4	18.1	17.1	20.1	25.1	20.0	17.1	17.1	17.2
Total	225.9	216.4	228.2	221.2	216.7	225.5	234.9	211.1	203.3	219.2

Excludes antifungal agents.

(4) Agrochemicals

Source: Plant Products Safety Division, Food Safety and Consumer Affairs Bureau, Ministry of Agriculture, Forestry and Fisheries

The volume of shipment in Japan of antimicrobials that are used as agrochemicals is shown in the table, in terms of active ingredients (unit: tons). In the period from 2014 to 2023, the volume of shipments of antimicrobials used as agrochemicals remained at around the 150 t mark, ranging from 132.93 to 181.43 t.

Table 94. The volume of shipment in Japan of antimicrobials that are used as agrochemicals, in terms of active ingredients (t)

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Streptomycin	45.30	44.41	49.80	56.04	36.19	35.90	37.52	36.78	37.51	41.69
Oxytetracycline	22.23	23.25	19.46	17.81	0.13	0.16	0.35	0.91	0.87	1.47
Kasugamycin	23.92	23.69	23.68	23.90	21.22	19.79	18.41	18.35	18.88	18.24
Validamycin	25.50	24.97	24.80	24.71	23.35	23.85	24.78	23.67	23.64	22.27
Oxolinic acid	40.79	41.16	42.17	44.38	44.53	43.29	41.33	41.85	40.81	38.20
Polyoxins	15.49	15.25	15.80	14.59	13.65	13.23	13.52	11.67	13.20	11.06
Total	173.24	172.73	175.71	181.43	139.07	136.22	135.90	133.24	134.91	132.93

Figures shown are for the agrochemical year (the 2014 agrochemical year ran from October 2013 to September 2014). Figures do not include antifungal agents.

(5) Current status of antimicrobial use in Japan

Table 95 shows the total use (or sales) of antimicrobials in humans, livestock animals, aquatic animals, companion animals, antimicrobial feed additives, and agrochemicals. Antimicrobial selective pressure in Japan from a One Health perspective has decreased by approximately 2.2% compared to 2014. The proportion of tetracyclines decreased from 21% to 18%, while the use of penicillins was the highest at 19%. In contrast, the proportions of cephalosporins, fluoroquinolones, and macrolides showed little change, indicating that their future trends should continue to be closely monitored.

Table 95. Current volume of antimicrobial use (or sales) in Japan (t)

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Penicillins	229.0	249.0	262.8	268.3	279.9	302.8	265.5	267.3	287.1	312.4
Cephalosporins	163.7	166.5	165.6	160.5	156.6	154.9	131.3	130.4	131.4	143.1
Monobactams	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Carbapenems	9.9	10.1	10.2	10.1	9.8	10.0	8.8	9.1	9.1	8.2
Aminoglycosides	110.8	104.5	122.2	125.5	93.7	91.5	93.4	85.5	88.2	87.7
Macrolides	177.2	207.3	238.4	238.8	244.4	267.9	241.5	221.1	196.6	197.2
Lincosamides	45.9	31.3	24.4	27.7	25.2	24.0	23.6	24.6	25.9	23.3
Tetracyclines	356.3	366.8	360.1	371.9	318.6	320.9	313.2	315.4	309.8	293.7
Peptides and glycopeptides	40.5	46.5	48.5	37.6	24.1	28.5	28.8	31.1	25.9	29.6
Sulfonamides*	147.5	150.4	154.4	161.1	154.5	155.7	174.2	163.2	169.0	166.1
Fluoroquinolones	65.8	63.9	63.5	60.1	56.7	55.2	40.0	37.6	36.7	43.9
Other quinolones	43.1	43.2	44.2	46.5	46.1	45.9	43.7	43.6	43.1	39.7
Amphenicols, thiamphenicols and derivatives	26.3	29.8	26.6	27.2	24.9	27.5	25.6	27.1	28.3	29.3
Furan and derivatives	1.8	1.2	1.6	1.4	1.3	1.4	1.2	1.5	1.5	1.5
Polysaccharides	0.0	0.1	0.1	0.1	0.0	2.3	3.4	1.4	1.3	4.8
Polyethers	142.5	141.7	159.9	165.5	161.0	174.1	192.5	169.7	166.8	173.4
Polyoxins	15.5	15.3	15.8	14.6	13.7	13.2	13.5	11.7	13.2	11.1
Others*	132.5	124.6	118.5	125.5	133.3	127.5	115.2	111.9	109.2	105.9
Total	1708.3	1752.2	1816.9	1842.3	1743.8	1803.3	1715.4	1652.2	1643.0	1670.8

*Sulfonamides used as antimicrobial feed additives and the agrochemical validamycin are included in Others. Figures do not include antifungal agents.

Table 96. Changes in the volume of antimicrobial use (or sales) in Japan by year (unit: metric tons) (cont.) (1/4)

	2014						2015						2016					
	Humans	Livestock animals	Aquatic animals	Companion animals	Antimicrobial feed additives	Agrochemicals	Humans	Livestock animals	Aquatic animals	Companion animals	Antimicrobial feed additives	Agrochemicals	Humans	Livestock animals	Aquatic animals	Companion animals	Antimicrobial feed additives	Agrochemicals
Penicillins	151.1	62.0	13.9	2.1	0.0	0.0	165.3	67.3	14.4	2.1	0.0	0.0	172.8	73.8	14.6	1.6	0.0	0.0
Cephalosporins	158.2	3.1	0.0	2.4	0.0	0.0	160.6	3.2	0.0	2.7	0.0	0.0	159.1	3.3	0.0	3.1	0.0	0.0
Monobactams	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
Carbapenems	9.9	0.0	0.0	0.0	0.0	0.0	10.1	0.0	0.0	0.0	0.0	0.0	10.2	0.0	0.0	0.0	0.0	0.0
Aminoglycosides	0.9	38.7	0.0	2.0	0.0	69.2	0.9	34.1	0.0	1.4	0.0	68.1	0.8	47.5	0.0	0.4	0.0	73.5
Macrolides	101.4	53.3	17.1	0.0	5.3	0.0	103.4	60.4	38.0	0.0	5.5	0.0	102.9	72.7	61.4	0.0	1.4	0.0
Lincosamides	2.7	36.6	6.6	0.1	0.0	0.0	2.6	23.6	4.9	0.1	0.0	0.0	2.5	15.6	6.1	0.1	0.0	0.0
Tetracyclines	6.9	275.8	49.0	0.0	2.2	22.2	7.1	276.2	57.6	0.0	2.6	23.2	7.2	280.7	50.9	0.0	2.0	19.5
Peptides and glycopeptides	2.1	10.0	0.0	0.0	28.3	0.0	2.3	14.5	0.0	0.0	29.6	0.0	2.4	14.0	0.0	0.0	32.1	0.0
Sulfonamides	49.9	88.4	8.6	0.6	0.0	0.0	53.7	84.4	11.7	0.6	0.0	0.0	58.6	78.6	16.7	0.5	0.0	0.0
Fluoroquinolones	60.2	4.7	0.0	0.9	0.0	0.0	56.6	6.4	0.0	0.9	0.0	0.0	57.4	5.2	0.0	0.9	0.0	0.0
Other quinolones	0.4	0.2	1.7	0.0	0.0	40.8	0.3	0.2	1.5	0.0	0.0	41.2	0.3	0.2	1.6	0.0	0.0	42.2
Amphenicols, thiamphenicols and derivatives	0.1	25.1	1.0	0.0	0.0	0.0	0.1	27.4	2.3	0.0	0.0	0.0	0.1	24.8	1.7	0.0	0.0	0.0
Furan and derivatives	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0
Polysaccharides	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0
Polyethers	0.0	0.0	0.0	0.0	142.5	0.0	0.0	0.0	0.0	0.0	141.7	0.0	0.0	0.0	0.0	0.0	159.9	0.0
Polyoxins	0.0	0.0	0.0	0.0	0.0	15.5	0.0	0.0	0.0	0.0	0.0	15.3	0.0	0.0	0.0	0.0	0.0	15.8
Others*	16.6	42.4	0.5	0.0	47.6	25.5	16.9	45.5	0.2	0.0	37.0	25.0	17.0	43.6	0.5	0.0	32.6	24.8
Total	560.6	640.2	100.1	8.1	226.0	173.2	580.1	643.3	131.9	7.8	216.4	172.7	591.4	659.9	155.1	6.7	228.1	175.7
Total for year	1708.3						1752.2						1816.9					

Table 96. Changes in the volume of antimicrobial use (or sales) in Japan by year (unit: metric tons) (cont.) (2/4)

	2017						2018						2019					
	Humans	Livestock animals	Aquatic animals	Companion animals	Antimicrobial feed additives	Agrochemicals	Humans	Livestock animals	Aquatic animals	Companion animals	Antimicrobial feed additives	Agrochemicals	Humans	Livestock animals	Aquatic animals	Companion animals	Antimicrobial feed additives	Agrochemicals
Penicillins	180.2	71.7	14.7	1.7	0.0	0.0	190.9	74.5	12.9	1.7	0.0	0.0	210.4	73.8	17.0	1.6	0.0	0.0
Cephalosporins	153.8	3.4	0.0	3.2	0.0	0.0	149.5	3.9	0.0	3.2	0.0	0.0	146.9	4.1	0.0	3.9	0.0	0.0
Monobactams	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
Carbapenems	10.1	0.0	0.0	0.0	0.0	0.0	9.8	0.0	0.0	0.0	0.0	0.0	10.0	0.0	0.0	0.0	0.0	0.0
Aminoglycosides	0.8	44.4	0.0	0.4	0.0	79.9	0.7	34.7	0.0	0.9	0.0	57.4	0.7	34.8	0.0	0.4	0.0	55.7
Macrolides	94.5	72.0	68.9	0.0	3.5	0.0	89.7	72.1	82.6	0.0	0.0	0.0	87.2	73.3	107.4	0.0	0.0	0.0
Lincosamides	2.4	19.4	5.7	0.1	0.0	0.0	2.4	16.7	5.9	0.1	0.0	0.0	2.7	16.3	4.9	0.1	0.0	0.0
Tetracyclines	7.0	286.0	61.0	0.0	0.0	17.8	7.3	257.4	52.5	1.3	0.0	0.1	7.7	242.9	69.6	0.5	0.0	0.2
Peptides and glycopeptides	2.5	20.0	0.0	0.0	15.2	0.0	2.4	12.3	0.0	0.0	9.4	0.0	2.6	19.6	0.0	0.0	6.4	0.0
Sulfonamides	62.1	84.1	14.4	0.6	0.0	0.0	65.7	78.6	9.6	0.5	0.0	0.0	71.0	68.6	15.6	0.5	0.0	0.0
Fluoroquinolones	53.2	5.9	0.0	0.9	0.0	0.0	50.1	5.8	0.0	0.8	0.0	0.0	47.7	6.7	0.0	0.9	0.0	0.0
Other quinolones	0.2	0.3	1.5	0.0	0.0	44.4	0.1	0.0	1.5	0.0	0.0	44.5	0.1	0.1	2.5	0.0	0.0	43.3
Amphenicols, thiamphenicols and derivatives	0.1	25.3	1.8	0.0	0.0	0.0	0.1	23.3	1.5	0.0	0.0	0.0	0.1	23.9	3.5	0.0	0.0	0.0
Furan and derivatives	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0
Polysaccharides	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0
Polyethers	0.0	0.0	0.0	0.0	165.5	0.0	0.0	0.0	0.0	0.0	161.0	0.0	0.0	0.0	0.0	0.0	174.1	0.0
Polyoxins	0.0	0.0	0.0	0.0	0.0	14.6	0.0	0.0	0.0	0.0	0.0	13.7	0.0	0.0	0.0	0.0	0.0	13.2
Others*	14.6	48.7	0.5	0.0	37.0	24.7	14.1	48.8	0.6	0.0	46.3	23.4	13.3	47.3	0.3	0.0	42.7	23.8
Total	581.6	681.3	169.9	6.9	221.2	181.4	582.9	628.1	168.5	8.6	216.7	139.1	600.2	611.3	222.0	8.0	225.5	136.2
Total for year	1842.3						1743.8						1803.3					

Table 96. Changes in the volume of antimicrobial use in Japan by year (unit: metric tons) (cont.) (3/4)

	2020						2021						2022					
	Humans	Livestock animals	Aquatic animals	Companion animals	Antimicrobial feed additives	Agrochemicals	Humans	Livestock animals	Aquatic animals	Companion animals	Antimicrobial feed additives	Agrochemicals	Humans	Livestock animals	Aquatic animals	Companion animals	Antimicrobial feed additives	Agrochemicals
Penicillins	168.6	76.2	19.2	1.5	0.0	0.0	178.3	72.4	14.3	2.3	0.0	0.0	196.0	72.9	16.2	2.1	0.0	0.0
Cephalosporins	123.5	3.8	0.0	3.9	0.0	0.0	122.3	4.1	0.0	4.0	0.0	0.0	124.0	4.0	0.0	3.4	0.0	0.0
Monobactams	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
Carbapenems	8.8	0.0	0.0	0.0	0.0	0.0	9.1	0.0	0.0	0.0	0.0	0.0	9.1	0.0	0.0	0.0	0.0	0.0
Aminoglycosides	0.5	36.5	0.0	0.4	0.0	55.9	0.5	29.8	0.0	0.1	0.0	55.1	0.5	31.2	0.0	0.1	0.0	56.4
Macrolides	67.8	72.7	101.0	0.0	0.0	0.0	63.4	73.0	84.7	0.0	0.0	0.0	61.9	61.0	73.7	0.0	0.0	0.0
Lincosamides	2.1	17.5	3.8	0.2	0.0	0.0	2.1	19.1	3.2	0.2	0.0	0.0	2.2	19.6	3.9	0.2	0.0	0.0
Tetracyclines	8.4	240.1	63.8	0.4	0.0	0.3	8.7	236.5	68.8	0.4	0.0	0.9	8.5	220.7	79.3	0.4	0.0	0.9
Peptides and glycopeptides	2.7	19.0	0.0	0.0	7.1	0.0	2.4	18.4	0.0	0.0	10.4	0.0	2.6	18.5	0.0	0.0	4.7	0.0
Sulfonamides	75.7	84.4	13.4	0.8	0.0	0.0	81.2	64.2	17.5	0.3	0.0	0.0	84.6	62.5	21.5	0.4	0.0	0.0
Fluoroquinolones	33.0	6.2	0.0	0.9	0.0	0.0	29.2	7.5	0.0	0.8	0.0	0.0	29.1	6.7	0.0	0.8	0.0	0.0
Other quinolones	0.1	0.2	2.2	0.0	0.0	41.3	0.0	0.2	1.6	0.0	0.0	41.8	0.0	0.3	2.0	0.0	0.0	40.8
Amphenicols, thiamphenicols and derivatives	0.1	23.1	2.4	0.0	0.0	0.0	0.1	24.2	2.8	0.0	0.0	0.0	0.1	25.3	3.0	0.0	0.0	0.0
Furan and derivatives	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0
Polysaccharides	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	1.3	0.0
Polyethers	0.0	0.0	0.0	0.0	192.5	0.0	0.0	0.0	0.0	0.0	169.7	0.0	0.0	0.0	0.0	0.0	166.8	0.0
Polyoxins	0.0	0.0	0.0	0.0	0.0	13.5	0.0	0.0	0.0	0.0	0.0	11.7	0.0	0.0	0.0	0.0	0.0	13.2
Others*	10.5	47.1	0.9	0.0	31.9	24.8	9.6	48.7	0.3	0.0	29.6	23.7	9.2	45.3	0.5	0.0	30.5	23.6
Total	501.9	626.8	208.0	8.1	234.7	135.9	507.0	598.1	194.7	8.1	211.1	133.3	527.8	568.0	201.5	7.4	203.4	134.9
Total for year	1715.4						1652.2						1643.0					

*Sulfonamides used as antimicrobial feed additives and the agrochemical validamycin are included in "Others." Antifungal antibiotics used as veterinary agents are not included in "Others." Figures do not include antifungal agents.

Table 96. Changes in the volume of antimicrobial use in Japan by year (unit: metric tons) (cont.) (4/4)

	2023					
	Humans	Livestock animals	Aquatic animals	Companion animals	Antimicrobial feed additives	Agrochemicals
Penicillins	228.9	69.8	11.4	2.2	0.0	0.0
Cephalosporins	135.6	4.0	0.0	3.4	0.0	0.0
Monobactams	0.1	0.0	0.0	0.0	0.0	0.0
Carbapenems	8.2	0.0	0.0	0.0	0.0	0.0
Aminoglycosides	0.5	27.0	0.0	0.3	0.0	59.9
Macrolides	79.0	74.6	43.7	0.0	0.0	0.0
Lincosamides	2.4	18.8	2.0	0.1	0.0	0.0
Tetracyclines	9.0	213.9	68.9	0.4	0.0	1.5
Peptides and glycopeptides	2.8	15.6	0.0	0.0	11.2	0.0
Sulfonamides	87.5	61.6	16.6	0.3	0.0	0.0
Fluoroquinolones	36.9	6.1	0.0	0.9	0.0	0.0
Other quinolones	0.0	0.2	1.4	0.0	0.0	38.2
Amphenicols, thiamphenicols and derivatives	0.1	24.5	4.7	0.0	0.0	0.0
Furan and derivatives	0.0	0.0	1.5	0.0	0.0	0.0
Polysaccharides	0.0	0.0	0.0	0.0	4.8	0.0
Polyethers	0.0	0.0	0.0	0.0	173.4	0.0
Polyoxins	0.0	0.0	0.0	0.0	0.0	11.1
Others*	10.2	43.3	0.3	0.0	29.8	22.3
Total	601.1	559.4	150.4	7.7	219.2	133.0
Total for year	1670.8					

*Sulfonamides used as antimicrobial feed additives and the agrochemical validamycin are included in "Others." Antifungal antibiotics used as veterinary agents are not included in "Others." Figures do not include antifungal agents.

(6) Research into antimicrobial stewardship

The following provides a summary of past reports on key studies related to the appropriate use of antimicrobial agents in Japan and those published since this report last year (from the latter half of 2024). It covers only studies using medical insurance claims data for outpatient consultations across the whole of Japan and excludes studies limited to a specific region and studies that analyzed only the amount of antimicrobials used.

The medical insurance claims data used includes the NDB developed by the Ministry of Health, Labour and Welfare, the National Health Insurance database, and commercial databases created by combining medical insurance claims data from multiple health insurance societies (JMDC Inc.'s JMDC Claims Database, IQVIA Inc.'s IQVIA Claims, and MDV's MDV analyzer, DeSC Healthcare's DeSC database). Unless otherwise indicated, figures in square brackets ([]) in the text show the 95% confidence interval.

1. Past reports on antimicrobial stewardship

Studies have been reported on the appropriate use of antimicrobial agents for acute respiratory tract infections and acute diarrhea, which are addressed in the Manual of Antimicrobial Stewardship¹⁻⁷. It was suggested that although antimicrobial use has been gradually decreasing, there is room for intervention to support appropriate use, as there are still many prescribed for acute respiratory tract infections and acute diarrhea. Furthermore, Kitano et al. investigated the factors underlying regional differences in antibiotic use using the NDB and found that the number of outpatient visits for respiratory tract infections was particularly associated with antibiotic use, with an adjusted relative risk of 1.21, indicating a positive correlation.⁸ In this context, in 2018, the appropriate use of pediatric antimicrobial agents was introduced as a premium national health insurance (NHI) item for children under 3 years of age, and the eligible age was further raised to under 6 years of age in the 2020 revision. Muraki et al. examined the effect of this premium item in 2018 for children under 15 years of age using the IQVIA's database, revealing that the percentage of antimicrobial prescriptions was lower at facilities that had claimed this premium item compared to those that had not.^[9] As for children, a new study investigating the effects of Action Plans targeting pediatric clinics has been reported and is described in the next section.⁹ With regard to acute diarrhea, Okubo et al. previously showed antimicrobial use from April 2012 to December 2015 for children (<18 years old) using the JMDC's database⁷. Insurance claims on 4,493 outpatients with acute diarrhea were studied, of which 29.6% of the patients were prescribed some type of antimicrobial agent, with fosfomycin being the most common antimicrobial agent (20.3%). For adults, Ohno et al. used the JMDC database to investigate antimicrobial use for acute diarrhoea among 0–65-year-olds from January 2013 to December 2018.¹¹ Over the 6-year study period, 94.6% of all subjects had non-bacterial diarrhoea, but the antimicrobial prescription rate (number of prescriptions/visits) was 46.5% in adult males and 40.8% in adult females. The antimicrobial prescription rate for children (0-17 years) was 30.5% for boys and 30.4% for girls, which was not significantly different from a previous survey by Okubo et al.⁷ Sugiyama et al. also investigated the status of oral antimicrobial prescriptions for acute diarrhoea using a practice database-based analysis tool (MDV analyzer: Medical Data Vision Inc., Tokyo, Japan).¹² The investigation was conducted between January 2013 and December 2019 with hospitals participating in the Diagnosis Procedure Combination / Per-Diem Payment System and registered on the MDV analyzer nationwide, which showed that the number of patients prescribed has decreased over time, similarly to the results of Ohno et al.'s study.

On the other hand, Tsuzuki et al. pointed out that despite a continuous decrease in antibiotic usage from 2015 to 2021, there was no significant reduction in the disease burden of bacteremia caused by resistant bacteria during the same period. Several hypotheses can be proposed to explain this phenomenon; however, it suggests that merely reducing antibiotic usage may be insufficient as an effective strategy for antimicrobial resistance (AMR) control.¹³

Additionally, Ito et al. used IQVIA Claims to examine comorbid conditions and the status of diagnostic testing among pediatric patients diagnosed with respiratory tract infections in otolaryngology outpatient clinics.¹⁴ The study revealed that only 6.5% of patients were diagnosed solely with a respiratory tract infection, with conditions such as allergic rhinitis, acute bronchitis, acute sinusitis, and cerumen impaction frequently recorded concurrently. Moreover, the implementation rate of diagnostic tests was low, ranging from 2.9% to 21.7%, highlighting the need to improve the infrastructure for conducting tests in outpatient settings.

Furthermore, various factors influencing the appropriate use of antibiotics, such as the introduction of incentives for appropriate use of antibiotics, the introduction of Pharmacist for Primary Antimicrobial Chemotherapy certified by the Japanese Society of Chemotherapy, and supply issues, including those related to amoxicillin, must be taken into account. This underscores the need for further investigation in the future.

[Study on the impact of the introduction of the premium for appropriate use of pediatric antimicrobials].

Using the JMDC database, Jindai investigated the impact of the premium, introduced in April 2018, that offers incentives for not prescribing antimicrobials for respiratory tract infections and diarrhoea (0-2 years) and the healthcare provider education (6 years and older) based on the information from April 2013 to March 2020. The effect was assessed using interrupted time series analysis.^[15] The results showed that antimicrobial prescribing decreased significantly after the introduction of the premium in the 0-2 age group (-47.5 prescriptions [77.3 to -

17.6] per 1,000 monthly clinic visits). Education for healthcare providers reduced antimicrobial prescribing for all ages. These showed an immediate effect after introduction, but no long-term effect. Okubo et al. used NDB to similarly assess the effect of the premium using finite differential methods and found a reduction in antimicrobial prescribing (DID estimate, -228.6 DOT per 1,000 cases [-272.4 to -184.9]) [16]. There was also no increase in out-of-hour consultations with treatment of respiratory symptoms (DID estimate, -256.9 DOT [-379.3 to -134.5] per 1,000 cases) or antihistamines (DID estimate, -198.5 DOT [-282.1 to -114.9] per 1,000 cases) [DID estimate, -4.43 per 1,000 cases [-12.8 to -3.97]. There was also no increase in hospital admissions [DID estimate, -0.08 per 1,000 cases [-0.48 to 0.31]. The study showed that it led to a reduction in unnecessary antimicrobial prescribing without any negative impact on healthcare.

[Research on prescribing status]

Using JMDC, Sato et al. analysed the prescribing of prophylactic antimicrobials after tooth extractions for people aged 18 years and older between September 2015 and August 2018 to investigate the impact of the AMR Action Plan [17]. The results showed that of the 662,435 eligible patients, those who were prescribed prophylactic antimicrobials accounted for 83% of the overall patients and 82% of those defined as being at low risk of post-operative infection. Although this proportion did not change within the study period, the breakdown by class showed a decrease in the prescriptions for third generation cephalosporins from 58% to 34% (hospitals) and from 57% to 56% (clinics).

There was an increase in amoxicillin from 16% to 37% (hospitals) and from 6% to 10% (clinics). Araki et al. also used JMDC to survey 18,659 working-age population members who had undergone medical examinations for at least five years and had been diagnosed with the common cold at least twice between January 2005 and February 2016 [18]. The results showed 49.2% (9,180 patients) were prescribed antimicrobials, and it was revealed that its factors included lack of chronic disease, male patients, and clinics or hospitals with less than 20 beds. In addition, 40-45% were prescribed cephalosporins. In interpretation, it should be noted that the study subjects were from the working age population.

The situation of inappropriate prescribing was revealed, with cephalosporins being the most commonly used, indicating the need to promote ASP.

Ide et al. used JMDC to study the prescribing of oral macrolide antimicrobials from 2013 to 2018. Macrolides accounted for 30% of oral antimicrobial prescriptions, of which clarithromycin accounted for 60%. Most prescriptions were for the common cold, with some prescriptions for chronic conditions such as allergic diseases and skin conditions. The study suggests a need to review the use of macrolides for the common cold and to properly evaluate their long-term use for skin and allergic diseases.[19]

Muramatsu et al. conducted a study using the JMDC database to investigate the prescribing patterns and effectiveness of oral antibiotics in the treatment of pediatric urinary tract infections (UTI) [20]. The study focused on UTI patients under the age of six who were prescribed oral antibiotics between 2016 and 2020. The results showed that 67.0% of the patients were prescribed third-generation cephalosporins, 8.4% were prescribed amoxicillin, 1.5% were prescribed trimethoprim/sulfamethoxazole (TMP-SMX), and 1.2% were prescribed amoxicillin/clavulanate. Treatment failure occurred in 2.9% of cases, with a higher failure rate observed in patients treated with amoxicillin compared to cefcapene pivoxil [OR 2.18 (95% CI: 1.04-4.58)].

Sato et al. conducted a study using the JMDC database to investigate the prescribing patterns of prophylactic antibiotics and the incidence of postoperative infections during the extraction of impacted mandibular third molars in dentistry [21]. The study focused on amoxicillin, the first-choice antibiotic, and third-generation cephalosporins, which are widely used in Japan. The results showed that amoxicillin was prescribed to 36.2% of patients, while third-generation cephalosporins were prescribed to 67.8%. After adjusting for background factors, the incidence of surgical site infections was 3.5% in the amoxicillin group and 3.7% in the third-generation cephalosporin group ($p=0.003$). These findings highlight the need for promoting the appropriate use of antibiotics in the field of dentistry also.

2. New research reports on the antimicrobial stewardship

Okubo et al. used the DeSC database to investigate the long-term effects of the premium for appropriate use of pediatric antimicrobials, introduced in Japan in 2018.[22] This incentive is applied when physicians determine that antimicrobial agents are unnecessary and therefore do not prescribe them for children under three years of age diagnosed with upper respiratory infections or diarrhea. A comparison was conducted between cases in which the incentive was applied and those in which it was not. The results showed that antimicrobial use decreased by 19.5% (24.4% for broad-spectrum antimicrobials). Furthermore, the study demonstrated that this policy did not lead to increases in hospitalizations or healthcare expenditures.

Yamazaki et al. used the JMDC to investigate the impact of long-term macrolide therapy on antimicrobial use

when evaluated according to the World Health Organization AWaRe classification.[23] The analysis included patients who were prescribed oral antimicrobials in outpatient settings in 2022. The results showed that macrolides accounted for more than 30% of total antimicrobial use. Among older adults, 11.2% received macrolide prescriptions for 91 days or longer, accounting for 66.4% of macrolide use in this population. In addition, 70–88% of patients receiving long-term macrolide therapy (≥ 91 days) had diagnoses of chronic airway diseases. These findings indicate that the impact of long-term macrolide prescribing should be considered when evaluating antimicrobial use according to the AWaRe classification.

Hirayama et al. used the NDB to investigate trends in antimicrobial prescribing in dental practice.[26] An analysis of prescribing patterns from 2015 to 2020 showed that third-generation cephalosporins accounted for 52.3% of all prescriptions. Although their use in hospitals decreased markedly from 64.9% in 2015 to 20.3% in 2020, the proportion in dental clinics remained relatively high, declining only from 60.5% to 53.1%. These findings highlight the particular need to promote appropriate antimicrobial use in dental clinics.

Hashimoto et al. used the NDB to investigate antimicrobial prescribing rates among outpatients.[27] The prescribing rate decreased by 54% between 2012 and 2020, indicating a significant impact of the AMR Action Plan. However, broad-spectrum antimicrobials continued to be widely used. In addition, patients with Human Immunodeficiency Virus Infection (HIV) had an antimicrobial prescribing rate approximately 2.5 times higher than that of non-HIV patients, highlighting the importance of continuing efforts to address this issue.

Koizumi et al. similarly used the NDB to examine the impact of the AMR Action Plan and the emergence of COVID-19 on antimicrobial prescribing rates for various diseases.[28] Antimicrobial use decreased between 2016 and 2019 and declined further in 2020. Prescribing rates for upper respiratory tract infections, otitis media, and pneumonia showed significant reductions following both the implementation of the AMR Action Plan and the emergence of COVID-19. These findings demonstrate the effects of antimicrobial stewardship efforts and indicate the need for continued monitoring, including the long-term impact of COVID-19.

3. New data collection and analysis methods for appropriate use of antimicrobial agents

The AMR Clinical Reference Center compiled the proportion of antimicrobial use for major infectious diseases, including respiratory tract infections, using data from the NDB. For details of the results, see the report by Koizumi et al. cited above.[28] Future plans include continuing such analyses using similar methods, with consideration given to ongoing monitoring by region, age group, and type of antimicrobial agent.

References

1. Yoshida S, Takeuchi M, Kawakami K. Prescription of antibiotics to pre-school children from 2005 to 2014 in Japan: a retrospective claims database study. *J Public Health (Oxf)*. 2018; 40:397–403.
2. Uda K, Okubo Y, Kinoshita N, Morisaki N, Kasai M, Horikoshi Y, et al. Nationwide survey of indications for oral antimicrobial prescription for pediatric patients from 2013 to 2016 in Japan. *J Infect Chemother*. 2019; 25:758–63.
3. Hashimoto H, Saito M, Sato J, Goda K, Mitsutake N, Kitsuregawa M, et al. Indications and classes of outpatient antibiotic prescriptions in Japan: A descriptive study using the national database of electronic health insurance claims, 2012–2015. *Int J Infect Dis*. 2020; 91:1–8.
4. Hashimoto H, Matsui H, Sasabuchi Y, Yasunaga H, Kotani K, Nagai R, et al. Antibiotic prescription among outpatients in a prefecture of Japan, 2012–2013: a retrospective claims database study. *BMJ Open*. 2019; 9:e026251.
5. Kimura Y, Fukuda H, Hayakawa K, Ide S, Ota M, Saito S, et al. Longitudinal trends of and factors associated with inappropriate antibiotic prescribing for non-bacterial acute respiratory tract infection in Japan: A retrospective claims database study, 2012–2017. *PLoS One*. 2019; 14: e0223835.
6. Koyama T, Hagiya H, Teratani Y, Tatebe Y, Ohshima A, Adachi M, et al. Antibiotic prescriptions for Japanese outpatients with acute respiratory tract infections (2013–2015): A retrospective Observational Study. *J Infect Chemother*. 2020; 26:660–6.
7. Okubo Y, Miyairi I, Michihata N, Morisaki N, Kinoshita N, Urayama KY, et al. Recent Prescription Patterns for Children with Acute Infectious Diarrhea. *J Pediatr Gastroenterol Nutr*. 2019; 68:13–6.
8. Kitano T, Tsuzuki S, Koizumi R, Aoyagi K, Yusuke A, Kusama Y, Ohmagari N. Factors Associated with Geographical Variability of Antimicrobial Use in Japan. *Infect Dis Ther*. 2023 Dec;12(12):2745–2755.
9. Muraki Y, Kusama Y, Tanabe M, Hayakawa K, Gu Y, Ishikane M, et al. Impact of antimicrobial stewardship fee on prescribing for Japanese pediatric patients with upper respiratory infections. *BMC Health Serv Res*. 2020;20(1):399.
10. Okubo, Y., Nariai, H., Michels, K. B., Kim-Farley, R. J., Nishi, A., Arah, O. A., Kinoshita, N., Uda, K., & Miyairi, I. (2021). Change in clinical practice variations for antibiotic prescriptions across different

pediatric clinics: A Japan's nationwide observational study. *Journal of Infection and Chemotherapy*.
<https://doi.org/10.1016/j.jiac.2021.07.020>

11. Ono, A., Aoyagi, K., Muraki, Y. et al. Trends in healthcare visits and antimicrobial prescriptions for acute infectious diarrhea in individuals aged 65 years or younger in Japan from 2013 to 2018 based on administrative claims database: a retrospective observational study. *BMC Infect Dis* 21, 983 (2021).
<https://doi.org/10.1186/s12879-021-06688-2>
12. S. Sugiyama, H. Shimizu, J. Tsukiji, S. Hashimoto: Prescription of Oral Antimicrobial Agents to Outpatients with Acute Respiratory Tract Infection and Acute Diarrhea-The Survey Based on Medical Data Using MDV analyzer- , *Journal of Japanese Society of Hospital Pharmacists*, 56(10), 1187-1194, 2020.
13. Tsuzuki S, Koizumi R, Matsunaga N, Ohmagari N. Decline in Antimicrobial Consumption and Stagnation in Reducing Disease Burden due to Antimicrobial Resistance in Japan. *Infect Dis Ther*. 2023. DOI: 10.1007/s40121-023-00829-7.
14. Ito S, Muraki Y, Inose I, Mizuno K, Goto R, Kiyosuke M, Inuma Y, Yagi T, Ohge H. Characteristics of pediatric patients claimed with acute upper respiratory infection during otorhinolaryngology consultations: A descriptive study of a large Japanese medical claims database. *J Infect Chemother*. 2024 Aug;30(8):815-819.
15. Jindai K, Itaya T, Ogawa Y, Kamitani T, Fukuhara S, Goto M, Yamamoto Y. Decline in oral antimicrobial prescription in the outpatient setting after nationwide implementation of financial incentives and provider education: An interrupted time-series analysis. *Infect Control Hosp Epidemiol*. 2022 Apr 6;1-7.
16. Okubo Y, Nishi A, Michels K B, Nariai H, Kim-Farley R J, Arah O A, Uda K, Kinoshita, Miyairi I. The consequence of financial incentives for not prescribing antibiotics: a Japan's nationwide quasi-experiment. *Int J Epidemiol*. 2022 Oct 13;51(5)
17. Sato M, Yamana H, Ono S, Ishimaru M, Matsui H, Yasunaga H. Trends in prophylactic antibiotic use for tooth extraction from 2015 to 2018 in Japan: An analysis using a health insurance claims database. *J Infect Chemother*. 2022 Apr;28(4):504-509.
18. Araki Y, Momo K, Yasu T, Ono K, Uchikura T, Koinuma M, Sasaki T. Prescription pattern analysis for antibiotics in working-age workers diagnosed with common cold. *Sci Rep*. 2021 Nov 22;11(1):22701
19. Tsuzuki S, Koizumi R, Matsunaga N, Ohmagari N. Decline in Antimicrobial Consumption and Stagnation in Reducing Disease Burden due to Antimicrobial Resistance in Japan. *Infect Dis Ther*. 2023. DOI: 10.1007/s40121-023-00829-7.
20. D, Yanai T, Yoshida S, Kawakami K. Prescribing Pattern and Efficacy of Oral Antibiotics for Pediatric Urinary Tract Infections in Japan: A Descriptive Study Using a Nationwide Claims Database. *Pediatr Infect Dis J*. 2024 Jan 1;43(1):21-25.
21. Sato M, Yamana H, Ono S, Ishimaru M, Matsui H, Yasunaga H. Amoxicillin vs third-generation cephalosporin for infection prophylaxis after third molar extraction. *Oral Dis*. 2024 Mar;30(2):660-668.
22. Okubo Y, Uda K, Miyairi I. Long-term Effectiveness of Financial Incentives for Not Prescribing Unnecessary Antibiotics to Children with Acute Respiratory and Gastrointestinal Infections: A Japan's Nationwide QuasiExperimental Study. *Clin Infect Dis*. 2024 Nov 23;ciae577. doi: 10.1093/cid/ciae577.
23. Yamasaki D, Ito S, Ochiai N, Yamaguchi T, Suzuki K, Tanabe M. Impact of long-term macrolide therapy on the evaluation indicator of outpatient oral antimicrobial use according to the AWaRe classification. *J Infect Chemother*. 2025 Feb;31(2):102491. doi: 10.1016/j.jiac.2024.08.006.
24. Oda K, Okamoto S, Iwanaga E, Nakata H. Investigating the WHO's AWaRe classification for assessing antimicrobial stewardship programs: A single-center study. *J Infect Chemothe*. 2025;31:102511.
25. Tsuzuki S, Koizumi R, Aoyagi K, Asai Y, Ohmagari N. Rethinking the WHO AWaRe classification: the need for more detailed guidance. *eClinicalMedicine*. 2025. In press.
26. Hirayama K, Kanda N, Hashimoto H, Yoshimoto H, Goda K, Mitsutake N, Hatakeyama S. Antibiotic Prescription Trends in Dentistry: A Descriptive Study Using Japan's National Database. *J Public Health Dent*. 2025 Jun;85(2):153-159. doi: 10.1111/jphd.12663.
27. Hashimoto H, Kanda N, Yoshimoto H, Goda K, Mitsutake N, Hatakeyama S. Significant reduction in antibiotic prescription rates in Japan following implementation of the national action plan on antimicrobial resistance (2016-20): a 9-year interrupted time-series analysis. *JAC Antimicrob Resist*. 2025 Apr 30;7(3):dlaf062. doi: 10.1093/jacamr/dlaf062.
28. Koizumi R, Tsuzuki S, Asai Y, Aoyagi K, Ohmagari N. Impact of antimicrobial resistance measures and the emergence of COVID-19 on antimicrobial use throughout the Japanese population: A retrospective cohort study using a national claims database. *Int J Antimicrob Agents*. 2025 Nov 13:107667. doi: 10.1016/j.ijantimicag.2025.107667.

(7) Research on the prudent use of antimicrobial agents for veterinary use

A new Action Plan has been published, setting targets for the reduction of antimicrobial agents in the animal (livestock) sector. While building up information on diseases for which veterinary antimicrobial agents are used, it is necessary to develop prevention and treatment guidelines for major diseases. In addition, since companion animals share living space with their family members in the home, it has been pointed out that antimicrobial-resistant bacteria may be cross-transmitted within the home, so it is extremely important to understand the actual status of antimicrobial agent use. The following is a survey on the prudent use of antimicrobial agents for veterinary antimicrobial settings although the study area is limited.

1. Utilization of digital medical record data of Agricultural Mutual Ais Associations

Terashi et al. used digital medical record data maintained by NOSAI Gifu to tabulate the therapeutic purposes and net end equivalents of antimicrobial agents used to treat cattle.[1] Antimicrobial agents were used predominantly (85%) for gastrointestinal (50.4%) and respiratory (34.4%) diseases, with sulfoamides (49.2%) for coccidiosis and phenicol agents (21.7%), mainly florfenicol, for respiratory disease, being the main components. National data from the Ministry of Agriculture, Forestry, and Fisheries (MAFF) indicate that tetracycline antibiotics are also commonly used in cattle, suggesting that there are regional differences in antimicrobial use.

2. Use of second-line drugs in companion animals

Murakami et al. in cooperation with the Gifu Veterinary Medical Association surveyed 35 animal hospitals where cases receiving fluoroquinolone (FQ), third generation cephalosporins, carbapenems, and/or vancomycin products were investigated.[2] They were used in 1,209 cases during the study period, including 7 animals 34 cases of FQ, 467 cases of third generation cephalosporins, and 8 cases of carbapenems, and no vancomycin products were used; for both FQ and third generation cephalosporins, the percentage of injectable formulations used was significantly higher in cats than in dogs. These two agents tended to be used more frequently for skin/ear diseases regardless of animal species, but their use for other diseases differed between dogs and cats.

References

1. Terashi Y, Hirata Y, Asai T. Antimicrobial usage surveys using electronic medical records in cattle practice in Gifu Prefecture. *J Vet Med Sci.* 85(10): 1106-1109, 2023
2. Murakami M, Harada K, Asai T. Survey of Actual Usage Status of Medically Important Antimicrobials in Small Animal Practices in Gifu. *J. Jpn. Vet. Med. Assoc.*, 76: e164-e169, 2023

(8) -Environment

Pharmaceutical products including antimicrobials, agents, and daily necessities, are collectively referred to as “Pharmaceuticals and Personal Care Products (PPCPs).” PPCPs may have physiological activity even at low concentration, causing concerns about effect on aquatic ecosystems.[1] Regarding antimicrobials as a type of PPCPs, several studies have indicated the measurements of antimicrobial concentrations in the environment (e.g. sewage, treated wastewater, recycled water, environmental water, and sludge).[2]

In some cases, a part of sewage sludge (biomass) that is generated from sewage treatment is reused as agricultural fertilizers through anaerobic digestion and composting. The extent to which PPCPs are degraded in the sewage treatment process or in the sewage sludge digestion process varies by the type of PPCPs. For example, among other antimicrobials, most sulfonamides are decomposed, while fluoroquinolones, such as ofloxacin and norfloxacin, reside in sludge at high concentrations without being degraded.[3] The biodegradation process of PPCPs is affected by water temperature. The removability of PPCPs is affected by treatment conditions in the sewage treatment process, such as hydraulic retention time, the processing concentration and retention time of activated sludge. To further promote removal, research is in progress to improve the removability of antimicrobials using membrane bioreactor.[1] Many research activities are also undertaken both in Japan and overseas to improve efficiency in removing antimicrobials, by introducing ozone and advanced oxidation process.[2] It is required to identify the current status of discharge and developmental trends in Japan.

A study that measured the concentrations of antimicrobials detected in Japanese urban rivers, based on influent sewage at sewage treatment plants, reported that the actual measurements of CPFX and clarithromycin indicated certain similarity to concentrations expected from the volumes of shipment or sales of these antimicrobials, and pointed out that it may be possible to predict sewage concentrations of antimicrobials based on their volumes of shipment or sales.[4] The study reported that, for example, CPFX and clarithromycin were contained in sewage at the respective concentrations of 51 to 442 ng/L and 886 to 1,866 ng/L.

1. Survey on the Presence of Antibiotics in the Environment [5, 6, 7, 8]

The Ministry of the Environment conducts an ongoing survey on the residual status of chemicals in the general environment, known as the Environmental Survey and Monitoring of Chemicals, to continuously track the presence of various chemicals, including antibiotics, in the environment.

As a result, antibiotics have been detected in river water and other environmental samples, with the following maximum concentrations: erythromycin at 30 ng/L, clarithromycin at 490 ng/L, roxithromycin at 47 ng/L, clindamycin at 11 ng/L, lincomycin at 17 ng/L, sulfamethoxazole at 190 ng/L, sulfadiazine at 29 ng/L, sulfanilamide at 210 ng/L, sulfapyridine at 290 ng/L, sulfisomidine at 13 ng/L, ormetoprim at 11 ng/L, diaveridine at 10 ng/L, trimethoprim at 61 ng/L, azithromycin at 130 ng/L, amoxicillin at 2.3 ng/L, tiamulin at 3.1 ng/L, levofloxacin at 540 ng/L, the clarithromycin metabolite 14-(R)-hydroxycarithromycin at 230 ng/L, ampicillin at 1.4 ng/L, streptomycin at 2.3 ng/L, miconazole at 13 ng/L, fluconazole at 66 ng/L, and ciprofloxacin at 3.8 ng/L.

2. Initial Environmental Risk Assessment of Antibiotics [9, 10, 11, 12]

The Ministry of the Environment compiles reports of initial environmental risk assessments to screen substances that are considered to pose relatively high environmental risks among a wide range of chemicals. These assessments include evaluations of risks to human health (health risk) and risks to ecosystems (ecological risk).

In the initial environmental risk assessment of antibiotics, all substances were evaluated for their ecological risks. Roxithromycin and sulfamethoxazole were identified as agents of potential concern and were selected as candidates for detailed assessment, while lincomycin, sulfadiazine, and erythromycin were noted as requiring further information gathering. Trimethoprim, however, was determined not to require additional information collection at this time.

References

1. Tanaka H, et al. Occurrence of pharmaceuticals and personal care products in the water environment and development of physicochemical treatment technology for their reduction. *Journal of environmental conservation engineering*. Vol.37 No. 12., 2008.
2. Park J, et al. “Removal characteristics of PPCPs: comparison between membrane bioreactor and various biological treatment process.” *Chemosphere*. 2017; 179: 347e358.
3. Narumiya M, et al. “Phase distribution and removal of PPCPs during anaerobic sludge digestion” *Journal of Hazardous Materials* 2013; 260: 305-312.
4. Azuma T, et al. “Evaluation of concentrations of pharmaceuticals detected in sewage influents in Japan by using annual shipping and sales data” *Chemosphere*. 2015;138 :770-776.
5. Report on Environmental Survey and Monitoring of Chemicals in FY2015
<http://www.env.go.jp/chemi/kurohon/2015/index.html>

6. Report on Environmental Survey and Monitoring of Chemicals in FY2019
<http://www.env.go.jp/chemi/kurohon/2020/index.html>
7. Report on Environmental Survey and Monitoring of Chemicals in FY2020
<http://www.env.go.jp/chemi/kurohon/2021/index.html>
8. Report on Environmental Survey and Monitoring of Chemicals in FY2024
https://www.env.go.jp/chemi/kurohon/2024/sokutei_shoki.html
9. ENVIRONMENTAL RISK ASSESSMENT OF CHEMICALS Vol.17
<https://www.env.go.jp/chemi/report/ierac17/index.html>
10. ENVIRONMENTAL RISK ASSESSMENT OF CHEMICALS Vol.18
<https://www.env.go.jp/chemi/report/ierac18/index.html>
11. ENVIRONMENTAL RISK ASSESSMENT OF CHEMICALS Vol.19
<https://www.env.go.jp/chemi/report/ierac19/index.html>
12. ENVIRONMENTAL RISK ASSESSMENT OF CHEMICALS Vol.20
<https://www.env.go.jp/chemi/report/ierac20/index.html>

8. Public Awareness regarding Antimicrobial Resistance in Japan

(1) Surveys of the general public

1) Surveys of attitudes among the public

Public awareness surveys concerning antimicrobial resistance funded by a Ministry of Health, Labour and Welfare research grant were conducted in March 2017, February 2018, September 2019, September 2020, and October 2022, October 2023, and the seventh survey in December 2024. [1-5] In these studies, consumers (excluding medical professionals) who had registered with INTAGE Research Inc. to participate in various market research surveys completed an online questionnaire. The survey was initiated with a target number of 3,000 respondents, and the 2017 survey had 3,390 valid responses, the 2018 survey 3,192, the 2019 survey 3,218, the 2020 survey 3,200, the 2022 survey 3,193, the 2023 survey 3,202, and the 2024 survey 3,213. Women comprised 48.8% of respondents in 2017, 49.7% in 2018, 52.2% in 2019, 50.4% in 2020, 50.4% in 2022, 49.9% in 2023, and 48.0% in 2024. Until 2019, more than 40% of all respondents experienced taking antibiotics because of cold, which decreased to 19.6% in 2022. Subsequently, an increasing trend was again observed, reaching 31.4% in 2024. For COVID-19, 13.3% of respondents reported having taken oral antibiotics, representing a decrease from 20.2% in 2023. Compared to the period before 2019, the percentage of respondents taking antimicrobials against a cold remains low. However, 45.2% of respondents indicating that “antibiotics are effective against colds and influenza”. Also, 18.6% indicated that they have “discontinued taking antibiotics or adjusted the dosage based on their own judgment”; and approximately 9.3% indicated that they “keep the remaining antibiotics at home”. Among the respondents who “keep remaining antibiotics at home”, 78.9% have “used them based on their own judgment”. The results of this survey showed no substantial changes when compared with the trends of responses in the previous six surveys, so ongoing efforts to raise public awareness using a variety of measures, including behavioural economics methodology, are required in order to change attitudes among the public.

Table 97. Reasons for taking oral antibiotics (multiple responses)

	2017 (%) (n=1,566)	2018 (%) (n=1,737)	2019 (%) (n=1,330)	2020 (%) (n=1,078)	2022 (%) (n=1,051)	2023 (%) (n=1,100)	2024 (%) (n=1,026)
Cold	45.5	44.7	41.2	29.8	19.6	22.9	31.4
Others/unknown	24.3	21.2	23.2	30.4	32.5	29.4	18.1
Influenza	11.6	12.4	12.0	5.8	2.6	3.7	10.4
Fever	10.7	11.3	8.5	7.8	9.9	9.4	12.0
Nasopharyngitis	9.5	10.8	10.5	9.9	8.3	9.1	10.5
Cough	9.0	10.8	6.9	4.5	5.0	8.6	12.5
Sore throat	7.7	7.8	8.2	7.1	8.1	7.5	9.8
Skin or wound infection	6.5	7.0	9.0	14.5	11.8	10.8	8.9
Bronchitis	5.4	6.6	5.1	5.9	5.8	5.4	6.0
Headache	4.3	5.0	4.1	5.0	7.0	4.5	6.0
Diarrhea	3.1	3.2	2.6	3.1	2.3	2.5	2.6
Urinary tract infection	2.3	2.5	2.7	4.7	3.5	3.0	2.3
Pneumonia	1.4	1.7	1.3	1.2	1.2	1.7	3.0
Novel coronavirus infection	-	-	-	-	15.5	20.2	13.3

*Applicable only to respondents who reported having taken antibiotics within the past year.

Table 98. Do you think each of the following statements is correct or incorrect? (%)

		2017 (n=3,390)	2018 (n=3,192)	2019 (n=3,218)	2020 (n=3,200)	2022 (n=3,193)	2023 (n=3,202)	2024 (n=3,213)
Antibiotics beat viruses	Correct	46.8	46.6	52.4	42.6	46.3	45.3	48.2
	Incorrect	21.9	20.3	17.7	23.5	19.5	20.5	19.5
	Do not know	31.3	33.0	29.9	33.9	34.2	34.3	32.2
Antibiotics have effect on cold and influenza	Correct	40.6	43.8	43.9	40.4	43.1	44.5	45.2
	Incorrect	24.6	22.1	22.7	23.1	20.7	20.6	20.0
	Do not know	34.8	34.1	33.4	36.4	36.2	34.8	34.8
Unnecessary use of antibiotics may result in the loss of their effect	Correct	67.5	68.8	66.4	64.9	60.8	61.4	60.9
	Incorrect	3.1	3.7	3.4	3.3	4.3	5.2	4.4
	Do not know	29.4	27.5	30.2	31.8	34.9	33.4	34.7
Adverse effects are involved in the use of antibiotics	Correct	38.8	41.5	45.7	45.6	42.6	58.2	46.9
	Incorrect	12.7	13.4	10.5	9.9	11.2	16.3	9.0
	Do not know	48.6	45.0	43.8	44.5	46.2	25.5	44.2

Table 99. Do any of the statements below apply to you? (%)

		2017 (n=3,390)	2018 (n=3,192)	2019 (n=3,218)	2020 (n=3,200)	2022 (n=3,193)	2023 (n=3,202)	2024 (n=3,213)
I have discontinued taking antibiotics, or adjusted a dose or frequency based on my own judgment	Yes	23.6	24.0	24.6	23.3	22.2	19.7	18.6
	No	76.4	76.0	75.4	76.7	77.8	80.3	81.4
I keep antibiotics in my house	Yes	11.7	11.9	9.8	9.3	10.2	9.6	9.3
	No	88.3	88.1	90.2	90.7	89.8	90.4	90.7

Table 100. Do any of the statements below apply to you? (%)

		2017 (n=396*)	2018 (n=426*)	2019 (n=3,218)	2020 (n=298)	2022 (n=326)	2023 (n=307)	2024 (n=299)
I have used antibiotics that I kept at home for myself	Yes	75.8	77.5	75.6	76.2	81.3	75.9	78.9
	No	24.2	22.5	24.4	23.8	18.7	24.1	21.1
I have given antibiotics that I kept at home to my family or friend	Yes	26.5	27.2	28.5	25.5	35.6	24.4	29.4
	No	73.5	72.8	71.5	74.5	64.4	75.6	70.6

* Only respondents with valid responses that kept antibiotics at home.

References

1. Ohmagari N, et al. “‘Research on the Public Awareness Concerning Antimicrobial Resistance’, under ‘Research Concerning the Infection Control of Antimicrobial-Resistant Bacteria in Medical Institutions’ (2016- Emg-Adm-General-003), Shared Research Report, Grants for Research from the Ministry of Health, Labour and Welfare of Japan) (Research Project concerning Emerging and Re-emerging Infectious Diseases and Vaccination Policies) FY2016.” 2017
2. Ohmagari N, et al. “‘Research on the Public Awareness Concerning Antimicrobial Resistance: Follow-up Study One Year Later’, under ‘Research Concerning the AMR Action Plan’ (2017- Emg-Adm-Designated-005), Shared Research Report, Grants for Research from the Ministry of Health, Labour and Welfare of Japan) (Research Project concerning Emerging and Re-emerging Infectious Diseases and Vaccination Policies: Measures to Combat Disease and Disability) FY2017.” The estimated use (or sales) of antimicrobials in 2021, based on sales volumes and other data for each sector, were 507.0 t for humans, 598.1 t for livestock, 194.7 t for aquatic animals, 8.1 t for pets, 211.1 t for antimicrobial feed additives, and 133.2 t for agrochemicals, totalling 1,652.2 t.
3. Ohmagari N, et al. “‘Research Concerning AMR Countermeasures Education and Awareness’, under ‘Research Concerning AMR’ (2017- Emg-Adm-Designated-005), Shared Research Report, Grants for Research from the Ministry of Health, Labour and Welfare of Japan) (Research Project concerning Emerging and Re-emerging Infectious Diseases and Vaccination Policies: Measures to Combat Disease and Disability) FY2017.” 2020
4. Ohmagari N, et al. “Health and Labour Sciences Research Grant for Research Project concerning Emerging and Re-emerging Infectious Diseases and Vaccination Policies: Measures to Combat Disease and Disability, Shared Research Report FY2022 ‘Research Concerning AMR Action Plan - Research Concerning Education and Awareness of AMR Countermeasures’”, 2022
5. Ohmagari N, et al. “Health and Labour Sciences Research Grant for Research Project concerning Emerging and Re-emerging Infectious Diseases and Vaccination Policies: Measures to Combat Disease and Disability, Shared Research Report FY2023 ‘Research on Addressing Challenges in the Implementation of the Antimicrobial Resistance (AMR) Action Plan 2023-2027’”, 2023

(2) Surveys of healthcare providers

1) Awareness survey of clinic physicians

The Joint Survey Committee on Appropriate Use of Antimicrobial Agents in Outpatients of the Japanese Society of Chemotherapy and the Japanese Association of Infectious Diseases conducted the second survey of awareness among physicians working in clinics in February 2018, from September to October 2020, and from December 2022 to February 2023. The survey questionnaire was distributed to 3,000 randomly selected clinics nationwide, and the forms were filled and returned. Compared to the survey in 2020, awareness of the Action Plan decreased, with responses indicating "able to explain to others" or "understanding" declining from 31.6% to 25.2% (Table 101). Regarding the proportion of antibiotic prescriptions for the common cold, the number of respondents selecting the lowest prescription rate, "0-20%," increased from 71.1% to 82.4%, indicating a decrease in the prescription rate for the common cold (Table 102). Responding to requests for antimicrobial prescriptions, 39.2% of the respondents said they would "explain and not prescribe," while 6.8% and 51.3% said they would "prescribe as requested" and "prescribe if not satisfied after explanation," respectively, hardly different from the results of the previous survey (Table 103). It is possible that intention to be actively involved in patient education and communication is not necessarily high. As in the previous survey, the percentage of prescribing antimicrobial agents for acute bronchitis was also high (Table 104). The development of simpler pathogen diagnostic tests may be effective in promoting the appropriate use of antimicrobial agents. The majority of respondents cited the campaign to the public as necessary to achieve the Action Plan, which was unchanged from the previous survey.

Table 101. Awareness of Action Plan (%)

	2018 (n=267)	2020 (n=627)	2022 (n=389)
Able to explain it to people	1.9	3.5	2.3
Understand	21.0	27.8	22.9
Only know the name	32.2	33.1	37.3
Do not know anything	44.9	34.8	37.5

Table 102. Percentage of antimicrobials prescribed when diagnosing with a common cold (%)

	2018 (n=242)	2020 (n=543)	2022 (n=323)
0-20%	62.0	71.1	82.4
21-40%	17.8	16.6	10.2
41-60%	7.4	6.8	5.0
61-80%	8.3	3.5	1.5
81% or more	4.5	2.0	0.9

Table 103. Response when patients or family members diagnosed with a common cold request for antimicrobial agent (%)

	2018 (n=252)	2020 (n=609)	2022 (n=380)
Prescribe it if they are not convinced by explanation	50.4	49.1	51.3
Explain and not prescribe	32.9	35.5	39.2
Prescribe as requested	12.7	10.8	6.8
Other	3.7	4.6	2.6

Table 104. Frequency of antimicrobial prescription when diagnosing an acute bronchitis (in the past year) (%)

	2018 (n=232)	2020 (n=522)	2022 (n=308)
0-20%	31.0	35.4	46.1
21-40%	23.7	24.9	24.7
41-60%	14.2	15.7	13.6
61-80%	9.5	9.0	6.8
81% or more	21.6	14.9	8.8

2) Research on infectious diseases and antimicrobials in pharmacy education

Pharmacists are important members of the healthcare team responsible for in-hospital and community ICT and ASP activities, and the need for education on AMR and clinical infectious diseases among pharmacists is increasing. However, the current state of education on clinical infectious diseases in the faculty of pharmacy of Japanese universities was not clear, so a nationwide survey of pharmacy schools in Japan was conducted from February to March 2022. Questionnaires were sent to pharmacy schools across Japan and 44 out of 74 universities responded.

The median number of teaching staff members in charge of infectious disease education was 7 [4-12], of which practitioners were 3 [1-6].

62.8% of the universities had teaching staff members with clinical experience in infectious diseases. Regarding the contents of education, the most frequently reported as “inadequate” or “not implemented” were: the concept of prophylactic antimicrobials in the perioperative period (74.5% inadequate or not implemented in total), how to explain to patients when antimicrobial is not necessary (76.8% total), patient education on prudent antimicrobial (79% in total), team approach to infectious disease care and infection control (53.5% in tot), and education on antimicrobial research and development (76.8%in total). Insufficient time for lectures and lack of specialists were the top issues in clinical infectious disease education. The survey also revealed that educational status and resources for clinical infectious diseases and AMR varied widely. It was suggested that resources, including the overall curriculum and the number of teachers, need to be examined and improved.

(3) Survey of Stakeholders in the Animal Field

The Ministry of Agriculture, Forestry and Fisheries conducted a survey in the 2023 fiscal year to assess awareness of antimicrobial resistance among producers, veterinary clinicians specializing in livestock, veterinary clinicians specializing in small animals, and pet owners.

The survey was conducted via an online questionnaire.

It should be noted that the following results represent the responses from producers and pet owners by species who have responded.

1) Awareness Survey of Producers and Pet Owners

The number of respondents was 238 producers and 1,112 pet owners. Among the producers, 141 (59.2%) raised cattle, 55 (23.1%) raised swine, and 41 (17.2%) raised chickens. Among the pet owners, 402 (36.2%) owned dogs, and 748 (67.3%) owned cats.

Awareness of Japan's Antimicrobial Resistance (AMR) Action Plan was reported by approximately 25% of producers and less than 10% of pet owners (Table 105). In terms of awareness of specific AMR measures, nearly 80% of producers recognized that "antimicrobial-resistant bacteria make it difficult to treat bacterial infections in humans and livestock/pets," while less than 50% of pet owners were aware of this (Table 106). Approximately 85% of producers and about 70% of pet owners were aware that "inappropriate use of antibiotics leads to an increase in antimicrobial-resistant bacteria" (Table 107).

Additionally, 60% of producers were aware of "the types of antimicrobial feed additives mixed into feed," and 90% recognized that "improving farming conditions and using vaccines can help prevent disease outbreaks," with 80% reporting they had implemented such measures.

When compared to the results of the awareness surveys conducted by the Japan Livestock Industry Association in fiscal years 2017 and 2018 among livestock keepers and veterinary clinicians specializing in industrial animals, awareness levels across various items remained relatively stable.

However, it was revealed that awareness of AMR measures among pet owners, who were newly surveyed, was generally lower compared to livestock producers.

Table 105. Awareness of Japan's Antimicrobial Resistance Action Plan (%)

	Producers (n=238)	Veterinary clinicians specializing in livestock (n=315)	Veterinary clinicians specializing in small animals (n=279)	Pet owners (n=1112)
Aware	26.1	73.3	66.6	6.8
Not aware	73.9	26.7	33.3	93.2

Table 106. Awareness of the Impact of Antimicrobial Resistant Bacteria on the Treatment of Bacterial Infections in Humans and Livestock/Pets (%)

	Producers (n=238)	Pet owners (n=1112)
Aware	78.2	46.7
Not aware	21.8	53.3

Table 107. Awareness of the Link Between Inappropriate Use of Antibiotics and the Increase in Antimicrobial-Resistant Bacteria (%)

	Producers (n=238)	Pet owners (n=1112)
Aware	85.3	69.2
Not aware	14.7	30.8

2) Awareness Survey of Veterinary Clinicians Specializing in Industrial and Small Animals

A total of 594 responses were received, with 315 (53.0%) from veterinary clinicians specializing in industrial animals and 279 (47.0%) from those specializing in small animals. Among the industrial animal clinicians, 251 (79.7%) provided care for dairy cattle, 274 (87.0%) for beef cattle, 51 (16.2%) for swine, 13 (4.1%) for broiler chickens, and 15 (4.8%) for laying hens (note that multiple selections were allowed, resulting in overlaps).

The awareness level for various items was as follows: 70% of industrial animal clinicians and about 65% of small animal clinicians were aware of Japan's Antimicrobial Resistance (AMR) Action Plan (Table 105).

Additionally, when asked how often they "make a conscious effort in daily practice to limit antibiotic use to cases where it is truly necessary, based on proper diagnosis", about 50% of industrial animal clinicians and around 60% of small animal clinicians answered as often as 61% or more of their consultations. Regarding "administering appropriate vaccinations," about 75% of industrial animal clinicians and around 60% of small animal clinicians responded positively (Table 108). Compared to surveys conducted in fiscal years 2017 and 2018 among industrial animal veterinarians, the awareness levels showed a decline.

Furthermore, awareness of "selecting antibiotics with a narrow spectrum of activity initially" was low, raising concerns about the easy use of broad-spectrum antibiotics. While awareness of "conducting antimicrobial susceptibility testing" (Table 108) exceeded 70%, more than half of the respondents reported that the "percentage of cases in daily practice where antimicrobial susceptibility testing was performed" (Table 109) was between 0% and 20%. This suggests that although there is knowledge about the prudent use of antibiotics, the proportion of such practices in daily clinical settings remains low, indicating that there has been no change since fiscal year 2018.

Table 108. Awareness of the "Basic Principles on the Prudent Use of Veterinary Antimicrobial Medicines in Livestock Production" (%)

	Veterinary clinicians specializing in livestock (n=315)	Veterinary clinicians specializing in small animals (n=279)
To prevent infectious diseases through appropriate husbandry and hygiene management	82.5	71.0
To administer appropriate vaccinations	75.6	59.9
To provide appropriate feeding and nutritional management	67.0	51.6
To conduct antimicrobial susceptibility testing	71.7	84.6
To use antibiotics for the minimum necessary duration	81.3	91.0
To select antibiotics with a narrow spectrum of activity initially	49.2	56.3
To use antibiotics critical for human health only when the initial antibiotic was ineffective.	73.7	62.7
Where possible, to select antibiotics with minimum exposure to enteric bacteria	34.9	40.5
To avoid administering antibiotics to healthy livestock animals	81.3	90.0
To avoid using more than one antibiotic in combination	54.6	36.9
To consider providing symptomatic treatment in combination to improve or alleviate symptoms in livestock animals	58.7	58.4
To assess the effect of the antibiotic agent prescribed at the initial consultation to determine whether to continue or change the use of antibiotics diagnosis	78.7	82.1

Table 109. Frequency of Antimicrobial Susceptibility Testing in the Past Year When Using Antibiotics in Daily Practice (Including Testing Commissioned to External Organizations) (%)

	Veterinary clinicians specializing in livestock (n=315)	Veterinary clinicians specializing in small animals (n=279)
0-20%	56.8	63.1
21-40%	24.4	20.4
41-60%	13.3	11.1
61-80%	2.9	3.6
81%-	2.5	1.8

(4) Survey of veterinary medicine students

The Ministry of Agriculture, Forestry and Fisheries has been conducting lectures and awareness surveys on antimicrobial resistance measures for veterinary students nationwide since 2019. Until 2020, awareness surveys were conducted after lectures, but since 2021 surveys have also been conducted before lectures in order to assess the effectiveness of the lectures. To the 2024 survey 734 students from 16 universities (2nd and 3rd year students: 514, 4th year students: 148, 5th year students: 72) responded.

In the awareness survey conducted prior to the lecture, 91.0% of the students answered "effective against bacterial infections" in the question about antimicrobial agents (Table 110), showing that the number of students with correct knowledge has remained over 90%. It was suggested that veterinary education has successfully imparted a certain level of knowledge about antibiotics, which has been retained over time. However, a certain number of students chose "effective against a common cold" or "effective against viral infection," with a response rate of 35.0% and 22.8%, respectively, suggesting that continued efforts should be made to ensure the dissemination of correct knowledge.

Similarly, in the awareness survey conducted before the lecture, the question "What do you know about antimicrobial resistance control in the veterinary field?" (Table 111) revealed that 43.7% of students were aware of "the existence of antibiotics referred to as second-line drugs," showing a decrease compared to the previous year. In contrast, the percentage of students who chose "Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM) is being conducted." and "Partnership between the veterinary and human medicine fields," was relatively high, with 42.2% and 45.1%, respectively, showing an increase from the previous year. In addition, 35.1% of students were aware that vaccination, by reducing opportunities for infection, contributes to antimicrobial resistance mitigation, which has shown an increasing trend over the past four years.

Because veterinarians play a key role in antimicrobial resistance control in the veterinary field, it is important to continue to educate veterinary students on the correct knowledge and prudent use of antimicrobial agents.

Table 110. Please give your perceptions about antimicrobials (%)

	2nd and 3rd year (n=514)	4th year (n=148)	5th year (n=72)	Whole (2020) (n=394)	Whole (2021) (n=404)	Whole (2022) (n=530)	Whole (2023) (n=530)	Whole (2024) (n=734)
Effective against a common cold	34.4	42.6	23.6	26.6	32.2	32.5	33.6	35
Effective against viral infections*	25.9	16.9	12.5	4.8	10.4	22.8	17.4	22.8
Effective against bacterial infections	89.7	91.9	98.6	92.4	91	93.6	93.6	91
Effective to prevent complications after surgery	47.7	65.5	58.3	58.6	64.9	48.5	56.6	52.3
Used as a feed additive to be mixed with feed	29.6	40.5	38.9	53.8	41.6	36.4	36.8	32.7
Used in pesticides for vegetables and other produce	14.2	16.9	5.6	8.4	13.6	16.4	14.2	13.9

*This had been phrased as "effective against an influenza" until 2021

.**The 2020 awareness survey was conducted only after the lecture, which may have biased the numbers (The years 2021 and 2022 show the results of surveys conducted prior to the lecture).

Table 111. Please select what you know about antimicrobial resistance control in the veterinary sector (%)

	2nd and 3rd year (n=514)	4th year (n=148)	5th year (n=72)	Whole (2020) (n=394)	Whole (2021) (n=404)	Whole (2022) (n=530)	Whole (2023) (n=530)	Whole (2024) (n=734)
An Action Plan on Antimicrobial Resistance (AMR) has been developed and is being implemented	25.3	43.9	38.9	43.9	18.8	30.9	29.8	30.4
The existence of antimicrobial agents called second-line drugs	37	68.2	41.7	32.7	33.4	34.3	54.5	43.7
Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM) is being conducted	40.1	50.7	40.3	21.6	18.6	45.8	41.3	42.2
Reduction of infection opportunities through vaccination contributes to antimicrobial resistance control.	36.4	32.4	32	28.9	29	29.1	32.8	35.1
Partnership between the veterinary and human medicine fields	43	52	45.8	45.9	44.6	46.2	41.1	45.1
Determination of risk management measures based on risk assessment	31.7	44.6	32	31.7	21.3	37.4	37.4	34.3
Do not know	14	1.4	6.9	9.9	18.1	12.1	12.1	10.8

9. Way Forward

The National Action Plan on Antimicrobial Resistance (AMR) (2016-2020), published in 2016, aimed to conduct an integrated One Health trend survey on the current status of drug-resistant bacteria and antimicrobial usage in the human, animal, agricultural, food and environmental sectors. This report consolidates the results and contributes to the further promotion of AMR countermeasures. It has allowed for a detailed understanding of the challenge of antimicrobial resistance in Japan and the development of measures on the basis of this understanding. The National Action Plan on Antimicrobial Resistance (AMR) (2023-2027) proposes updated goals and strategies based on the achievements to date and presents a new path forward in the fight against AMR. The importance of a One Health approach to the AMR problem has been reemphasized, and it is expected that information on AMR trends and countermeasures be analyzed and evaluated on a regular basis by linking information from human, animal, agricultural, food, and environmental trends studies and by making international comparisons. It also emphasizes the importance of updating methodologies for collecting and analysing data on trends in drug resistance and antimicrobial use in Japan and abroad, as well as international cooperation and collaboration for AMR countermeasures. Continued efforts to conduct advanced research is considered important for leading the global effort to combat AMR.

In the human field, with reference to the "Manual of Antimicrobial Stewardship" and other guidelines, unnecessary antimicrobial prescriptions should be reduced, particularly for acute respiratory tract infections, and when antimicrobial agents are prescribed, appropriateness is expected. Advancement of appropriate use of antimicrobial agents is dependent on the availability of appropriate antimicrobial agents when they are needed. Given the current circumstances where some antimicrobial agents have become difficult to obtain in clinical settings, it is important to ensure a stable supply of essential antimicrobial agents. Considering that it has become possible to obtain information on antimicrobial resistance and antimicrobial use on a regional basis using various surveillance systems related to AMR, it is advisable to select antimicrobial agents and promote appropriate infection control measures according to local conditions. Furthermore, in promoting the appropriate use of antimicrobial agents, it is necessary to continue and develop educational and awareness-raising activities for the public and healthcare professionals using various methods, including behavioral economics.

In the animal sector, the Veterinary AMR Center at the National Veterinary Assay Laboratory, a core laboratory for AMR, was established in October 2023. Moving forward, the Japan Veterinary Antimicrobial Resistance Monitoring (JVARM) will continue to enhance and conduct ongoing and accurate surveys on antimicrobial resistance trends in livestock, aquaculture, and companion animals, as well as antimicrobial usage. It is crucial to provide scientific knowledge essential for various AMR measures, such as risk assessment of antimicrobial resistant bacteria, risk management, public awareness campaigns, international efforts, and initiatives based on the One Health approach.

The resistance rates of *E. coli* from healthy livestock, outcome indices in the "National Action Plan on Antimicrobial Resistance (AMR) (2023-2027)," are expected to remain low against third-generation cephalosporins and fluoroquinolones, which are critically important for human medicine. However, for tetracyclines, widely used in animals, while a decrease in sales has been observed in swine, the resistance rates have not shown significant changes. The "National Action Plan on Antimicrobial Resistance (AMR) (2023-2027)" has newly set the usage levels of antimicrobial agents for livestock and second-line drugs as outcome indices.

Therefore, continued efforts are required to reduce the overall use of antimicrobial agents through the development and commercialization of vaccines, the promotion of their use, and the improvement of husbandry hygiene standards. In addition to ensuring appropriate and prudent use, it is essential to analyze and evaluate the factors that contribute to resistance rates being maintained, as well as the trends in resistance rates to various antimicrobial agents, and to respond accordingly.

In the field of companion animals, there has been a noticeable presence of bacterial strains derived from diseased animals with high resistance rates to third-generation cephalosporins and fluoroquinolones.

Therefore, in addition to further promoting the "Guide for Antimicrobial Prudent Use in Companion Animals," it is essential to continue and strengthen AMR measures in the companion animal sector, including appropriate antimicrobial selection, prioritization of companion animal-specific antimicrobials, and implementation of infection control measures.

This report presents the status of antimicrobial-resistant bacteria in various sectors, the usage (or sales volume) of antimicrobial agents in humans, animals, and agriculture, as well as the differences in antimicrobial usage by class across these sectors. Additionally, it highlights significant progress in the collection of data on antimicrobial-resistant bacteria in the food sector and the environment, as well as the analysis of cross-sector genomic data. These advancements indicate considerable progress, and further developments are anticipated in the trend surveys across various sectors in the coming years.

Furthermore, in the National Action Plan on Antimicrobial Resistance (AMR) (2016-2020), the annual Nippon AMR One Health Report has been playing an important role as a one-stop hub to confirm drug susceptibility data of drug-resistant bacteria in humans, animals, and foods. In the future, the analysis of drug-resistant genes and drug-

resistant bacteria genome data will be extremely crucial in understanding whether and to what extent specific drug-resistant bacteria and drug-resistant genes increase or decrease and migrate between different sectors within the One Health framework, and in applying this information to risk assessment and risk management. It is also vital to steadily implement this point based on the National Action Plan on Antimicrobial Resistance (AMR) (2023-2027). Industry, government, and academia will work closely together to promote collaboration among organizations in charge of different fields, while conducting cross-sectional assessments of risks to humans, animals, and the environment. These efforts will facilitate effective responses to the AMR challenge both domestically and internationally and will also play an important role in Japan's leading role in the global AMR control effort. In addition, the collection and analysis of data on antimicrobial resistance is an indispensable foundation for AMR countermeasures, and progress is expected to be made in these efforts in the future. These efforts are anticipated to make a significant contribution to AMR countermeasures in Japan and to improve the people's health and public health.

Appendix

(1) Japan Nosocomial Infections Surveillance (JANIS)

1) Overview

JANIS is conducted for the purpose of having an overview of nosocomial infections in Japan, by surveying the status of health care associated infections at medical institutions in Japan, the isolation of antimicrobial-resistant bacteria, and the status of infections caused by antimicrobial-resistant bacteria, while providing useful information for the control of health care associated infections in medical settings. The aggregated data of information from all medical institutions participated are published on the website of JANIS (<https://janis.mhlw.go.jp/english/index.asp>). A result of the analysis is reported back to each institution so that such feedback can be utilized for the formulation and evaluation of infection control measures at each institution. JANIS participation is voluntary with approximately 3,420 medical institutions and 1,607 clinics participating as of January 2025.

Clinical Laboratory Division of JANIS collects the laboratory data of bacteria that are isolated at hospitals across Japan and publish aggregated data regarding the proportion of clinically important bacterial species that are resistant to major antimicrobials. As of January 2025, 3,380 hospitals participated in the laboratory section. Bacteria that are isolated from specimens from inpatients as well as outpatients at participating hospitals are included in aggregated data. Since 2014, figures have also been compiled on the basis of hospital scale, divided into hospitals with 200 or more beds and those with fewer than 200 beds. To provide more representative information as a national surveillance system, protocols of sampling including selection of sentinel sites and their stratification need to be improved further. The assessment of antimicrobial susceptibility tests is interpreted based on CLSI Criteria (However, some of them are under Japan's Act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases).

Quality control for antimicrobial susceptibility tests depends on medical institutions. To improve the quality of antimicrobial susceptibility tests at hospital laboratories, a quality control program was developed under the leadership of the Japanese Society for Clinical Microbiology, and it has been piloted since 2016.

JANIS is a surveillance program regulated by the Statistics Act and it differs from the National Epidemiological Surveillance of Infectious Diseases based on the Infectious Diseases Control Act. While participation is voluntary, from 2014, Premiums for infection control 1 in medical reimbursement requires participation in JANIS or equivalent surveillance programs. JANIS is organized and operated by the Ministry of Health, Labour and Welfare, and its operating policy is determined at the operation council that comprises of experts in infectious diseases, antimicrobial resistance and other relevant professional fields. Antimicrobial Resistance Research Center (AMR-RC), National Institute of Infectious Diseases functions as a secretariat office for JANIS.

Under the Global Antimicrobial Resistance Surveillance System (GLASS), launched by WHO in 2015, individual countries are encouraged to submit data regarding resistant bacteria in the human health area.[1] Japan has provided necessary data from JANIS and other pertinent monitoring systems to GLASS. Of note, data for 2014 to 2024 have already been submitted. Techniques for compiling data are being considered as part of the JANIS program, to facilitate international cooperation in surveillance. Under GLASS, the expansion of the scope of surveillance to livestock animals and other areas are discussed.[1] It is expected that the data from this national One

Health report can be contributed to GLASS.

2) Methods for submission

JANIS consists of five divisions: (1) Clinical Laboratory, (2) Antimicrobial-Resistant Bacterial Infection, (3) SSI, (4) ICU and (5) NICU. Medical institutions select divisions to participate in, in accordance with their purposes and conditions. Among the five divisions, Clinical Laboratory division handles surveillance regarding the status of isolates of antimicrobial resistant bacteria. In Clinical Laboratory division, all data concerning isolated bacteria are collected from bacteriological examination units installed in the laboratories of medical institutions, computerized systems, and other sources, and converted into the JANIS format before submitted online. The submitted data are aggregated, and the shares of clinically important bacterial species that are resistant to key antimicrobials are calculated and published as the national data of Japan.

3) Prospects

Most medical institutions participating in JANIS are of a relatively large scale with 200 or more beds. The bias based on this sampling policy in JANIS should be addressed. With regard to clinics that were not previously covered by JANIS, clinics that perform at least one bacterial culture test per month will be able to participate in the JANIS laboratory section beginning in 2022, and these data have been compiled and made publicly available since 2023.

(2) National Epidemiological Surveillance of Infectious Disease

1) Overview

The National Epidemiological Surveillance of Infectious Disease collects and publishes domestic information regarding infectious diseases and monitors the occurrence of and trends in infectious diseases, based on reports from physicians and veterinarians. At present, the NESID program is conducted in accordance with the Act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases (hereinafter referred to as "Infectious Diseases Control Law"), which took effect in April 1999. The goal of this program is to accurately identify and analyze information regarding the occurrence of infectious diseases and to rapidly provide and publish the results to the general public and healthcare practitioners, thereby promoting measures for the effective and adequate prevention, diagnosis and treatment of infectious diseases, and preventing the occurrence and spread of various infectious diseases, while verifying the detection status and characteristics of circulating pathogens, and facilitating appropriate infection control measures, through the collection and analysis of pathogen information.

As of July 2019, the following seven antimicrobial-resistant bacteria infections are designated as reportable under National Epidemiological Surveillance of Infectious Disease, which are all classified as Category V Infectious Diseases. The four diseases that are subject to notifiable disease surveillance, which requires reporting by all physicians, are vancomycin-resistant enterococcal (VRE) infection (designated in April 1999), vancomycin-resistant *Staphylococcus aureus* (VRSA) infection (designated in November 2003), carbapenem-resistant *Enterobacteriales* (CRE) infection (designated in September 2014), and multidrug-resistant *Acinetobacter* (MDRA) infection (designated as a disease reportable from designated sentinel sites in February 2011, and changed to a disease reportable under notifiable disease surveillance in September 2014). The three diseases that are reportable from approximately 500 designated sentinel sites (medical institutions that have 300 or more beds, with internal medicine and surgery departments) across Japan are penicillin-resistant *Streptococcus pneumoniae* (PRSP) infection (designated in April 1999), methicillin-resistant *Staphylococcus aureus* (MRSA) infection (designated in April 1999), and multidrug-resistant *Pseudomonas aeruginosa* (MDRP) infection (designated in April 1999).

2) Reporting criteria

A physician who has diagnosed a reportable disease listed above (the manager of a designated notification facility in the case of a disease subject to sentinel surveillance) should report to a Public Health Center using a designated reporting form. The scope of reporting includes cases where bacteria that satisfy the laboratory findings specified in Table 112 are detected, and the isolated bacteria are regarded as the cause of the relevant infectious disease, or cases where it was detected from specimens that normally should be aseptic. In the case of antimicrobial-resistant bacterial infections classified as Category 5 infectious diseases, carriers are excluded from the scope of reporting.

Table 112. Reporting criteria

Reportable disease	Summary of reporting criteria
VRE	<i>Enterococcus</i> is isolated and identified, and the MIC of vancomycin is ≥ 16 $\mu\text{g/mL}$.
VRSA	<i>Staphylococcus aureus</i> is isolated and identified, and the MIC of vancomycin is ≥ 16 $\mu\text{g/mL}$.
CRE	<i>Enterobacteriales</i> is isolated and identified, and either A) or B) below is satisfied: A) The MIC of meropenem is ≥ 2 $\mu\text{g/mL}$, or the diameter of the inhibition circle of the meropenem susceptibility disk (KB) is ≤ 22 mm. B) Even if the results of the antimicrobial susceptibility test do not meet criterion A) above, carbapenemase production is confirmed by immunochromatographic assay or a carbapenemase gene is detected
MDRA	<i>Acinetobacter</i> spp. is isolated and identified, and all three conditions below are satisfied: A) The MIC of imipenem is ≥ 16 $\mu\text{g/mL}$, or the diameter of the inhibition circle of the imipenem susceptibility disk (KB) is ≤ 13 mm. B) The MIC of amikacin is ≥ 32 $\mu\text{g/mL}$, or the diameter of the inhibition circle of the amikacin susceptibility disk (KB) is ≤ 14 mm. C) The MIC of ciprofloxacin is ≥ 4 $\mu\text{g/mL}$, or the diameter of the inhibition circle of the ciprofloxacin susceptibility disk (KB) is ≤ 15 mm.
PRSP	<i>Streptococcus pneumoniae</i> is isolated and identified, and the MIC of penicillin is ≥ 0.125 $\mu\text{g/mL}$,
MRSA	<i>Staphylococcus aureus</i> is isolated and identified, and either criterion A) or B) is met: A) The MIC of oxacillin is ≥ 4 $\mu\text{g/mL}$. B) The MIC of ceftiofloxacin is ≥ 8 $\mu\text{g/mL}$, or the diameter of the inhibition circle of the ceftiofloxacin susceptibility disk (KB) is ≤ 21 mm.
MDRP	<i>Pseudomonas aeruginosa</i> is isolated and identified, and all three conditions below are satisfied: A) The MIC of imipenem is ≥ 16 $\mu\text{g/mL}$, or the diameter of the inhibition circle of the imipenem susceptibility disk (KB) is ≤ 13 mm. B) The MIC of amikacin is ≥ 32 $\mu\text{g/mL}$, or the diameter of the inhibition circle of the amikacin susceptibility disk (KB) is ≤ 14 mm. C) The MIC of ciprofloxacin is ≥ 4 $\mu\text{g/mL}$, or the diameter of the inhibition circle of the ciprofloxacin susceptibility disk (KB) is ≤ 15 mm.

From April 2025, the reporting criteria for the three antimicrobial-resistant bacterial infections have been revised, and these changes will be reflected in annual reports from the following fiscal year onward. Specifically, for CRE infections, the criteria based on disk diffusion testing with imipenem and cefmetazole and the broth microdilution method were removed, and the presence of carbapenemase production or confirmation of carbapenemase genes was added. For MRSA infections, the reporting criterion based on oxacillin disk diffusion was removed, and criteria based on ceftiofur disk diffusion (inhibition zone ≤ 21 mm) and broth microdilution (minimum inhibitory concentration ≥ 8 $\mu\text{g/mL}$) were added. For PRSP infections, the minimum inhibitory concentration threshold for isolates other than from sterile specimens was changed from ≥ 0.125 $\mu\text{g/mL}$ to ≥ 4 $\mu\text{g/mL}$. (As of January 2026)

3) System

Physicians/Hospitals directly input and register the information into NESID, or Public Health Centers input and register the information into NESID after confirming the details notified by physicians/hospitals. The registered information is further confirmed and analyzed, and additional information is collected, by local infectious disease surveillance centers, Japan Institute for Health Security National Institute of Infectious Diseases (Central infectious disease surveillance center), and other relevant bodies. Patient information (e.g. the reported numbers of patients, and trends) that is collected under the Infectious Diseases Control Law, and other related information, are provided to the general public through the Infectious Diseases Weekly Reports (IDWRs) and other media. A March 2017 notification issued by the Director of the Tuberculosis and Infectious Diseases Control Division, Health Service Bureau, MHLW imposed on local public health institutes and other organizations a requirement to test strains isolated from notified cases of CRE infection. Since then, data concerning the detection of major carbapenemase genes in strains isolated from notified cases of CRE infection have been collected and analyzed within the framework of the monitoring of trends in outbreaks of infection and have been published in the Infectious Agents Surveillance Report (IASR), among others.

4) Prospects

A certain level of quality is considered to be guaranteed in the reporting of antimicrobial-resistant bacteria infections under NESID, since reporting is based on case definitions specified by the Infectious Diseases Control Law. Although cases may be underestimated in notifiable disease surveillance, an overall picture of trends in occurrence can be monitored. This surveillance system is also considered useful because, when an unusual trend is observed, it may trigger an intervention (e.g. investigation, guidance) at the relevant medical institution by the Public Health Center. Trends in diseases reportable from designated sentinel sites have been recorded since the launch of the NESID program in 1999 and considered useful for monitoring medium- to long-term trends in the occurrence of the target diseases. In addition, pathogen surveillance focused primarily on CRE was launched in 2017 and, with data on resistance genes set to be gathered and analyzed for VRE and MDRA in due course, it is anticipated that information that will be valuable in devising measures to combat antimicrobial-resistant bacteria will be collected and utilized.

(3) Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE)

1) Overview

In 2017, the governance of the Regional Infection Control Support System (RICSS) was transferred to the AMR Clinical Reference Centre to utilize the system for AMR control as a surveillance platform for infection control at regional as well as national levels. The system was renamed to Japan Surveillance for Infection Prevention and Healthcare Epidemiology: J-SIPHE.

The system has been launched as a system that can be utilized for AMR measures in hospitals as well as for the promotion of regional cooperation, and a large amount of data has been accumulated and an annual report is published annually to return the data to the facilities using the system. The J-SIPHE 2024 Annual Report covers a total of 3,471 participating medical institutions. The system is designed to collect information on the status of infectious disease treatment, infection control measures and the appropriate use of antimicrobials, the occurrence of healthcare-associated infections, the occurrence of major bacteria and drug-resistant bacteria, the occurrence of bloodstream infections caused by them, and the use of antimicrobials at participating facilities, and to make use of this information at the facilities themselves and in regional networks. With these as its purpose, the system also to establish indicators as an indicator for AMR control.

2) System

This system is based on participation in a regional cooperation network within the framework of the medical fee premium for infection control enhancement. In order to support AMR measures by utilizing the regional cooperation network, etc., information can be shared within the group based on unified standards, and the system visualizes data that are necessary and adequate for AMR measures by making secondary use of existing information such as returned JANIS laboratory section data and integrated inpatients EF files, while reducing the burden on participating facilities.

3) Prospects

The system needs to be further renovated so that it can be utilized for activities such as regional collaborative conferences, and to make it more accessible and meaningful for facilities that lack human resources for infection control. The system aims to make the system more effectively used in building infection control networks at the regional level and in decision-making on infection control.

(4) Trend surveillance of antimicrobial-resistant *Mycobacterium tuberculosis*

1) Overview

registered tuberculosis patient information system is a part of NESID including: new tuberculosis patients and latent tuberculosis patients who are registered from January 1 to December 31 of a registration year; and all tuberculosis patients who are registered as of December 31 of the calendar year. In principle, information in this system pertains to tuberculosis patients, and focuses on the number of incidence case and incidence rate, the number of patients with tuberoses, treatment status, the number of deaths from tuberculosis, and so on. Information regarding tuberculosis bacillus as the causal bacteria is limited to the smear positive ratio, the number of culture-positive patients, agent-susceptibility testing data, and so on. Though limited, this report exclusively provides routine national information regarding antimicrobial-resistant tuberculosis bacillus.

2) Survey methods

Based on the registered tuberculosis patient information, the results of agent-susceptibility testing in newly registered patients with culture-positive pulmonary tuberculosis are aggregated. The entry of this information item used to be optional, before the Ordinance for the Partial Revision of the Enforcement Regulation of the Act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases (MHLW Ordinance No. 101 of 2015, effective May 21, 2015) added "the results of agent-susceptibility testing" under "Conditions of disease" in Item 4, Paragraph 1, Article 27-8.

3) System

When physicians diagnose and report a tuberculosis case to Public Health Center collect, corresponding public health nurses collect detailed information from patients and physicians. Agent-susceptibility testing data are considered to be collected mostly from hospital and commercial laboratories. Those individual data are entered by Public Health Centers across Japan into National Epidemiological Surveillance of Infectious Diseases.

4) Prospects

The surveillance based on the registered tuberculosis patient information system contains the susceptibility results of newly registered patients with culture-positive pulmonary tuberculosis, as reported from all medical institutions. Therefore, data are considered nationally representative. Improvement in the entry rate of agent-susceptibility testing results (approximately 80% at present); the establishment of a system for nationwide quality assurance for agent-susceptibility testing; and the quality control of data entry are warranted.

(5) Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM)

1) Overview

JVARM is a nationwide system for monitoring antimicrobial-resistant bacteria among animals. This monitoring has been conducted by the Ministry of Agriculture, Forestry and Fisheries since 1999 through its network of connections with livestock hygiene service centers across Japan. JVARM provides globally important information and is cited as an example of a monitoring system in the WHO report "Antimicrobial resistance: global report on surveillance 2014."

Under JVARM, three types of monitoring are conducted: (1) monitoring of the volumes of use of antimicrobials (estimated from the volumes of sales); (2) monitoring of antimicrobial resistance among indicator bacteria and foodborne pathogens derived from healthy animals; and (3) monitoring of antimicrobial resistance in pathogenic bacteria (clinical isolates) derived from diseased animals. While verifying the efficacy of veterinary antimicrobials, JVARM also provides basic data for risk assessment and risk management concerning antimicrobial resistance, taking into account influence on human healthcare (Figure 25). The results of JVARM are published on the website of the National Veterinary Assay Laboratory, Ministry of Agriculture, Forestry and Fisheries [2]. In FY2016, reviews were carried out to consider how to strengthen antimicrobial resistance surveillance in aquatic animals and how to conduct antimicrobial resistance surveillance in companion animals, in accordance with the strategies of the National Action Plan on AMR. Antimicrobial resistance surveillance in diseased dogs and cats was launched in FY2017 and in healthy dogs and cats in FY2018. In FY2021, discussion about methodologies for antimicrobial resistance monitoring in the livestock environment started.




Figure 25. Overview of veterinary antimicrobial resistance monitoring

2) System for the antimicrobial resistance monitoring

When JVARM first began, surveillance of foodborne pathogenic bacteria and indicator bacteria from healthy animals was carried out using samples of strains isolated and identified from the feces of livestock animals collected at farms by livestock hygiene service centers. Surveillance using strains isolated and identified by the contracted testing agency from feces collected at animal and poultry slaughterhouses was launched in 2012, as this facilitated more intensive sampling at a stage closer to the final food product. In 2016, as it had been confirmed that there was no major difference in the findings of both surveys, JVARM shifted completely from sampling at farms to sampling at animal and poultry slaughterhouses (Figure 26). Bacteria were isolated from faecal samples collected from slaughterhouses (five sites nationwide) and poultry slaughterhouses (13 sites nationwide), using species-selective media and data are based on one strain per bacterial species per farm (the farm's representative strain).

In the case of clinical isolates from livestock animals, bacterial strains isolated and identified from materials for pathological appraisal by livestock hygiene service centers across the country were collected. One or two strains isolated from a different individual affected in a single case of infectious disease were collected for the monitoring. The MIC values for these strains are measured by the National Veterinary Assay Laboratory using a broth microdilution method based on the CLSI Criteria (Figure 26). The scope of antimicrobial monitoring includes a broad range of active ingredients that are considered important in antimicrobials used exclusively for animals, antimicrobials used for both animals and humans, and antimicrobial feed additives, among others. Antimicrobial agents subject to monitoring are selected for each bacterial species, according to the past monitoring results and Chapter 6.7 of the WOAHA Terrestrial Animal Health Code.[3]

Antimicrobial Resistance from healthy and diseased animals




Figure 26. Monitoring system for drug-resistant bacteria from healthy livestock (slaughterhouses and poultry slaughterhouses) and from diseased livestock (farms).

For the companion animal survey, the survey method was determined based on the results of the discussion at the Working Group on Companion Animal AMR Surveillance, and from 2017, strains derived from diseased dogs and cats were collected from clinical laboratories. Also, from 2018, healthy dogs and cats were targeted, and specimens were collected from veterinary hospitals nationwide with the cooperation of the Japan Veterinary Medical Association (Figure 27).




Figure 27. System for antimicrobial resistance monitoring in healthy and diseased dogs and cats

Isolation of bacteria from specimens was carried using selective media in all cases, with one strain of one species per hospital. The MICs of the collected strains were determined at the contract laboratory using the micro-broth dilution method according to CLSI. Antimicrobial substances to survey were selected for each species of bacteria, taking into account the drugs used in clinical settings for companion animals in addition to those targeted in the livestock survey.

Efforts are made to achieve standardization in the isolation and identification of strains and antimicrobial susceptibility testing, by such means as training sessions for the staff of livestock hygiene service centers who carry out this work at the National Veterinary Assay Laboratory each year and checks of quality control at the contracted testing agency. In addition, a parallel survey of the origin of the samples and the date on which they were collected is carried out. Isolated strains collected under JVARM are examined and stocked by the National Veterinary Assay Laboratory, which also performs the analysis of genetic properties and the clarification of antimicrobial resistance mechanism, in order for the molecular epidemiological survey of antimicrobial-resistant strains. Antimicrobial feed additives are analyzed by the FAMIC. Data collected through JVARM are published on the website of the National Veterinary Assay Laboratory every year. The data are also utilized for risk assessment by the Food Safety Commission as well as for science-based risk management measures.




Figure 28. Comparison of the proportion of third generation cephalosporin-resistant *Escherichia coli* derived from humans and livestock animals

Comparing data from JVARM and JANIS, which monitors resistant bacteria in human medical settings, the resistance rate to third generation cephalosporins had increased until 2011 in both human-derived and broiler-derived *E. coli*, but then has decreased drastically in broiler since 2012. This may be due to the discontinuation of the off-label use of third generation, which had been practiced cephalosporins in some egg hatcheries, in response to the guidance given to the relevant organizations advising to stop it by presenting the JVARM results.[5] In humans, on the other hand, the rate has continued to increase showing different trends in humans broiler (Figure 28).

While an increasing trend in the fluoroquinolone resistance rate of human *E. coli* has been observed since 2003, the fluoroquinolone resistance rate of *E. coli* from livestock has remained below 5% for swine and beef cattle-derived strains and below 20% for broiler-derived strains, showing different trends between human and livestock (Figure 29)




Figure 29. Comparison of the proportion of fluoroquinolone-resistant *Escherichia coli* derived from humans and livestock animals

3) Monitoring the sales volumes of veterinary antimicrobials

An annual monitoring is conducted on the volumes of sales of veterinary antimicrobials, based on the reported quantities of veterinary agents handled by marketing authorization holders, pursuant to Article 71-2 of the Regulatory Rules for Veterinary Medicinal Products (MAFF Ordinance No. 107 of 2004) (Figure 30). Starting 2001, the monitoring has included the volume of sales by active pharmaceutical ingredient, and the estimated percentage of sales by animal species, in addition to the sales volumes by antimicrobial class and route of administration. The data are aggregated and published on the website of the National Veterinary Assay Laboratory as “Annual Report of Sales Amount and Sales Volume of Veterinary agents, Quasi-agents and Medical Devices.” Under the WOAHP Terrestrial Animal Health Code’s section on antimicrobial usage (Chapter 6.8), [6] these data are submitted to the WOAHP for the activity to understand and compare usage in each country of the world.



Figure 30. Monitoring on the sales volumes of veterinary antimicrobials

4) Future prospects

The main issues to be addressed by JVARM in the future are: 1) further promotion of more advanced investigation and analysis of antimicrobial resistance genes and others through whole-genome analysis of bacteria from livestock and companion animals, and consideration of their use in trend surveys and comparison with the human field; and 2) evaluation of the amount of veterinary antimicrobial use standardized by biomass weight calculated with reference to the method proposed by WOA, these data accumulated will lay the ground for risk assessment and risk management by clarifying the transmission of process of antimicrobial resistance bacteria through collaborating with other fields.

(6) Trend Surveillance of Antimicrobial Agents in Japan (JSAC, J-SIPHE)

1) Overview

The governance of Japan Antimicrobial Consumption Surveillance (JACS), an antimicrobial use surveillance system established in 2015 through the Ministry of Health, Labour and Welfare (MHLW) Science Research, was transferred to the AMRCRC and it was renamed to Japan Surveillance of Antimicrobial Consumption (JSAC) (Antimicrobial Use Surveillance) in 2022 in order to conduct a monitoring of antimicrobial use in humans in Japan on an annual and continuous basis at national level and utilize it for in AMR measures. Currently, JSAC (<https://amrcrc.jihs.go.jp/surveillance/index.html>) investigates antimicrobials use (AMU) in Japan and by prefecture using sales volume information and NDB. In addition, AUDs and DOTs of each participating facility are compiled and published as an annual report in J-SIPHE (<https://j-siphe.jihs.go.jp>).

2) Monitoring methods

The sales volume data is used to calculate the potency for each agent for overall use and by dosage form (oral and parenteral) and by prefecture, and figures are collated based on either the ATC or AWaRe classification advocated by the WHO. In the case of AMU in humans, these figures are shown over time, adjusted by defined daily dose (DDD) as defined by the WHO, then adjusted by population to calculate DID (DDDs/1,000 inhabitants/day). To monitor AMU from a One Health perspective, figures converted into titer values are summarized by weight for each ATC category and are then shown totalled with AMU elsewhere. Figures shown for AMU at medical institutions are the results from J-SIPHE monitoring.

* ATC Classification: Anatomical Therapeutic Chemical Classification System, a classification system for pharmaceutical products proposed by WHO.

* AWaRe classification: an indicator of appropriate antimicrobial use recommended by WHO (see p.121)

3) Prospects

The establishment of Japan's first AMU surveillance programs in the form of JSAC and J-SIPHE put in place a system that enables trends in AMU over time to be fed back to the public. Sources of AMU information include both data on the volume of sales and insurance billing data. The sources of information used and the way in which they are presented need to be altered according to their purpose and further consideration is required regarding the form in which they should be collated and fed back on an ongoing basis.

(7) Monitoring on the antimicrobial-resistant *Campylobacter* spp. isolated from humans and from food

1) Overview

Currently the monitoring regarding the emergence of antimicrobial-resistant *Campylobacter* spp. derived from humans is undertaken as research activities by the Tokyo Metropolitan Institute of Public Health, as part of the food safety assurance and promotion research project, with grants for research from the Ministry of Health, Labour and Welfare of Japan.[9]

2) Survey methods

Antimicrobial susceptibility tests were conducted on *Campylobacter jejuni* and *Campylobacter coli* isolated from sporadic cases of diarrheal patients' feces in hospitals within Tokyo. The testing was performed using the disk method, in accordance with the CLSI standards in US, and the five tested antimicrobials were ABPC, TC, NA, CPFX, and EM. Results were determined by measuring the zone of inhibition and following the susceptibility determination table in the protocol.[7]

3) Prospects

To identify the emergence of antimicrobial-resistant *C. jejuni* /*C. coli* on a wide-area basis, it is required to standardize tested antimicrobials, implementation methods, assessment criteria, and other details. While tests were conducted using the disk method, in accordance with U.S. CLSI standards, judgment criteria are provided for only three agents, namely CPFX and EM. Accordingly, other agents were assessed in accordance with standards unified as part of a Ministry of Health, Labour and Welfare-funded research project concerning the promotion of food safety, with reference to EUCAST breakpoints and various literature.[7] It is required to conduct antimicrobial susceptibility tests using common methods not only for strains isolated from humans, but also for strains isolated from food, in order to know the emergence of antimicrobial-resistant bacteria nationwide.

(8) Monitoring on the antimicrobial-resistant non-typhoidal *Salmonella* spp. isolated from humans and from food

1) Overview

Many Public Health Institutes conducted resistance monitoring regarding antimicrobial-resistant bacteria derived from food. Several Public Health Institutes were organized to undertake the monitoring of antimicrobial-resistant bacteria derived from food as research activities, as part of the food safety assurance and promotion research project, with Grants for research from the Ministry of Health, Labour and Welfare of Japan.[8] This is likely the first monitoring in Japan regarding antimicrobial-resistant bacteria derived from food on a nationwide scale, conducted by standardized methods. The collected data were also reported to GLASS, which was launched by WHO.

2) Methods

With cooperation from 23 Public Health Institutes across Japan, an antimicrobial resistance monitoring was conducted using the common protocol, antimicrobials, instruments, etc., concerning bacteria, particularly *Salmonella* spp., derived from human patients and from food, as collected by these Public Health Institutes.[8] The monitoring was targeted at *Salmonella* spp. strains that were isolated from human patients and from food in 2015 and 2024. Strains derived from humans included those isolated from specimens of patients with infectious gastroenteritis or with food poisoning. For each strain derived from food, the type of source food and the date of isolation were identified. When the source food was chicken meat, information was collected concerning the country of production (domestic, imported (country name), and unknown). The 21 cooperating Public Health Institutes performed antimicrobial susceptibility tests by the CLSI disk diffusion method, in accordance with the Public Health Institute Group Protocol for Antimicrobial Susceptibility Tests, using strains that were assessed as *Salmonella* spp. The susceptible discs were ABPC, GM, KM, SM, TC, ST, CP, CTX, CAZ, and CFX, FOM, NA, CPFX, NFLX, AMK, IPM and MEPM 17 agent disks were used. All Public Health Institutes used common reagents (e.g. susceptibility disks) and instruments (e.g. disk dispensers, vernier calipers) for the tests. Susceptibility disks were laid out on an agar plate as indicated in the layout drawing in the protocol, so that inhibition zone would not be coalesced. The diameters of inhibition zone was measured, and the measurements were assessed based on the susceptibility assessment chart in the protocol.

3) Prospects

Clear similarity was observed in the proportion of antimicrobial-resistant strains derived from humans and of those derived from food. As these data are vital to the One Health approach, which covers the environment, animals, food, and humans, a system has been established that uses conversion software to integrate the data with JANIS and JVARM data to facilitate integrated evaluation of all three.

(9) Monitoring on the antimicrobial-resistant *Neisseria gonorrhoeae*

1) Overview

In the diagnosis of gonococcal infection, the utilization of nucleic acid testing has been promoted. Isolation culture is only implemented for some patients. Because antimicrobial susceptibility tests for *Neisseria gonorrhoeae* cannot be easily implemented in general laboratories or laboratory companies, it is difficult for JANIS to monitor trends in these bacteria. Therefore, a monitoring on the antimicrobial-resistant *N. gonorrhoeae* has been undertaken as research activities at AMED since 2015. The collected data are also reported to GLASS, which is operated by WHO.

2) Survey methods

More than 40 cooperating clinics are designated across Japan. Antimicrobial susceptibility tests were performed at six facilities capable of testing across Japan, after collecting specimens from the cooperating clinics, or collecting strains through laboratory companies. Antimicrobial susceptibility tests were performed using an agar plate dilution method, recommended by CLSI or EUCAST, or using Etest. MIC values were measured for CTRX and spectinomycin as recommended agents; for AZM, which was used as part of the two-agent combination therapy overseas; and for PCG, CFIX, and CPFX, which had been used as recommended agents in the past. The EUCAST standards were used for susceptibility and resistance assessment (Table 113). For reference, the proportion of resistant strain based on CLSI Guidelines (M100- S25) (Table 114) is indicated in Table 115. The figures for AZM in the tables are based on the MIC distribution of strains that have antimicrobial-resistant gene, as indicated by CLSI Guideline (M100-S27).

3) Prospects

Physicians need to empirically choose therapeutic agents for gonococcal infection according to the result of the monitoring given the difficulty in routinely performing antimicrobial susceptibility tests.

For empiric treatment, it is recommended to use an agent with the potential success rate of 95% or higher. At present, CTRX and SPCM are the only recommendable agents in Japan. Because *N. gonorrhoeae* that are present in the pharynx are an important source of infection, *N. gonorrhoeae* in pharynx should be treated. Due to its *in vivo* pharmacokinetics, SPCM does not have effect on *N. gonorrhoeae* present in the pharynx. Therefore, CTRX is the only practically recommendable agent.

In sporadic cases, strains isolated in Japan indicate the ceftriaxone MIC of 0.5 µg/mL in antimicrobial susceptibility tests. CTRX is administered by intramuscular injection overseas, and therefore subject to dose limitation. Therefore, if strains that indicate the CTRX MIC of 0.5 µg/mL are transmitted overseas, it is likely that CTRX loses its effect. Hence, it is required to continue with the careful monitoring of isolated strains in coming years. Reports of the isolation of strains with the same resistance gene as the resistant strain isolated in Osaka in 2015 [9] have been received from across the globe since 2017.[10]

Table 113. Antimicrobial susceptibility assessment criteria based on EUCAST (µg/mL) for *N. gonorrhoeae*

	Susceptible		Resistant
PCG	≤ 0.06	0.125–1	> 1
CFIX	≤ 0.125	-	> 0.125
CTRX	≤ 0.125	-	> 0.125
SPCM	≤ 64	-	> 64
AZM	≤ 0.25	0.5	> 0.5
CPFX	≤ 0.03	0.06	> 0.06

Table 114. Antimicrobial susceptibility assessment criteria based on CLSI (µg/mL) for *N. gonorrhoeae*

	Susceptible		Resistant
PCG	≤ 0.06	0.125–1	≥ 2
CFIX	≤ 0.25	-	-
CTRX	≤ 0.25	-	-
SPCM	≤ 32	64	≥ 128
AZM*	-	-	-
CPFX	≤ 0.06	0.12–0.5	≥ 1

* Epidemiological cutoff value indicated in CLSI Standards (M100-S27): wild type (WT) ≤ 1; non-WT ≥ 2

Table 115. The proportion (%) of antimicrobial-resistant *N. gonorrhoeae* based on the CLSI (M100-S25)

	2015	2016	2017
CTRX [§]	0.6	0.4	0.5
SPCM	0	0	0
AZM*	3.2	4.0	4.0
PCG [†]	36.0 (96.1)	35.8 (96.7)	37.8 (99.0) [†]
CFIX [§]	16.1	11.0	10.0
CPFX [†]	79.0 (79.4)	77.9 (78.3)	74.2 (75.8)

[§] Non-susceptibility rate

* The figures are based on the epidemiological cutoff value (non-WT ≥ 2 µg/mL) indicated in CLSI Standards (M100-S27), and differ from resistance proportion.

[†]*Figures in parentheses indicate the sum of resistance and intermediate resistance.

(10) Monitoring on the antimicrobial-resistant *Salmonella* Typhi, *Salmonella* Paratyphi A, and *Shigella* spp.

1) Overview

For typhoid and paratyphoid fever, and shigellosis, definitive diagnosis is undertaken based on bacterial isolation. Given there is no routine antimicrobial resistance monitoring regarding *Salmonella* Typhi, *Salmonella* Paratyphi A, and *Shigella* spp., susceptibility tests are performed at the National Institute of Infectious Diseases, using strains submitted based on the Notification for Epidemiological Surveillance. Antimicrobial resistance information concerning *Shigella* spp. is also used as data reported to GLASS.

2) Methods

Antimicrobial susceptibility tests are performed using strains that are submitted based on the Notification for Epidemiological Surveillance (HSB/TIDCD Notification No. 100901, PFSB/ISD Notification No. 100902). In antimicrobial susceptibility tests, assessment was performed in accordance with CLSI standards, using a broth microdilution method for *Salmonella* Typhi, *Salmonella* Paratyphi A, and *Shigella* spp. in 2022 and after, and using a disk diffusion method for *Shigella* spp. in 2021 and before.

3) Prospects

Treatment with antimicrobials is essential for typhoid and paratyphoid. To enable the proper selection of effective therapeutic agents, it is necessary to conduct continuous monitoring. The proportion of strains that are resistant to quinolones and other commonly used antibacterials are high in *Shigella* spp., and therefore recurrence is also possible even after administering antimicrobials. Careful monitoring is required to prevent possible spread of infection in Japan.

(11) Antimicrobial Resistance (AMR) One Health Platform

Overview

In October 2019, the AMRCRC published the “Antimicrobial Resistance (AMR) One Health Platform” (<https://amr-onehealth-platform.jihs.go.jp/home>), a website that provides easy-to-understand information related to infectious diseases in the human, animal and environmental fields.

This system allows users to freely view trends in agent resistance rates, antimicrobial use, and other AMR-related indicators by field, prefecture, and year. The information handled is mainly secondary use from outputs of this report, AMED research and other deliverables.

In November 2021, prefectural homepage was newly established, which allows users to view various indicators in one place from the homepage of each prefecture. We hope that this platform will be utilized to further promote AMR measures in each region.



Websites of Key Trend Surveys

AMR Clinical Reference Center

<https://amrcrc.jihs.go.jp/>

Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE)

<https://j-siphe.jihs.go.jp/>

Antimicrobial Resistance (AMR) One Health Platform

<https://amr-onehealth-platform.jihs.go.jp/home>

Japan Surveillance of Antimicrobial Consumption (JSAC)

<https://amrcrc.jihs.go.jp/surveillance/index.html>

Japan Nosocomial Infections Surveillance (JANIS), Ministry of Health, Labour and Welfare

<https://janis.mhlw.go.jp/>

National Epidemiological Surveillance of Infectious Disease (NESID)

<https://id-info.jihs.go.jp/surveillance/idwr/annual/2023/index.html>

Infectious Disease Surveillance Program: Request for Physician Reporting Under the Infectious Diseases Control Law (Ministry of Health, Labour and Welfare)

https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryoku/kenkou/kekkaku-kansenshou/kekkaku-kansenshou11/01.html

Infectious Disease Surveillance Program: Infectious Diseases and Animals Reportable by Veterinarians Under the Infectious Diseases Control Law (Ministry of Health, Labour and Welfare)

https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryoku/kenkou/kekkaku-kansenshou/kekkaku-kansenshou11/02.html

Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM)

http://www.maff.go.jp/nval/yakuzai/yakuzai_p3.html

The Tuberculosis Surveillance Center, The Research Institute of Tuberculosis, Japan Antituberculosis Association

<https://jata-ekigaku.jp/>

The Antimicrobial Resistance One Health Surveillance Committee: Terms of References

January 16, 2017
Partially amended on October 4, 2023

1. Objective

As a sentiment is being elevated to promote Antimicrobial Resistance (AMR)-related measures, an integrated AMR trend surveillance with human health, animals, food, and the environment is regarded as important.

The National Action Plan on Antimicrobial Resistance (AMR) (2023-2027), enacted on April 7, 2023, also requires promoting systems for such One Health AMR surveillance.

Under these circumstances, the Antimicrobial Resistance One Health Surveillance Committee (hereinafter referred to as "Committee") is to be held, requesting the participation of experts under the Director-General of Department of Infectious Disease Prevention and Control, Public Health Bureau, Ministry of Health, Labour and Welfare (MHLW), in order to review necessary technical matters that pertain to One Health AMR surveillance and prepare annual reports.

2. Structure of the Committee

- (1) The Committee should consist of experienced experts and other stakeholders.
- (2) The Chair should be elected from members by mutual voting.
- (3) The Committee should be presided over by the Chair.
- (4) The Director of the Department of Infectious Disease Prevention and Control, Public Health Bureau may request non-member experts to participate at Committee when necessary.

3. Term of office

- (1) In principle, the term of office of a member should be two years. The term of office of a member elected to fill a vacancy should be the remaining term of his/her predecessor.
- (2) A member may be re-elected.

4. Others

- (1) Sessions of the Committee should be held by the Director-General of Department of Infectious Disease Prevention and Control, Public Health Bureau, HLW.
- (2) Clerical affairs for the Committee should be handled by the Division of Infectious Disease Prevention and Control, Department of Infectious Disease Prevention and Control, Public Health Bureau, MHLW, with cooperation from the Animal Products Safety Division, Food Safety and Consumer Affairs Bureau, Ministry of Agriculture, Forestry and Fisheries, and from the General Affairs Division, Environmental Management Bureau, Ministry of the Environment.
- (3) Sessions of the Committee should be held openly in principle.
- (4) Necessary matters concerning the operation of the Committee, other than those specified in this Overview, should be determined at the Committee.

The Process of Preparation of This Report

The annual Nippon AMR One Health Report was created through discussion at a series of the AMR One Health Surveillance committee in cooperation with additional experts and cooperating governmental agencies: 1st meeting on 2/3/2017, 2nd meeting on 3/8/2017, 3rd meeting on 8/21/2017, 4th meeting on 10/2/2017, 5th meeting on 9/5/2018, 6th meeting on 10/22/2018, 7th meeting on 10/17/2019, and 8th meeting on 11/6/2020, 9th meeting on 1/17/2022, 10th meeting on 11/21/2022, 11th meeting on 12/13/2023, and 12th meeting on 1/8/2025. And this report has been created through discussion at a series of the AMR One Health Surveillance committee in cooperation with additional experts and cooperating governmental agencies: 13th meeting on 12/4/2025.

Members of the Antimicrobial Resistance (AMR) One Health Surveillance Committee

ASAI Tetsuo, D.V.M., Ph.D.	United Graduate School of Veterinary Science, Gifu University
KATSUDA Ken, D.V.M., Ph.D.	Department of Animal Disease Control and Prevention, National Institute of Animal Health, National Agriculture and Food Research Organization
KOBAYASHI Sota, D.V.M., Ph.D.	Head, Research Promotion Office, Department of Research Promotion, National Institute of Animal Health, National Agriculture and Food Research Organization
SASAMOTO Yoichi, M.D., Ph.D.	Japan Medical Association
SHINOMIYA Hiroto, M.D., Ph.D.	Ehime Prefectural Institute of Public Health and Environmental Science
SHIBAYAMA Keigo, M.D., Ph.D.	Nagoya University Graduate School of Medicine
SUGAI Motoyuki, Ph.D.	Antimicrobial Resistance Research Center, National Institute of Infectious Diseases
SUGAWARA Yo	Antimicrobial Resistance Research Center, National Institute of Infectious Diseases
SEKIYA Tatsuro, D.V.M.	Assay Division II, National Veterinary Assay Laboratory, Ministry of Agriculture, Forestry & Fisheries
TANAKA Hiroaki, Ph.D.	Faculty of Engineering, Shinshu University, Kyoto University
FUJII Yuuki	Ibaraki Prefectural Kenzai Livestock Health Center, Health Guidance Section
FUSHIMI Keiji	Japan Veterinary Medical Association
FUJIMOTO Shuhei, M.D., Ph.D.	Gunma University; National Institute of Infectious Diseases; National Health Insurance Matsuda Municipal Clinic
MATSUNAGA Nobuaki M.D., MPH, Ph.D.	Deputy Director / Chief of Clinical Epidemiology Division, AMR Clinical Reference Center, National Center for Global Health and Medicine, Japan Institute for Health Security
MITARAI Satoshi, M.D., Ph.D.	Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association
MIYAZAKI Yoshitsugu	Pathogen Genomics Center, Department of Fungal Infection, National Institute of Infectious Diseases, Japan Institute for Health Security
MURAKI Yuichi, Ph.D.	Laboratory of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University
WATANABE Haruo, M.D., Ph.D.* (*Chair)	National Institute of Infectious Diseases; Kurozumi Medical Foundation

Additional experts who contributed to this report

AKEDA Yukihiro	Department of Bacteriology I, National Institute of Infectious Diseases
IZUMIYA Hidemasa, M.D., Ph.D.	Department of Bacteriology I, National Institute of Infectious Diseases
YU Liansheng	Antimicrobial Resistance Research Center, National Institute of Infectious Diseases
UECHI Kohei	Antimicrobial Resistance Research Center, National Institute of Infectious Diseases
OHMAGARI Norio, M.D., M.Sc., Ph.D.	Director, AMR Clinical Reference Center, National Center for Global Health and Medicine, Japan Institute for Health Security
KANAMORI Hajime, M.D., MPH, PhD	Department of Infectious Diseases and Laboratory Medicine, Graduate School of Medical Sciences, Kanazawa University
KAMIGAKI Taro	Infectious Disease Surveillance Research Division, National Institute of Infectious Diseases
KAYAMA Shizuo	Antimicrobial Resistance Research Center, National Institute of Infectious Diseases
KAWANISHI Michiko, D.V.M., Ph.D.	Veterinary AMR Center, Inspection II, National Veterinary Assay Laboratory, Ministry of Agriculture, Forestry and Fisheries
KITAMURA Norikazu	Antimicrobial Resistance Research Center, National Institute of Infectious Diseases
KONISHI Noriko, Ph.D.	Division of Food Microbiology, Tokyo Metropolitan Institute of Public Health
SUZUKI Satowa, M.D., MPH, PhD	Antimicrobial Resistance Research Center, National Institute of Infectious Diseases
SUZUKI Motoi, M.D., M.Sc., PHDC, Ph.D.	Infectious Disease Surveillance Center, National Institute of Infectious Diseases
SUNAGAWA Tomimasa, M.D., Ph.D.	Center for Field Epidemic Intelligence, Research and Professional Development National Institute of Infectious Diseases
SEKIGUCHI Hideto, D.V.M.	Veterinary AMR Center, Inspection II, National Veterinary Assay Laboratory, Ministry of Agriculture, Forestry and Fisheries
TSUZUKI Shinya	Chief of Pharmacoepidemiology Division, AMR Clinical Reference Center, National Center for Global Health and Medicine, Japan Institute for Health Security
NISHIYAMA Masateru, Ph. D.	Faculty of Agriculture, Yamagata University
FUJITOMO Yumiko, M.D.	Chief of Information and Education Division, AMR Clinical Reference Center, National Center for Global Health and Medicine, Japan Institute for Health Security
YAHARA Koji, Ph.D.	Antimicrobial Resistance Research Center, National Institute of Infectious Diseases
YAMAGISHI Takuya, M.D., Ph.D.	Antimicrobial Resistance Research Center, National Institute of Infectious Diseases

Cooperating governmental agencies

Food Safety Commission Secretariat	Ministry of the Environment
Ministry of Agriculture, Forestry and Fisheries	Ministry of Land, Infrastructure, Transport and Tourism

Secretariat (Division of Infectious Disease Prevention and Control, Department of Infectious Disease Prevention and Control, Public Health Bureau, Ministry of Health, Labour and Welfare)

KOBA Ai	Director, Division of Infectious Disease Prevention and Control
OTSUKA Kazuko	Director, Office of infectious Disease Information Management
KOTANI Satoshi	Principal Deputy Director, Division of Infectious Disease Prevention and Control
KAMEGAI Kohei	Deputy Director
NAKAMURA Takafumi	Deputy Director
MIYAHARA Yuta	Chief Officer
KURISHIMA Akira	Chief Officer
YAMAJI Masato	Chief Officer

Nippon AMR One Health Report (NAOR) 2025

Published on: July 10, 2026

Published by:

Division of Infectious Disease Prevention and Control, Department of Infectious Disease Prevention and Control, Public Health Bureau, Ministry of Health, Labour and Welfare Address: 1-2-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-8916, Japan

Suggested citation: The AMR One Health Surveillance Committee. Nippon AMR One Health Report (NAOR) 2025. Tokyo: Division of Infectious Diseases Prevention and Control, Department of Infectious Disease Prevention and Control, Public Health Bureau, Ministry of Health, Labour and Welfare; 2025